
<html lang="en"     class="pb-page"  data-request-id="1c21a9b0-8659-4881-90d7-20d7ec08431b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c01193;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Repurposing of Drugs–The Ketamine Story" /></meta><meta name="dc.Creator" content="Joydip  Das" /></meta><meta name="dc.Description" content="An intranasal formulation of esketamine, the S enantiomer of ketamine, in conjunction with an oral antidepressant, has been approved by the FDA for treating treatment-resistant major depressive dis..." /></meta><meta name="Description" content="An intranasal formulation of esketamine, the S enantiomer of ketamine, in conjunction with an oral antidepressant, has been approved by the FDA for treating treatment-resistant major depressive dis..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 11, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01193" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01193" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01193" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01193" /></link>
        
    
    

<title>Repurposing of Drugs–The Ketamine Story | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01193" /></meta><meta property="og:title" content="Repurposing of Drugs–The Ketamine Story" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0008.jpeg" /></meta><meta property="og:description" content="An intranasal formulation of esketamine, the S enantiomer of ketamine, in conjunction with an oral antidepressant, has been approved by the FDA for treating treatment-resistant major depressive disorder (TRD) in 2019, almost 50 years after it was approved as an intravenous anesthetic. In contrast to traditional antidepressants, ketamine shows a rapid (within 2 h) and sustained (∼7 days) antidepressant effect and has significant positive effects on antisuicidal ideation. Ketamine’s antidepressant mechanism is predominantly mediated by the N-methyl-d-aspartate receptor (NMDA) receptor, although NMDA-independent mechanisms are not ruled out. At the neurocircuitry level, ketamine affects the brain’s reward and mood circuitry located in the corticomesolimbic structures involving the hippocampus, nucleus accumbens, and prefrontal cortex. Repurposing of ketamine for treating TRD provided a new understanding of the pathophysiology of depression, a paradigm shift from monoamine to glutamatergic neurotransmission, thus making it a unique tool to investigate the brain and its complex neurocircuitries." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01193"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01193">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01193&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01193&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01193&amp;href=/doi/10.1021/acs.jmedchem.0c01193" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 13514-13525</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01049" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00272" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Repurposing of Drugs–The Ketamine Story</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Joydip Das</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joydip Das</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacological & Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas 77204, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#81ebe5e0f2c1f4e9afe4e5f4"><span class="__cf_email__" data-cfemail="dcb6b8bdaf9ca9b4f2b9b8a9">[email protected]</span></a>. Tel: 713-743-1708.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joydip++Das">Joydip Das</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1540-5804" title="Orcid link">http://orcid.org/0000-0003-1540-5804</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01193&amp;href=/doi/10.1021%2Facs.jmedchem.0c01193" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 13514–13525</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 11, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 July 2020</li><li><span class="item_label"><b>Published</b> online</span>11 September 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01193" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01193</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D13514%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJoydip%2BDas%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D22%26contentID%3Dacs.jmedchem.0c01193%26title%3DRepurposing%2Bof%2BDrugs%25E2%2580%2593The%2BKetamine%2BStory%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D13525%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01193"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2225</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01193" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Repurposing of Drugs–The Ketamine Story&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Joydip&quot;,&quot;last_name&quot;:&quot;Das&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;11&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;13514-13525&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01193&quot;},&quot;abstract&quot;:&quot;An intranasal formulation of esketamine, the S enantiomer of ketamine, in conjunction with an oral antidepressant, has been approved by the FDA for treating treatment-resistant major depressive disorder (TRD) in 2019, almost 50 years after it was approved as an intravenous anesthetic. In contrast to traditional antidepressants, ketamine shows a rapid (within 2 h) and sustained (∼7 days) antidepressant effect and has significant positive effects on antisuicidal ideation. Ketamine’s antidepressant mechanism is predominantly mediated by the N-methyl-d-aspartate receptor (NMDA) receptor, although NMDA-independent mechanisms are not ruled out. At the neurocircuitry level, ketamine affects the brain’s reward and mood circuitry located in the corticomesolimbic structures involving the hippocampus, nucleus accumbens, and prefrontal cortex. Repurposing of ketamine for treating TRD provided a new understanding of the pathophysiology of depression, a paradigm shift from monoamine to glutamatergic neurotransmission, thus&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01193&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01193" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01193&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01193" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01193&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01193" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01193&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01193&amp;href=/doi/10.1021/acs.jmedchem.0c01193" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01193" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01193" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01193%26sid%3Dliteratum%253Aachs%26pmid%3D32915563%26genre%3Darticle%26aulast%3DDas%26date%3D2020%26atitle%3DRepurposing%2Bof%2BDrugs%25E2%2580%2593The%2BKetamine%2BStory%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D22%26spage%3D13514%26epage%3D13525%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/jmcmar.2020.63.issue-22/20201125/jmcmar.2020.63.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">An intranasal formulation of esketamine, the <i>S</i> enantiomer of ketamine, in conjunction with an oral antidepressant, has been approved by the FDA for treating treatment-resistant major depressive disorder (TRD) in 2019, almost 50 years after it was approved as an intravenous anesthetic. In contrast to traditional antidepressants, ketamine shows a rapid (within 2 h) and sustained (∼7 days) antidepressant effect and has significant positive effects on antisuicidal ideation. Ketamine’s antidepressant mechanism is predominantly mediated by the <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor (NMDA) receptor, although NMDA-independent mechanisms are not ruled out. At the neurocircuitry level, ketamine affects the brain’s reward and mood circuitry located in the corticomesolimbic structures involving the hippocampus, nucleus accumbens, and prefrontal cortex. Repurposing of ketamine for treating TRD provided a new understanding of the pathophysiology of depression, a paradigm shift from monoamine to glutamatergic neurotransmission, thus making it a unique tool to investigate the brain and its complex neurocircuitries.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07832" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07832" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The 50th anniversary of ketamine’s first approval as an intravenous anesthetic remains very special. A glorious chapter was added in its otherwise tranquil life in 2019, when an intranasal formulation of esketamine (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), the <i>S</i> enantiomer of ketamine, in combination with an oral antidepressant, was approved by the Food and Drug Administration (FDA) for treating treatment-resistant major depressive disorder (TRD).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> By definition, patients who failed to respond to at least two different treatments with antidepressants in the moderate to severe depressive episodes are considered to have TRD. The FDA has given esketamine a fast-track and breakthrough status. Also, following the recommendation of the Committee for Medicinal Products for Human Use (CHMP), the European Medicines Agency (EMA) has approved esketamine nasal spray (Spravato) for treatment of adults with TRD in December 2019.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of phencyclidine (PCP), ketamine, and its isomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This is a major milestone in antidepressant drug discovery considering the fact that more than 300 million people of all ages suffer from depression, which is a major contributor to the overall global burden of disease.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Approximately one-third of depressed patients have a treatment-resistant form of depression after trying typical antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs). These drugs typically take ∼2–4 weeks to exert measurable antidepressant effects and months to achieve full remission of symptoms and are ineffective for about 30% of the patients.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In clinical trials, ketamine is found to be superior to any other existing treatment for TRD due to its rapid action and antisuicidal effects.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a></div><div class="NLM_p last">In drug discovery, repurposing of drugs is a strategy by which an approved or investigational drug for a particular medical indication can be used for a new indication.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> Lower cost, lower risk of failure, and reduced time frame for approval are some of the advantages of this strategy over the conventional drug discovery approach. In repurposing a drug for a new indication, new mechanisms of action are explored and generally adjustments of doses and routes of administration are made. Highly successful examples of drug repurposing are aspirin, one of the world’s oldest drugs,<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> and sildenafil (Viagra), one of the world’s most talked about drugs,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> both of which have been repurposed multiple times. While sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, was originally developed for treating angina pectoris, it is now used for treating erectile dysfunction. The oldest analgesic drug aspirin, a nonselective inhibitor of cyclooxygenase 1 and 2 (COX-1/2) enzymes, is now used to treat colorectal cancer and ischemic heart disease. Ketamine is one of the most significant additions to the list of repurposed drugs. It has already been included in the List of Essential Medicines of the World Health Organization (WHO) that represents the safest and most effective medicines needed in a health system.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Ketamine as an Anesthetic</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12201" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12201" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Ketamine was first synthesized in 1962 in an effort to identify an alternative to the anesthetic drug phencyclidine (PCP) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) to alleviate its serious psychotomimetic side effects, but retaining its excellent anesthetic effects.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> While the first study of the anesthetic effects of ketamine was performed in healthy prisoners in 1964, ketamine was confirmed to be an effective analgesic and anesthetic in 1965.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In the first clinical study, ketamine was reported to induce a unique state of altered consciousness, described as being dissociative.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> In this state, the patient remains conscious and appears to be awake but does not respond to apparent surgical pain, a situation analogous to “the lights are on, but no one’s home”.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The dissociative state is believed to arise from a functional dissociation that stimulates the limbic regions of the brain and inhibits the thalamocortical pathways,<a onclick="showRef(event, 'ref17 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref19">(17,19)</a> which are implicated in maintaining the neuronal connections required for consciousness. Later, in 1970, ketamine was approved by the FDA as an intravenous anesthetic drug.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.1.  Ketamine’s Anesthetic Mechanism of Action</h3><div class="NLM_p">For its anesthetic mechanism, ketamine acts as an antagonist of the <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor (NMDA) receptor, which is a cation channel. It binds to the same cationic channel of the NMDA receptor where PCP and MK-801 (dizocilpine) bind<a onclick="showRef(event, 'ref15 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref15 ref21 ref22">(15,21,22)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). MK-801 is a noncompetitive antagonist of NMDA receptor. NMDA receptors are tetrameric ionotropic glutamate receptors that are present throughout the CNS, including the cerebral cortex, cerebellum, brain stem, and spinal cord, and play a critical role in synaptic plasticity and memory function. The NMDA receptor is composed of two GluN1 and two GluN2 subunits.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> GluN1 and GluN2 are also referred to as NR1 and NR2, respectively. The two GluN2 subunits may be either GluN2A, GluN2B, GluN2C, or GluN2D, or a combination of any two of these subunits. The NMDA receptor is highly permeable to Ca<sup>2+</sup> ions, and under physiological conditions, Mg<sup>2+</sup> blocks the channel and prevents Ca<sup>2+</sup> flux into neurons. In the open state, one Ca<sup>2+</sup> and one Na<sup>+</sup> ion enter the pore in exchange for one K<sup>+</sup> ion. Activation of the NMDA receptor occurs by simultaneous binding of glutamate to its binding site at the GluN2 subunit, and binding of glycine/<span class="smallcaps smallerCapital">d</span>-serine at the GluN1 subunits. Mg<sup>2+</sup> is released from its binding site when a significant depolarization of the membrane occurs, and ketamine and other channel blockers enter the channel. Ketamine blocks the channel in a noncompetitive manner by binding to a specific site and preventing the flow of cations through this channel. This ultimately prevents neuronal activation, a prerequisite for the conscious state. Ketamine has ∼86% trapping capability as compared to >98% for PCP and 100% for MK-801 to block the NMDA receptor.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Recent structural studies<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> reported that MK-801 binds to the NMDA receptor in a pyramidal vestibule formed by the M3 helix and the tip of the P loop, with its two aromatic rings positioned toward the M3 helices of GluN2A and GluN2B. Asn-612 of GluN2B, Val-642 of GluN1, and Leu-640 of the M3 helix of GluN2B closely interact with MK-801. Although there is no ketamine-bound NMDA receptor structure reported to date, its binding mode is expected to be similar to that of MK-801. Ketamine’s affinity for the NMDA receptor is in the low micromolar range (<i>K</i><sub>i</sub> = 0.18–3.1 μM) in the presence of Mg<sup>2+</sup>, and the inhibitory concentration at half-maximum (IC<sub>50</sub>) in brain slices is approximately 10 μM.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> There are disagreements on ketamine’s specificity for NMDA receptor with a particular subunit. While one study reports that ketamine exerts greater inhibition on GluN2C- and GluN2D-containing NMDA receptors than GluN2A- and GluN2B-containing ones,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> other studies report against such selectivity.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Ketamine binding site in the NMDA receptor. NMDA receptors are tetrameric ionotropic glutamate receptors composed of two NR1 and two NR2 subunits. Ketamine binds within the channel and acts as a noncompetitive antagonist of the NMDA receptor. By blocking the channel, ketamine prevents the influx of Ca<sup>2+</sup> or Na<sup>+</sup> ions and depolarization of the neuronal membrane, leading to decreased neurotransmitter release or downstream signaling. The figure is modeled after Pham and Gardier (ref <a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Ketamine is known to bind with many other receptors. It is believed that ketamine exerts it analgesic activity by binding with an opioid receptor or a nonopioid sigma receptor, or possibly serotonin and muscarinic receptors. Ketamine also binds with dopamine, serotonin, and cholinergic receptors and HCN channels. However, ketamine’s affinity for these receptors is much lower than that for the NMDA receptor.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.2.  Pharmacokinetics and Route of Administration</h3><div class="NLM_p">In drug development and drug repurposing, route of administration and the pharmacokinetic properties, specifically the absorption, distribution, metabolism, and elimination (ADME) properties of a drug, are of critical significance. The neutral form of ketamine is highly lipid soluble (log <i>P</i> = 2.18)<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and has p<i>K</i><sub>a</sub> value of 7.5. It has a poor aqueous solubility (0.046 g/L), and therefore it is generally used as a hydrochloride salt, which is highly soluble in water (200 g/L). Ketamine hydrochloride is an injectable, highly potent, and rapidly acting anesthetic agent. In addition to intravenous infusions, ketamine can also be administered via intramuscular, nasal, oral, rectal, subcutaneous, and sublingual routes.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31,32)</a> Different doses are used for different routes of administration. For example, doses of 0.5–1.5 mg/kg intravenously, 4–6 mg/kg intramuscularly, and 8–10 mg/kg rectally are used. An intravenous infusion of 25–100 (μg/kg)/min is used for the maintenance of anesthesia.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Esketamine induces sedation at doses of 3–9 mg/kg intranasally.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p">The bioavailability of ketamine is also dependent on the route of administration. Due to the first-pass metabolism, ketamine’s oral bioavailability is about 17%–29% as compared to intravenous infusion (100%). Ketamine’s bioavailability for intramuscular injection and intranasal, rectal, and sublingual administrations is 93%, 8%–45%, 11%–25%, and 24%–30%, respectively. Intravenous ketamine’s onset of action is fast, occurring within seconds. The values are 1–5 min for intramuscular administration, 15–30 min for subcutaneous administration, 5–10 min for administration via insufflation, and 15–30 min for oral administration.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> Ketamine’s duration of action has been reported to be 0.5–2 h for intramuscular administration and 4–6 h for oral administration.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">Ketamine is a lipophilic molecule that rapidly crosses the blood–brain barrier and distributes rapidly into the brain, with a distribution half-life of 7–11 min.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The efficient distribution is also reflected in its relatively low plasma protein binding at 12–47%.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> When racemic ketamine is administered intravenously in humans (2 mg/kg), the plasma concentrations of both (<i>S</i>)-ketamine and (<i>R</i>)-ketamine were equal (<i>C</i><sub>max</sub> ≈ 1800 ng/mL or 7.6 μM) 1 min after administration.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Administration of subanesthetic doses of either (<i>S</i>)- or (<i>R</i>)-ketamine (10 mg/kg) via intraperitoneal injection showed <i>C</i><sub>max</sub> = 1743 ± 560.6 ng/g or 7.33 ± 2.36 μmol/kg for (<i>S</i>)-ketamine and 1886 ± 459.6 ng/g or 7.93 ± 1.93 μmol/kg for (<i>R</i>)-ketamine 10 min after the injection suggesting similar concentrations in the brain.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">The therapeutic potency of ketamine depends on its metabolism, as it generates several active metabolites. In the liver, ketamine is metabolized by cytochrome P450 isozymes CYP3A4 (major), CYP2B6 (minor), and CYP2C9 (minor) into its major metabolite, norketamine through an <i>N</i>-demethylation reaction.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Norketamine is then hydroxylated to generate hydroxynorketamine by CYP2B6 and CYP2A6.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> (<i>S</i>)- and (<i>R</i>)<i>-</i>Ketamine generate the corresponding <i>S</i> and <i>R</i> metabolites. For example, (2<i>S</i>,6<i>S</i>)-hydroxynorketamine and (2<i>R</i>,6<i>R</i>)-hydroxynorketamine are the major products from (<i>S</i>)-ketamine and (<i>R</i>)-ketamine, respectively. (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Hydroxynorketamine eliminates a water molecule nonenzymatically to generate dehydronorketamine. The hydroxy metabolites can also form glucuronides that can be eliminated renally. The anesthetic potency of norketamine is one-third to one-fifth that of ketamine, and following oral administration its concentration in the plasma can be 3-fold that of ketamine.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Major metabolic pathways of (<i>S</i>)-ketamine and (<i>R</i>)-ketamine. In the presence of specific cytochrome P450 isoforms, ketamine is <i>N</i>-demethylated to generate corresponding norketamine and then hydroxylated to the corresponding hydroxynorketamine. Hydroxylation can occur at different positions of the cyclohexane ring. Some of the hydroxylated compounds can form glucuronides. The hydroxynorketamine can also eliminate a water molecule nonenzymatically to generate dehydronorketamine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The major portion (90%) of administered ketamine is eliminated in urine in the form of norketamine and dehydronorketamine, and only 2–4% of the drug is eliminated unchanged.<a onclick="showRef(event, 'ref37 ref40'); return false;" href="javascript:void(0);" class="ref ref37 ref40">(37,40)</a> Ketamine’s elimination half-life is ∼2–4 h in adult humans.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The available data for the active metabolite (2<i>S</i>,6<i>S</i>)-hydroxynorketamine show an elimination half-life of 8.0 ± 4.0 h in rats following intravenous administration (20 mg/kg).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">3.  Current Antidepressant Drugs and Their Mechanisms of Action</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58773" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58773" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the 1950s, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) were used primarily to treat depressive symptoms. Then, in the 1990s came the second generation antidepressants, such as SSRIs and SNRIs (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). All of these classes of drugs target the serotonin and norepinephrine brain systems following the monoamine hypothesis of depression, which proposes that depression results from a deficiency in monoamine neurotransmitters, such as 5-hydroxytryptamine (5-HT) and norepinephrine (NE),<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and these deficiencies can be corrected by treating with antidepressants. It is believed that the use of MAOIs, SSRIs, and SNRIs reduce the symptoms of depression by increasing the levels of NE or 5-HT or both in the brain. The sites of actions of these antidepressants are known (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), but the mechanism by which the increased concentrations of these neurotransmitters and their synergism reduce depression is not clearly understood. MAOIs inhibit the activity of monoamine oxidases, which inactivate the monoamine neurotransmitters NE and 5HT, thereby increasing the levels of NE and 5-HT. SSRIs, SNRIs, and TCAs, on the other hand, increase levels of these neurotransmitters by blocking the norepinephrine reuptake transporter (NET) or serotonin reuptake transporter (SERT) at the presynaptic terminals. These monoamine reuptake transporters are members of a large sodium-dependent transporter family and are involved in a mechanism that terminates the action of released monoamine neurotransmitters in the synaptic cleft. The TCAs and SNRIs block both NET and SERT and the SSRIs selectively block SERT (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The antidepressant reuptake inhibitors may also contribute to reduced depression by decreasing the expression of their respective transporter proteins.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Chronic treatment with these antidepressants desensitizes presynaptic autoreceptors and heteroreceptors, which produces long-lasting changes in monoaminergic neurotransmission. Postsynaptically, these antidepressants modulate the signaling pathways involving GPCRs, such as β-adrenergic receptor (βAR), α<sub>1</sub>-adrenergic receptor (α<sub>1</sub>AR), and 5-hydroxytryptamine receptors 1–7 (5HTR<sub>1–7</sub>), and activate protein kinases and ion channels, showing long-term effects of these drugs.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structure of some clinically important antidepressants: MAOIs (monoamine oxidase inhibitors), TCAs (tricyclic antidepressants), SSRIs (selective serotonin reuptake inhibitors), and SNRIs (serotonin–norepinephrine reuptake inhibitors).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Simplified diagram showing the sites of action of antidepressants. TCAs, SSRIs, and SNRIs increase noradrenergic or serotonergic neurotransmission by blocking corresponding reuptake transporters (NET or SERT). MAOIs inhibit monoamine oxidases that inactivate the monoamine neurotransmitter. Antidepressants produce long-lasting changes in monoaminergic neurotransmission by modulating both presynaptic and postsynaptic receptors. Postsynaptic GPCRs, such as βAR, αAR, 5HTR<sub>1–7</sub> are known to participate in this mechanism. SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin–norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; MAOI, monoamine oxidase inhibitor; AR, adrenergic receptor; HT, hydroxytryptamine; NE, norepinephrine; GPCR, G-protein coupled receptor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">There are differences in general tolerability and side effect profiles of these antidepressants. For example, SSRIs are superior to TCAs in causing less cardiotoxicity, dry mouth, constipation, dizziness, sweating, and blurred vision and are more suitable for elderly patients. TCAs also show significant anticholinergic effects. On the other hand, TCAs are superior to SSRIs in causing less nausea, diarrhea, agitation, sexual dysfunction, anorexia, insomnia, nervousness, and anxiety.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> As mentioned earlier, these antidepressants, MAOIs, TCAs, SSRIs, and SNRIs, typically take weeks to produce measurable antidepressant effects and do not improve patient’s suicidal ideation.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In addition to the delayed onset of the antidepressant effect, the vegetative side effects occur nearly immediately, which threaten the compliance of the patients.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">4.  Ketamine as an Antidepressant</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The antidepressant potency of ketamine was realized as early as the 1970s.<a onclick="showRef(event, 'ref15 ref45'); return false;" href="javascript:void(0);" class="ref ref15 ref45">(15,45)</a> In 1975, (<i>R</i>,<i>S</i>)-ketamine was reported to show antidepressant-like effects in animal models.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In 1990, Trullas and Skolnick first reported the antidepressant effects NMDA receptor antagonists.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The rapid (within hours) antidepressant effects of ketamine, at subanesthetic doses, was demonstrated in patients suffering from severe depression in 2000.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Later these findings were replicated by Zarate et al.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> in treatment-resistant patients with major depressive disorder (MDD). Since then, many studies have confirmed the antidepressant effects of ketamine for treatment-resistant patients with MDD, bipolar disorder, and suicidal ideation.<a onclick="showRef(event, 'ref20 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref20 ref49 ref50">(20,49,50)</a> This has led to numerous investigations to understand the mechanism of action for the rapid antidepressant activity of ketamine at subanesthetic doses (0.1–0.5 mg/kg).<a onclick="showRef(event, 'ref51 ref52 ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54 ref55">(51−55)</a></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">4.1.  Ketamine’s Antidepressant Mechanism of Action</h3><div class="NLM_p">Ketamine is a noncompetitive antagonist of the NMDA receptor.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Several NMDA receptor-mediated mechanisms have been proposed for the antidepressant action of ketamine<a onclick="showRef(event, 'ref50 ref57'); return false;" href="javascript:void(0);" class="ref ref50 ref57">(50,57)</a> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). In one proposed mechanism, ketamine preferentially inhibits NMDA receptors located on GABAergic interneurons<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a> leading to the release of glutamate and activation of postsynaptic AMPA glutamate receptors. This, in turn, activates a signaling cascade that raises brain-derived neurotrophic factor (BDNF) levels. Local release of BDNF stimulates TrkB receptors, which activates the molecular target of rapamycin complex 1 (mTORC1). These processes result in the activation of local protein synthesis, ultimately leading to the restoration of synaptic connectivity, and increases in synaptic strength,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> which is weakened in depression. A second mechanism proposes that the inhibition of postsynaptic NMDA receptor activity by ketamine leads to a cascade of intracellular changes involving the activation of AKT and ERK/MAPK pathways and the suppression of eukaryotic elongation factor 2 (eEF2). This results in an increase in translation and release of BDNF, leading to synaptic potentiation.<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a> A third hypothesis proposes that ketamine inhibits the extrasynaptic GluN2B-containing NMDA receptors leading to the activation of cellular plasticity cascades<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The common end point of these three mechanisms is the activation of cellular plasticity cascades and strengthening of excitatory synapses in the brain’s positive valence or reward circuitry,<a onclick="showRef(event, 'ref57 ref65'); return false;" href="javascript:void(0);" class="ref ref57 ref65">(57,65)</a> providing strong support for the role of glutamatergic neurotransmission in the pathophysiology of depression.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Simplified diagram showing the mechanism associated with ketamine’s rapid antidepressant action. Ketamine may preferentially block NMDA receptors located at the GABAergic interneurons and reduce inhibition of glutamate release that stimulates the AMPA receptors, which then activates a signaling cascade that raises BDNF levels. Local release of BDNF stimulates TrkB receptors, resulting in the activation of ERK/MAPK, AKT, and the mTORC1 pathways and suppression of eEF2. These processes activate local protein synthesis and restore dendritic spine formation and synaptic connectivity. Ketamine can also activate cellular plasticity cascade by inhibiting extrasynaptic NMDA receptor. AKT, protein kinase B; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; BDNF, brain-derived neurotrophic factor; eEF2, eukaryotic elongation factor 2; ERK/MAPK, extracellular signal-regulated kinase/mitogen-activated kinase; GABA, γ-aminobutyric acid; mTORC1, mechanistic target of rapamycin complex 1; NMDAR, <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor; TrkB, tropomyosin receptor kinase B.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, studies with some NMDA receptor antagonists did not produce the rapid antidepressant effect exerted by ketamine, suggesting that the rapid antidepressant effect could be, at least partly, independent of NMDA receptor antagonism. For example, the potent NMDA receptor antagonist (+)-MK-801 showed rapid antidepressant effects in chronic social defeat stress (CSDS)-susceptible mice, but it did not exert a long-lasting antidepressant effect.<a onclick="showRef(event, 'ref62 ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref62 ref66 ref67">(62,66,67)</a> Experiments with rodents showed that (<i>R</i>)-ketamine is more potent as an antidepressant than (<i>S</i>)-ketamine, although the affinity of the former for the NMDA receptor is 4-fold lower the latter, again suggesting that ketamine’s antidepressant activity may not be mediated exclusively through the NMDA receptor. Additionally, one of the metabolites of (<i>R</i>)-ketamine, (2<i>R</i>,6<i>R</i>)-hydroxynorketamine, shows ketamine-like antidepressant activity in rodents but does not inhibit NMDA receptor at antidepressant-relevant concentrations,<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> indicating an NMDA receptor-independent mechanism. A recent study indicated that the opioid system has a role in ketamine’s antidepressant activity<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> and the ketamine-like antidepressant activity of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine is mediated through mGlu<sub>2</sub> receptor.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div><div class="NLM_p">Modulators of AMPA receptor, muscarinic receptor, mGlu<sub>2/3</sub> receptors, and others are also being investigated as rapid-acting antidepressants.<a onclick="showRef(event, 'ref71 ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref71 ref72 ref73">(71−73)</a> Some of the examples are scopolamine, psilocybin, and LY3020371.</div><div class="NLM_p last">To summarize, ketamine’s antidepressant mechanism is complex, and both NMDA receptor-dependent and NMDA receptor-independent mechanisms are proposed. However, the most important take-home message from these mechanistic studies on the antidepressant activity of ketamine has firmly established the major role of glutamatergic neurotransmission in the pathophysiology of depression, a paradigm shift from the traditional monoaminergic neurotransmission.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">4.2.  Enantiomer Specificity</h3><div class="NLM_p">Ketamine or, more correctly, (<i>R</i>,<i>S</i>)-ketamine is a racemic mixture of equal amounts of (<i>R</i>)-enantiomer and (<i>S</i>)-enantiomer. (<i>S</i>)-Ketamine binds to the NMDA receptor (<i>K</i><sub>i</sub> = 0.30 μM or <i>K</i><sub>i</sub> = 0.69 μM) with a 3–4-fold higher affinity than (<i>R</i>)-ketamine (<i>K</i><sub>i</sub> = 1.4 μM or <i>K</i><sub>i</sub> = 2.57 μM).<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> The IC<sub>50</sub> values of (<i>S</i>)-ketamine for the NMDA receptor containing four different subunits expressed in <i>Xenopus</i> oocytes were lower than those of (<i>R</i>)-ketamine, suggesting higher potency of the former.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> In humans, the anesthetic potency of (<i>S</i>)-ketamine is 2-fold higher than that of (<i>R</i>,<i>S</i>)-ketamine and about 3-fold higher than that of (<i>R</i>)-ketamine.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Because of its higher potency, (<i>S</i>)-ketamine is preferred as an anesthetic compared with (<i>R</i>)-ketamine.</div><div class="NLM_p">As for the antidepressant potency, in rodents, the order of potency was (<i>R</i>)-ketamine > (<i>R</i>,<i>S</i>)-ketamine > (<i>S</i>)-ketamine. Also, the order of the observed side-effects was (<i>S</i>)-ketamine > (<i>R</i>,<i>S</i>)-ketamine > (<i>R</i>)-ketamine. Based on these preclinical and clinical studies, Hashimoto et al. predicted that (<i>R</i>)-ketamine may be a safer antidepressant than (<i>S</i>)- ketamine or (<i>R</i>,<i>S</i>)-ketamine in humans.<a onclick="showRef(event, 'ref20 ref49'); return false;" href="javascript:void(0);" class="ref ref20 ref49">(20,49)</a> A recent open-label pilot study suggested that (<i>R</i>)-ketamine might produce fast-onset and sustained antidepressant effects in TRD patients with a favorable safety profile.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><div class="NLM_p">The studies related to the antidepressant activity of the ketamine metabolites are critical as they can contribute to the overall antidepressant activity of ketamine. (<i>S</i>)-Norketamine, the metabolite of (<i>S</i>)-ketamine, binds to the NMDA receptor with a <i>K</i><sub>i</sub> value of 1.70 or 2.25 μM<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> and shows rapid antidepressant activity in the CSDS and LPS models of depression. (<i>S</i>)-Norketamine’s antidepressant potency is similar to that of its parent drug, (<i>S</i>)-ketamine, but lower than that of (<i>R</i>)-ketamine. In mice, (<i>S</i>)-norketamine did not show major side effects that are more prominent for (<i>S</i>)-ketamine.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Extrapolating these results to human, this group of researchers argued that (<i>S</i>)-norketamine’s side effects would be significantly lower than those of (<i>S</i>)-ketamine and (<i>S</i>)-norketamine would be safer choice than (<i>S</i>)-ketamine for treatment in humans.<a onclick="showRef(event, 'ref79 ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref79 ref80 ref81">(79−81)</a></div><div class="NLM_p last">The other metabolites of ketamine, (2<i>S</i>,6<i>S</i>)-hydroxynorketamine and (2<i>R</i>,6<i>R</i>)-hydroxynorketamine, contribute to ketamine’s antidepressant effects in mice.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The (2<i>R</i>,6<i>R</i>)-hydroxynorketamine was found to exert rapid ketamine-like activity<a onclick="showRef(event, 'ref68 ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref68 ref82 ref83">(68,82,83)</a> with no side effects. On the other hand, the (2<i>S</i>,6<i>S</i>)-hydroxynorketamine metabolite shows antidepressant activity but possesses ketamine-like side effects.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The antidepressant activity of ketamine’s metabolites and their contribution to the parent drug’s activity remains the subject matter of active research with a focus on their species-specific activity and associated mechanisms.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">4.3.  Ketamine’s Effect on Depression-Associated Brain Regions</h3><div class="NLM_p">Several brain regions and neurocircuitries have been implicated in the pathophysiology of depression.<a onclick="showRef(event, 'ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref84 ref85">(84,85)</a> The prefrontal cortex (PFC),<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> the amygdala,<a onclick="showRef(event, 'ref88 ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref88 ref89 ref90">(88−90)</a> the nucleus accumbens (NAc),<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> the hippocampus (HPC),<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> and the lateral habenula (LHb)<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> are the most widely studied brain regions in relation to depression.</div><div class="NLM_p">The PFC is involved in executive functions, the higher cognitive functions, of the brain. The dorsolateral prefrontal cortex (DLPFC), dorsomedial prefrontal cortex (DMPFC), ventromedial prefrontal cortex (VMPFC), orbitofrontal cortex (OFC), medial PFC (mPFC), and anterior cingulate cortex (ACC) are the major sections of PFC. The DLPFC is responsible for motivation and executive function. The OFC has been implicated in correcting behavioral or emotional responses. The ACC is involved in reward anticipation, decision making, empathy, emotion, and impulse control. Underactive DLPFC and DMPFC and overactive subgenual anterior cingulate cortex (SGACC), OFC, or amygdala in depression have been reported.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94,95)</a> A functional MRI (fMRI) study found decreased activity in the VMPFC, OFC, and SGACC, accompanied by increased activity in the posterior cingulate upon ketamine treatment.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Studies using magnetoencephalographic (MEG) recordings in TRD patients suggest the role of ACC activity in the antidepressant response of low-dose ketamine.<a onclick="showRef(event, 'ref97 ref98'); return false;" href="javascript:void(0);" class="ref ref97 ref98">(97,98)</a> Optogenetics studies in mice show an immediate antidepressant effect upon direct stimulation of the mPFC,<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(99,100)</a> and ketamine infusion into the infralimbic region of the mPFC reproduced antidepressant actions similar to systemic ketamine administration,<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> all indicative of the importance of the mPFC in ketamine’s antidepressant action. Neuroimaging studies in human also showed elevated cortical activity of PFC and ACC upon treatment with subanesthetic doses of ketamine.<a onclick="showRef(event, 'ref101 ref102 ref103'); return false;" href="javascript:void(0);" class="ref ref101 ref102 ref103">(101−103)</a> At the receptor level, ketamine inhibits the NMDA receptor located at the GABAergic interneurons and enhances glutamatergic signaling in the cortex of rodents, resulting in disinhibition of cortical pyramidal neurons.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a></div><div class="NLM_p">The hippocampus (HPC) plays an important role in learning and memory. It is subdivided into several regions such as CA1, CA2, CA3, and dentate gyrus (DG). The hippocampus and several regions of the cerebral cortex, including the ACC, play a significant role in depression.<a onclick="showRef(event, 'ref104 ref105'); return false;" href="javascript:void(0);" class="ref ref104 ref105">(104,105)</a> Brain imaging studies showed reduced activity of the hippocampus and frontal cortex in depressed patients.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> They also identified deficits in reward-related network connectivity in learning and memory in depressed patients.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Magnetic resonance studies showed moderate volume reductions in the hippocampus of depressed patients as compared with healthy controls. In mice, ketamine attenuates the decreased levels of BDNF and PSD-95 in the DG and CA3 regions of the hippocampus and PFC in the CSDS model.<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107,108)</a></div><div class="NLM_p">The amygdala is involved in the processing of memory, decision-making, and emotional responses. There is a correlation between the severity of depression and abnormal activation of the amygdala.<a onclick="showRef(event, 'ref88 ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref88 ref89 ref90">(88−90)</a> An MRI study showed a reduction in amygdala size in depressed patients who were not on medication.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> In healthy individuals, ketamine reduced amygdalo-hippocampal reactivity to emotional stimulation,<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> and in TRD patients, ketamine altered the amygdala and PFC activity.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> A recent proteomic analysis found that (<i>S</i>)-ketamine altered the levels of metabotropic glutamate receptor 5 (mGlu5), and β3 and α1 subunits of GABA<sub>A</sub> receptor in amygdala.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div><div class="NLM_p">The nucleus accumbens (NAc) is critically involved in reward circuitry and has been studied extensively in preclinical models of depression.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> It has also a significant role in the cognitive processing of motivation, aversion, and reinforcement learning. Animal models of depression showed stress-induced hypertrophy of the NAc.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Magnetic resonance imaging showed that ketamine treatment enlarged NAc volume in MDD patients.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> In another study, ketamine restored stress-induced neuroplasticity changes in the NAc.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></div><div class="NLM_p last">The lateral habenula (LHb) is a brain structure that is conserved in virtually all vertebrates and has been implicated in the processing of reward and aversive information, cognitive flexibility, and emotion<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> and in regulating depressive-like behavior.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> It is also known as the “anti-reward center” of the brain. Increased activation of neurons projecting from the LHb to the ventral tegmental area (VTA) was observed in mice in LH and CSDS models.<a onclick="showRef(event, 'ref84 ref118'); return false;" href="javascript:void(0);" class="ref ref84 ref118">(84,118)</a> The VTA is a structure in the midbrain that plays an important role in the reward pathway. A recent study shows that ketamine’s inhibition of the NMDA receptor and subsequent block of the glutamatergic input to the LHb caused disinhibition of VTA dopamine neurons, resulting in increased dopamine neurotransmission.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">4.4.  Ketamine and Brain Neurocircuitries</h3><div class="NLM_p">Following a single administration, ketamine’s antidepressant activity lasts up to a week or longer in patients, even though its half-life is just 155 min in humans.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> This suggests that ketamine induces rapid changes in the synaptic structure and function that persist long after ketamine is eliminated from the body. This has been attributed to activity-dependent plasticity, such as long-term potentiation (LTP), that shows long-lasting changes in synaptic strength after a brief induction period of a high frequency stimulus. Ketamine is believed to interfere with endogenous processes that promote synaptic growth and strengthening.<a onclick="showRef(event, 'ref65 ref120'); return false;" href="javascript:void(0);" class="ref ref65 ref120">(65,120)</a> Ketamine is believed to exert its rapid antidepressant by affecting the corticomesolimbic structures that form the backbone of the brain’s reward and mood circuitry, specifically involving the NAc,<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> PFC,<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> and HPC<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Generally, the rewarding stimuli perceived in the HPC and PFC are relayed by excitatory glutamate projections to the NAc. The VTA sends dopaminergic projections to the NAc, HPC, and mPFC. GABAergic medium spiny neurons in the NAc synapse project onto GABAergic interneurons in the VTA. An aversive stimuli activates excitatory glutamate neurons projecting from the LHb to the VTA, which results in a decrease in dopamine output from the VTA and a decrease in reward. It has been shown that ketamine reduces depression-induced high-frequency burst firing of LHb neurons,<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> thus restoring VTA dopamine output and downstream reward and mood circuitry.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Neurocircuits implicated in the rapid antidepressant action of ketamine. Projections for glutamatergic neurons (blue), GABAergic neurons (green), and dopaminergic neurons (red) are shown. The reward pathway in the corticomesolimibic structure, consisting of the VTA, HPC, NAc, and mPFC, is primarily involved in ketamine’s antidepressant action by increasing dopamine output. An aversive stimuli decreases dopamine output as the result of glutamatergic projections from the LHb to the VTA. The figure is modeled after Gould et al. (ref <a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a>) and Kokane et al. (ref <a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a>). GABA, γ-aminobutyric acid; HPC, hippocampus; LHb, lateral habenula; mPFC, medial prefrontal cortex; NAc, nucleus accumbens; VTA, ventral tegmental area.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Ketamine affects the levels of several neurotransmitters, such as 5-HT, GABA, glutamate, and dopamine.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Particularly, it is important to know how ketamine maintains the balance between the excitatory and inhibitory neurotransmission in different brain regions during its antidepressant action.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">5.  Side Effects</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32224" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32224" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The major adverse effects of ketamine use are its abuse potential<a onclick="showRef(event, 'ref122 ref123 ref124'); return false;" href="javascript:void(0);" class="ref ref122 ref123 ref124">(122−124)</a> and toxicities.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Because of its psychotomimetic effects, ketamine is used as a recreational drug and is popular among party-goers, as it can produce a dream-like state at higher doses. The neurocircuits associated with ketamine’s antidepressant activity are overlapped with the reward pathways in the brain,<a onclick="showRef(event, 'ref126 ref127'); return false;" href="javascript:void(0);" class="ref ref126 ref127">(126,127)</a> suggesting a close association of ketamine’s antidepressant and addiction potential. Ketamine can cause neurotoxicity,<a onclick="showRef(event, 'ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref128 ref129">(128,129)</a> cognitive impairment<a onclick="showRef(event, 'ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref130 ref131">(130,131)</a> and urinary tract toxicity.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> These adverse effects have always limited the enthusiasm for ketamine use. A single subanesthetic dose of intravenous infusion of ketamine is reported to cause a strange, weird, or loopy feeling. Most side effects peaked within an hour of ketamine administration and resolved completely by 2 h postinfusion. There were no serious drug-related adverse events or increased ketamine cravings or abuse postadministration.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> For the ketamine nasal spray with an antidepressant, the common side effects observed were dissociation, nausea, vertigo, dysgeusia, and dizziness.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> For this reason, this formulation should be administered to adults in a certified doctor’s office or clinic.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">6.  Conclusions and Future Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The repurposing of ketamine for TRD is a fascinating story of how a drug that was once dubbed as a pharmacologist’s nightmare<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> (because of its action on numerous receptors, proteins, and enzymes) can turn into the most significant drug for treating an illness that affects more than 300 million people worldwide. This has brought ketamine back into spotlight again after 50 years. Is this the timeline typical for drug repurposing? Generally, drug repurposing is a strategy to shortcut some of the steps in drug discovery stages so that drugs can be brought to market in a relatively shorter time. If one looks at the repurposing history of aspirin and sildenafil, aspirin was marketed as an analgesic way back in 1899 and was first repurposed in the 1980s as an antiplatelet aggregation drug with a reduced dose.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> It was repurposed again in 2015 for colorectal cancer, based on its inhibition of COX-2, which shows antiapoptotic effects in malignant cells.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> In 1985, Pfizer initiated a project to develop sildenafil as a potential antianginal drug based on its vasodilation and antiplatelet activity by inhibiting PDE5. However, exploiting the unexpected side effect of penile erections, the drug was repurposed for treating erectile dysfunction and received FDA approval in 1998 under the brand name Viagra. Sildenafil was subsequently repurposed for a second time in 2005 at one-fifth of the dose used in erectile dysfunction to treat pulmonary arterial hypertension under the brand name Revatio.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> Therefore, the timeline of ketamine repurposing is more similar to that of aspirin than that of sildenafil. However, the mechanism of ketamine’s antidepressant activity is far more complex and intriguing at the same time: ketamine acts on multiple receptors and multiple neurocircuits in the brain to produce its unique rapid and long-lasting antidepressant activity, while aspirin targets primarily COX-1/2 and sildenafil targets only PDE5 for their new indications.</div><div class="NLM_p">From a medicinal chemist’s perspective, will it be possible to rationally design newer antidepressants based on ketamine’s mechanism of actions? Ketamine’s rapid (within 2 h) and sustained (∼7 days) antidepressant activity is believed to be the result of complex cross-talk among different neurotransmitters, receptors, and indirect and direct pathways, as well as the monosynaptic and disynaptic connections in different brain regions. Additionally, more studies on the neurocircuitry, isomer selectivity, NMDA receptor subunit selectivity, and its downstream signaling pathways are required to fully understand ketamine’s antidepressant mechanism of action. Moreover, designing molecules based only on NMDA receptor inhibition was not successful as pure NMDA receptor antagonists did not replicate the rapid, robust, and sustained antidepressant activity of ketamine. However, developing molecules around the ketamine scaffold and combining ketamine with drugs that target other glutamate receptors could be potential options for improving antidepressant activity, of course keeping in mind the addiction potential and toxicity issues associated with ketamine.<a onclick="showRef(event, 'ref125 ref126'); return false;" href="javascript:void(0);" class="ref ref125 ref126">(125,126)</a></div><div class="NLM_p last">In conclusion, repurposing ketamine for treating TRD provided us a new understanding of the pathophysiology of depression, a paradigm shift from monoamine to glutamatergic neurotransmission. This has made ketamine a unique tool to investigate the brain and its complex neurocircuitries. The article ends here, but the ketamine story is far from over.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01193" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joydip Das</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmacological
& Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, Texas 77204, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1540-5804" title="Orcid link">http://orcid.org/0000-0003-1540-5804</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bed4dadfcdfecbd690dbdacb"><span class="__cf_email__" data-cfemail="620806031122170a4c070617">[email protected]</span></a></span></div></li></ul></li><li><ul></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The author declares no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Biography</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31674" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31674" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Joydip Das</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=BIO-d7e1124-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Joydip Das</b> is currently a Professor of Medicinal Chemistry at the Department of Pharmacological and Pharmaceutical Sciences, University of Houston. He received his Ph.D. from the Indian Institute of Technology, Bombay, and postdoctoral training at the Medical University of South Carolina, Massachusetts Institute of Technology, and Massachusetts General Hospital. His current research goal is to understand the presynaptic mechanism of ethanol’s action in the brain with a long term goal of developing drugs for alcohol addiction, which is a major health problem worldwide. In another project, his laboratory is studying the structure and function of C1 domain-containing proteins with a goal of developing small molecules for selectively modulating C1 domain-containing proteins.</p></figure></div><div class="ack" id="ACK-d7e1129-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27626" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27626" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This research has been supported by funding from National Institutes of Health, Grant 1R01 AA022414 to J.D. J.D. thanks Youngki You for reproducing some of the graphics and Courtney Hunt for editing the manuscript.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ACC</td><td class="NLM_def"><p class="first last">anterior cingulate cortex</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and elimination</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">AMPA</td><td class="NLM_def"><p class="first last">α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">adrenergic receptor</p></td></tr><tr><td class="NLM_term">BDNF</td><td class="NLM_def"><p class="first last">brain-derived neurotrophic factor</p></td></tr><tr><td class="NLM_term">CHMP</td><td class="NLM_def"><p class="first last">Committee for Medicinal Products for Human Use</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">COX</td><td class="NLM_def"><p class="first last">cyclooxygenase</p></td></tr><tr><td class="NLM_term">CSDS</td><td class="NLM_def"><p class="first last">chronic social defeat stress</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DAT</td><td class="NLM_def"><p class="first last">dopamine reuptake transporter</p></td></tr><tr><td class="NLM_term">DG</td><td class="NLM_def"><p class="first last">dentate gyrus</p></td></tr><tr><td class="NLM_term">DLPFC</td><td class="NLM_def"><p class="first last">dorsolateral prefrontal cortex</p></td></tr><tr><td class="NLM_term">DMPFC</td><td class="NLM_def"><p class="first last">dorsomedial prefrontal cortex</p></td></tr><tr><td class="NLM_term">eEF2</td><td class="NLM_def"><p class="first last">eukaryotic elongation factor 2</p></td></tr><tr><td class="NLM_term">EMA</td><td class="NLM_def"><p class="first last">European Medicines Agency</p></td></tr><tr><td class="NLM_term">ERK/MAPK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase/mitogen-activated kinase</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and drug administration</p></td></tr><tr><td class="NLM_term">GABA</td><td class="NLM_def"><p class="first last">γ-aminobutyric acid</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein coupled receptor</p></td></tr><tr><td class="NLM_term">HCN</td><td class="NLM_def"><p class="first last">hyperpolarization-activated cyclic nucleotide-gated</p></td></tr><tr><td class="NLM_term">HT</td><td class="NLM_def"><p class="first last">hydroxytryptamine</p></td></tr><tr><td class="NLM_term">HPC</td><td class="NLM_def"><p class="first last">hippocampus</p></td></tr><tr><td class="NLM_term">LH</td><td class="NLM_def"><p class="first last">learned helplessness</p></td></tr><tr><td class="NLM_term">LHb</td><td class="NLM_def"><p class="first last">lateral habenula</p></td></tr><tr><td class="NLM_term">LTP</td><td class="NLM_def"><p class="first last">long-term potentiation</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">MAOI</td><td class="NLM_def"><p class="first last">monoamine oxidase inhibitor</p></td></tr><tr><td class="NLM_term">MEG</td><td class="NLM_def"><p class="first last">magnetoencephalographic</p></td></tr><tr><td class="NLM_term">MDD</td><td class="NLM_def"><p class="first last">major depressive disorder</p></td></tr><tr><td class="NLM_term">mPFC</td><td class="NLM_def"><p class="first last">medial prefrontal cortex</p></td></tr><tr><td class="NLM_term">mTORC1</td><td class="NLM_def"><p class="first last">molecular target of rapamycin complex 1</p></td></tr><tr><td class="NLM_term">NAc</td><td class="NLM_def"><p class="first last">nucleus accumbens</p></td></tr><tr><td class="NLM_term">NE</td><td class="NLM_def"><p class="first last">norepinephrine</p></td></tr><tr><td class="NLM_term">NET</td><td class="NLM_def"><p class="first last">norepinephrine reuptake transporter</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term">OFC</td><td class="NLM_def"><p class="first last">orbitofrontal cortex</p></td></tr><tr><td class="NLM_term">PCP</td><td class="NLM_def"><p class="first last">phencyclidine</p></td></tr><tr><td class="NLM_term">PDE5</td><td class="NLM_def"><p class="first last">phosphodiesterase type 5</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">prepulse inhibition</p></td></tr><tr><td class="NLM_term">PSD</td><td class="NLM_def"><p class="first last">postsynaptic density protein</p></td></tr><tr><td class="NLM_term">PV</td><td class="NLM_def"><p class="first last">parvalbumin</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin reuptake transporter</p></td></tr><tr><td class="NLM_term">SGACC</td><td class="NLM_def"><p class="first last">subgenual anterior cingulate cortex</p></td></tr><tr><td class="NLM_term">SNRI</td><td class="NLM_def"><p class="first last">serotonin–norepinephrine reuptake inhibitor</p></td></tr><tr><td class="NLM_term">SSRI</td><td class="NLM_def"><p class="first last">selective serotonin reuptake inhibitor</p></td></tr><tr><td class="NLM_term">TCA</td><td class="NLM_def"><p class="first last">tricyclic antidepressant</p></td></tr><tr><td class="NLM_term">TRD</td><td class="NLM_def"><p class="first last">treatment resistant depression</p></td></tr><tr><td class="NLM_term">TrkB</td><td class="NLM_def"><p class="first last">tropomyosin receptor kinase B</p></td></tr><tr><td class="NLM_term">VMPFC</td><td class="NLM_def"><p class="first last">ventromedial prefrontal cortex</p></td></tr><tr><td class="NLM_term">VTA</td><td class="NLM_def"><p class="first last">ventral tegmental area</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31255" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31255" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 137 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reardon, S.</span></span> <span> </span><span class="NLM_article-title">Antidepressant based on party drug gets backing from FDA advisory group</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">10</span>, <span class="refDoi"> DOI: 10.1038/d41586-019-00559-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fd41586-019-00559-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=10&author=S.+Reardon&title=Antidepressant+based+on+party+drug+gets+backing+from+FDA+advisory+group&doi=10.1038%2Fd41586-019-00559-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fd41586-019-00559-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41586-019-00559-2%26sid%3Dliteratum%253Aachs%26aulast%3DReardon%26aufirst%3DS.%26atitle%3DAntidepressant%2520based%2520on%2520party%2520drug%2520gets%2520backing%2520from%2520FDA%2520advisory%2520group%26jtitle%3DNature%26date%3D2019%26spage%3D10%26doi%3D10.1038%2Fd41586-019-00559-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span>US Food
and Drug Administration press release FDA Approves New Nasal Spray
Medication for Treatment-Resistant Depression; Available Only at a
Certified Doctor’s Office or Clinic, March 05, <span class="NLM_year">2019</span>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=US+Food%0Aand+Drug+Administration+press+release+FDA+Approves+New+Nasal+Spray%0AMedication+for+Treatment-Resistant+Depression%3B+Available+Only+at+a%0ACertified+Doctor%E2%80%99s+Office+or+Clinic%2C+March+05%2C+2019.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span>Depression
and Other Common Mental Disorders: Global Health Estimates; World
Health Organization, 2017. WHO reference number: WHO/MSD/MER/2017.2.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Depression%0Aand+Other+Common+Mental+Disorders%3A+Global+Health+Estimates%3B+World%0AHealth+Organization%2C+2017.+WHO+reference+number%3A+WHO%2FMSD%2FMER%2F2017.2."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rush, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nierenberg, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederehe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavori, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, B. D.</span></span> <span> </span><span class="NLM_article-title">Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">1905</span>– <span class="NLM_lpage">1917</span>, <span class="refDoi"> DOI: 10.1176/ajp.2006.163.11.1905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1176%2Fajp.2006.163.11.1905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=17074942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD28njslKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2006&pages=1905-1917&author=A.+J.+Rushauthor=M.+H.+Trivediauthor=S.+R.+Wisniewskiauthor=A.+A.+Nierenbergauthor=J.+W.+Stewartauthor=D.+Wardenauthor=G.+Niedereheauthor=M.+E.+Thaseauthor=P.+W.+Lavoriauthor=B.+D.+Lebowitz&title=Acute+and+longer-term+outcomes+in+depressed+outpatients+requiring+one+or+several+treatment+steps%3A+a+STAR*+D+report&doi=10.1176%2Fajp.2006.163.11.1905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report</span></div><div class="casAuthors">Rush A John; Trivedi Madhukar H; Wisniewski Stephen R; Nierenberg Andrew A; Stewart Jonathan W; Warden Diane; Niederehe George; Thase Michael E; Lavori Philip W; Lebowitz Barry D; McGrath Patrick J; Rosenbaum Jerrold F; Sackeim Harold A; Kupfer David J; Luther James; Fava Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1905-17</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.  METHOD:  A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N=3,671) to four (N=123) successive acute treatment steps.  Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step.  Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase.  A score of <or=5 on the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR(16)) (equivalent to <or=7 on the 17-item Hamilton Rating Scale for Depression [HRSD(17)]) defined remission; a QIDS-SR(16) total score of >or=11 (HRSD(17)>or=14) defined relapse.  RESULTS:  The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively.  The overall cumulative remission rate was 67%.  Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.  In addition, lower relapse rates were found among participants who were in remission at follow-up entry than for those who were not after the first three treatment steps.  CONCLUSIONS:  When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.  Studies to identify the best multistep treatment sequences for individual patients and the development of more broadly effective treatments are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4B4LcnXBaZ-2mnZh2OgS0fW6udTcc2eYeuWc3ud8d37ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28njslKgug%253D%253D&md5=56cee0c64d3d97549fe77b36aeab6ebd</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1176%2Fajp.2006.163.11.1905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fajp.2006.163.11.1905%26sid%3Dliteratum%253Aachs%26aulast%3DRush%26aufirst%3DA.%2BJ.%26aulast%3DTrivedi%26aufirst%3DM.%2BH.%26aulast%3DWisniewski%26aufirst%3DS.%2BR.%26aulast%3DNierenberg%26aufirst%3DA.%2BA.%26aulast%3DStewart%26aufirst%3DJ.%2BW.%26aulast%3DWarden%26aufirst%3DD.%26aulast%3DNiederehe%26aufirst%3DG.%26aulast%3DThase%26aufirst%3DM.%2BE.%26aulast%3DLavori%26aufirst%3DP.%2BW.%26aulast%3DLebowitz%26aufirst%3DB.%2BD.%26atitle%3DAcute%2520and%2520longer-term%2520outcomes%2520in%2520depressed%2520outpatients%2520requiring%2520one%2520or%2520several%2520treatment%2520steps%253A%2520a%2520STAR%252A%2520D%2520report%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2006%26volume%3D163%26spage%3D1905%26epage%3D1917%26doi%3D10.1176%2Fajp.2006.163.11.1905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nock, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S. J.</span></span> <span> </span><span class="NLM_article-title">Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">522</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2009.04.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2009.04.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=19545857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=522-526&author=R.+B.+Priceauthor=M.+K.+Nockauthor=D.+S.+Charneyauthor=S.+J.+Mathew&title=Effects+of+intravenous+ketamine+on+explicit+and+implicit+measures+of+suicidality+in+treatment-resistant+depression&doi=10.1016%2Fj.biopsych.2009.04.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression</span></div><div class="casAuthors">Price, Rebecca B.; Nock, Matthew K.; Charney, Dennis S.; Mathew, Sanjay J.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">522-526</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">I.v. ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide.  The Implicit Assocn. Test (IAT), a performance-based measure of assocn. between concepts, may have utility in suicide assessment.  Twenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 h before and 24 h following a single subanesthetic dose of i.v. ketamine.  Ten patients also completed IATs assessing implicit suicidal assocns. at comparable time points.  In a second study, nine patients received three times-weekly ketamine infusions over a 12-day period.  Twenty-four hours after a single infusion, MADRS-SI scores were reduced on av. by 2.08 points on a 0 to 6 scale (p < .001; d = 1.37), and 81% of patients received a rating of 0 or 1 postinfusion.  Implicit suicidal assocns. were also reduced following ketamine (p = .003; d = 1.36), with redns. correlated across implicit and explicit measures.  MADRS-SI redns. were sustained for 12 days by repeated-dose ketamine (p < .001; d = 2.42).  These preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Fx48ILoJsbVg90H21EOLACvtfcHk0lgFDywgB4EUQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFyhsLY%253D&md5=ebe4a33be519795ccbd0fb0c318c5d96</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2009.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2009.04.029%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DR.%2BB.%26aulast%3DNock%26aufirst%3DM.%2BK.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DMathew%26aufirst%3DS.%2BJ.%26atitle%3DEffects%2520of%2520intravenous%2520ketamine%2520on%2520explicit%2520and%2520implicit%2520measures%2520of%2520suicidality%2520in%2520treatment-resistant%2520depression%26jtitle%3DBiol.%2520Psychiatry%26date%3D2009%26volume%3D66%26spage%3D522%26epage%3D526%26doi%3D10.1016%2Fj.biopsych.2009.04.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iosifescu, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrough, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Jurdi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soleimani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foulkes, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S. J.</span></span> <span> </span><span class="NLM_article-title">Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression</span>. <i>Depression Anxiety</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1002/da.22253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1002%2Fda.22253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=24668760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Sgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=335-343&author=R.+B.+Priceauthor=D.+V.+Iosifescuauthor=J.+W.+Murroughauthor=L.+C.+Changauthor=R.+K.+Al+Jurdiauthor=S.+Z.+Iqbalauthor=L.+Soleimaniauthor=D.+S.+Charneyauthor=A.+L.+Foulkesauthor=S.+J.+Mathew&title=Effects+of+ketamine+on+explicit+and+implicit+suicidal+cognition%3A+A+randomized+controlled+trial+in+treatment-resistant+depression&doi=10.1002%2Fda.22253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION</span></div><div class="casAuthors">Price, Rebecca B.; Iosifescu, Dan V.; Murrough, James W.; Chang, Lee C.; Al Jurdi, Rayan K.; Iqbal, Syed Z.; Soleimani, Laili; Charney, Dennis S.; Foulkes, Alexandra L.; Mathew, Sanjay J.</div><div class="citationInfo"><span class="NLM_cas:title">Depression and Anxiety</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">335-343</span>CODEN:
                <span class="NLM_cas:coden">DEANF5</span>;
        ISSN:<span class="NLM_cas:issn">1091-4269</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Preliminary evidence suggests i.v. ketamine has rapid effects on suicidal cognition, making it an attractive candidate for depressed patients at imminent risk of suicide.  In the first randomized controlled trial of ketamine using an anesthetic control condition, we tested ketamine's acute effects on explicit suicidal cognition and a performance-based index of implicit suicidal cognition (Implicit Assocn. Test; IAT) previously linked to suicidal behavior.  Method : Symptomatic patients with treatment-resistant unipolar major depression (inadequate response to ≥3 antidepressants) were assessed using a composite index of explicit suicidal ideation (Beck Scale for Suicidal Ideation, Montgomery-Asberg Rating Scale suicide item, Quick Inventory of Depressive Symptoms suicide item) and the IAT to assess suicidality implicitly.  Measures were taken at baseline and 24 h following a single subanesthetic dose of ketamine (n = 36) or midazolam (n = 21), a psychoactive placebo agent selected for its similar, rapid anesthetic effects.  Twenty four hours postinfusion, explicit suicidal cognition was significantly reduced in the ketamine but not the midazolam group.  Results : Fifty three percent of ketamine-treated patients scored zero on all three explicit suicide measures at 24 h, compared with 24% of the midazolam group (χ2 = 4.6; P = .03).  Implicit assocns. between self- and escape-related words were reduced following ketamine (P = .01; d = .58) but not midazolam (P = .68; d = .09).  Ketamine-specific decreases in explicit suicidal cognition were largest in patients with elevated suicidal cognition at baseline, and were mediated by decreases in nonsuicide-related depressive symptoms.  Conclusions : I.v. ketamine produces rapid redns. in suicidal cognition over and above active placebo.  Further study is warranted to test ketamine's antisuicidal effects in higher-risk samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNV--LTDcJXrVg90H21EOLACvtfcHk0lgFDywgB4EUQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Sgtrc%253D&md5=11433330ff6633720429f72d33bbf817</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fda.22253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fda.22253%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DR.%2BB.%26aulast%3DIosifescu%26aufirst%3DD.%2BV.%26aulast%3DMurrough%26aufirst%3DJ.%2BW.%26aulast%3DChang%26aufirst%3DL.%2BC.%26aulast%3DAl%2BJurdi%26aufirst%3DR.%2BK.%26aulast%3DIqbal%26aufirst%3DS.%2BZ.%26aulast%3DSoleimani%26aufirst%3DL.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DFoulkes%26aufirst%3DA.%2BL.%26aulast%3DMathew%26aufirst%3DS.%2BJ.%26atitle%3DEffects%2520of%2520ketamine%2520on%2520explicit%2520and%2520implicit%2520suicidal%2520cognition%253A%2520A%2520randomized%2520controlled%2520trial%2520in%2520treatment-resistant%2520depression%26jtitle%3DDepression%2520Anxiety%26date%3D2014%26volume%3D31%26spage%3D335%26epage%3D343%26doi%3D10.1002%2Fda.22253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murrough, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soleimani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWilde, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacoviello, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lener, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kautz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial</span>. <i>Psychol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3571</span>– <span class="NLM_lpage">3580</span>, <span class="refDoi"> DOI: 10.1017/S0033291715001506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1017%2FS0033291715001506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26266877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC287itVaqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=3571-3580&author=J.+W.+Murroughauthor=L.+Soleimaniauthor=K.+DeWildeauthor=K.+Collinsauthor=K.+Lapidusauthor=B.+Iacovielloauthor=M.+Lenerauthor=M.+Kautzauthor=J.+Kimauthor=J.+Stern&title=Ketamine+for+rapid+reduction+of+suicidal+ideation%3A+a+randomized+controlled+trial&doi=10.1017%2FS0033291715001506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial</span></div><div class="casAuthors">Murrough J W; Soleimani L; DeWilde K E; Collins K A; Iacoviello B M; Lener M; Kautz M; Iosifescu D V; Charney D S; Lapidus K A; Kim J; Stern J B; Price R B; Perez A M; Brallier J W; Rodriguez G J; Goodman W K</div><div class="citationInfo"><span class="NLM_cas:title">Psychological medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3571-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Suicide is a devastating public health problem and very few biological treatments have been found to be effective for quickly reducing the intensity of suicidal ideation (SI).  We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression.  METHOD:  We conducted a randomized, controlled trial of ketamine in patients with mood and anxiety spectrum disorders who presented with clinically significant SI (n = 24).  Patients received a single infusion of ketamine or midazolam (as an active placebo) in addition to standard of care.  SI measured using the Beck Scale for Suicidal Ideation (BSI) 24 h post-treatment represented the primary outcome.  Secondary outcomes included the Montgomery-Asberg Depression Rating Scale--Suicidal Ideation (MADRS-SI) score at 24 h and additional measures beyond the 24-h time-point.  RESULTS:  The intervention was well tolerated and no dropouts occurred during the primary 7-day assessment period.  BSI score was not different between the treatment groups at 24 h (p = 0.32); however, a significant difference emerged at 48 h (p = 0.047).  MADRS-SI score was lower in the ketamine group compared to midazolam group at 24 h (p = 0.05).  The treatment effect was no longer significant at the end of the 7-day assessment period.  CONCLUSIONS:  The current findings provide initial support for the safety and tolerability of ketamine as an intervention for SI in patients who are at elevated risk for suicidal behavior.  Larger, well-powered studies are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyrVioJTA195Pq5LRczm8ffW6udTcc2eYfosJlEbfNgrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287itVaqsw%253D%253D&md5=c9eb9a5c60ebce2066430b1229d24609</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1017%2FS0033291715001506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0033291715001506%26sid%3Dliteratum%253Aachs%26aulast%3DMurrough%26aufirst%3DJ.%2BW.%26aulast%3DSoleimani%26aufirst%3DL.%26aulast%3DDeWilde%26aufirst%3DK.%26aulast%3DCollins%26aufirst%3DK.%26aulast%3DLapidus%26aufirst%3DK.%26aulast%3DIacoviello%26aufirst%3DB.%26aulast%3DLener%26aufirst%3DM.%26aulast%3DKautz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DStern%26aufirst%3DJ.%26atitle%3DKetamine%2520for%2520rapid%2520reduction%2520of%2520suicidal%2520ideation%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DPsychol.%2520Med.%26date%3D2015%26volume%3D45%26spage%3D3571%26epage%3D3580%26doi%3D10.1017%2FS0033291715001506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pushpakom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iorio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escott, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilliams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamee, C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Drug repurposing: progress, challenges and recommendations</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnrd.2018.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30310233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvV2gtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=41-58&author=S.+Pushpakomauthor=F.+Iorioauthor=P.+A.+Eyersauthor=K.+J.+Escottauthor=S.+Hopperauthor=A.+Wellsauthor=A.+Doigauthor=T.+Guilliamsauthor=J.+Latimerauthor=C.+McNamee&title=Drug+repurposing%3A+progress%2C+challenges+and+recommendations&doi=10.1038%2Fnrd.2018.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repurposing: progress, challenges and recommendations</span></div><div class="casAuthors">Pushpakom, Sudeep; Iorio, Francesco; Eyers, Patrick A.; Escott, K. Jane; Hopper, Shirley; Wells, Andrew; Doig, Andrew; Guilliams, Tim; Latimer, Joanna; McNamee, Christine; Norris, Alan; Sanseau, Philippe; Cavalla, David; Pirmohamed, Munir</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-58</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old' drugs to treat both common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked compds., with potentially lower overall development costs and shorter development timelines.  Various data-driven and exptl. approaches have been suggested for the identification of repurposable drug candidates; however, there are also major technol. and regulatory challenges that need to be addressed.  In this Review, we present approaches used for drug repurposing (also known as drug repositioning), discuss the challenges faced by the repurposing community and recommend innovative ways by which these challenges could be addressed to help realize the full potential of drug repurposing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUl_N5c2iDerVg90H21EOLACvtfcHk0lgPPlzMzh9ntg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvV2gtr7I&md5=6bcc8f26828414de02564494fb4d3296</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.168%26sid%3Dliteratum%253Aachs%26aulast%3DPushpakom%26aufirst%3DS.%26aulast%3DIorio%26aufirst%3DF.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26aulast%3DEscott%26aufirst%3DK.%2BJ.%26aulast%3DHopper%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DA.%26aulast%3DDoig%26aufirst%3DA.%26aulast%3DGuilliams%26aufirst%3DT.%26aulast%3DLatimer%26aufirst%3DJ.%26aulast%3DMcNamee%26aufirst%3DC.%26atitle%3DDrug%2520repurposing%253A%2520progress%252C%2520challenges%2520and%2520recommendations%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D41%26epage%3D58%26doi%3D10.1038%2Fnrd.2018.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nowak-Sliwinska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scapozza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz i Altaba, A.</span></span> <span> </span><span class="NLM_article-title">Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer</span>. <i>Biochim. Biophys. Acta, Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1871</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1016/j.bbcan.2019.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.bbcan.2019.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=31034926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFent7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1871&publication_year=2019&pages=434-454&author=P.+Nowak-Sliwinskaauthor=L.+Scapozzaauthor=A.+Ruiz+i+Altaba&title=Drug+repurposing+in+oncology%3A+Compounds%2C+pathways%2C+phenotypes+and+computational+approaches+for+colorectal+cancer&doi=10.1016%2Fj.bbcan.2019.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer</span></div><div class="casAuthors">Nowak-Sliwinska, Patrycja; Scapozza, Leonardo; Altaba, Ariel Ruiz i</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1871</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">434-454</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields.  Such drug repurposing promises faster access of drugs to patients while reducing costs in the long and difficult process of drug development.  However, the no. of existing drugs and diseases, together with the heterogeneity of patients and diseases, notably including cancers, can make repurposing time consuming and inefficient.  The key question we address is how to efficiently repurpose an existing drug to treat a given indication.  As drug efficacy remains the main bottleneck for overall success, we discuss the need for machine-learning computational methods in combination with specific phenotypic studies along with mechanistic studies, chem. genetics and omics assays to successfully predict disease-drug pairs.  Such a pipeline could be particularly important to cancer patients who face heterogeneous, recurrent and metastatic disease and need fast and personalized treatments.  Here we focus on drug repurposing for colorectal cancer and describe selected therapeutics already repositioned for its prevention and/or treatment as well as potential candidates.  We consider this review as a selective compilation of approaches and methodologies, and argue how, taken together, they could bring drug repurposing to the next level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDgG6Bc5SoMLVg90H21EOLACvtfcHk0lgPPlzMzh9ntg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFent7o%253D&md5=70957ccf92ba748d6cb564fd1f3de533</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2019.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2019.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DNowak-Sliwinska%26aufirst%3DP.%26aulast%3DScapozza%26aufirst%3DL.%26aulast%3DRuiz%2Bi%2BAltaba%26aufirst%3DA.%26atitle%3DDrug%2520repurposing%2520in%2520oncology%253A%2520Compounds%252C%2520pathways%252C%2520phenotypes%2520and%2520computational%2520approaches%2520for%2520colorectal%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2019%26volume%3D1871%26spage%3D434%26epage%3D454%26doi%3D10.1016%2Fj.bbcan.2019.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bureau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallemagne, P.</span></span> <span> </span><span class="NLM_article-title">Drug repositioning: a brief overview</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1145</span>– <span class="NLM_lpage">1151</span>, <span class="refDoi"> DOI: 10.1111/jphp.13273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1111%2Fjphp.13273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32301512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFynsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=1145-1151&author=J.+P.+Jourdanauthor=R.+Bureauauthor=C.+Rochaisauthor=P.+Dallemagne&title=Drug+repositioning%3A+a+brief+overview&doi=10.1111%2Fjphp.13273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning: a brief overview</span></div><div class="casAuthors">Jourdan, Jean-Pierre; Bureau, Ronan; Rochais, Christophe; Dallemagne, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1145-1151</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Objectives : Drug repositioning, i.e., the use of a drug in an indication other than the one for which it was initially marketed, is a growing trend.  Its origins lie mainly in the attrition experienced in recent years in the field of new drug discovery.  Key findings : Despite some regulatory and economic challenges, drug repositioning offers many advantages, and a no. of recent successes have confirmed both its public health benefits and its com. value.  The first examples of successful drug repositioning mainly came about through serendipity like acetylsalicylic acid, thalidomide, sildenafil or dimethylfumarate.  Conclusion : The history of great-repositioned drugs has given some solns. to various pathologies.  Serendipity is not yet useful to find repositioning drugs.  Drug repositioning is of growing interest.  Nowadays, a more rational approach to the identification of drug candidates for repositioning is possible, esp. using data mining.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKhYOs_wF60LVg90H21EOLACvtfcHk0lgPPlzMzh9ntg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFynsb4%253D&md5=d524624854fda65d7b411afb37638c76</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fjphp.13273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjphp.13273%26sid%3Dliteratum%253Aachs%26aulast%3DJourdan%26aufirst%3DJ.%2BP.%26aulast%3DBureau%26aufirst%3DR.%26aulast%3DRochais%26aufirst%3DC.%26aulast%3DDallemagne%26aufirst%3DP.%26atitle%3DDrug%2520repositioning%253A%2520a%2520brief%2520overview%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2020%26volume%3D72%26spage%3D1145%26epage%3D1151%26doi%3D10.1111%2Fjphp.13273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desborough, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, D. M.</span></span> <span> </span><span class="NLM_article-title">The aspirin story–from willow to wonder drug</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.1111/bjh.14520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1111%2Fbjh.14520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=28106908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ns1yruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2017&pages=674-683&author=M.+J.+Desboroughauthor=D.+M.+Keeling&title=The+aspirin+story%E2%80%93from+willow+to+wonder+drug&doi=10.1111%2Fbjh.14520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The aspirin story - from willow to wonder drug</span></div><div class="casAuthors">Desborough Michael J R; Desborough Michael J R; Keeling David M</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">674-683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The story of the discovery of aspirin stretches back more than 3500 years to when bark from the willow tree was used as a pain reliever and antipyretic.  It involves an Oxfordshire clergyman, scientists at a German dye manufacturer, a Nobel Prize-winning discovery and a series of pivotal clinical trials.  Aspirin is now the most commonly used drug in the world.  Its role in preventing cardiovascular and cerebrovascular disease has been revolutionary and one of the biggest pharmaceutical success stories of the last century.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTb-EOs4b09frJzI8owOhpDfW6udTcc2ebljAARUfPOKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ns1yruw%253D%253D&md5=1fa9f7b773a87120df07e4c7de7ff5cb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fbjh.14520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.14520%26sid%3Dliteratum%253Aachs%26aulast%3DDesborough%26aufirst%3DM.%2BJ.%26aulast%3DKeeling%26aufirst%3DD.%2BM.%26atitle%3DThe%2520aspirin%2520story%25E2%2580%2593from%2520willow%2520to%2520wonder%2520drug%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2017%26volume%3D177%26spage%3D674%26epage%3D683%26doi%3D10.1111%2Fbjh.14520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montinari, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Caterina, R.</span></span> <span> </span><span class="NLM_article-title">The first 3500 years of aspirin history from its roots–A concise summary</span>. <i>Vasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.vph.2018.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.vph.2018.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30391545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ymsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2019&pages=1-8&author=M.+R.+Montinariauthor=S.+Minelliauthor=R.+De+Caterina&title=The+first+3500+years+of+aspirin+history+from+its+roots%E2%80%93A+concise+summary&doi=10.1016%2Fj.vph.2018.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The first 3500 years of aspirin history from its roots - A concise summary</span></div><div class="casAuthors">Montinari, Maria Rosa; Minelli, Sergio; De Caterina, Raffaele</div><div class="citationInfo"><span class="NLM_cas:title">Vascular Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">VPAHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1537-1891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Aspirin is currently the most widely used drug worldwide, and has been clearly one of the most important pharmacol. achievements of the twentieth century.  Historians of medicine have traced its birth in 1897, but the fascinating history of aspirin actually dates back >3500 years, when willow bark was used as a painkiller and antipyretic by Sumerians and Egyptians, and then by great physicians from ancient Greece and Rome.  The modern history of aspirin precursors, salicylates, began in 1763 with Reverend Stone - who first described their antipyretic effects - and continued in the 19th century with many researchers involved in their extn. and chem. synthesis.  Bayer chemist Felix Hoffmann synthesized aspirin in 1897, and 70 years later the pharmacologist John Vane elucidated its mechanism of action in inhibiting prostaglandin prodn.  Originally used as an antipyretic and anti-inflammatory drug, aspirin then became, for its antiplatelet properties, a milestone in preventing cardiovascular and cerebrovascular diseases.  The aspirin story continues today with the growing evidence of its chemopreventive effect against colorectal and other types of cancer, now awaiting the results of ongoing primary prevention trials in this setting.  This concise review revisits the history of aspirin with a focus on its most remote origins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Kfy_hlJnD7Vg90H21EOLACvtfcHk0lhjcL1H8m-HKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ymsL%252FE&md5=e4f1102998af42a5c6851495e9359979</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.vph.2018.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vph.2018.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DMontinari%26aufirst%3DM.%2BR.%26aulast%3DMinelli%26aufirst%3DS.%26aulast%3DDe%2BCaterina%26aufirst%3DR.%26atitle%3DThe%2520first%25203500%2520years%2520of%2520aspirin%2520history%2520from%2520its%2520roots%25E2%2580%2593A%2520concise%2520summary%26jtitle%3DVasc.%2520Pharmacol.%26date%3D2019%26volume%3D113%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.vph.2018.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterloh, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span> <span> </span><span class="NLM_article-title">Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.1038/nrd2030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnrd2030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=16883306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFCkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=689-702&author=H.+A.+Ghofraniauthor=I.+H.+Osterlohauthor=F.+Grimminger&title=Sildenafil%3A+from+angina+to+erectile+dysfunction+to+pulmonary+hypertension+and+beyond&doi=10.1038%2Fnrd2030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond</span></div><div class="casAuthors">Ghofrani, Hossein A.; Osterloh, Ian H.; Grimminger, Friedrich</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">689-702</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In less than 20 years, the first selective type 5 phosphodiesterase inhibitor, sildenafil, has evolved from a potential anti-angina drug to an on-demand oral treatment for erectile dysfunction (Viagra), and more recently to a new orally active treatment for pulmonary hypertension (Revatio).  Here we describe the key milestones in the development of sildenafil for these diverse medical conditions, discuss the advances in science and clin. medicine that have accompanied this journey and consider possible future indications for this versatile drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0RYuF_xCiO7Vg90H21EOLACvtfcHk0lhjcL1H8m-HKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFCkuro%253D&md5=efe63ba98a0914f1a9e4a0b9257cfeba</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd2030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2030%26sid%3Dliteratum%253Aachs%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DOsterloh%26aufirst%3DI.%2BH.%26aulast%3DGrimminger%26aufirst%3DF.%26atitle%3DSildenafil%253A%2520from%2520angina%2520to%2520erectile%2520dysfunction%2520to%2520pulmonary%2520hypertension%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D689%26epage%3D702%26doi%3D10.1038%2Fnrd2030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">World Health Organization</span>. World
Health Organization Model List of Essential Medicines: 21st list 2019. <span class="NLM_publisher-name">World Health Organization</span>. <a href="https://apps.who.int/iris/handle/10665/325771" class="extLink">https://apps.who.int/iris/handle/10665/325771</a>. License: CC BY-NC-SA 3.0 IGO, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization.+World%0AHealth+Organization+Model+List+of+Essential+Medicines%3A+21st+list+2019.+World+Health+Organization.+https%3A%2F%2Fapps.who.int%2Firis%2Fhandle%2F10665%2F325771.+License%3A+CC+BY-NC-SA+3.0+IGO%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26pub%3DWorld%2520Health%2520Organization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domino, E. F.</span></span> <span> </span><span class="NLM_article-title">Taming the ketamine tiger</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">678</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1097/ALN.0b013e3181ed09a2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2FALN.0b013e3181ed09a2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=20693870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC3cjnslSjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2010&pages=678-684&author=E.+F.+Domino&title=Taming+the+ketamine+tiger&doi=10.1097%2FALN.0b013e3181ed09a2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Taming the ketamine tiger. 1965</span></div><div class="casAuthors">Domino Edward F</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">678-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pharmacologic actions of CI-581, a chemical derivative of phencyclidine, were determined in 20 volunteers from a prison population.  The results indicate that this drug is an effective analgesic and anesthetic agent in doses of 1.0 to 2.0 mg per kilogram.  With intravenous administration the onset of action is within 1 min and the effects last for about 5 to 10 min, depending on dosage level and individual variation.  No tachyphylaxis was evident on repeat doses.  Respiratory depression was slight and transient.  Hypertension, tachycardia, and psychic changes are undesirable characteristics of the drug.  Whether these can be modified by preanesthetic medication was not determined in this study.  Recovery from analgesia and coma usually took place within 10 min, although from electroencephalographic evidence it may be assumed that subjects were not completely normal until after 1 to 2 h.  No evidence of liver or kidney toxicity was obtained.  CI-581 produces pharmacologic effects similar to those reported for phencyclidine, but of shorter duration.  The drug deserves further pharmacologic and clinical trials.  It is proposed that the words "dissociative anesthetic" be used to describe the mental state produced by this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrRg8-SzzmV0PI-fCgwosgfW6udTcc2ebQZt1C3bC1Tbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjnslSjtQ%253D%253D&md5=e037b14d9d90569965b2ff687f13dc47</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1097%2FALN.0b013e3181ed09a2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FALN.0b013e3181ed09a2%26sid%3Dliteratum%253Aachs%26aulast%3DDomino%26aufirst%3DE.%2BF.%26atitle%3DTaming%2520the%2520ketamine%2520tiger%26jtitle%3DAnesthesiology%26date%3D2010%26volume%3D113%26spage%3D678%26epage%3D684%26doi%3D10.1097%2FALN.0b013e3181ed09a2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domino, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodoff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corssen, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic effects of CI-581, a new dissociative anesthetic, in man</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1002/cpt196563279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1002%2Fcpt196563279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=14296024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADyaF2M7gtVKgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1965&pages=279-291&author=E.+F.+Dominoauthor=P.+Chodoffauthor=G.+Corssen&title=Pharmacologic+effects+of+CI-581%2C+a+new+dissociative+anesthetic%2C+in+man&doi=10.1002%2Fcpt196563279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">PHARMACOLOGIC EFFECTS OF CI-581, A NEW DISSOCIATIVE ANESTHETIC, IN MAN</span></div><div class="casAuthors">DOMINO E F; CHODOFF P; CORSSEN G</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">279-91</span>
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuQWQYmYA2eX6HPRus0rAafW6udTcc2ebQZt1C3bC1Tbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF2M7gtVKgsw%253D%253D&md5=664315adbde3f2f7c64edcc5388ac28e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcpt196563279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt196563279%26sid%3Dliteratum%253Aachs%26aulast%3DDomino%26aufirst%3DE.%2BF.%26aulast%3DChodoff%26aufirst%3DP.%26aulast%3DCorssen%26aufirst%3DG.%26atitle%3DPharmacologic%2520effects%2520of%2520CI-581%252C%2520a%2520new%2520dissociative%2520anesthetic%252C%2520in%2520man%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1965%26volume%3D6%26spage%3D279%26epage%3D291%26doi%3D10.1002%2Fcpt196563279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corssen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domino, E. F.</span></span> <span> </span><span class="NLM_article-title">Dissociative anesthesia: Further pharmacologic studies and first clinical experience with the phencyclidine derivative Cl-581</span>. <i>Anesth. Analg.</i> <span class="NLM_year" style="font-weight: bold;">1966</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1213/00000539-196601000-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1213%2F00000539-196601000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=5325977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaF28XhtVyntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1966&pages=29-40&author=G.+Corssenauthor=E.+F.+Domino&title=Dissociative+anesthesia%3A+Further+pharmacologic+studies+and+first+clinical+experience+with+the+phencyclidine+derivative+Cl-581&doi=10.1213%2F00000539-196601000-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative, CI-581</span></div><div class="casAuthors">Corssen, Guenter; Domino, Edward F.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia & Analgesia (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">1966</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-40</span>CODEN:
                <span class="NLM_cas:coden">AACRAT</span>;
        ISSN:<span class="NLM_cas:issn">0003-2999</span>.
    </div><div class="casAbstract">I.v. 2-(O-chlorophenyl)-2-methylaminocyclohexanone-HCl (CI-581) produced profound analgesia assocd. with a peculiar state of altered consciousness.  Respiratory function was transiently reduced at the onset of anesthesia and returned to normal within 1-3 min.  In adults, i.v. administration sometime elevated both systolic and diastolic blood pressures to undesirable levels.  CI-581 had no discernible toxic effects on humans.  CI-581 is a potent anesthetic agent with a fast onset of action and limited duration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9J6zoN-HzwLVg90H21EOLACvtfcHk0lha9Iy7n05aaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF28XhtVyntr8%253D&md5=a6db146429a940227efb723faff63af4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1213%2F00000539-196601000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1213%252F00000539-196601000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DCorssen%26aufirst%3DG.%26aulast%3DDomino%26aufirst%3DE.%2BF.%26atitle%3DDissociative%2520anesthesia%253A%2520Further%2520pharmacologic%2520studies%2520and%2520first%2520clinical%2520experience%2520with%2520the%2520phencyclidine%2520derivative%2520Cl-581%26jtitle%3DAnesth.%2520Analg.%26date%3D1966%26volume%3D45%26spage%3D29%26epage%3D40%26doi%3D10.1213%2F00000539-196601000-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. R.</span>; <span class="NLM_string-name">Hedges, J. R.</span></span> <i>Roberts and Hedges’ Clinical Procedures in Emergency Medicine E-Book</i>; <span class="NLM_publisher-name">Elsevier Health Sciences</span>: <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+R.+Roberts&author=J.+R.+Hedges&title=Roberts+and+Hedges%E2%80%99+Clinical+Procedures+in+Emergency+Medicine+E-Book"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DJ.%2BR.%26btitle%3DRoberts%2520and%2520Hedges%25E2%2580%2599%2520Clinical%2520Procedures%2520in%2520Emergency%2520Medicine%2520E-Book%26pub%3DElsevier%2520Health%2520Sciences%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Way, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevor, a. J.</span></span> <span> </span><span class="NLM_article-title">Ketamine—its pharmacology and therapeutic uses</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1097/00000542-198202000-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2F00000542-198202000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=6892475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaL38XhsleltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1982&pages=119-136&author=P.+F.+Whiteauthor=W.+L.+Wayauthor=a.+J.+Trevor&title=Ketamine%E2%80%94its+pharmacology+and+therapeutic+uses&doi=10.1097%2F00000542-198202000-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine - its pharmacology and therapeutic uses</span></div><div class="casAuthors">White, Paul F.; Way, Walter L.; Trevor, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-36</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    </div><div class="casAbstract">A review with 255 refs. of the pharmacol. of ketamine (I)  [6740-88-1].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr53dU39Epv97Vg90H21EOLACvtfcHk0lj5R8zybPVBcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XhsleltL4%253D&md5=969f9a0021526ce2975b06549d899a86</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1097%2F00000542-198202000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-198202000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DP.%2BF.%26aulast%3DWay%26aufirst%3DW.%2BL.%26aulast%3DTrevor%26aufirst%3Da.%2BJ.%26atitle%3DKetamine%25E2%2580%2594its%2520pharmacology%2520and%2520therapeutic%2520uses%26jtitle%3DAnesthesiology%26date%3D1982%26volume%3D56%26spage%3D119%26epage%3D136%26doi%3D10.1097%2F00000542-198202000-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">A historical review of antidepressant effects of ketamine and its enantiomers</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">172870</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2020.172870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.pbb.2020.172870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32035078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsVOlt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=172870&author=Y.+Weiauthor=L.+Changauthor=K.+Hashimoto&title=A+historical+review+of+antidepressant+effects+of+ketamine+and+its+enantiomers&doi=10.1016%2Fj.pbb.2020.172870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A historical review of antidepressant effects of ketamine and its enantiomers</span></div><div class="casAuthors">Wei, Yan; Chang, Lijia; Hashimoto, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172870</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The robust antidepressant effects of (R,S)-ketamine are among the most important discoveries in mood research over the last half century.  Off-label use of (R,S)-ketamine, which is an equal mixt. of (R)-ketamine and (S)-ketamine, has become esp. popular in the United States (US) for treatment-resistant depression.  On March 5, 2019, the US Food and Drug Administration approved an (S)-ketamine nasal spray for use in treatment-resistant depression, though its use has been limited to certified medical offices or clinics.  On Dec. 19, 2019, (S)-ketamine nasal spray was approved for the same indication in Europe.  However, despite its potential for benefit, there are several concerns about the efficacy of (S)-ketamine nasal spray.  Accumulating evidence from preclin. studies show that (R)-ketamine has greater potency and longer lasting antidepressant effects than (S)-ketamine in animal models of depression, and that (R)-ketamine has fewer detrimental side effects than either (R,S)-ketamine or (S)-ketamine.  As such, clin. studies of (R)-ketamine in humans are now underway by Perception Neuroscience Ltd.  In this article, we review the brief history of (R,S)-ketamine and its two enantiomers as novel antidepressants.  We also discuss the mechanisms of ketamine's antidepressant actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKVy8HLcOtC7Vg90H21EOLACvtfcHk0lj5R8zybPVBcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsVOlt74%253D&md5=d9988745234ff150632b74708e6cdb79</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2020.172870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2020.172870%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DA%2520historical%2520review%2520of%2520antidepressant%2520effects%2520of%2520ketamine%2520and%2520its%2520enantiomers%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2020%26volume%3D190%26spage%3D172870%26doi%3D10.1016%2Fj.pbb.2020.172870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmotsu, O.</span></span> <span> </span><span class="NLM_article-title">Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor?</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">704</span>– <span class="NLM_lpage">710</span>, <span class="refDoi"> DOI: 10.1097/00000542-199004000-00021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2F00000542-199004000-00021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1969718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK3cXitFSru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1990&pages=704-710&author=T.+Yamamuraauthor=K.+Haradaauthor=A.+Okamuraauthor=O.+Kemmotsu&title=Is+the+site+of+action+of+ketamine+anesthesia+the+N-methyl-D-aspartate+receptor%3F&doi=10.1097%2F00000542-199004000-00021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor?</span></div><div class="casAuthors">Yamamura, Takeyasu; Harada, Kohji; Okamura, Atsushi; Kemmotsu, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">704-10</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    </div><div class="casAbstract">Synaptic mechanisms underlying ketamine anesthesia were studied using in vitro prepns. of the lamprey CNS.  Axonal conduction, transmitter release from the presynaptic terminal, postsynaptic response to the putative neurotransmitters, and resting and activated membrane properties were studied in the absence and the presence of various concns. of ketamine.  Ketamine markedly reduced N-methyl-D-aspartate (NMDA)-activated responses, such as depolarizations to bath-applied NMDA and bursting rhythm during "fictive locomotion.".  The 50% block of the responses took place in the presence of 10-20 μM ketamine, whereas those induced by kainate and quisqualate (the other two subclasses of L-glutamate/L-aspartate agonists) were spared at concns. > 600-800 μM.  None of the other neuronal events tested were suppressed in the presence of still higher concns. of ketamine.  The results support the hypothesis that ketamine might exert its anesthetic effect by a pharmacol. specific interaction with the NMDA receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgbDmPsofTYbVg90H21EOLACvtfcHk0linlThV0SQB3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXitFSru7Y%253D&md5=97405a4571126a128e31f76c2e4ea8fa</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1097%2F00000542-199004000-00021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-199004000-00021%26sid%3Dliteratum%253Aachs%26aulast%3DYamamura%26aufirst%3DT.%26aulast%3DHarada%26aufirst%3DK.%26aulast%3DOkamura%26aufirst%3DA.%26aulast%3DKemmotsu%26aufirst%3DO.%26atitle%3DIs%2520the%2520site%2520of%2520action%2520of%2520ketamine%2520anesthesia%2520the%2520N-methyl-D-aspartate%2520receptor%253F%26jtitle%3DAnesthesiology%26date%3D1990%26volume%3D72%26spage%3D704%26epage%3D710%26doi%3D10.1097%2F00000542-199004000-00021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, D.</span></span> <span> </span><span class="NLM_article-title">The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1983.tb11031.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1111%2Fj.1476-5381.1983.tb11031.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=6317114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaL3sXkvF2itbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1983&pages=565-575&author=N.+Anisauthor=S.+Berryauthor=N.+Burtonauthor=D.+Lodge&title=The+dissociative+anaesthetics%2C+ketamine+and+phencyclidine%2C+selectively+reduce+excitation+of+central+mammalian+neurones+by+N-methyl-aspartate&doi=10.1111%2Fj.1476-5381.1983.tb11031.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The dissociative anesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate</span></div><div class="casAuthors">Anis, N. A.; Berry, S. C.; Burton, N. R.; Lodge, D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">565-75</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">The interaction of 2 dissociative anesthetics, ketamine (I)  [6740-88-1] and phencyclidine (II)  [77-10-1], with the responses of spinal neurons to the electrophoretic administration of amino acids and acetylcholine  [51-84-3] was studied in decerebrate or pentobarbitone-anesthetized cats and rats.  Both ketamine and phencyclidine selectively blocked excitation by N-methyl-D-aspartate (NMA)  [6384-92-5], with little effect on excitation by quisqualate  [52809-07-1] or kainate  [487-79-6].  Ketamine reduced responses to L-aspartate  [56-84-8] somewhat more than those to L-glutamate  [56-86-0]; the sensitivity of responses to these 2 putative transmitters was between that to NMA on one hand and that to quisqualate or kainate on the other.  In Renshaw cells, ketamine and phencyclidine reduced responses to acetylcholine less than those to NMA, but more than those to quisqualate or kainate.  Dorsal root-evoked synaptic excitation of Renshaw cells was reduced to a greater extent than that following ventral root excitation.  I.v. ketamine, 2.5-20 mg/kg, and phencyclidine, 0.2-0.5 mg/kg, also selectively blocked excitation of neurons by NMA.  Ketamine showed no consistent or selective effect on inhibition of spinal neurons by electrophoretically administered glycine  [56-40-6] or γ-aminobutyric acid (GABA)  [56-12-2].  The results suggest that redn. of synaptic excitation mediated via NMA receptors contributes to the anesthetic analgesic properties of these 2 dissociative anesthetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp29LbcqvL2YLVg90H21EOLACvtfcHk0linlThV0SQB3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXkvF2itbw%253D&md5=6465c36de28c2096ef223618ef09fe8c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1983.tb11031.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1983.tb11031.x%26sid%3Dliteratum%253Aachs%26aulast%3DAnis%26aufirst%3DN.%26aulast%3DBerry%26aufirst%3DS.%26aulast%3DBurton%26aufirst%3DN.%26aulast%3DLodge%26aufirst%3DD.%26atitle%3DThe%2520dissociative%2520anaesthetics%252C%2520ketamine%2520and%2520phencyclidine%252C%2520selectively%2520reduce%2520excitation%2520of%2520central%2520mammalian%2520neurones%2520by%2520N-methyl-aspartate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1983%26volume%3D79%26spage%3D565%26epage%3D575%26doi%3D10.1111%2Fj.1476-5381.1983.tb11031.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, K. B.</span>; <span class="NLM_string-name">Yi, F.</span>; <span class="NLM_string-name">Perszyk, R. E.</span>; <span class="NLM_string-name">Menniti, F. S.</span>; <span class="NLM_string-name">Traynelis, S. F.</span></span> <span> </span><span class="NLM_article-title">NMDA Receptors in the Central Nervous System</span>. In  <i>NMDA Receptors</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnashev, N.</span>, <span class="NLM_string-name">Szepetowski, P.</span></span>, Eds.; <span class="NLM_series">Methods in Molecular Biology</span>; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">1677</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2F978-1-4939-7321-7_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.+B.+Hansen&author=F.+Yi&author=R.+E.+Perszyk&author=F.+S.+Menniti&author=S.+F.+Traynelisauthor=N.+Burnashev&author=P.+Szepetowski&title=NMDA+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-7321-7_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-7321-7_1%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DK.%2BB.%26atitle%3DNMDA%2520Receptors%2520in%2520the%2520Central%2520Nervous%2520System%26btitle%3DNMDA%2520Receptors%26aulast%3DBurnashev%26aufirst%3DN.%26pub%3DHumana%2520Press%26date%3D2017%26volume%3D1677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moaddel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggs, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Highland, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albuquerque, E. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, T. D.</span></span> <span> </span><span class="NLM_article-title">Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1124/pr.117.015198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1124%2Fpr.117.015198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29945898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVKnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=621-660&author=P.+Zanosauthor=R.+Moaddelauthor=P.+J.+Morrisauthor=L.+M.+Riggsauthor=J.+N.+Highlandauthor=P.+Georgiouauthor=E.+F.+Pereiraauthor=E.+X.+Albuquerqueauthor=C.+J.+Thomasauthor=C.+A.+Zarateauthor=T.+D.+Gould&title=Ketamine+and+ketamine+metabolite+pharmacology%3A+insights+into+therapeutic+mechanisms&doi=10.1124%2Fpr.117.015198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms</span></div><div class="casAuthors">Zanos, Panos; Moaddel, Ruin; Morris, Patrick J.; Riggs, Lace M.; Highland, Jaclyn N.; Georgiou, Polymnia; Pereira, Edna F. R.; Albuquerque, Edson X.; Thomas, Craig J.; Zarate, Carlos A.; Gould, Todd D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">621-660</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Ketamine, a racemic mixt. consisting of (S)- and (R)-ketamine, has been in clin. use since 1970.  Although best characterized for its dissociative anesthetic properties, ketamine also exerts analgesic, anti-inflammatory, and antidepressant actions.  We provide a comprehensive review of these therapeutic uses, emphasizing drug dose, route of administration, and the time course of these effects.  Dissociative, psychotomimetic, cognitive, and peripheral side effects assocd. with short-term or prolonged exposure, as well as recreational ketamine use, are also discussed.  We further describe ketamine's pharmacokinetics, including its rapid and extensive metab. to norketamine, dehydronorketamine, hydroxyketamine, and hydroxynorketamine (HNK) metabolites.  Whereas the anesthetic and analgesic properties of ketamine are generally attributed to direct ketamine-induced inhibition of N-methyl-D-aspartate receptors, other putative lower-affinity pharmacol. targets of ketamine include, but are not limited to, γ-amynobutyric acid (GABA), dopamine, serotonin, sigma, opioid, and cholinergic receptors, as well as voltage-gated sodium and hyperpolarization-activated cyclic nucleotide-gated channels.  We examine the evidence supporting the relevance of these targets of ketamine and its metabolites to the clin. effects of the drug.  Ketamine metabolites may have broader clin. relevance than was previously considered, given that HNK metabolites have antidepressant efficacy in preclin. studies.  Overall, pharmacol. target deconvolution of ketamine and its metabolites will provide insight crit. to the development of new pharmacotherapies that possess the desirable clin. effects of ketamine, but limit undesirable side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYhDD-d6NivLVg90H21EOLACvtfcHk0ljfchaCnZjdDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVKnsbo%253D&md5=b7a464be9a74eeead29c6fe3eecf115d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fpr.117.015198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.117.015198%26sid%3Dliteratum%253Aachs%26aulast%3DZanos%26aufirst%3DP.%26aulast%3DMoaddel%26aufirst%3DR.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26aulast%3DRiggs%26aufirst%3DL.%2BM.%26aulast%3DHighland%26aufirst%3DJ.%2BN.%26aulast%3DGeorgiou%26aufirst%3DP.%26aulast%3DPereira%26aufirst%3DE.%2BF.%26aulast%3DAlbuquerque%26aufirst%3DE.%2BX.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DGould%26aufirst%3DT.%2BD.%26atitle%3DKetamine%2520and%2520ketamine%2520metabolite%2520pharmacology%253A%2520insights%2520into%2520therapeutic%2520mechanisms%26jtitle%3DPharmacol.%2520Rev.%26date%3D2018%26volume%3D70%26spage%3D621%26epage%3D660%26doi%3D10.1124%2Fpr.117.015198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lü, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goehring, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structures of the triheteromeric NMDA receptor and its allosteric modulation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">eaal3729</span>, <span class="refDoi"> DOI: 10.1126/science.aal3729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1126%2Fscience.aal3729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=28232581" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=eaal3729&author=W.+L%C3%BCauthor=J.+Duauthor=A.+Goehringauthor=E.+Gouaux&title=Cryo-EM+structures+of+the+triheteromeric+NMDA+receptor+and+its+allosteric+modulation&doi=10.1126%2Fscience.aal3729"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1126%2Fscience.aal3729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aal3729%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BC%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DGoehring%26aufirst%3DA.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DCryo-EM%2520structures%2520of%2520the%2520triheteromeric%2520NMDA%2520receptor%2520and%2520its%2520allosteric%2520modulation%26jtitle%3DScience%26date%3D2017%26volume%3D355%26spage%3Deaal3729%26doi%3D10.1126%2Fscience.aal3729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. Ø.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jogini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mchaourab, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">Mechanism of NMDA receptor channel block by MK-801 and memantine</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>556</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0039-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fs41586-018-0039-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29670280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=556&publication_year=2018&pages=515-519&author=X.+Songauthor=M.+%C3%98.+Jensenauthor=V.+Joginiauthor=R.+A.+Steinauthor=C.-H.+Leeauthor=H.+S.+Mchaourabauthor=D.+E.+Shawauthor=E.+Gouaux&title=Mechanism+of+NMDA+receptor+channel+block+by+MK-801+and+memantine&doi=10.1038%2Fs41586-018-0039-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of NMDA receptor channel block by MK-801 and memantine</span></div><div class="casAuthors">Song, Xianqiang; Jensen, Morten Oe.; Jogini, Vishwanath; Stein, Richard A.; Lee, Chia-Hsueh; Mchaourab, Hassane S.; Shaw, David E.; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">556</span>
        (<span class="NLM_cas:issue">7702</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The NMDA (N-methyl-D-aspartate) receptor transduces the binding of glutamate and glycine, coupling it to the opening of a Ca2+-permeable ion channel.  Owing to the lack of high-resoln. structural studies of the NMDA receptor, the mechanism by which ion-channel blockers occlude ion permeation is not well understood.  Here, we show that removal of the N-terminal domains from the GluN1-GluN2B NMDA receptor yields a functional receptor and crystals with good diffraction properties, allowing us to map the binding site of NMDA receptor blocker MK-801.  This crystal structure, together with long-timescale mol. dynamics simulations, shows how MK-801 and memantine (a drug approved for the treatment of Alzheimer's disease) bind within the vestibule of the ion channel, promote closure of the ion channel gate and lodge between the M3-helix-bundle crossing and the M2-pore loops, phys. blocking ion permeation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoObAwT_zZL77Vg90H21EOLACvtfcHk0liotQH4OvfoEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgurs%253D&md5=999ad75bd573b0120b425b9fd451b5ae</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0039-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0039-9%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%26aulast%3DJensen%26aufirst%3DM.%2B%25C3%2598.%26aulast%3DJogini%26aufirst%3DV.%26aulast%3DStein%26aufirst%3DR.%2BA.%26aulast%3DLee%26aufirst%3DC.-H.%26aulast%3DMchaourab%26aufirst%3DH.%2BS.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DMechanism%2520of%2520NMDA%2520receptor%2520channel%2520block%2520by%2520MK-801%2520and%2520memantine%26jtitle%3DNature%26date%3D2018%26volume%3D556%26spage%3D515%26epage%3D519%26doi%3D10.1038%2Fs41586-018-0039-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotermanski, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. W.</span></span> <span> </span><span class="NLM_article-title">Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer’s drug memantine</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2774</span>– <span class="NLM_lpage">2779</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.3703-08.2009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1523%2FJNEUROSCI.3703-08.2009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=19261873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1Wmurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=2774-2779&author=S.+E.+Kotermanskiauthor=J.+W.+Johnson&title=Mg2%2B+imparts+NMDA+receptor+subtype+selectivity+to+the+Alzheimer%E2%80%99s+drug+memantine&doi=10.1523%2FJNEUROSCI.3703-08.2009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine</span></div><div class="casAuthors">Kotermanski, Shawn E.; Johnson, Jon W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2774-2779</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">N-Methyl-D-aspartate receptors (NMDARs) mediate interneuronal communication and are broadly involved in nervous system physiol. and pathol. (Dingledine et al., 1999).  Memantine, a drug that blocks the ion channel formed by NMDARs, is a widely prescribed treatment of Alzheimer's disease (Schmitt, 2005; Lipton, 2006; Parsons et al., 2007).  Research on memantine's mechanism of action has focused on the NMDAR subtypes most highly expressed in adult cerebral cortex, NR1/2A and NR1/2B receptors (Cull-Candy and Leszkiewicz, 2004), and has largely ignored interactions with extracellular Mg2+ (Mg2+o).  Mg2+o is an endogenous NMDAR channel blocker that binds near memantine's binding site (Kashiwagi et al., 2002; Chen and Lipton, 2005).  We report that a physiol. concn. (1 mM) of Mg2+o decreased memantine inhibition of NR1/2A and NR1/2B receptors nearly 20-fold at a membrane voltage near rest.  In contrast, memantine inhibition of the other principal NMDAR subtypes, NR1/2C and NR1/2D receptors, was decreased only ∼3-fold.  As a result, therapeutic memantine concns. should have negligible effects on NR1/2A or NR1/2B receptor activity but pronounced effects on NR1/2C and NR1/2D receptors.  Quant. modeling showed that the voltage dependence of memantine inhibition also is altered by 1 mM Mg2+o.  We report similar results with the NMDAR channel blocker ketamine, a drug used to model schizophrenia (Krystal et al., 2003).  These results suggest that currently hypothesized mechanisms of memantine and ketamine action should be reconsidered and that NR1/2C and/or NR1/2D receptors play a more important role in cortical physiol. and pathol. than previously appreciated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzuamppfCmt7Vg90H21EOLACvtfcHk0ljRp7j_bO0_EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1Wmurc%253D&md5=a89ad44a47ec6d46992814cc130c99d6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3703-08.2009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3703-08.2009%26sid%3Dliteratum%253Aachs%26aulast%3DKotermanski%26aufirst%3DS.%2BE.%26aulast%3DJohnson%26aufirst%3DJ.%2BW.%26atitle%3DMg2%252B%2520imparts%2520NMDA%2520receptor%2520subtype%2520selectivity%2520to%2520the%2520Alzheimer%25E2%2580%2599s%2520drug%2520memantine%26jtitle%3DJ.%2520Neurosci.%26date%3D2009%26volume%3D29%26spage%3D2774%26epage%3D2779%26doi%3D10.1523%2FJNEUROSCI.3703-08.2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dravid, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erreger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyuboslavsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almonte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>581</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1113/jphysiol.2006.124958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1113%2Fjphysiol.2006.124958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=17303642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD2s3ovVyguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=581&publication_year=2007&pages=107-128&author=S.+M.+Dravidauthor=K.+Erregerauthor=H.+Yuanauthor=K.+Nicholsonauthor=P.+Leauthor=P.+Lyuboslavskyauthor=A.+Almonteauthor=E.+Murrayauthor=C.+Mosleyauthor=J.+Barber&title=Subunit-specific+mechanisms+and+proton+sensitivity+of+NMDA+receptor+channel+block&doi=10.1113%2Fjphysiol.2006.124958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block</span></div><div class="casAuthors">Dravid Shashank M; Erreger Kevin; Yuan Hongjie; Nicholson Katherine; Le Phuong; Lyuboslavsky Polina; Almonte Antoine; Murray Ernest; Mosely Cara; Barber Jeremy; French Adam; Balster Robert; Murray Thomas F; Traynelis Stephen F</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">581</span>
        (<span class="NLM_cas:issue">Pt 1</span>),
    <span class="NLM_cas:pages">107-28</span>
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    </div><div class="casAbstract">We have compared the potencies of structurally distinct channel blockers at recombinant NR1/NR2A, NR1/NR2B, NR1/NR2C and NR1/NR2D receptors.  The IC50 values varied with stereochemistry and subunit composition, suggesting that it may be possible to design subunit-selective channel blockers.  For dizocilpine (MK-801), the differential potency of MK-801 stereoisomers determined at recombinant NMDA receptors was confirmed at native receptors in vitro and in vivo.  Since the proton sensor is tightly linked both structurally and functionally to channel gating, we examined whether blocking molecules that interact in the channel pore with the gating machinery can differentially sense protonation of the receptor.  Blockers capable of remaining trapped in the pore during agonist unbinding showed the strongest dependence on extracellular pH, appearing more potent at acidic pH values that promote channel closure.  Determination of pK(a) values for channel blockers suggests that the ionization of ketamine but not of other blockers can influence its pH-dependent potency.  Kinetic modelling and single channel studies suggest that the pH-dependent block of NR1/NR2A by (-)MK-801 but not (+)MK-801 reflects an increase in the MK-801 association rate even though protons reduce channel open probability and thus MK-801 access to its binding site.  Allosteric modulators that alter pH sensitivity alter the potency of MK-801, supporting the interpretation that the pH sensitivity of MK-801 binding reflects the changes at the proton sensor rather than a secondary effect of pH.  These data suggest a tight coupling between the proton sensor and the ion channel gate as well as unique subunit-specific mechanisms of channel block.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStu9_z3ViyDvIW7hznt0zpfW6udTcc2ebp33gYeWxlOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3ovVyguw%253D%253D&md5=925d12d73740bf616173011163f9945b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.2006.124958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.2006.124958%26sid%3Dliteratum%253Aachs%26aulast%3DDravid%26aufirst%3DS.%2BM.%26aulast%3DErreger%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DNicholson%26aufirst%3DK.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DLyuboslavsky%26aufirst%3DP.%26aulast%3DAlmonte%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DE.%26aulast%3DMosley%26aufirst%3DC.%26aulast%3DBarber%26aufirst%3DJ.%26atitle%3DSubunit-specific%2520mechanisms%2520and%2520proton%2520sensitivity%2520of%2520NMDA%2520receptor%2520channel%2520block%26jtitle%3DJ.%2520Physiol.%26date%3D2007%26volume%3D581%26spage%3D107%26epage%3D128%26doi%3D10.1113%2Fjphysiol.2006.124958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamakura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, M.</span></span> <span> </span><span class="NLM_article-title">Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists</span>. <i>NeuroReport</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">687</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1097/00001756-199306000-00021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2F00001756-199306000-00021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=8347808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK3sXlslCjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1993&pages=687-690&author=T.+Yamakuraauthor=H.+Moriauthor=H.+Masakiauthor=K.+Shimojiauthor=M.+Mishina&title=Different+sensitivities+of+NMDA+receptor+channel+subtypes+to+non-competitive+antagonists&doi=10.1097%2F00001756-199306000-00021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists</span></div><div class="casAuthors">Yamakura, Tomohiro; Mori, Hisashi; Masaki, Hisashi; Shimoji, Koki; Mishina, Masayoshi</div><div class="citationInfo"><span class="NLM_cas:title">NeuroReport</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">687-90</span>CODEN:
                <span class="NLM_cas:coden">NERPEZ</span>;
        ISSN:<span class="NLM_cas:issn">0959-4965</span>.
    </div><div class="casAbstract">Four kinds of heteromeric N-methyl-D-aspartate (NMDA) receptor channels, the ε1/ζ1, ε2/ζ1, ε3/ζ1 and ε4/ζ1 channels, were expressed in Xenopus oocytes and their sensitivities to various non-competitive antagonists were examd.  The ε1/ζ1 and ε2/ζ1 channels were more sensitive to (+)MK-801 (dizocilpine) than the ε3/ζ1 and ε4/ζ1 channels, whereas the sensitivities to phencyclidine (PCP), ketamine and N-allylnormetazocine (SKF-10,047) were only slightly variable among the four ε/ζ channels.  Furthermore, the replacement by glutamine or arginine of the conserved asparagine residue in segment M2 of the ε2 and ζ1 NMDA receptor channel subunits reduced the sensitivities to PCP, ketamine and SKF-10,047, though to different extents.  These results, together with previous findings, suggest that these non-competitive antagonists as well as (+)MK-801 and Mg2+ act on a common site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxjm7lee0_SrVg90H21EOLACvtfcHk0lj6SEBdWnl_0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlslCjsb0%253D&md5=dd0c9e2a34022b418ef601d3146ac9f3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1097%2F00001756-199306000-00021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001756-199306000-00021%26sid%3Dliteratum%253Aachs%26aulast%3DYamakura%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DH.%26aulast%3DMasaki%26aufirst%3DH.%26aulast%3DShimoji%26aufirst%3DK.%26aulast%3DMishina%26aufirst%3DM.%26atitle%3DDifferent%2520sensitivities%2520of%2520NMDA%2520receptor%2520channel%2520subtypes%2520to%2520non-competitive%2520antagonists%26jtitle%3DNeuroReport%26date%3D1993%26volume%3D4%26spage%3D687%26epage%3D690%26doi%3D10.1097%2F00001756-199306000-00021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björkroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, A.</span></span> <span> </span><span class="NLM_article-title">Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1002/jps.2600760902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1002%2Fjps.2600760902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=11002801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaL2sXmt1yhur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1987&pages=663-687&author=C.+Hanschauthor=J.+Bj%C3%B6rkrothauthor=A.+Leo&title=Hydrophobicity+and+central+nervous+system+agents%3A+on+the+principle+of+minimal+hydrophobicity+in+drug+design&doi=10.1002%2Fjps.2600760902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrophobicity and central nervous system agents:  on the principle of minimal hydrophobicity in drug design</span></div><div class="casAuthors">Hansch, Corwin; Bjoerkroth, J. P.; Leo, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">663-87</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    </div><div class="casAbstract">A review with 110 refs. of hydrophobicity of central nervous system drugs in relation to their desired or undesired penetration through the blood-brain barrier.  A method is presented for detn. of optimal drug hydrophobicity and lipophilicity based on evaluation of the partition coeffs. on the octanol-water hydrophobic scale.  A large no. of drugs are evaluated as examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvoksnH-zmbrVg90H21EOLACvtfcHk0ljC4Ue2aqP7Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXmt1yhur0%253D&md5=601e31e52a18871eac3e95bb264f21bf</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fjps.2600760902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.2600760902%26sid%3Dliteratum%253Aachs%26aulast%3DHansch%26aufirst%3DC.%26aulast%3DBj%25C3%25B6rkroth%26aufirst%3DJ.%26aulast%3DLeo%26aufirst%3DA.%26atitle%3DHydrophobicity%2520and%2520central%2520nervous%2520system%2520agents%253A%2520on%2520the%2520principle%2520of%2520minimal%2520hydrophobicity%2520in%2520drug%2520design%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D1987%26volume%3D76%26spage%3D663%26epage%3D687%26doi%3D10.1002%2Fjps.2600760902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlisides, P. E.</span></span> <span> </span><span class="NLM_article-title">Ketamine: 50 years of modulating the mind</span>. <i>Front. Hum. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">612</span>, <span class="refDoi"> DOI: 10.3389/fnhum.2016.00612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.3389%2Ffnhum.2016.00612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27965560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2itrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=612&author=L.+Liauthor=P.+E.+Vlisides&title=Ketamine%3A+50+years+of+modulating+the+mind&doi=10.3389%2Ffnhum.2016.00612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: 50 years of modulating the mind</span></div><div class="casAuthors">Li, Linda; Vlisides, Phillip E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Human Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">612/1-612/15</span>CODEN:
                <span class="NLM_cas:coden">FHNRAI</span>;
        ISSN:<span class="NLM_cas:issn">1662-5161</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Ketamine was introduced into clin. practice in the 1960s and continues to be both clin. useful and scientifically fascinating.  With considerably diverse mol. targets and neurophysiol. properties, ketamine's effects on the central nervous system remain incompletely understood.  Investigators have leveraged the unique characteristics of ketamine to explore the invariant, fundamental mechanisms of anesthetic action.  Emerging evidence indicates that ketamine-mediated anesthesia may occur via disruption of corticocortical information transfer in a frontal-to-parietal ("top down") distribution.  This proposed mechanism of general anesthesia has since been demonstrated with anesthetics in other pharmacol. classes as well.  Ketamine remains invaluable to the fields of anesthesiol. and crit. care medicine, in large part due to its ability to maintain cardiorespiratory stability while providing effective sedation and analgesia.  Furthermore, there may be an emerging role for ketamine in treatment of refractory depression and Post-Traumatic Stress Disorder.  In this article, we review the history of ketamine, its pharmacol., putative mechanisms of action and current clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokopoVkR3447Vg90H21EOLACvtfcHk0ljC4Ue2aqP7Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2itrjE&md5=b7df8f181691f0a4469e41551e82b4ab</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3389%2Ffnhum.2016.00612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnhum.2016.00612%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DVlisides%26aufirst%3DP.%2BE.%26atitle%3DKetamine%253A%252050%2520years%2520of%2520modulating%2520the%2520mind%26jtitle%3DFront.%2520Hum.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D612%26doi%3D10.3389%2Ffnhum.2016.00612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peltoniemi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagelberg, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olkkola, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saari, T. I.</span></span> <span> </span><span class="NLM_article-title">Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1077</span>, <span class="refDoi"> DOI: 10.1007/s40262-016-0383-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2Fs40262-016-0383-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27028535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsF2iurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=1059-1077&author=M.+A.+Peltoniemiauthor=N.+M.+Hagelbergauthor=K.+T.+Olkkolaauthor=T.+I.+Saari&title=Ketamine%3A+a+review+of+clinical+pharmacokinetics+and+pharmacodynamics+in+anesthesia+and+pain+therapy&doi=10.1007%2Fs40262-016-0383-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy</span></div><div class="casAuthors">Peltoniemi, Marko A.; Hagelberg, Nora M.; Olkkola, Klaus T.; Saari, Teijo I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1059-1077</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ketamine is a phencyclidine deriv., which functions primarily as an antagonist of the N-methyl-D-aspartate receptor.  It has no affinity for gamma-aminobutyric acid receptors in the central nervous system.  Ketamine shows a chiral structure consisting of two optical isomers.  It undergoes oxidative metab., mainly to norketamine by cytochrome P 450 (CYP) 3A and CYP2B6 enzymes.  The use of S-ketamine is increasing worldwide, since the S(+)-enantiomer has been postulated to be a four times more potent anesthetic and analgesic than the R(-)-enantiomer and approx. two times more effective than the racemic mixt. of ketamine.  Because of extensive first-pass metab., oral bioavailability is poor and ketamine is vulnerable to pharmacokinetic drug interactions.  Sublingual and nasal formulations of ketamine are being developed, and esp. nasal administration produces rapid max. plasma ketamine concns. with relatively high bioavailability.  Ketamine produces hemodynamically stable anesthesia via central sympathetic stimulation without affecting respiratory function.  Animal studies have shown that ketamine has neuroprotective properties, and there is no evidence of elevated intracranial pressure after ketamine dosing in humans.  Low-dose perioperative ketamine may reduce opioid consumption and chronic postsurgical pain after specific surgical procedures.  However, long-term analgesic effects of ketamine in chronic pain patients have not been demonstrated.  Besides analgesic properties, ketamine has rapid-acting antidepressant effects, which may be useful in treating therapy-resistant depressive patients.  Well-known psychotomimetic and cognitive adverse effects restrict the clin. usefulness of ketamine, even though fewer psychomimetic adverse effects have been reported with S-ketamine in comparison with the racemate.  Safety issues in long-term use are yet to be resolved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLqyI74DCcnbVg90H21EOLACvtfcHk0ljC4Ue2aqP7Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsF2iurw%253D&md5=92bb0dcd7d034220f58418af4cee164c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs40262-016-0383-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-016-0383-6%26sid%3Dliteratum%253Aachs%26aulast%3DPeltoniemi%26aufirst%3DM.%2BA.%26aulast%3DHagelberg%26aufirst%3DN.%2BM.%26aulast%3DOlkkola%26aufirst%3DK.%2BT.%26aulast%3DSaari%26aufirst%3DT.%2BI.%26atitle%3DKetamine%253A%2520a%2520review%2520of%2520clinical%2520pharmacokinetics%2520and%2520pharmacodynamics%2520in%2520anesthesia%2520and%2520pain%2520therapy%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2016%26volume%3D55%26spage%3D1059%26epage%3D1077%26doi%3D10.1007%2Fs40262-016-0383-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rejaei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Ketamine use in current clinical practice</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1038/aps.2016.5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Faps.2016.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27018176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2iu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=865-872&author=M.+Gaoauthor=D.+Rejaeiauthor=H.+Liu&title=Ketamine+use+in+current+clinical+practice&doi=10.1038%2Faps.2016.5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine use in current clinical practice</span></div><div class="casAuthors">Gao, Mei; Rejaei, Damoon; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">865-872</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">After nearly half a century on the market, ketamine still occupies a unique corner in the medical armamentarium of anesthesiologists or clinicians treating pain.  Over the last two decades, much research has been conducted highlighting the drug's mechanisms of action, specifically those of its enantiomers.  Nowadays, ketamine is also being utilized for pediatric pain control in emergency department, with its anti-hyperalgesic and anti-inflammatory effects being revealed in acute and chronic pain management.  Recently, new insights have been gained on ketamine's potential anti-depressive and antisuicidal effects.  This article provides an overview of the drug's pharmacokinetics and pharmacodynamics while also discussing the potential benefits and risks of ketamine administration in various clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprxv2CkTeEJ7Vg90H21EOLACvtfcHk0li0tXktmxtnTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2iu7jP&md5=29b44ebb7b25d9c2a41a04d7b8f6bf10</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Faps.2016.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2016.5%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DRejaei%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DKetamine%2520use%2520in%2520current%2520clinical%2520practice%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2016%26volume%3D37%26spage%3D865%26epage%3D872%26doi%3D10.1038%2Faps.2016.5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsze, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machan, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhlaghi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linakis, J. G.</span></span> <span> </span><span class="NLM_article-title">Intranasal ketamine for procedural sedation in pediatric laceration repair: a preliminary report</span>. <i>Pediatr. Emerg. Care</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1097/PEC.0b013e3182624935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2FPEC.0b013e3182624935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=22858745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC38fltFOlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2012&pages=767-770&author=D.+S.+Tszeauthor=D.+W.+Steeleauthor=J.+T.+Machanauthor=F.+Akhlaghiauthor=J.+G.+Linakis&title=Intranasal+ketamine+for+procedural+sedation+in+pediatric+laceration+repair%3A+a+preliminary+report&doi=10.1097%2FPEC.0b013e3182624935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Intranasal ketamine for procedural sedation in pediatric laceration repair: a preliminary report</span></div><div class="casAuthors">Tsze Daniel S; Steele Dale W; Machan Jason T; Akhlaghi Fatemeh; Linakis James G</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric emergency care</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">767-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  The objective of this study was to compare the efficacy of 3 doses of intranasal ketamine (INK) for sedation of children from 1 to 7 years old requiring laceration repair.  METHODS:  This was a randomized, prospective, double-blind trial of children requiring sedation for laceration repair.  Patients with simple lacerations were randomized by age to receive 3, 6, or 9 mg/kg INK.  Adequacy and efficacy of sedation were measured with the Ramsay sedation score and the Observational Scale of Behavioral Distress-Revised.  Serum ketamine and norketamine levels were drawn during the procedure.  Sedation duration and adverse events were recorded.  RESULTS:  Of the 12 patients enrolled, 3 patients achieved adequate sedation, all at the 9-mg/kg dose.  The study was suspended at that time as per predetermined criteria.  CONCLUSIONS:  Nine milligrams of INK per kilogram produced a significantly higher proportion of successful sedations than the 3- and 6-mg/kg doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSa-KaX86UKAGPgL4LrC-0VfW6udTcc2eZQ42SniJ9m5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fltFOlsQ%253D%253D&md5=76b8092fd39c0939eea697ff35fe3bc5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1097%2FPEC.0b013e3182624935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPEC.0b013e3182624935%26sid%3Dliteratum%253Aachs%26aulast%3DTsze%26aufirst%3DD.%2BS.%26aulast%3DSteele%26aufirst%3DD.%2BW.%26aulast%3DMachan%26aufirst%3DJ.%2BT.%26aulast%3DAkhlaghi%26aufirst%3DF.%26aulast%3DLinakis%26aufirst%3DJ.%2BG.%26atitle%3DIntranasal%2520ketamine%2520for%2520procedural%2520sedation%2520in%2520pediatric%2520laceration%2520repair%253A%2520a%2520preliminary%2520report%26jtitle%3DPediatr.%2520Emerg.%2520Care%26date%3D2012%26volume%3D28%26spage%3D767%26epage%3D770%26doi%3D10.1097%2FPEC.0b013e3182624935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinner, B.</span>; <span class="NLM_string-name">Graf, B.</span></span> <span> </span><span class="NLM_article-title">Ketamine</span>. In  <i>Modern Anesthetics</i>; <span class="NLM_publisher-name">Springer</span>, <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2008</span>; pp  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">333</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2F978-3-540-74806-9_15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=313-333&author=B.+Sinner&author=B.+Graf&title=Modern+Anesthetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-74806-9_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-540-74806-9_15%26sid%3Dliteratum%253Aachs%26aulast%3DSinner%26aufirst%3DB.%26atitle%3DKetamine%26btitle%3DModern%2520Anesthetics%26pub%3DSpringer%26date%3D2008%26spage%3D313%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quibell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prommer, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihalyo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twycross, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcock, A.</span></span> <span> </span><span class="NLM_article-title">Ketamine</span>. <i>J. Pain Symptom Manage.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1016/j.jpainsymman.2011.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.jpainsymman.2011.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=21419322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs12hsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=640-649&author=R.+Quibellauthor=E.+E.+Prommerauthor=M.+Mihalyoauthor=R.+Twycrossauthor=A.+Wilcock&title=Ketamine&doi=10.1016%2Fj.jpainsymman.2011.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine*</span></div><div class="casAuthors">Quibell, Rachel; Prommer, Eric E.; Mihalyo, Mary; Twycross, Robert; Wilcock, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain and Symptom Management</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">640-649</span>CODEN:
                <span class="NLM_cas:coden">JPSMEU</span>;
        ISSN:<span class="NLM_cas:issn">0885-3924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Therapeutic Reviews aim to provide essential independent information for health professionals about drugs used in palliative and hospice care.  Addnl. content is available on www.palliativedrugs.com.  Country-specific books (Hospice and Palliative Care Formulary USA, and Palliative Care Formulary, British and Canadian editions) are also available and can be ordered from www.palliativebooks.com.  The series editors welcome feedback on the articles (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="c2aab382b2a3aeaeaba3b6abb4a7a6b0b7a5b1eca1adaf">[email protected]</a>).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHNpCOGO1hjrVg90H21EOLACvtfcHk0ligJcdv4QBVqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs12hsro%253D&md5=45b7b2fc655b69b4ee17b7b472b25f74</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.jpainsymman.2011.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpainsymman.2011.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DQuibell%26aufirst%3DR.%26aulast%3DPrommer%26aufirst%3DE.%2BE.%26aulast%3DMihalyo%26aufirst%3DM.%26aulast%3DTwycross%26aufirst%3DR.%26aulast%3DWilcock%26aufirst%3DA.%26atitle%3DKetamine%26jtitle%3DJ.%2520Pain%2520Symptom%2520Manage.%26date%3D2011%26volume%3D41%26spage%3D640%26epage%3D649%26doi%3D10.1016%2Fj.jpainsymman.2011.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cromhout, A.</span></span> <span> </span><span class="NLM_article-title">Ketamine: its use in the emergency department</span>. <i>Emerg. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1046/j.1442-2026.2003.00433.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1046%2Fj.1442-2026.2003.00433.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=12675625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD3s7lvFKitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2003&pages=155-159&author=A.+Cromhout&title=Ketamine%3A+its+use+in+the+emergency+department&doi=10.1046%2Fj.1442-2026.2003.00433.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: its use in the emergency department</span></div><div class="casAuthors">Cromhout Andries</div><div class="citationInfo"><span class="NLM_cas:title">Emergency medicine (Fremantle, W.A.)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-9</span>
        ISSN:<span class="NLM_cas:issn">1035-6851</span>.
    </div><div class="casAbstract">Ketamine has been known to the medical world for over 30 years, yet is not widely used to its full potential.  It is often considered to be a 'third world' drug only.  In light of a recent increase in interest in its use in the developed world, this review is for emergency physicians to use as a quick reference.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJPSIGyUS4OrmQt-ICR3qNfW6udTcc2ea1fPnRXgocqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s7lvFKitQ%253D%253D&md5=dc37c1746eb691bf4bbabd1e9b8e08ce</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1046%2Fj.1442-2026.2003.00433.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1442-2026.2003.00433.x%26sid%3Dliteratum%253Aachs%26aulast%3DCromhout%26aufirst%3DA.%26atitle%3DKetamine%253A%2520its%2520use%2520in%2520the%2520emergency%2520department%26jtitle%3DEmerg.%2520Med.%26date%3D2003%26volume%3D15%26spage%3D155%26epage%3D159%26doi%3D10.1046%2Fj.1442-2026.2003.00433.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aroni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacovidou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dontas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourzitaki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xanthos, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1177/0091270009337941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1177%2F0091270009337941" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=19546251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVSqur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=957-964&author=F.+Aroniauthor=N.+Iacovidouauthor=I.+Dontasauthor=C.+Pourzitakiauthor=T.+Xanthos&title=Pharmacological+aspects+and+potential+new+clinical+applications+of+ketamine%3A+reevaluation+of+an+old+drug&doi=10.1177%2F0091270009337941"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug</span></div><div class="casAuthors">Aroni, Filippia; Iacovidou, Nicoletta; Dontas, Ismene; Pourzitaki, Chryssa; Xanthos, Theodoros</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">957-964</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Ketamine, the phencyclidine deriv. described in 1965, is an i.v. anesthetic with a variety of applications.  The enthusiasm following its initial release subsided due to side effects from the central nervous system.  New anesthetics limited the role of ketamine in anesthetic practice.  However, its hemodynamically stable profile, along with its beneficial respiratory properties and analgesic potency, rendered the drug invaluable in battlefield medicine, sedation of the uncooperative child, analgesia, and sedation in burn units.  Reevaluation, though, of analgesic properties of ketamine resulted in new interest regarding its use in perioperative and chronic pain management.  Moreover, recent studies in the effects of the substance on intracranial pressure and cerebral blood flow led to revising the recommendation against its use in brain injury.  Furthermore, the bronchodilating effects of the substance led to increasing interest for potential use in asthma treatment.  In addn., sepn. of the 2 enantiomers and subsequent sep. studies indicated beneficial results of the S(+) one.  Thus, new controlled multicentered clin. trials are to be conducted to justify approval for new uses of ketamine and take advantage of its unique range of applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP4ry9lXzq0bVg90H21EOLACvtfcHk0ligJcdv4QBVqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVSqur%252FL&md5=4d74fed4e68a393e9809fe9020d5bfe8</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1177%2F0091270009337941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009337941%26sid%3Dliteratum%253Aachs%26aulast%3DAroni%26aufirst%3DF.%26aulast%3DIacovidou%26aufirst%3DN.%26aulast%3DDontas%26aufirst%3DI.%26aulast%3DPourzitaki%26aufirst%3DC.%26aulast%3DXanthos%26aufirst%3DT.%26atitle%3DPharmacological%2520aspects%2520and%2520potential%2520new%2520clinical%2520applications%2520of%2520ketamine%253A%2520reevaluation%2520of%2520an%2520old%2520drug%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D957%26epage%3D964%26doi%3D10.1177%2F0091270009337941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, D. G.</span></span> <span> </span><span class="NLM_article-title">Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia</span>. <i>Anesth. Prog.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1308374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADyaK3szntVKqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1992&pages=61&author=D.+A.+Haasauthor=D.+G.+Harper&title=Ketamine%3A+a+review+of+its+pharmacologic+properties+and+use+in+ambulatory+anesthesia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia</span></div><div class="casAuthors">Haas D A; Harper D G</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia progress</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">61-8</span>
        ISSN:<span class="NLM_cas:issn">0003-3006</span>.
    </div><div class="casAbstract">The administration of intravenous agents is the most commonly used method in Canada and the United States to produce sedation or general anesthesia for dental procedures.  Ketamine, a dissociative anesthetic, has several advantageous physical, pharmacokinetic, and pharmacodynamic properties.  It can be used to induce anesthesia, sedation, analgesia, and amnesia.  Ketamine can maintain functional residual capacity, induce bronchodilation, and avoid cardiovascular depression.  However, adverse effects have been demonstrated, such as cardiovascular stimulation and unpleasant emergence phenomena, both of which may be modulated by supplementation with benzodiazepines.  An increase in the use of ketamine for ambulatory anesthesia has recently been advocated.  This review of the literature supports the use of ketamine as an effective agent for selected anesthetic procedures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnipagfkjBp_tos8R3JUhXfW6udTcc2eb4faj99op1C7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szntVKqtQ%253D%253D&md5=d99781724220188faa8554931134310f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaas%26aufirst%3DD.%2BA.%26aulast%3DHarper%26aufirst%3DD.%2BG.%26atitle%3DKetamine%253A%2520a%2520review%2520of%2520its%2520pharmacologic%2520properties%2520and%2520use%2520in%2520ambulatory%2520anesthesia%26jtitle%3DAnesth.%2520Prog.%26date%3D1992%26volume%3D39%26spage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasinather, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, Y.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurhidayat, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarlais, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schottenfeld, R.</span></span> <span> </span><span class="NLM_article-title">To use or not to use: an update on licit and illicit ketamine use</span>. <i>Subst Abuse Rehabil.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">11</span>, <span class="refDoi"> DOI: 10.2147/SAR.S15458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.2147%2FSAR.S15458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=24474851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsFyqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=11&author=J.-H.+Liauthor=V.+Kasinatherauthor=Y.-w.+Cheungauthor=W.+Zhouauthor=A.+W.+Nurhidayatauthor=D.+C.+Jarlaisauthor=R.+Schottenfeld&title=To+use+or+not+to+use%3A+an+update+on+licit+and+illicit+ketamine+use&doi=10.2147%2FSAR.S15458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">To use or not to use: an update on licit and illicit ketamine use</span></div><div class="casAuthors">Li Jih-Heng; Vicknasingam Balasingam; Cheung Yuet-Wah; Zhou Wang; Nurhidayat Adhi Wibowo; Jarlais Don C Des; Schottenfeld Richard</div><div class="citationInfo"><span class="NLM_cas:title">Substance abuse and rehabilitation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11-20</span>
        ISSN:<span class="NLM_cas:issn">1179-8467</span>.
    </div><div class="casAbstract">Ketamine, a derivative of phencyclidine that was developed in the 1960s, is an anesthetic and analgesic with hallucinogenic effects.  In this paper, the pharmacological and toxicological effects of ketamine are briefly reviewed.  Ketamine possesses a wide safety margin but such a therapeutic benefit is somewhat offset by its emergence phenomenon (mind-body dissociation and delirium) and hallucinogenic effects.  The increasing abuse of ketamine, initially predominantly in recreational scenes to experience a "k-hole" and other hallucinatory effects but more recently also as a drug abused during the workday or at home, has further pushed governments to confine its usage in many countries.  Recently, urinary tract dysfunction has been associated with long-term ketamine use.  In some long-term ketamine users, such damage can be irreversible and could result in renal failure and dialysis.  Although ketamine has not yet been scheduled in the United Nations Conventions, previous studies using different assessment parameters to score the overall harms of drugs indicated that ketamine may cause more harm than some of the United Nations scheduled drugs.  Some countries in Southeast and East Asia have reported an escalating situation of ketamine abuse.  Dependence, lower urinary tract dysfunction, and sexual impulse or violence were the most notable among the ketamine-associated symptoms in these countries.  These results implied that the danger of ketamine may have been underestimated previously.  Therefore, the severity levels of the ketamine-associated problems should be scrutinized more carefully and objectively.  To prevent ketamine from being improperly used and evolving into an epidemic, a thorough survey on the prevalence and characteristics of illicit ketamine use is imperative so that suitable policy and measures can be taken.  On the other hand, recent findings that ketamine could be useful for treating major depressive disorder has given this old drug a new impetus.  If ketamine is indeed a remedy for treating depression, more research on the risks and benefits of its clinical use will be indispensable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0KN9U3mPo0I3yKPtYViAGfW6udTcc2eb4faj99op1C7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsFyqtQ%253D%253D&md5=be1f7d17db8ced43f2da251357f4beb7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2147%2FSAR.S15458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FSAR.S15458%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.-H.%26aulast%3DKasinather%26aufirst%3DV.%26aulast%3DCheung%26aufirst%3DY.-w.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DNurhidayat%26aufirst%3DA.%2BW.%26aulast%3DJarlais%26aufirst%3DD.%2BC.%26aulast%3DSchottenfeld%26aufirst%3DR.%26atitle%3DTo%2520use%2520or%2520not%2520to%2520use%253A%2520an%2520update%2520on%2520licit%2520and%2520illicit%2520ketamine%2520use%26jtitle%3DSubst%2520Abuse%2520Rehabil.%26date%3D2011%26volume%3D2%26spage%3D11%26doi%3D10.2147%2FSAR.S15458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moaddel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanghvi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dossou, K. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bupp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swezey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Loughlin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span> <span> </span><span class="NLM_article-title">The distribution and clearance of (2S, 6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e00157</span>, <span class="refDoi"> DOI: 10.1002/prp2.157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1002%2Fprp2.157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26171236" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=e00157&author=R.+Moaddelauthor=M.+Sanghviauthor=K.+S.+S.+Dossouauthor=A.+Ramamoorthyauthor=C.+Greenauthor=J.+Buppauthor=R.+Swezeyauthor=K.+O%E2%80%99Loughlinauthor=I.+W.+Wainer&title=The+distribution+and+clearance+of+%282S%2C+6S%29-hydroxynorketamine%2C+an+active+ketamine+metabolite%2C+in+Wistar+rats&doi=10.1002%2Fprp2.157"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fprp2.157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.157%26sid%3Dliteratum%253Aachs%26aulast%3DMoaddel%26aufirst%3DR.%26aulast%3DSanghvi%26aufirst%3DM.%26aulast%3DDossou%26aufirst%3DK.%2BS.%2BS.%26aulast%3DRamamoorthy%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DC.%26aulast%3DBupp%26aufirst%3DJ.%26aulast%3DSwezey%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Loughlin%26aufirst%3DK.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26atitle%3DThe%2520distribution%2520and%2520clearance%2520of%2520%25282S%252C%25206S%2529-hydroxynorketamine%252C%2520an%2520active%2520ketamine%2520metabolite%252C%2520in%2520Wistar%2520rats%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2015%26volume%3D3%26spage%3De00157%26doi%3D10.1002%2Fprp2.157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boku, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hishimoto, A.</span></span> <span> </span><span class="NLM_article-title">Neural basis of major depressive disorder: beyond monoamine hypothesis</span>. <i>Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1111/pcn.12604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1111%2Fpcn.12604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=28926161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2018&pages=3-12&author=S.+Bokuauthor=S.+Nakagawaauthor=H.+Todaauthor=A.+Hishimoto&title=Neural+basis+of+major+depressive+disorder%3A+beyond+monoamine+hypothesis&doi=10.1111%2Fpcn.12604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Neural basis of major depressive disorder: Beyond monoamine hypothesis</span></div><div class="casAuthors">Boku, Shuken; Nakagawa, Shin; Toda, Hiroyuki; Hishimoto, Akitoyo</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry and Clinical Neurosciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-12</span>CODEN:
                <span class="NLM_cas:coden">PCNEFP</span>;
        ISSN:<span class="NLM_cas:issn">1323-1316</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The monoamine hypothesis has been accepted as the most common hypothesis of major depressive disorder (MDD) for a long period because of its simplicity and understandability.  Actually, most currently used antidepressants have been considered to act based on the monoamine hypothesis.  However, an important problem of the monoamine hypothesis has been pointed out as follows: it fails to explain the latency of response to antidepressants.  In addn., many patients with MDD have remained refractory to currently used antidepressants.  Therefore, monoamine-alternate hypotheses are required to explain the latency of response to antidepressants.  Such hypotheses have been expected to contribute to identifying hopeful new therapeutic targets for MDD.  Past studies have revealed that the vol. of the hippocampus is decreased in patients with MDD, which is likely caused by the failure of the hypothalamic-pituitary-adrenal axis and following elevation of glucocorticoids.  Two hypotheses have been proposed to explain the vol. of the hippocampus: (i) the neuroplasticity hypothesis; and (ii) the neurogenesis hypothesis.  The neuroplasticity hypothesis explains how the hippocampal vol. is decreased by the morphol. changes of hippocampal neurons, such as the shortening length of dendrites and the decreased no. and d. of spines.  The neurogenesis hypothesis explains how the hippocampal vol. is decreased by the decrease of neurogenesis in the hippocampal dentate gyrus.  These hypotheses are able to explain the latency of response to antidepressants.  In this review, we first overview how the neuroplasticity and neurogenesis hypotheses have been developed.  We then describe the details of these hypotheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ-o-pmwi-M7Vg90H21EOLACvtfcHk0lgH9SnGqejWag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVehsg%253D%253D&md5=36b5009c7c8c80dd123cfd1a862fc85b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fpcn.12604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpcn.12604%26sid%3Dliteratum%253Aachs%26aulast%3DBoku%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DS.%26aulast%3DToda%26aufirst%3DH.%26aulast%3DHishimoto%26aufirst%3DA.%26atitle%3DNeural%2520basis%2520of%2520major%2520depressive%2520disorder%253A%2520beyond%2520monoamine%2520hypothesis%26jtitle%3DPsychiatry%2520Clin.%2520Neurosci.%26date%3D2018%26volume%3D72%26spage%3D3%26epage%3D12%26doi%3D10.1111%2Fpcn.12604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aulakh, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolozin, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolliver, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D. L.</span></span> <span> </span><span class="NLM_article-title">Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants</span>. <i>Mol. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/0169-328X(93)90069-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2F0169-328X%2893%2990069-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=8381906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK3sXpsVajsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1993&pages=31-35&author=K.+P.+Leschauthor=C.+S.+Aulakhauthor=B.+L.+Wolozinauthor=T.+J.+Tolliverauthor=J.+L.+Hillauthor=D.+L.+Murphy&title=Regional+brain+expression+of+serotonin+transporter+mRNA+and+its+regulation+by+reuptake+inhibiting+antidepressants&doi=10.1016%2F0169-328X%2893%2990069-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants</span></div><div class="casAuthors">Lesch, K. Peter; Aulakh, Charanjit S.; Wolozin, Benjamin L.; Tolliver, Teresa J.; Hill, James L.; Murphy, Dennis L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Brain Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">31-5</span>CODEN:
                <span class="NLM_cas:coden">MBREE4</span>;
        ISSN:<span class="NLM_cas:issn">0169-328X</span>.
    </div><div class="casAbstract">Regional expression and antidepressant drug-induced regulation of mRNA encoding the serotonin (5-HT) transporter were studied in rat brain.  While 5-HT transporter mRNA is abundantly expressed in the midbrain raphe complex, lower concns. were also found in frontal cortex, hippocampus, and neostriatum using a combination of reverse transcriptase-polymerase chain reaction (RT-PCR), Southern hybridization, and sequence anal.  Long-term administration of antidepressants which inhibit 5-HT reuptake, but not monoamine oxidase inhibitors or 5-HT receptor agonists, decrease 5-HT transporter mRNA steady-state concns.  Based on these observations, we conclude that (1) mRNA coding for the 5-HT transporter is present in several brain areas assocd. with ascending HT pathways, and (2) chronic treatment with reuptake inhibiting antidepressants may be assocd. with regulation of the 5-HT transporter at the level of gene expression which may contribute to the neuroadaptive mechanisms that likely underlie their therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5vDCJu2GApLVg90H21EOLACvtfcHk0lgH9SnGqejWag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXpsVajsg%253D%253D&md5=34eb78f79ed46ce897a49fca297a82c8</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2F0169-328X%2893%2990069-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0169-328X%252893%252990069-2%26sid%3Dliteratum%253Aachs%26aulast%3DLesch%26aufirst%3DK.%2BP.%26aulast%3DAulakh%26aufirst%3DC.%2BS.%26aulast%3DWolozin%26aufirst%3DB.%2BL.%26aulast%3DTolliver%26aufirst%3DT.%2BJ.%26aulast%3DHill%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DD.%2BL.%26atitle%3DRegional%2520brain%2520expression%2520of%2520serotonin%2520transporter%2520mRNA%2520and%2520its%2520regulation%2520by%2520reuptake%2520inhibiting%2520antidepressants%26jtitle%3DMol.%2520Brain%2520Res.%26date%3D1993%26volume%3D17%26spage%3D31%26epage%3D35%26doi%3D10.1016%2F0169-328X%2893%2990069-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. M.</span>; <span class="NLM_string-name">Bies, R. R.</span>; <span class="NLM_string-name">Shelton, R. C.</span></span> <span> </span><span class="NLM_article-title">Drug Therapy of Depression and Anxiety Disorders</span>. In  <i>Goodman & Gilman’s: The Pharmacological Basis of Therapeutics</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, L. L.</span>, <span class="NLM_string-name">Hilal-Dandan, R.</span>, <span class="NLM_string-name">Knollmann, B. C.</span></span>, Eds.; <span class="NLM_publisher-name">McGraw-Hill</span>, <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">13e</span>. <a href="https://accesspharmacy.mhmedical.com/content.aspx?bookid=2189&amp;sectionid=169518711" class="extLink">https://accesspharmacy.mhmedical.com/content.aspx?bookid=2189&sectionid=169518711</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+M.+O%E2%80%99Donnell&author=R.+R.+Bies&author=R.+C.+Sheltonauthor=L.+L.+Brunton&author=R.+Hilal-Dandan&author=B.+C.+Knollmann&title=Goodman+%26+Gilman%E2%80%99s%3A+The+Pharmacological+Basis+of+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26atitle%3DDrug%2520Therapy%2520of%2520Depression%2520and%2520Anxiety%2520Disorders%26btitle%3DGoodman%2520%2526%2520Gilman%25E2%2580%2599s%253A%2520The%2520Pharmacological%2520Basis%2520of%2520Therapeutics%26aulast%3DBrunton%26aufirst%3DL.%2BL.%26pub%3DMcGraw-Hill%26date%3D2017%26volume%3D13e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappiello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oren, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heninger, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span> <span> </span><span class="NLM_article-title">Antidepressant effects of ketamine in depressed patients</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1016/S0006-3223(99)00230-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2FS0006-3223%2899%2900230-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10686270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1KqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2000&pages=351-354&author=R.+M.+Bermanauthor=A.+Cappielloauthor=A.+Anandauthor=D.+A.+Orenauthor=G.+R.+Heningerauthor=D.+S.+Charneyauthor=J.+H.+Krystal&title=Antidepressant+effects+of+ketamine+in+depressed+patients&doi=10.1016%2FS0006-3223%2899%2900230-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant effects of ketamine in depressed patients</span></div><div class="casAuthors">Berman, R. M.; Cappiello, A.; Anand, A.; Oren, D. A.; Heninger, G. R.; Charney, D. S.; Krystal, J. H.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">351-354</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Subjects with major depression completed 2 test days that involved i.v. treatment with ketamine-HCl [an N-methyl-D-aspartate (NMDA) receptor antagonist] (0.5 mg/kg) or saline solns. under randomized, double-blind conditions. The subjects evidenced significant improvement in depressive symptoms within 72 h after ketamine but not placebo infusion. These results suggest a potential role for NMDA receptor-modulating drugs in the treatment of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe9INO5Rp16bVg90H21EOLACvtfcHk0liNrENE435TMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1KqtrY%253D&md5=45ef4a17496654912e0bf515ba3fce2a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2899%2900230-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252899%252900230-9%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DR.%2BM.%26aulast%3DCappiello%26aufirst%3DA.%26aulast%3DAnand%26aufirst%3DA.%26aulast%3DOren%26aufirst%3DD.%2BA.%26aulast%3DHeninger%26aufirst%3DG.%2BR.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26atitle%3DAntidepressant%2520effects%2520of%2520ketamine%2520in%2520depressed%2520patients%26jtitle%3DBiol.%2520Psychiatry%26date%3D2000%26volume%3D47%26spage%3D351%26epage%3D354%26doi%3D10.1016%2FS0006-3223%2899%2900230-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harakal, J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of ketamine HCl for anti-depressant activity</span>. <i>Arch Int. Pharmacodyn. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">74</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1156026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaE2MXksFemtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=1975&pages=68-74&author=R.+Sofiaauthor=J.+Harakal&title=Evaluation+of+ketamine+HCl+for+anti-depressant+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of ketamine hydrochloride for antidepressant activity</span></div><div class="casAuthors">Sofia, R. D.; Harakal, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Archives Internationales de Pharmacodynamie et de Therapie</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-74</span>CODEN:
                <span class="NLM_cas:coden">AIPTAK</span>;
        ISSN:<span class="NLM_cas:issn">0003-9780</span>.
    </div><div class="casAbstract">Ketamine-HCl (I-HCl) [1867-66-9] had significant antidepressant activities in mice and rats over a wide range of oral doses.  The tests used were (1) reversal of tetrabenazine-induced ptosis in mice, (2) reversal of reserpine-induced hypothermia in rats, (3) enhancement of yohimbine toxicity in mice, and (4) inhibition of oxotremorine-induced tremors in mice.  In general, the antidepressant potency of I was less than that of imipramine-HCl [113-52-0].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_u_EETY_DPrVg90H21EOLACvtfcHk0liNrENE435TMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXksFemtro%253D&md5=192f63e5fc42a0f3fddaa5f01c0d89fb</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DR.%26aulast%3DHarakal%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520ketamine%2520HCl%2520for%2520anti-depressant%2520activity%26jtitle%3DArch%2520Int.%2520Pharmacodyn.%2520Ther.%26date%3D1975%26volume%3D214%26spage%3D68%26epage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trullas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span> <span> </span><span class="NLM_article-title">Functional antagonists at the NMDA receptor complex exhibit antidepressant actions</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(90)90204-J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2F0014-2999%2890%2990204-J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=2171955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK3cXls1Gqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=1990&pages=1-10&author=R.+Trullasauthor=P.+Skolnick&title=Functional+antagonists+at+the+NMDA+receptor+complex+exhibit+antidepressant+actions&doi=10.1016%2F0014-2999%2890%2990204-J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Functional antagonists at the NMDA receptor complex exhibit antidepressant actions</span></div><div class="casAuthors">Trullas, Ramon; Skolnick, Phil</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">Inescapable, but not escapable, stress inhibits the induction of long-term potentiation (LTP) in the CA1 region of hippocampus, a process that is dependent upon activation of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.  Since inescapable stress also produces a syndrome of behavioral depression sensitive to clin. effective antidepressants, the actions of functional antagonists were examd. at the NMDA receptor complex in animal models commonly used to evaluate potential antidepressants.  A competitive NMDA antagonist 2-amino-7-phosphonoheptanoic acid (AP 7), a noncompetitive NMDA antagonist Dizolcipine (MK 801), and a partial agonist at strychnine-insensitive glycine receptors 1-aminocyclopropanecarboxylic acid (ACPC) mimicked the effects of clin. effective antidepressants in these models.  These findings indicate that the NMDA receptor complex may be involved in the behavioral deficits induced by inescapable stress, and that substances capable of reducing neurotransmission at the NMDA receptor complex may represent a new class of antidepressants.  Based on these findings, the hypothesis that pathways subserved by the NMDA subtype of glutamate receptors are involved in the pathophysiol. of affective disorders may have heuristic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofvVFlsLw007Vg90H21EOLACvtfcHk0liNrENE435TMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXls1Gqtbk%253D&md5=cf9c6c36e42862e7f6a093a79e5f6817</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2890%2990204-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252890%252990204-J%26sid%3Dliteratum%253Aachs%26aulast%3DTrullas%26aufirst%3DR.%26aulast%3DSkolnick%26aufirst%3DP.%26atitle%3DFunctional%2520antagonists%2520at%2520the%2520NMDA%2520receptor%2520complex%2520exhibit%2520antidepressant%2520actions%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1990%26volume%3D185%26spage%3D1%26epage%3D10%26doi%3D10.1016%2F0014-2999%2890%2990204-J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brutsche, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ameli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckenbaugh, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manji, H. K.</span></span> <span> </span><span class="NLM_article-title">A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">856</span>– <span class="NLM_lpage">864</span>, <span class="refDoi"> DOI: 10.1001/archpsyc.63.8.856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1001%2Farchpsyc.63.8.856" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=16894061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD28XovF2lsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2006&pages=856-864&author=C.+A.+Zarateauthor=J.+B.+Singhauthor=P.+J.+Carlsonauthor=N.+E.+Brutscheauthor=R.+Ameliauthor=D.+A.+Luckenbaughauthor=D.+S.+Charneyauthor=H.+K.+Manji&title=A+randomized+trial+of+an+N-methyl-D-aspartate+antagonist+in+treatment-resistant+major+depression&doi=10.1001%2Farchpsyc.63.8.856"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression</span></div><div class="casAuthors">Zarate, Carlos A., Jr.; Singh, Jaskaran B.; Carlson, Paul J.; Brutsche, Nancy E.; Ameli, Rezvan; Luckenbaugh, David A.; Charney, Dennis S.; Manji, Husseini K.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">856-864</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity.  Exploring pharmacol. strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care.  Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiol. and treatment of mood disorders.  To det. whether a rapid antidepressant effect can be achieved with an antagonist at the N-methyl-D-aspartate receptor in subjects with major depression.  A randomized, placebo-controlled, double-blind crossover study from Nov. 2004 to Sept. 2005.  Setting: Mood Disorders Research Unit at the National Institute of Mental Health.  Eighteen subjects with DSM-IV major depression (treatment resistant).  After a 2-wk drug-free period, subjects were given an i.v. infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart.  Subjects were rated at baseline and at 40, 80, 110, and 230 min and 1, 2, 3, and 7 days postinfusion.  Changes in scores on the primary efficacy measure, the 21-item Hamilton Depression Rating Scale.  Subjects receiving ketamine showed significant improvement in depression compared with subjects receiving placebo within 110 min after injection, which remained significant throughout the following week.  The effect size for the drug difference was very large (d=1.46 [95% confidence interval, 0.91-2.01]) after 24 h and moderate to large (d=0.68 [95% confidence interval, 0.13-1.23]) after 1 wk.  Of the 17 subjects treated with ketamine, 71% met response and 29% met remission criteria the day following ketamine infusion.  Thirty-five percent of subjects maintained response for at least 1 wk.  Robust and rapid antidepressant effects resulted from a single i.v. dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 h postinfusion and continued to remain significant for 1 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG5iDWz2z98LVg90H21EOLACvtfcHk0ljj1JlM2lCqfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovF2lsLo%253D&md5=dc1c435252fa602a404e35a260fa5ef1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.63.8.856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.63.8.856%26sid%3Dliteratum%253Aachs%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DSingh%26aufirst%3DJ.%2BB.%26aulast%3DCarlson%26aufirst%3DP.%2BJ.%26aulast%3DBrutsche%26aufirst%3DN.%2BE.%26aulast%3DAmeli%26aufirst%3DR.%26aulast%3DLuckenbaugh%26aufirst%3DD.%2BA.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DManji%26aufirst%3DH.%2BK.%26atitle%3DA%2520randomized%2520trial%2520of%2520an%2520N-methyl-D-aspartate%2520antagonist%2520in%2520treatment-resistant%2520major%2520depression%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2006%26volume%3D63%26spage%3D856%26epage%3D864%26doi%3D10.1001%2Farchpsyc.63.8.856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective</span>. <i>Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">613</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1111/pcn.12902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1111%2Fpcn.12902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=31215725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCjurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2019&pages=613-627&author=K.+Hashimoto&title=Rapid-acting+antidepressant+ketamine%2C+its+metabolites+and+other+candidates%3A+A+historical+overview+and+future+perspective&doi=10.1111%2Fpcn.12902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective</span></div><div class="casAuthors">Hashimoto, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry and Clinical Neurosciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">613-627</span>CODEN:
                <span class="NLM_cas:coden">PCNEFP</span>;
        ISSN:<span class="NLM_cas:issn">1323-1316</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence suggests that the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine produces rapid and sustained antidepressant effects in treatment-resistant patients with MDD or BD.  Ketamine is a racemic mixt. comprising equal parts of (R)-ketamine (or arketamine) and (S)-ketamine (or esketamine).  Because (S)-ketamine has higher affinity for NMDAR than (R)-ketamine, esketamine was developed as an antidepressant.  On 5 March 2019, esketamine nasal spray was approved by the US Food and Drug Administration.  However, preclin. data suggest that (R)-ketamine exerts greater potency and longer-lasting antidepressant effects than (S)-ketamine in animal models of depression and that (R)-ketamine has less detrimental side-effects than (R,S)-ketamine or (S)-ketamine.  In this article, the author reviews the historical overview of the antidepressant actions of enantiomers of ketamine and its major metabolites norketamine and hydroxynorketamine.  Furthermore, the author discusses the other potential rapid-acting antidepressant candidates (i.e., NMDAR antagonists and modulators, low-voltage-sensitive T-type calcium channel inhibitor, potassium channel Kir4.1 inhibitor, neg. modulators of γ-aminobutyric acid, and type A [GABAA] receptors) to compare them with ketamine.  Moreover, the mol. and cellular mechanisms of ketamine s antidepressant effects are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJMfLuDM80E7Vg90H21EOLACvtfcHk0ljj1JlM2lCqfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCjurzL&md5=c332c590edd834e5f38b8675c482020a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fpcn.12902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpcn.12902%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DRapid-acting%2520antidepressant%2520ketamine%252C%2520its%2520metabolites%2520and%2520other%2520candidates%253A%2520A%2520historical%2520overview%2520and%2520future%2520perspective%26jtitle%3DPsychiatry%2520Clin.%2520Neurosci.%26date%3D2019%26volume%3D73%26spage%3D613%26epage%3D627%26doi%3D10.1111%2Fpcn.12902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gould, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S. M.</span></span> <span> </span><span class="NLM_article-title">Molecular pharmacology and neurobiology of rapid-acting antidepressants</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010617-052811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1146%2Fannurev-pharmtox-010617-052811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30296896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOjtLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=213-236&author=T.+D.+Gouldauthor=C.+A.+Zarateauthor=S.+M.+Thompson&title=Molecular+pharmacology+and+neurobiology+of+rapid-acting+antidepressants&doi=10.1146%2Fannurev-pharmtox-010617-052811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants</span></div><div class="casAuthors">Gould, Todd D.; Zarate, Carlos A.; Thompson, Scott M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">213-236</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  For decades, symptoms of depression have been treated primarily with medications that directly target the monoaminergic brain systems, which typically take weeks to exert measurable effects and months to exert remission of symptoms.  Low, subanesthetic doses of (R,S)-ketamine (ketamine) result in the rapid improvement of core depressive symptoms, including mood, anhedonia, and suicidal ideation, occurring within hours following a single administration, with relief from symptoms typically lasting up to a week.  The discovery of these actions of ketamine has resulted in a reconceptualization of how depression could be more effectively treated in the future.  In this review, we discuss clin. data pertaining to ketamine and other rapid-acting antidepressant drugs, as well as the current state of pharmacol. knowledge regarding their mechanism of action.  Addnl., we discuss the neurobiol. circuits that are engaged by this drug class and that may be targeted by a future generation of medications, for example, hydroxynorketamine; metabotropic glutamate receptor 2/3 antagonists; and N-methyl-d-aspartate, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, and γ-aminobutyric acid receptor modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgU_1LWtV2xLVg90H21EOLACvtfcHk0lj24tQby3t2cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOjtLbO&md5=5cb69da4e6e99fdf5134e9a81235de71</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010617-052811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010617-052811%26sid%3Dliteratum%253Aachs%26aulast%3DGould%26aufirst%3DT.%2BD.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DThompson%26aufirst%3DS.%2BM.%26atitle%3DMolecular%2520pharmacology%2520and%2520neurobiology%2520of%2520rapid-acting%2520antidepressants%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2019%26volume%3D59%26spage%3D213%26epage%3D236%26doi%3D10.1146%2Fannurev-pharmtox-010617-052811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beautrais, A. L.</span></span> <span> </span><span class="NLM_article-title">A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1127</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1017/S1461145711000629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1017%2FS1461145711000629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=21557878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1eitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=1127-1131&author=G.+L.+Larkinauthor=A.+L.+Beautrais&title=A+preliminary+naturalistic+study+of+low-dose+ketamine+for+depression+and+suicide+ideation+in+the+emergency+department&doi=10.1017%2FS1461145711000629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department</span></div><div class="casAuthors">Larkin, Gregory Luke; Beautrais, Annette L.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1127-1131</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">We examd. the preliminary feasibility, tolerability and efficacy of single-dose, i.v. ketamine in depressed emergency department (ED) patients with suicide ideation (SI).  Fourteen depressed ED patients with SI received a single i.v. bolus of ketamine (0.2 mg/kg) over 1-2 min.  Patients were monitored for 4 h, then re-contacted daily for 10 d.  Treatment response and time to remission were evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS) and Kaplan-Meier survival anal., resp.  Mean MADRS scores fell significantly from 40.4 (s.e.m. = 1.8) at baseline to 11.5 (s.e.m. = 2.2) at 240 min.  Median time to MADRS score ≤10 was 80 min (interquartile range 0.67-24 h).  SI scores (MADRS item 10) decreased significantly from 3.9 (s.e.m. = 0.4) at baseline to 0.6 (s.e.m. = 0.2) after 40 min post-administration; SI improvements were sustained over 10 d.  These data provide preliminary, open-label support for the feasibility and efficacy of ketamine as a rapid-onset antidepressant in the ED.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3n1-ulQFRRLVg90H21EOLACvtfcHk0lj24tQby3t2cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1eitb4%253D&md5=baa32d2ac03c9ed00a6884ec7e57fb0f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1017%2FS1461145711000629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145711000629%26sid%3Dliteratum%253Aachs%26aulast%3DLarkin%26aufirst%3DG.%2BL.%26aulast%3DBeautrais%26aufirst%3DA.%2BL.%26atitle%3DA%2520preliminary%2520naturalistic%2520study%2520of%2520low-dose%2520ketamine%2520for%2520depression%2520and%2520suicide%2520ideation%2520in%2520the%2520emergency%2520department%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2011%26volume%3D14%26spage%3D1127%26epage%3D1131%26doi%3D10.1017%2FS1461145711000629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueorguieva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span> <span> </span><span class="NLM_article-title">Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2482</span>– <span class="NLM_lpage">2492</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.94</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnpp.2017.94" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=28492279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFGhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=2482-2492&author=T.-P.+Suauthor=M.-H.+Chenauthor=C.-T.+Liauthor=W.-C.+Linauthor=C.-J.+Hongauthor=R.+Gueorguievaauthor=P.-C.+Tuauthor=Y.-M.+Baiauthor=C.-M.+Chengauthor=J.+H.+Krystal&title=Dose-related+effects+of+adjunctive+ketamine+in+Taiwanese+patients+with+treatment-resistant+depression&doi=10.1038%2Fnpp.2017.94"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression</span></div><div class="casAuthors">Su, Tung-Ping; Chen, Mu-Hong; Li, Cheng-Ta; Lin, Wei-Chen; Hong, Chen-Jee; Gueorguieva, Ralitza; Tu, Pei-Chi; Bai, Ya-Mei; Cheng, Chih-Ming; Krystal, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2482-2492</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The antidepressant effects of ketamine are thought to depend on brain-derived neurotrophic factor (BDNF) genotype and dose.  The purpose of this study was to characterize the dose-related antidepressant effects of ketamine in patients with treatment-resistant depression drawn from a Chinese population predominately possessing lower activity BDNF genotypes (Val/Met, Met/Met).  We conducted a double-blind, randomized, parallel-group, placebo-controlled trial of a single ketamine infusion (saline, 0.2 mg/kg, 0.5 mg/kg).  Patients (N=71; BDNF genotype: Val/Val (N=12, 17%), Val/Met (N=40, 56.3%), and Met/Met (N=19, 26.8%)) received mood ratings before infusion, after infusion, and for the subsequent 14 days.  Plasma ketamine levels and BDNF genotypes were assessed.  This study found a significant dose-related ketamine effect on scores on the Hamilton Depression Rating Scale (HAMD).  The responder anal. (>50% redn. from baseline HAMD on at least 2 days between days 2 and 5) also revealed a significant dose-related effect (saline: 12.5%, 0.2 mg/kg: 39.1%; 0.5 mg/kg: 45.8%).  This is the first report to our knowledge to demonstrate the dose-related efficacy of R/S-ketamine for treatment-resistant depression and the first to characterize ketamine effects in a genotyped Chinese population in which most (83%) patients possessed at least one copy of the lower functioning Met allele of the BDNF gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCoQDDPQblILVg90H21EOLACvtfcHk0lj24tQby3t2cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFGhu74%253D&md5=38c9f0256aa7c7ee7f0d5aa61e3adec4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.94&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.94%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DT.-P.%26aulast%3DChen%26aufirst%3DM.-H.%26aulast%3DLi%26aufirst%3DC.-T.%26aulast%3DLin%26aufirst%3DW.-C.%26aulast%3DHong%26aufirst%3DC.-J.%26aulast%3DGueorguieva%26aufirst%3DR.%26aulast%3DTu%26aufirst%3DP.-C.%26aulast%3DBai%26aufirst%3DY.-M.%26aulast%3DCheng%26aufirst%3DC.-M.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26atitle%3DDose-related%2520effects%2520of%2520adjunctive%2520ketamine%2520in%2520Taiwanese%2520patients%2520with%2520treatment-resistant%2520depression%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D2482%26epage%3D2492%26doi%3D10.1038%2Fnpp.2017.94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murrough, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iosifescu, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Jurdi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillemer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foulkes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">1134</span>– <span class="NLM_lpage">1142</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2013.13030392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1176%2Fappi.ajp.2013.13030392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=23982301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC3sbivVeluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=1134-1142&author=J.+W.+Murroughauthor=D.+V.+Iosifescuauthor=L.+C.+Changauthor=R.+K.+Al+Jurdiauthor=C.+E.+Greenauthor=A.+M.+Perezauthor=S.+Iqbalauthor=S.+Pillemerauthor=A.+Foulkesauthor=A.+Shah&title=Antidepressant+efficacy+of+ketamine+in+treatment-resistant+major+depression%3A+a+two-site+randomized+controlled+trial&doi=10.1176%2Fappi.ajp.2013.13030392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial</span></div><div class="casAuthors">Murrough James W; Iosifescu Dan V; Chang Lee C; Al Jurdi Rayan K; Green Charles E; Perez Andrew M; Iqbal Syed; Pillemer Sarah; Foulkes Alexandra; Shah Asim; Charney Dennis S; Mathew Sanjay J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1134-42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has shown rapid antidepressant effects, but small study groups and inadequate control conditions in prior studies have precluded a definitive conclusion.  The authors evaluated the rapid antidepressant efficacy of ketamine in a large group of patients with treatment-resistant major depression.  METHOD:  This was a two-site, parallel-arm, randomized controlled trial of a single infusion of ketamine compared to an active placebo control condition, the anesthetic midazolam.  Patients with treatment-resistant major depression experiencing a major depressive episode were randomly assigned under double-blind conditions to receive a single intravenous infusion of ketamine or midazolam in a 2:1 ratio (N=73).  The primary outcome was change in depression severity 24 hours after drug administration, as assessed by the Montgomery-ÅAsberg Depression Rating Scale (MADRS).  RESULTS:  The ketamine group had greater improvement in the MADRS score than the midazolam group 24 hours after treatment.  After adjustment for baseline scores and site, the MADRS score was lower in the ketamine group than in the midazolam group by 7.95 points (95% confidence interval [CI], 3.20 to 12.71).  The likelihood of response at 24 hours was greater with ketamine than with midazolam (odds ratio, 2.18; 95% CI, 1.21 to 4.14), with response rates of 64% and 28%, respectively.  CONCLUSIONS:  Ketamine demonstrated rapid antidepressant effects in an optimized study design, further supporting NMDA receptor modulation as a novel mechanism for accelerated improvement in severe and chronic forms of depression.  More information on response durability and safety is required before implementation in clinical practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTK3l9x7dQJ9DEwO064Z95rfW6udTcc2eZObwbH69DFr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbivVeluw%253D%253D&md5=69bb383250da1e7a6824a593541aa214</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2013.13030392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2013.13030392%26sid%3Dliteratum%253Aachs%26aulast%3DMurrough%26aufirst%3DJ.%2BW.%26aulast%3DIosifescu%26aufirst%3DD.%2BV.%26aulast%3DChang%26aufirst%3DL.%2BC.%26aulast%3DAl%2BJurdi%26aufirst%3DR.%2BK.%26aulast%3DGreen%26aufirst%3DC.%2BE.%26aulast%3DPerez%26aufirst%3DA.%2BM.%26aulast%3DIqbal%26aufirst%3DS.%26aulast%3DPillemer%26aufirst%3DS.%26aulast%3DFoulkes%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DA.%26atitle%3DAntidepressant%2520efficacy%2520of%2520ketamine%2520in%2520treatment-resistant%2520major%2520depression%253A%2520a%2520two-site%2520randomized%2520controlled%2520trial%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2013%26volume%3D170%26spage%3D1134%26epage%3D1142%26doi%3D10.1176%2Fappi.ajp.2013.13030392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murrough, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soleimani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWilde, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacoviello, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lener, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kautz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial</span>. <i>Psychol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3571</span>, <span class="refDoi"> DOI: 10.1017/S0033291715001506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1017%2FS0033291715001506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26266877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC287itVaqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=3571&author=J.+W.+Murroughauthor=L.+Soleimaniauthor=K.+DeWildeauthor=K.+Collinsauthor=K.+Lapidusauthor=B.+Iacovielloauthor=M.+Lenerauthor=M.+Kautzauthor=J.+Kimauthor=J.+Stern&title=Ketamine+for+rapid+reduction+of+suicidal+ideation%3A+a+randomized+controlled+trial&doi=10.1017%2FS0033291715001506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial</span></div><div class="casAuthors">Murrough J W; Soleimani L; DeWilde K E; Collins K A; Iacoviello B M; Lener M; Kautz M; Iosifescu D V; Charney D S; Lapidus K A; Kim J; Stern J B; Price R B; Perez A M; Brallier J W; Rodriguez G J; Goodman W K</div><div class="citationInfo"><span class="NLM_cas:title">Psychological medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3571-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Suicide is a devastating public health problem and very few biological treatments have been found to be effective for quickly reducing the intensity of suicidal ideation (SI).  We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression.  METHOD:  We conducted a randomized, controlled trial of ketamine in patients with mood and anxiety spectrum disorders who presented with clinically significant SI (n = 24).  Patients received a single infusion of ketamine or midazolam (as an active placebo) in addition to standard of care.  SI measured using the Beck Scale for Suicidal Ideation (BSI) 24 h post-treatment represented the primary outcome.  Secondary outcomes included the Montgomery-Asberg Depression Rating Scale--Suicidal Ideation (MADRS-SI) score at 24 h and additional measures beyond the 24-h time-point.  RESULTS:  The intervention was well tolerated and no dropouts occurred during the primary 7-day assessment period.  BSI score was not different between the treatment groups at 24 h (p = 0.32); however, a significant difference emerged at 48 h (p = 0.047).  MADRS-SI score was lower in the ketamine group compared to midazolam group at 24 h (p = 0.05).  The treatment effect was no longer significant at the end of the 7-day assessment period.  CONCLUSIONS:  The current findings provide initial support for the safety and tolerability of ketamine as an intervention for SI in patients who are at elevated risk for suicidal behavior.  Larger, well-powered studies are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyrVioJTA195Pq5LRczm8ffW6udTcc2eZObwbH69DFr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287itVaqsw%253D%253D&md5=c9eb9a5c60ebce2066430b1229d24609</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1017%2FS0033291715001506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0033291715001506%26sid%3Dliteratum%253Aachs%26aulast%3DMurrough%26aufirst%3DJ.%2BW.%26aulast%3DSoleimani%26aufirst%3DL.%26aulast%3DDeWilde%26aufirst%3DK.%26aulast%3DCollins%26aufirst%3DK.%26aulast%3DLapidus%26aufirst%3DK.%26aulast%3DIacoviello%26aufirst%3DB.%26aulast%3DLener%26aufirst%3DM.%26aulast%3DKautz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DStern%26aufirst%3DJ.%26atitle%3DKetamine%2520for%2520rapid%2520reduction%2520of%2520suicidal%2520ideation%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DPsychol.%2520Med.%26date%3D2015%26volume%3D45%26spage%3D3571%26doi%3D10.1017%2FS0033291715001506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grunebaum, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galfalvy, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, T.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilp, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moitra, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parris, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marver, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milak, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sublette, M. E.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2017.17060647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1176%2Fappi.ajp.2017.17060647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29202655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ns12htw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=327-335&author=M.+F.+Grunebaumauthor=H.+C.+Galfalvyauthor=T.-H.+Chooauthor=J.+G.+Keilpauthor=V.+K.+Moitraauthor=M.+S.+Parrisauthor=J.+E.+Marverauthor=A.+K.+Burkeauthor=M.+S.+Milakauthor=M.+E.+Sublette&title=Ketamine+for+rapid+reduction+of+suicidal+thoughts+in+major+depression%3A+a+midazolam-controlled+randomized+clinical+trial&doi=10.1176%2Fappi.ajp.2017.17060647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial</span></div><div class="casAuthors">Grunebaum Michael F; Galfalvy Hanga C; Choo Tse-Hwei; Keilp John G; Moitra Vivek K; Parris Michelle S; Marver Julia E; Burke Ainsley K; Milak Matthew S; Sublette M Elizabeth; Oquendo Maria A; Mann J John</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">327-335</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce suicide risk.  Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation.  The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major depressive disorder.  METHOD:  In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score ≥4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion.  The primary outcome measure was SSI score 24 hours after infusion (at day 1).  RESULTS:  The reduction in SSI score at day 1 was 4.96 points greater for the ketamine group compared with the midazolam group (95% CI=2.33, 7.59; Cohen's d=0.75).  The proportion of responders (defined as having a reduction ≥50% in SSI score) at day 1 was 55% for the ketamine group and 30% for the midazolam group (odds ratio=2.85, 95% CI=1.14, 7.15; number needed to treat=4.0).  Improvement in the Profile of Mood States depression subscale was greater at day 1 for the ketamine group compared with the midazolam group (estimate=7.65, 95% CI=1.36, 13.94), and this effect mediated 33.6% of ketamine's effect on SSI score.  Side effects were short-lived, and clinical improvement was maintained for up to 6 weeks with additional optimized standard pharmacotherapy in an uncontrolled follow-up.  CONCLUSIONS:  Adjunctive ketamine demonstrated a greater reduction in clinically significant suicidal ideation in depressed patients within 24 hours compared with midazolam, partially independently of antidepressant effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQh8z9TZaL7U2gRQsDqrjW_fW6udTcc2eY24WHb42znjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ns12htw%253D%253D&md5=6d562a138b50baab953a6e22267bc73e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2017.17060647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2017.17060647%26sid%3Dliteratum%253Aachs%26aulast%3DGrunebaum%26aufirst%3DM.%2BF.%26aulast%3DGalfalvy%26aufirst%3DH.%2BC.%26aulast%3DChoo%26aufirst%3DT.-H.%26aulast%3DKeilp%26aufirst%3DJ.%2BG.%26aulast%3DMoitra%26aufirst%3DV.%2BK.%26aulast%3DParris%26aufirst%3DM.%2BS.%26aulast%3DMarver%26aufirst%3DJ.%2BE.%26aulast%3DBurke%26aufirst%3DA.%2BK.%26aulast%3DMilak%26aufirst%3DM.%2BS.%26aulast%3DSublette%26aufirst%3DM.%2BE.%26atitle%3DKetamine%2520for%2520rapid%2520reduction%2520of%2520suicidal%2520thoughts%2520in%2520major%2520depression%253A%2520a%2520midazolam-controlled%2520randomized%2520clinical%2520trial%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2018%26volume%3D175%26spage%3D327%26epage%3D335%26doi%3D10.1176%2Fappi.ajp.2017.17060647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zorumski, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennerick, S.</span></span> <span> </span><span class="NLM_article-title">Ketamine: NMDA receptors and beyond</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">11158</span>– <span class="NLM_lpage">11164</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.1547-16.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1523%2FJNEUROSCI.1547-16.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27807158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Ohuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=11158-11164&author=C.+F.+Zorumskiauthor=Y.+Izumiauthor=S.+Mennerick&title=Ketamine%3A+NMDA+receptors+and+beyond&doi=10.1523%2FJNEUROSCI.1547-16.2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: NMDA receptors and beyond</span></div><div class="casAuthors">Zorumski, Charles F.; Izumi, Yukitoshi; Mennerick, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">11158-11164</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Human studies examg. the effects of the dissociative anesthetic ketamine as a model for psychosis and as a rapidly acting antidepressant have spurred great interest in understanding ketamine's actions at mol., cellular, and network levels.  Although ketamine has unequivocal uncompetitive inhibitory effects on N-methyl-d-aspartate receptors (NMDARs) and may preferentially alter the function of NMDARs on interneurons, recent work has questioned whether block of NMDARs is crit. for its mood enhancing actions.  In this viewpoint, we examine the evolving literature on ketamine supporting NMDARs as important triggers for certain psychiatric effects and the possibility that the antidepressant trigger is unrelated to NMDARs.  The rapidly evolving story of ketamine offers great hope for untangling and treating the biol. of both depressive and psychotic illnesses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZHmks6tBEArVg90H21EOLACvtfcHk0ljogKYvZsCbvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Ohuro%253D&md5=c01604b55dcce286edcfa5add52f82f2</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1547-16.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1547-16.2016%26sid%3Dliteratum%253Aachs%26aulast%3DZorumski%26aufirst%3DC.%2BF.%26aulast%3DIzumi%26aufirst%3DY.%26aulast%3DMennerick%26aufirst%3DS.%26atitle%3DKetamine%253A%2520NMDA%2520receptors%2520and%2520beyond%26jtitle%3DJ.%2520Neurosci.%26date%3D2016%26volume%3D36%26spage%3D11158%26epage%3D11164%26doi%3D10.1523%2FJNEUROSCI.1547-16.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, T. D.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of ketamine action as an antidepressant</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">801</span>– <span class="NLM_lpage">811</span>, <span class="refDoi"> DOI: 10.1038/mp.2017.255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fmp.2017.255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29532791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=801-811&author=P.+Zanosauthor=T.+D.+Gould&title=Mechanisms+of+ketamine+action+as+an+antidepressant&doi=10.1038%2Fmp.2017.255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of ketamine action as an antidepressant</span></div><div class="casAuthors">Zanos, P.; Gould, T. D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">801-811</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Clin. studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions.  Although this finding has been met with enthusiasm, ketamine's widespread use is limited by its abuse potential and dissociative properties.  Recent preclin. research has focused on unraveling the mol. mechanisms underlying the antidepressant actions of ketamine in an effort to develop novel pharmacotherapies, which will mimic ketamine's antidepressant actions but lack its undesirable effects.  Here we review hypotheses for the mechanism of action of ketamine as an antidepressant, including synaptic or GluN2B-selective extra-synaptic N-methyl-D-aspartate receptor (NMDAR) inhibition, inhibition of NMDARs localized on GABAergic interneurons, inhibition of NMDAR-dependent burst firing of lateral habenula neurons, and the role of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor activation.  We also discuss links between ketamine's antidepressant actions and downstream mechanisms regulating synaptic plasticity, including brain-derived neurotrophic factor (BDNF), eukaryotic elongation factor 2 (eEF2), mechanistic target of rapamycin (mTOR) and glycogen synthase kinase-3 (GSK-3).  Mechanisms that do not involve direct inhibition of the NMDAR, including a role for ketamine's (R)-ketamine enantiomer and hydroxynorketamine (HNK) metabolites, specifically (2R,6R)-HNK, are also discussed.  Proposed mechanisms of ketamine's action are not mutually exclusive and may act in a complementary manner to exert acute changes in synaptic plasticity, leading to sustained strengthening of excitatory synapses, which are necessary for antidepressant behavioral actions.  Understanding the mol. mechanisms underpinning ketamine's antidepressant actions will be invaluable for the identification of targets, which will drive the development of novel, effective, next-generation pharmacotherapies for the treatment of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Tp-KuHNxHbVg90H21EOLACvtfcHk0ljogKYvZsCbvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGqtLo%253D&md5=4ad9b04daba1abb6f408b976c8d75463</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fmp.2017.255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2017.255%26sid%3Dliteratum%253Aachs%26aulast%3DZanos%26aufirst%3DP.%26aulast%3DGould%26aufirst%3DT.%2BD.%26atitle%3DMechanisms%2520of%2520ketamine%2520action%2520as%2520an%2520antidepressant%26jtitle%3DMol.%2520Psychiatry%26date%3D2018%26volume%3D23%26spage%3D801%26epage%3D811%26doi%3D10.1038%2Fmp.2017.255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, D.</span></span> <span> </span><span class="NLM_article-title">Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2921</span>– <span class="NLM_lpage">2927</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.17-08-02921.1997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1523%2FJNEUROSCI.17-08-02921.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=9092613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK2sXisValurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=2921-2927&author=B.+Moghaddamauthor=B.+Adamsauthor=A.+Vermaauthor=D.+Daly&title=Activation+of+glutamatergic+neurotransmission+by+ketamine%3A+a+novel+step+in+the+pathway+from+NMDA+receptor+blockade+to+dopaminergic+and+cognitive+disruptions+associated+with+the+prefrontal+cortex&doi=10.1523%2FJNEUROSCI.17-08-02921.1997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex</span></div><div class="casAuthors">Moghaddam, Bita; Adams, Barbara; Verma, Anita; Daly, Darron</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2921-2927</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Subanesthetic doses of ketamine, a noncompetitive NMDA receptor antagonist, impair prefrontal cortex (PFC) function in the rat and produce symptoms in humans similar to those obsd. in schizophrenia and dissociative states, including impaired performance of frontal lobe-sensitive tests.  Several lines of evidence suggest that ketamine may impair PFC function in part by interacting with dopamine neurotransmission in this region.  This study sought to det. the mechanism by which ketamine may disrupt dopaminergic neurotransmission in, and cognitive functions assocd. with, the PFC.  A thorough dose-response study using microdialysis in conscious rats indicated that low doses of ketamine (10, 20, and 30 mg/kg) increase glutamate outflow in the PFC, suggesting that at these doses ketamine may increase glutamatergic neurotransmission in the PFC at non-NMDA glutamate receptors.  An anesthetic dose of ketamine (200 mg/kg) decreased, and an intermediate dose of 50 mg/kg did not affect, glutamate levels.  Ketamine, at 30 mg/kg, also increased the release of dopamine in the PFC.  This increase was blocked by intra-PFC application of the AMPA/kainate receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione CNQX.  Furthermore, ketamine-induced activation of dopamine release and impairment of spatial delayed alternation in the rodent, a PFC-sensitive cognitive task, was ameliorated by systemic pretreatment with AMPA/kainate receptor antagonist LY293558.  These findings suggest that ketamine may disrupt dopaminergic neurotransmission in the PFC as well as cognitive functions assocd. with this region, in part, by increasing the release of glutamate, thereby stimulating postsynaptic non-NMDA glutamate receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKNWCBwx_sLVg90H21EOLACvtfcHk0lgcNnM3Ld7f1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisValurk%253D&md5=74f7a1696b2c30f0a38e34963334eb0b</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.17-08-02921.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.17-08-02921.1997%26sid%3Dliteratum%253Aachs%26aulast%3DMoghaddam%26aufirst%3DB.%26aulast%3DAdams%26aufirst%3DB.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DDaly%26aufirst%3DD.%26atitle%3DActivation%2520of%2520glutamatergic%2520neurotransmission%2520by%2520ketamine%253A%2520a%2520novel%2520step%2520in%2520the%2520pathway%2520from%2520NMDA%2520receptor%2520blockade%2520to%2520dopaminergic%2520and%2520cognitive%2520disruptions%2520associated%2520with%2520the%2520prefrontal%2520cortex%26jtitle%3DJ.%2520Neurosci.%26date%3D1997%26volume%3D17%26spage%3D2921%26epage%3D2927%26doi%3D10.1523%2FJNEUROSCI.17-08-02921.1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Homayoun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, B.</span></span> <span> </span><span class="NLM_article-title">NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">11496</span>– <span class="NLM_lpage">11500</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.2213-07.2007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1523%2FJNEUROSCI.2213-07.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=17959792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Kms7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=11496-11500&author=H.+Homayounauthor=B.+Moghaddam&title=NMDA+receptor+hypofunction+produces+opposite+effects+on+prefrontal+cortex+interneurons+and+pyramidal+neurons&doi=10.1523%2FJNEUROSCI.2213-07.2007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons</span></div><div class="casAuthors">Homayoun, Houman; Moghaddam, Bita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">11496-11500</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">NMDA receptors mediate excitatory postsynaptic potentials throughout the brain but, paradoxically, NMDA receptor antagonists produce cortical excitation in humans and behaving rodents.  To elucidate a mechanism for these diverging effects, we examd. the effect of use-dependent inhibition of NMDA receptors on the spontaneous activity of putative GABA interneurons and pyramidal neurons in the prefrontal cortex of awake rats.  We find that inhibition of NMDA receptors predominately decreases the activity of putative GABA interneurons but, at a delayed rate, increases the firing rate of the majority of pyramidal neurons.  Thus, NMDA receptors preferentially drive the activity of cortical inhibitory interneurons suggesting that NMDA receptor inhibition causes cortical excitation by disinhibition of pyramidal neurons.  These findings support the hypothesis that NMDA receptor hypofunction, which has been implicated in the pathophysiol. of schizophrenia, diminishes the inhibitory control of PFC output neurons.  Reducing this effect may be crit. for treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphTQMv9YbXkrVg90H21EOLACvtfcHk0lgcNnM3Ld7f1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Kms7zK&md5=bb02a5b8f8b33e213c1a87f8e42530ff</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2213-07.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2213-07.2007%26sid%3Dliteratum%253Aachs%26aulast%3DHomayoun%26aufirst%3DH.%26aulast%3DMoghaddam%26aufirst%3DB.%26atitle%3DNMDA%2520receptor%2520hypofunction%2520produces%2520opposite%2520effects%2520on%2520prefrontal%2520cortex%2520interneurons%2520and%2520pyramidal%2520neurons%26jtitle%3DJ.%2520Neurosci.%26date%3D2007%26volume%3D27%26spage%3D11496%26epage%3D11500%26doi%3D10.1523%2FJNEUROSCI.2213-07.2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banasr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajanian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span> <span> </span><span class="NLM_article-title">mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1126/science.1190287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1126%2Fscience.1190287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=20724638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaqurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2010&pages=959-964&author=N.+Liauthor=B.+Leeauthor=R.-J.+Liuauthor=M.+Banasrauthor=J.+M.+Dwyerauthor=M.+Iwataauthor=X.-Y.+Liauthor=G.+Aghajanianauthor=R.+S.+Duman&title=mTOR-dependent+synapse+formation+underlies+the+rapid+antidepressant+effects+of+NMDA+antagonists&doi=10.1126%2Fscience.1190287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists</span></div><div class="casAuthors">Li, Nanxin; Lee, Boyoung; Liu, Rong-Jian; Banasr, Mounira; Dwyer, Jason M.; Iwata, Masaaki; Li, Xiao-Yuan; Aghajanian, George; Duman, Ronald S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">5994</span>),
    <span class="NLM_cas:pages">959-964</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The rapid antidepressant response after ketamine administration in treatment-resistant depressed patients suggests a possible new approach for treating mood disorders compared to the weeks or months required for std. medications.  However, the mechanisms underlying this action of ketamine [a glutamate N-methyl-D-aspartic acid (NMDA) receptor antagonist] have not been identified.  We obsd. that ketamine rapidly activated the mammalian target of rapamycin (mTOR) pathway, leading to increased synaptic signaling proteins and increased no. and function of new spine synapses in the prefrontal cortex of rats.  Moreover, blockade of mTOR signaling completely blocked ketamine induction of synaptogenesis and behavioral responses in models of depression.  Our results demonstrate that these effects of ketamine are opposite to the synaptic deficits that result from exposure to stress and could contribute to the fast antidepressant actions of ketamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpup6dg0BLy6bVg90H21EOLACvtfcHk0liVr0GRlOh9Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaqurzI&md5=10e346a65ae3aa8eb30f16fccbda28b3</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1126%2Fscience.1190287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1190287%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DR.-J.%26aulast%3DBanasr%26aufirst%3DM.%26aulast%3DDwyer%26aufirst%3DJ.%2BM.%26aulast%3DIwata%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.-Y.%26aulast%3DAghajanian%26aufirst%3DG.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DmTOR-dependent%2520synapse%2520formation%2520underlies%2520the%2520rapid%2520antidepressant%2520effects%2520of%2520NMDA%2520antagonists%26jtitle%3DScience%26date%3D2010%26volume%3D329%26spage%3D959%26epage%3D964%26doi%3D10.1126%2Fscience.1190287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monteggia, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gideons, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavalali, E. T.</span></span> <span> </span><span class="NLM_article-title">The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2012.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2012.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=23062356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1199-1203&author=L.+M.+Monteggiaauthor=E.+Gideonsauthor=E.+T.+Kavalali&title=The+role+of+eukaryotic+elongation+factor+2+kinase+in+rapid+antidepressant+action+of+ketamine&doi=10.1016%2Fj.biopsych.2012.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Eukaryotic Elongation Factor 2 Kinase in Rapid Antidepressant Action of Ketamine</span></div><div class="casAuthors">Monteggia, Lisa M.; Gideons, Erinn; Kavalali, Ege T.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1199-1203</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Major depressive disorder is a devastating mental disorder.  Current antidepressant medications can be effective for some patients with depression; however, these drugs exert mood-elevating effects only after prolonged administration, and a sizable fraction of the patient population fails to respond to treatment.  There is an urgent need for faster-acting antidepressants with reliable treatment outcomes and sustained efficacy for individuals with depression, in particular those contemplating suicide.  Recent clin. studies report that ketamine, an ionotropic glutamatergic N-methyl-D-aspartate (NMDA) receptor blocker, shows fast-acting antidepressant action, thus bringing fresh perspective into preclin. studies investigating novel antidepressant targets and treatments.  Our recent studies show that the effects of ketamine are dependent on brain-derived neurotrophic factor (BDNF) and subsequent activation of the high-affinity BDNF receptor, TrkB.  Our findings also suggest that the fast-acting antidepressant effects of ketamine require rapid protein translation, but not transcription, resulting in robust increases in dendritic BDNF protein levels that are important for the behavioral effect.  These findings also uncover eukaryotic elongation factor 2 kinase (eEF2K), a Ca2+/calmodulin dependent serine/threonine kinase that phosphorylates eEF2 and regulates the elongation step of protein translation, as a major mol. substrate mediating the rapid antidepressant effect of ketamine.  Our results show that ketamine-mediated suppression of resting NMDA receptor activity leads to inhibition of eEF2 kinase and subsequent dephosphorylation of eEF2 and augmentation of BDNF synthesis.  This article outlines our recent studies on the synaptic mechanisms that underlie ketamine action, in particular the properties of eEF2K as a potential antidepressant target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMxq-boIeY5rVg90H21EOLACvtfcHk0liVr0GRlOh9Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsbjE&md5=d8c874fa212e2dca424474e5224f1a7e</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2012.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2012.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DMonteggia%26aufirst%3DL.%2BM.%26aulast%3DGideons%26aufirst%3DE.%26aulast%3DKavalali%26aufirst%3DE.%2BT.%26atitle%3DThe%2520role%2520of%2520eukaryotic%2520elongation%2520factor%25202%2520kinase%2520in%2520rapid%2520antidepressant%2520action%2520of%2520ketamine%26jtitle%3DBiol.%2520Psychiatry%26date%3D2013%26volume%3D73%26spage%3D1199%26epage%3D1203%26doi%3D10.1016%2Fj.biopsych.2012.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Autry, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosyreva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, P.-f.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavalali, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteggia, L. M.</span></span> <span> </span><span class="NLM_article-title">NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>475</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1038/nature10130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnature10130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=21677641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFOktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=475&publication_year=2011&pages=91-95&author=A.+E.+Autryauthor=M.+Adachiauthor=E.+Nosyrevaauthor=E.+S.+Naauthor=M.+F.+Losauthor=P.-f.+Chengauthor=E.+T.+Kavalaliauthor=L.+M.+Monteggia&title=NMDA+receptor+blockade+at+rest+triggers+rapid+behavioural+antidepressant+responses&doi=10.1038%2Fnature10130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses</span></div><div class="casAuthors">Autry, Anita E.; Adachi, Megumi; Nosyreva, Elena; Na, Elisa S.; Los, Maarten F.; Cheng, Peng-fei; Kavalali, Ege T.; Monteggia, Lisa M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">475</span>
        (<span class="NLM_cas:issue">7354</span>),
    <span class="NLM_cas:pages">91-95</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Clin. studies consistently demonstrate that a single sub-psychomimetic dose of ketamine, an ionotropic glutamatergic NMDAR (N-methyl-D-aspartate receptor) antagonist, produces fast-acting antidepressant responses in patients suffering from major depressive disorder, although the underlying mechanism is unclear.  Depressed patients report the alleviation of major depressive disorder symptoms within two hours of a single, low-dose i.v. infusion of ketamine, with effects lasting up to two weeks, unlike traditional antidepressants (serotonin re-uptake inhibitors), which take weeks to reach efficacy.  This delay is a major drawback to current therapies for major depressive disorder and faster-acting antidepressants are needed, particularly for suicide-risk patients.  The ability of ketamine to produce rapidly acting, long-lasting antidepressant responses in depressed patients provides a unique opportunity to investigate underlying cellular mechanisms.  Here we show that ketamine and other NMDAR antagonists produce fast-acting behavioral antidepressant-like effects in mouse models, and that these effects depend on the rapid synthesis of brain-derived neurotrophic factor.  We find that the ketamine-mediated blockade of NMDAR at rest deactivates eukaryotic elongation factor 2 (eEF2) kinase (also called CaMKIII), resulting in reduced eEF2 phosphorylation and de-suppression of translation of brain-derived neurotrophic factor.  Furthermore, we find that inhibitors of eEF2 kinase induce fast-acting behavioral antidepressant-like effects.  Our findings indicate that the regulation of protein synthesis by spontaneous neurotransmission may serve as a viable therapeutic target for the development of fast-acting antidepressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxV9Fl5NiW-rVg90H21EOLACvtfcHk0liVr0GRlOh9Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFOktbw%253D&md5=4f3aadd45b6e5fbd2f26ddd36939321b</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnature10130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10130%26sid%3Dliteratum%253Aachs%26aulast%3DAutry%26aufirst%3DA.%2BE.%26aulast%3DAdachi%26aufirst%3DM.%26aulast%3DNosyreva%26aufirst%3DE.%26aulast%3DNa%26aufirst%3DE.%2BS.%26aulast%3DLos%26aufirst%3DM.%2BF.%26aulast%3DCheng%26aufirst%3DP.-f.%26aulast%3DKavalali%26aufirst%3DE.%2BT.%26aulast%3DMonteggia%26aufirst%3DL.%2BM.%26atitle%3DNMDA%2520receptor%2520blockade%2520at%2520rest%2520triggers%2520rapid%2520behavioural%2520antidepressant%2520responses%26jtitle%3DNature%26date%3D2011%26volume%3D475%26spage%3D91%26epage%3D95%26doi%3D10.1038%2Fnature10130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargroder, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delpire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, B. J.</span></span> <span> </span><span class="NLM_article-title">GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e03581</span>, <span class="refDoi"> DOI: 10.7554/eLife.03581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.7554%2FeLife.03581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=25340958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOmtr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=e03581&author=O.+H.+Millerauthor=L.+Yangauthor=C.-C.+Wangauthor=E.+A.+Hargroderauthor=Y.+Zhangauthor=E.+Delpireauthor=B.+J.+Hall&title=GluN2B-containing+NMDA+receptors+regulate+depression-like+behavior+and+are+critical+for+the+rapid+antidepressant+actions+of+ketamine&doi=10.7554%2FeLife.03581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine</span></div><div class="casAuthors">Miller, Oliver H.; Yang, Lingling; Wang, Chih-Chieh; Hargroder, Elizabeth A.; Zhang, Yihui; Delpire, Eric; Hall, Benjamin J.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">03581/1-03581/37, 37 pp.</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">A single, low dose of the NMDA receptor antagonist ketamine produces rapid antidepressant actions in treatment-resistant depressed patients.  Understanding the cellular mechanisms underlying this will lead to new therapies for treating major depression.  NMDARs are heteromultimeric complexes formed through assocn. of two GluN1 and two GluN2 subunits.  We show that in vivo deletion of GluN2B, only from principal cortical neurons, mimics and occludes ketamine's actions on depression-like behavior and excitatory synaptic transmission.  Furthermore, ketamine-induced increases in mTOR activation and synaptic protein synthesis were mimicked and occluded in 2BΔCtx mice.  We show here that cortical GluN2B-contg. NMDARs are uniquely activated by ambient glutamate to regulate levels of excitatory synaptic transmission.  Together these data predict a novel cellular mechanism that explains ketamine's rapid antidepressant actions.  In this model, basal glutamatergic neurotransmission sensed by cortical GluN2B-contg. NMDARs regulates excitatory synaptic strength in PFC detg. basal levels of depression-like behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJjqjA7UWBebVg90H21EOLACvtfcHk0lgPnpC5ARHZ6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOmtr%252FI&md5=2f630879bb1868d45b831b333afe61d8</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.7554%2FeLife.03581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.03581%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DO.%2BH.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DC.-C.%26aulast%3DHargroder%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDelpire%26aufirst%3DE.%26aulast%3DHall%26aufirst%3DB.%2BJ.%26atitle%3DGluN2B-containing%2520NMDA%2520receptors%2520regulate%2520depression-like%2520behavior%2520and%2520are%2520critical%2520for%2520the%2520rapid%2520antidepressant%2520actions%2520of%2520ketamine%26jtitle%3DeLife%26date%3D2014%26volume%3D3%26spage%3De03581%26doi%3D10.7554%2FeLife.03581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, B. J.</span></span> <span> </span><span class="NLM_article-title">Two cellular hypotheses explaining the initiation of ketamine’s antidepressant actions: Direct inhibition and disinhibition</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2015.07.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.neuropharm.2015.07.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26211972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVajsL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2016&pages=17-26&author=O.+H.+Millerauthor=J.+T.+Moranauthor=B.+J.+Hall&title=Two+cellular+hypotheses+explaining+the+initiation+of+ketamine%E2%80%99s+antidepressant+actions%3A+Direct+inhibition+and+disinhibition&doi=10.1016%2Fj.neuropharm.2015.07.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition</span></div><div class="casAuthors">Miller, Oliver H.; Moran, Jacqueline T.; Hall, Benjamin J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-26</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A single, low dose of ketamine evokes antidepressant actions in depressed patients and in patients with treatment-resistant depression (TRD).  Unlike classic antidepressants, which regulate monoamine neurotransmitter systems, ketamine is an antagonist of the N-methyl-D-aspartate (NMDA) family of glutamate receptors.  The effectiveness of NMDAR antagonists in TRD unveils a new set of targets for therapeutic intervention in major depressive disorder (MDD) and TRD.  However, a better understanding of the cellular mechanisms underlying these effects is required for guiding future therapeutic strategies, in order to minimize side effects and prolong duration of efficacy.  Here we review the evidence for and against two hypotheses that have been proposed to explain how NMDAR antagonism initiates protein synthesis and increases excitatory synaptic drive in corticolimbic brain regions, either through selective antagonism of inhibitory interneurons and cortical disinhibition, or by direct inhibition of cortical pyramidal neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSOVd93pk9PbVg90H21EOLACvtfcHk0lgPnpC5ARHZ6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVajsL3J&md5=66b7f60bcc70f977955cfe49d2831798</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2015.07.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2015.07.028%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DO.%2BH.%26aulast%3DMoran%26aufirst%3DJ.%2BT.%26aulast%3DHall%26aufirst%3DB.%2BJ.%26atitle%3DTwo%2520cellular%2520hypotheses%2520explaining%2520the%2520initiation%2520of%2520ketamine%25E2%2580%2599s%2520antidepressant%2520actions%253A%2520Direct%2520inhibition%2520and%2520disinhibition%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D100%26spage%3D17%26epage%3D26%26doi%3D10.1016%2Fj.neuropharm.2015.07.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallarackal, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kvarta, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeGates, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span> <span> </span><span class="NLM_article-title">An excitatory synapse hypothesis of depression</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1016/j.tins.2015.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.tins.2015.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=25887240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvFWmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=279-294&author=S.+M.+Thompsonauthor=A.+J.+Kallarackalauthor=M.+D.+Kvartaauthor=A.+M.+Van+Dykeauthor=T.+A.+LeGatesauthor=X.+Cai&title=An+excitatory+synapse+hypothesis+of+depression&doi=10.1016%2Fj.tins.2015.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">An excitatory synapse hypothesis of depression</span></div><div class="casAuthors">Thompson, Scott M.; Kallarackal, Angy J.; Kvarta, Mark D.; Van Dyke, Adam M.; LeGates, Tara A.; Cai, Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">279-294</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Depression is a common cause of mortality and morbidity, but the biol. bases of the deficits in emotional and cognitive processing remain incompletely understood.  Current antidepressant therapies are effective in only some patients and act slowly.  Here, we propose an excitatory synapse hypothesis of depression in which chronic stress and genetic susceptibility cause changes in the strength of subsets of glutamatergic synapses at multiple locations, including the prefrontal cortex (PFC), hippocampus, and nucleus accumbens (NAc), leading to a dysfunction of corticomesolimbic reward circuitry that underlies many of the symptoms of depression.  This hypothesis accounts for current depression treatments and suggests an updated framework for the development of better therapeutic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDTca5CsMw3bVg90H21EOLACvtfcHk0liPn4vaFOvCnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvFWmtro%253D&md5=ea8be597fe6fad3e14f5d108f24c7b0c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.tins.2015.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tins.2015.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DS.%2BM.%26aulast%3DKallarackal%26aufirst%3DA.%2BJ.%26aulast%3DKvarta%26aufirst%3DM.%2BD.%26aulast%3DVan%2BDyke%26aufirst%3DA.%2BM.%26aulast%3DLeGates%26aufirst%3DT.%2BA.%26aulast%3DCai%26aufirst%3DX.%26atitle%3DAn%2520excitatory%2520synapse%2520hypothesis%2520of%2520depression%26jtitle%3DTrends%2520Neurosci.%26date%3D2015%26volume%3D38%26spage%3D279%26epage%3D294%26doi%3D10.1016%2Fj.tins.2015.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schloesser, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCammon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manji, H. K.</span></span> <span> </span><span class="NLM_article-title">Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2007.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2007.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=17643398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVShs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=349-352&author=S.+Maengauthor=C.+A.+Zarateauthor=J.+Duauthor=R.+J.+Schloesserauthor=J.+McCammonauthor=G.+Chenauthor=H.+K.+Manji&title=Cellular+mechanisms+underlying+the+antidepressant+effects+of+ketamine%3A+role+of+%CE%B1-amino-3-hydroxy-5-methylisoxazole-4-propionic+acid+receptors&doi=10.1016%2Fj.biopsych.2007.05.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors</span></div><div class="casAuthors">Maeng, Sungho; Zarate, Carlos A., Jr.; Du, Jing; Schloesser, Robert J.; McCammon, Joseph; Chen, Guang; Manji, Husseini K.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">349-352</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Ketamine exerts a robust, rapid, and relatively sustained antidepressant effect in patients with major depression.  Understanding the mechanisms underlying the intriguing effects of N-Me d-aspartate (NMDA) antagonists could lead to novel treatments with a rapid onset of action.  Methods: The learned helplessness, forced swim, and passive avoidance tests were used to investigate ketamine's behavioral effects in mice.  Addnl. biochem. and behavioral expts. were undertaken to det. whether the antidepressant-like properties of ketamine and other NMDA antagonists involve α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor throughput.  Results: Subanesthetic doses of ketamine treatment caused acute and sustained antidepressant-like effects.  At these doses, ketamine did not impair fear memory retention.  MK-801 (dizocilpine) and Ro25-6981, an NR2B selective antagonist, also exerted antidepressant-like effects; these effects, however, were not sustained as long as those of ketamine.  Pre-treatment with NBQX, an AMPA receptor antagonist, attenuated both ketamine-induced antidepressant-like behavior and regulation of hippocampal phosphorylated GluR1 AMPA receptors.  Conclusions: NMDA antagonists might exert rapid antidepressant-like effects by enhancing AMPA relative to NMDA throughput in crit. neuronal circuits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot035lK7LpJbVg90H21EOLACvtfcHk0liPn4vaFOvCnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVShs7g%253D&md5=c2da1986b50b509c01d840f6348f6ce2</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2007.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2007.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DMaeng%26aufirst%3DS.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DSchloesser%26aufirst%3DR.%2BJ.%26aulast%3DMcCammon%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DManji%26aufirst%3DH.%2BK.%26atitle%3DCellular%2520mechanisms%2520underlying%2520the%2520antidepressant%2520effects%2520of%2520ketamine%253A%2520role%2520of%2520%25CE%25B1-amino-3-hydroxy-5-methylisoxazole-4-propionic%2520acid%2520receptors%26jtitle%3DBiol.%2520Psychiatry%26date%3D2008%26volume%3D63%26spage%3D349%26epage%3D352%26doi%3D10.1016%2Fj.biopsych.2007.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">Antidepressant effects of (+)-MK-801 and (−)-MK-801 in the social defeat stress model</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">pyw080</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyw080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1093%2Fijnp%2Fpyw080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27608811" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=pyw080&author=B.+Yangauthor=Q.+Renauthor=M.+Maauthor=Q.-X.+Chenauthor=K.+Hashimoto&title=Antidepressant+effects+of+%28%2B%29-MK-801+and+%28%E2%88%92%29-MK-801+in+the+social+defeat+stress+model&doi=10.1093%2Fijnp%2Fpyw080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyw080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyw080%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DB.%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DQ.-X.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DAntidepressant%2520effects%2520of%2520%2528%252B%2529-MK-801%2520and%2520%2528%25E2%2588%2592%2529-MK-801%2520in%2520the%2520social%2520defeat%2520stress%2520model%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2016%26volume%3D19%26spage%3Dpyw080%26doi%3D10.1093%2Fijnp%2Fpyw080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moaddel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmer, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alkondon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pribut, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N. S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">NMDAR inhibition-independent antidepressant actions of ketamine metabolites</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>533</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1038/nature17998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnature17998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27144355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnt1Ogs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=533&publication_year=2016&pages=481-486&author=P.+Zanosauthor=R.+Moaddelauthor=P.+J.+Morrisauthor=P.+Georgiouauthor=J.+Fischellauthor=G.+I.+Elmerauthor=M.+Alkondonauthor=P.+Yuanauthor=H.+J.+Pributauthor=N.+S.+Singh&title=NMDAR+inhibition-independent+antidepressant+actions+of+ketamine+metabolites&doi=10.1038%2Fnature17998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">NMDAR inhibition-independent antidepressant actions of ketamine metabolites</span></div><div class="casAuthors">Zanos, Panos; Moaddel, Ruin; Morris, Patrick J.; Georgiou, Polymnia; Fischell, Jonathan; Elmer, Greg I.; Alkondon, Manickavasagom; Yuan, Peixiong; Pribut, Heather J.; Singh, Nagendra S.; Dossou, Katina S. S.; Fang, Yuhong; Huang, Xi-Ping; Mayo, Cheryl L.; Wainer, Irving W.; Albuquerque, Edson X.; Thompson, Scott M.; Thomas, Craig J.; Zarate, Carlos A., Jr; Gould, Todd D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">533</span>
        (<span class="NLM_cas:issue">7604</span>),
    <span class="NLM_cas:pages">481-486</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Major depressive disorder affects around 16% of the world population at some point in their lives.  Despite the availability of numerous monoaminergic-based antidepressants, most patients require several weeks, if not months, to respond to these treatments, and many patients never attain sustained remission of their symptoms.  The noncompetitive, glutamatergic NMDAR (N-methyl-D-aspartate receptor) antagonist (R,S)-ketamine exerts rapid and sustained antidepressant effects after a single dose in patients with depression, but its use is assocd. with undesirable side effects.  Here the authors show that the metab. of (R,S)-ketamine to (2S,6S;2R,6R)-hydroxynorketamine (HNK) is essential for its antidepressant effects, and that the (2R,6R)-HNK enantiomer exerts behavioral, electroencephalog., electrophysiol. and cellular antidepressant-related actions in mice.  These antidepressant actions are independent of NMDAR inhibition but involve early and sustained activation of AMPARs (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors).  The authors also establish that (2R,6R)-HNK lacks ketamine-related side effects.  The data implicate a novel mechanism underlying the antidepressant properties of (R,S)-ketamine and have relevance for the development of next-generation, rapid-acting antidepressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzu3ydujHJ37Vg90H21EOLACvtfcHk0liPn4vaFOvCnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnt1Ogs70%253D&md5=fcb8479079696cf3dc0ee89f5fadd72a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnature17998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17998%26sid%3Dliteratum%253Aachs%26aulast%3DZanos%26aufirst%3DP.%26aulast%3DMoaddel%26aufirst%3DR.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26aulast%3DGeorgiou%26aufirst%3DP.%26aulast%3DFischell%26aufirst%3DJ.%26aulast%3DElmer%26aufirst%3DG.%2BI.%26aulast%3DAlkondon%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DP.%26aulast%3DPribut%26aufirst%3DH.%2BJ.%26aulast%3DSingh%26aufirst%3DN.%2BS.%26atitle%3DNMDAR%2520inhibition-independent%2520antidepressant%2520actions%2520of%2520ketamine%2520metabolites%26jtitle%3DNature%26date%3D2016%26volume%3D533%26spage%3D481%26epage%3D486%26doi%3D10.1038%2Fnature17998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Highland, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenne, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moaddel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, T. D.</span></span> <span> </span><span class="NLM_article-title">(2R, 6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">6441</span>– <span class="NLM_lpage">6450</span>, <span class="refDoi"> DOI: 10.1073/pnas.1819540116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1073%2Fpnas.1819540116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30867285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFentbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=6441-6450&author=P.+Zanosauthor=J.+N.+Highlandauthor=B.+W.+Stewartauthor=P.+Georgiouauthor=C.+E.+Jenneauthor=J.+Lovettauthor=P.+J.+Morrisauthor=C.+J.+Thomasauthor=R.+Moaddelauthor=C.+A.+Zarateauthor=T.+D.+Gould&title=%282R%2C+6R%29-hydroxynorketamine+exerts+mGlu2+receptor-dependent+antidepressant+actions&doi=10.1073%2Fpnas.1819540116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions</span></div><div class="casAuthors">Zanos, Panos; Highland, Jaclyn N.; Stewart, Brent W.; Georgiou, Polymnia; Jenne, Carleigh E.; Lovett, Jacqueline; Morris, Patrick J.; Thomas, Craig J.; Moaddel, Ruin; Zarate, Carlos A. Jr.; Gould, Todd D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6441-6450</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Currently approved antidepressant drugs often take months to take full effect, and a$$Hat$$ 1/430% of depressed patients remain treatment resistant.  In contrast, ketamine, when administered as a single subanesthetic dose, exerts rapid and sustained antidepressant actions.  Preclin. studies indicate that the ketamine metabolite (2R,6R)-hydroxynorketamine [(2R,6R)-HNK] is a rapid-acting antidepressant drug candidate with limited dissocn. properties and abuse potential.  We assessed the role of group II metabotropic glutamate receptor subtypes 2 (mGlu2) and 3 (mGlu3) in the antidepressant-relevant actions of (2R,6R)-HNK using behavioral, genetic, and pharmacol. approaches as well as cortical quant. EEG (qEEG) measurements in mice.  Both ketamine and (2R,6R)-HNK prevented mGlu2/3 receptor agonist (LY379268)-induced body temp. increases in mice lacking the Grm3, but not Grm2, gene.  This action was not replicated by NMDA receptor antagonists or a chem. variant of ketamine that limits metab. to (2R,6R)-HNK.  The antidepressant-relevant behavioral effects and 30- to 80-Hz qEEG oscillation (gamma-range) increases resultant from (2R,6R)-HNK administration were prevented by pretreatment with an mGlu2/3 receptor agonist and absent in mice lacking the Grm2, but not Grm3a$$Hat$$  /a$$Hat$$  , gene.  Combined subeffective doses of the mGlu2/3 receptor antagonist LY341495 and (2R,6R)-HNK exerted synergistic increases on gamma oscillations and antidepressant-relevant behavioral actions.  These findings highlight that (2R,6R)-HNK exerts antidepressant-relevant actions via a mechanism converging with mGlu2 receptor signaling and suggest enhanced cortical gamma oscillations as a marker of target engagement relevant to antidepressant efficacy.  Moreover, these results support the use of (2R,6R)-HNK and inhibitors of mGlu2 receptor function in clin. trials for treatment-resistant depression either alone or in combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVpuD2LnUuJLVg90H21EOLACvtfcHk0lg6Lbj2vuJMiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFentbo%253D&md5=42b259f71d373730a466a335d27663b0</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1819540116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1819540116%26sid%3Dliteratum%253Aachs%26aulast%3DZanos%26aufirst%3DP.%26aulast%3DHighland%26aufirst%3DJ.%2BN.%26aulast%3DStewart%26aufirst%3DB.%2BW.%26aulast%3DGeorgiou%26aufirst%3DP.%26aulast%3DJenne%26aufirst%3DC.%2BE.%26aulast%3DLovett%26aufirst%3DJ.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DMoaddel%26aufirst%3DR.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DGould%26aufirst%3DT.%2BD.%26atitle%3D%25282R%252C%25206R%2529-hydroxynorketamine%2520exerts%2520mGlu2%2520receptor-dependent%2520antidepressant%2520actions%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26spage%3D6441%26epage%3D6450%26doi%3D10.1073%2Fpnas.1819540116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heifets, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudheimer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pankow, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatzberg, A. F.</span></span> <span> </span><span class="NLM_article-title">Attenuation of antidepressant effects of ketamine by opioid receptor antagonism</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1215</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2018.18020138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1176%2Fappi.ajp.2018.18020138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30153752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BB3c3is1yjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=1205-1215&author=N.+R.+Williamsauthor=B.+D.+Heifetsauthor=C.+Blaseyauthor=K.+Sudheimerauthor=J.+Pannuauthor=H.+Pankowauthor=J.+Hawkinsauthor=J.+Birnbaumauthor=D.+M.+Lyonsauthor=C.+I.+Rodriguezauthor=A.+F.+Schatzberg&title=Attenuation+of+antidepressant+effects+of+ketamine+by+opioid+receptor+antagonism&doi=10.1176%2Fappi.ajp.2018.18020138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism</span></div><div class="casAuthors">Williams Nolan R; Heifets Boris D; Blasey Christine; Sudheimer Keith; Pannu Jaspreet; Pankow Heather; Hawkins Jessica; Birnbaum Justin; Lyons David M; Rodriguez Carolyn I; Schatzberg Alan F</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1205-1215</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  In addition to N-methyl-d-aspartate receptor antagonism, ketamine produces opioid system activation.  The objective of this study was to determine whether opioid receptor antagonism prior to administration of intravenous ketamine attenuates its acute antidepressant or dissociative effects.  METHOD:  In a proposed double-blind crossover study of 30 adults with treatment-resistant depression, the authors performed a planned interim analysis after studying 14 participants, 12 of whom completed both conditions in randomized order: placebo or 50 mg of naltrexone preceding intravenous infusion of 0.5 mg/kg of ketamine.  Response was defined as a reduction ≥50% in score on the 17-item Hamilton Depression Rating Scale (HAM-D) score on postinfusion day 1.  RESULTS:  In the interim analysis, seven of 12 adults with treatment-resistant depression met the response criterion during the ketamine plus placebo condition.  Reductions in 6-item and 17-item HAM-D scores among participants in the ketamine plus naltrexone condition were significantly lower than those of participants in the ketamine plus placebo condition on postinfusion days 1 and 3.  Secondary analysis of all participants who completed the placebo and naltrexone conditions, regardless of the robustness of response to ketamine, showed similar results.  There were no differences in ketamine-induced dissociation between conditions.  Because naltrexone dramatically blocked the antidepressant but not the dissociative effects of ketamine, the trial was halted at the interim analysis.  CONCLUSIONS:  The findings suggest that ketamine's acute antidepressant effect requires opioid system activation.  The dissociative effects of ketamine are not mediated by the opioid system, and they do not appear sufficient without the opioid effect to produce the acute antidepressant effects of ketamine in adults with treatment-resistant depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgjMyxF1SfVs-crCu0nI_sfW6udTcc2eb_l2AWSSu95bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3is1yjsw%253D%253D&md5=b1d6ebff5c84be9e6ac2021490cc77c0</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2018.18020138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2018.18020138%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BR.%26aulast%3DHeifets%26aufirst%3DB.%2BD.%26aulast%3DBlasey%26aufirst%3DC.%26aulast%3DSudheimer%26aufirst%3DK.%26aulast%3DPannu%26aufirst%3DJ.%26aulast%3DPankow%26aufirst%3DH.%26aulast%3DHawkins%26aufirst%3DJ.%26aulast%3DBirnbaum%26aufirst%3DJ.%26aulast%3DLyons%26aufirst%3DD.%2BM.%26aulast%3DRodriguez%26aufirst%3DC.%2BI.%26aulast%3DSchatzberg%26aufirst%3DA.%2BF.%26atitle%3DAttenuation%2520of%2520antidepressant%2520effects%2520of%2520ketamine%2520by%2520opioid%2520receptor%2520antagonism%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2018%26volume%3D175%26spage%3D1205%26epage%3D1215%26doi%3D10.1176%2Fappi.ajp.2018.18020138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nisenbaum, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleakman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkin, J. M.</span></span> <span> </span><span class="NLM_article-title">A role for AMPA receptors in mood disorders</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1273</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2005.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.bcp.2005.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=16442080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=1273-1288&author=A.+Altauthor=E.+S.+Nisenbaumauthor=D.+Bleakmanauthor=J.+M.+Witkin&title=A+role+for+AMPA+receptors+in+mood+disorders&doi=10.1016%2Fj.bcp.2005.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">A role for AMPA receptors in mood disorders</span></div><div class="casAuthors">Alt, Andrew; Nisenbaum, Eric S.; Bleakman, David; Witkin, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1273-1288</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Major antidepressant agents increase synaptic levels of monoamines.  Although the monoamine hypothesis of depression remains a cornerstone of our understanding of the pathophysiol. of depression, emerging data has suggested that the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subtype of glutamate receptor may also play a pivotal role in depression.  Pos. allosteric modulators of AMPA receptors increase brain levels of brain-derived neurotrophic factor (BDNF) that impacts the viability and generation of neurons in key brain structures.  AMPA receptor potentiators are active in rodent models predictive of antidepressant efficacy.  The mechanisms by which AMPA receptor potentiators produce these biol. effects, however, are uncertain.  Current evidence points to an antidepressant mechanism that is independent of monoaminergic facilitation that is driven by neurogenesis, a process facilitated by increased BDNF expression.  However, alternative hypotheses need to be considered given uncertainties in the relation between BDNF increases and the effects of conventional antidepressant medications.  Electrophysiol. and protein conformational data indicate that structural variants of AMPA receptor potentiators can differentially modulate AMPA receptor-mediated currents, although the manner in which this impacts antidepressant efficacy is yet to be understood.  Conventional antidepressants such as fluoxetine pos. modulate AMPA receptors.  This potentiation is engendered by specific phosphorylation pathways activated through the dopamine- and cAMP-regulated phosphoprotein of Mr 32,000 (DARPP-32).  Other novel compds. with antidepressant-like effects in rodents may also produce their in vivo effects through potentiation of AMPA receptors.  Thus, AMPA receptor potentiation might be a general mechanism through which the clin. outcome of antidepressant efficacy is achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-Px6E2FH8K7Vg90H21EOLACvtfcHk0ljqOqTAzA-Ibg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOjsbs%253D&md5=4887a0f9871c6371c535ded7c5ae6693</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2005.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2005.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DAlt%26aufirst%3DA.%26aulast%3DNisenbaum%26aufirst%3DE.%2BS.%26aulast%3DBleakman%26aufirst%3DD.%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26atitle%3DA%2520role%2520for%2520AMPA%2520receptors%2520in%2520mood%2520disorders%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2006%26volume%3D71%26spage%3D1273%26epage%3D1288%26doi%3D10.1016%2Fj.bcp.2005.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trullas, R.</span></span> <span> </span><span class="NLM_article-title">Glutamate-based antidepressants: 20 years on</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">569</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2009.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.tips.2009.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=19837463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCku7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=563-569&author=P.+Skolnickauthor=P.+Popikauthor=R.+Trullas&title=Glutamate-based+antidepressants%3A+20+years+on&doi=10.1016%2Fj.tips.2009.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate-based antidepressants: 20 years on</span></div><div class="casAuthors">Skolnick, Phil; Popik, Piotr; Trullas, Ramon</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">563-569</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Depression is a chronic recurring illness that affects more than 120 million people worldwide.  Drugs increasing the synaptic availability of serotonin and norepinephrine (biogenic amine-based agents) have been used to treat depression for more than 50 years.  However, significant symptom improvement requires ≥2-4 wk of treatment and a first course of therapy provides symptom relief to only 60-65% of patients.  Roche and Evotec recently announced plans to develop N-methyl-D-aspartate (NMDA) receptor antagonists targeting the NR2B subtype for treatment-resistant depression.  This announcement closely follows a report that another NR2B antagonist, traxoprodil (CP 101 606), has antidepressant effects in patients unresponsive to a serotonin selective reuptake inhibitor, as well as reports of rapid and sustained antidepressant effects following a single injection of the NMDA antagonist ketamine.  Here we describe evidence that glutamate-based therapies might represent an effective alternative to biogenic-amine-based agents for depression and provide perspectives on the development of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruh_p71UySDrVg90H21EOLACvtfcHk0ljqOqTAzA-Ibg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCku7zN&md5=516f9bbbbb71fbbe02933ca90eb90410</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2009.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2009.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DPopik%26aufirst%3DP.%26aulast%3DTrullas%26aufirst%3DR.%26atitle%3DGlutamate-based%2520antidepressants%253A%252020%2520years%2520on%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D563%26epage%3D569%26doi%3D10.1016%2Fj.tips.2009.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witkin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golani, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, N. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. L.</span></span> <span> </span><span class="NLM_article-title">Rapid-acting antidepressants</span>. <i>Adv. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/bs.apha.2019.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fbs.apha.2019.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=31378256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Oit7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2019&pages=47-96&author=J.+M.+Witkinauthor=A.+E.+Martinauthor=L.+K.+Golaniauthor=N.+Z.+Xuauthor=J.+L.+Smith&title=Rapid-acting+antidepressants&doi=10.1016%2Fbs.apha.2019.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid-acting antidepressants</span></div><div class="casAuthors">Witkin, Jeffrey M.; Martin, Anna E.; Golani, Lalit K.; Xu, Nina Z.; Smith, Jodi L.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Pharmacology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">Neuropsychotherapeutics</span>),
    <span class="NLM_cas:pages">47-96</span>CODEN:
                <span class="NLM_cas:coden">ADPHEL</span>;
        ISSN:<span class="NLM_cas:issn">1054-3589</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Mechanisms of action of rapid-acting antidepressants for treatment of refractory patients with anhedonia.  Rapid-acting antidepressant drug action has been demonstrated in controlled clin. studies for ketamine, a few other NMDA receptor antagonists and scopolamine.  Less clin. data are currently available for psychedelic drugs such as psilocybin, lysergic acid diethylamide, and ayahuasca.  A general triggering mechanism appears to involve potentiation of AMPA receptor function.  Although the durability of antidepressant effects of ketamine and scopolamine is limited, psychedelic drugs have been reported to produce effects for many months.  The primary impediment to generating a medicine of this type for depressed patients is side effects and the lack of methods to ensure enduring antidepressant effects.  Thus, further exploration of drug possibilities continues.  Esketamine ((S)-ketamine) was recently FDA approved.  Compds. currently in clin. development include the NMDA receptor antagonist (R)-ketamine, the NMDA receptor modulator, GLYX-13 (Rapastinel), and the AMPA receptor potentiator TAK-653.  Addnl. pharmacol. classes have produced effects in the preclin. lab. to suggest their potential as rapid-acting agents.  These include mGlu2/3 receptor antagonists, AMPA receptor potentiators, and neg. allosteric modulators of GABAA(α5) receptors.  In all cases, mols. exist that could be used to provide clin. proof of concept testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnh42zms7d37Vg90H21EOLACvtfcHk0lj6aM1oPp2i-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Oit7%252FF&md5=82daa8c215b13a74170a80664ec1fff9</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fbs.apha.2019.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.apha.2019.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DA.%2BE.%26aulast%3DGolani%26aufirst%3DL.%2BK.%26aulast%3DXu%26aufirst%3DN.%2BZ.%26aulast%3DSmith%26aufirst%3DJ.%2BL.%26atitle%3DRapid-acting%2520antidepressants%26jtitle%3DAdv.%2520Pharmacol.%26date%3D2019%26volume%3D86%26spage%3D47%26epage%3D96%26doi%3D10.1016%2Fbs.apha.2019.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorkildsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgbjerg, F. M.</span></span> <span> </span><span class="NLM_article-title">Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(97)01116-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2FS0014-2999%2897%2901116-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=9311667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK2sXltVCqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=1997&pages=99-104&author=B.+Ebertauthor=S.+Mikkelsenauthor=C.+Thorkildsenauthor=F.+M.+Borgbjerg&title=Norketamine%2C+the+main+metabolite+of+ketamine%2C+is+a+non-competitive+NMDA+receptor+antagonist+in+the+rat+cortex+and+spinal+cord&doi=10.1016%2FS0014-2999%2897%2901116-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord</span></div><div class="casAuthors">Ebert, Bjarke; Mikkelsen, Soren; Thorkildsen, Christian; Borgbjerg, Finn Molke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-104</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The enantiomers of the potent non-competitive NMDA receptor antagonist ketamine and its major metabolite, norketamine were evaluated as NMDA receptor antagonists using the rat cortical wedge prepn. and the neonatal rat spinal cord prepn., resp., for electrophysiol. studies and [3H](RS)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine ([3H]MK-801) in homogenate binding expts.  In agreement with earlier studies (S)-ketamine (Ki 0.3 μM) was found to possess a 5 times higher affinity for the NMDA receptor complex than (R)-ketamine (Ki 1.4 μM).  (S)-Norketamine (Ki 1.7 μM) had approx. an 8 times higher affinity than (R)-norketamine (Ki 13 μM) in the inhibition of [3H]MK-801 binding.  All compds. inhibited responses to NMDA in the rat cortical wedge prepn. and the hemisected neonatal rat spinal cord, being approx. four times more potent in the cortex than in the spinal cord except for (R)-norketamine being only twice as potent.  In light of the clin. obtained concns. of norketamine after oral administration of ketamine, these data strongly suggest that (S)-norketamine may contribute significantly to the clin. activity of (S)-ketamine, esp. when given orally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMBlstfg5EGLVg90H21EOLACvtfcHk0lib9pzWeVP3dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltVCqs7k%253D&md5=79dd6350eff094489159bea845e152f0</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2901116-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252901116-3%26sid%3Dliteratum%253Aachs%26aulast%3DEbert%26aufirst%3DB.%26aulast%3DMikkelsen%26aufirst%3DS.%26aulast%3DThorkildsen%26aufirst%3DC.%26aulast%3DBorgbjerg%26aufirst%3DF.%2BM.%26atitle%3DNorketamine%252C%2520the%2520main%2520metabolite%2520of%2520ketamine%252C%2520is%2520a%2520non-competitive%2520NMDA%2520receptor%2520antagonist%2520in%2520the%2520rat%2520cortex%2520and%2520spinal%2520cord%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D333%26spage%3D99%26epage%3D104%26doi%3D10.1016%2FS0014-2999%2897%2901116-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moaddel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdrakhmanova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jozwiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span> <span> </span><span class="NLM_article-title">Sub-anesthetic concentrations of (R, S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>698</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2012.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.ejphar.2012.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=23183107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCktL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=698&publication_year=2013&pages=228-234&author=R.+Moaddelauthor=G.+Abdrakhmanovaauthor=J.+Kozakauthor=K.+Jozwiakauthor=L.+Tollauthor=L.+Jimenezauthor=A.+Rosenbergauthor=T.+Tranauthor=Y.+Xiaoauthor=C.+A.+Zarateauthor=I.+W.+Wainer&title=Sub-anesthetic+concentrations+of+%28R%2C+S%29-ketamine+metabolites+inhibit+acetylcholine-evoked+currents+in+%CE%B17+nicotinic+acetylcholine+receptors&doi=10.1016%2Fj.ejphar.2012.11.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors</span></div><div class="casAuthors">Moaddel, Ruin; Abdrakhmanova, Galia; Kozak, Joanna; Jozwiak, Krzysztof; Toll, Lawrence; Jimenez, Lucita; Rosenberg, Avraham; Tran, Thao; Xiao, Yingxian; Zarate, Carlos A.; Wainer, Irving W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">698</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">228-234</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The effect of the (R,S)-ketamine metabolites (R,S)-norketamine, (R,S)-dehydronorketamine, (2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine on the activity of α7 and α3β4 neuronal nicotinic acetylcholine receptors was investigated using patch-clamp techniques.  The data indicated that (R,S)-dehydronorketamine inhibited acetylcholine-evoked currents in α7-nicotinic acetylcholine receptor, IC50=55±6 nM, and that (2S,6S)-hydroxynorketamine, (2R,6R)-hydroxynorketamine and (R,S)-norketamine also inhibited α7-nicotinic acetylcholine receptor function at concns. ≤1 μM, while (R,S)-ketamine was inactive at these concns.  The inhibitory effect of (R,S)-dehydronorketamine was voltage-independent and the compd. did not competitively displace selective α7-nicotinic acetylcholine receptor ligands [125I]-α-bungarotoxin and [3H]-epibatidine indicating that (R,S)-dehydronorketamine is a neg. allosteric modulator of the α7-nicotinic acetylcholine receptor. (R,S)-Ketamine and (R,S)-norketamine inhibited (S)-nicotine-induced whole-cell currents in cells expressing α3β4-nicotinic acetylcholine receptor, IC50 3.1 and 9.1 μM, resp., while (R,S)-dehydronorketamine, (2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine were weak inhibitors, IC50 >100 μM.  The binding affinities of (R,S)-dehydronorketamine, (2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine at the NMDA receptor were also detd. using rat brain membranes and the selective NMDA receptor antagonist [3H]-MK-801.  The calcd. Ki values were 38.95 μM for (S)-dehydronorketamine, 21.19 μM for (2S,6S)-hydroxynorketamine and>100 μM for (2R,6R)-hydroxynorketamine.  The results suggest that the inhibitory activity of ketamine metabolites at the α7-nicotinic acetylcholine receptor may contribute to the clin. effect of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGiMWFqBpCUrVg90H21EOLACvtfcHk0lib9pzWeVP3dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCktL%252FL&md5=4e42dd4e84025dfd2e703ecd3d4d5352</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DMoaddel%26aufirst%3DR.%26aulast%3DAbdrakhmanova%26aufirst%3DG.%26aulast%3DKozak%26aufirst%3DJ.%26aulast%3DJozwiak%26aufirst%3DK.%26aulast%3DToll%26aufirst%3DL.%26aulast%3DJimenez%26aufirst%3DL.%26aulast%3DRosenberg%26aufirst%3DA.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26atitle%3DSub-anesthetic%2520concentrations%2520of%2520%2528R%252C%2520S%2529-ketamine%2520metabolites%2520inhibit%2520acetylcholine-evoked%2520currents%2520in%2520%25CE%25B17%2520nicotinic%2520acetylcholine%2520receptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D698%26spage%3D228%26epage%3D234%26doi%3D10.1016%2Fj.ejphar.2012.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamakura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoji, K.</span></span> <span> </span><span class="NLM_article-title">The stereoselective effects of ketamine isomers on heteromeric N-methyl-D-aspartate receptor channels</span>. <i>Anesth. Analg.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1097/00000539-200007000-00042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2F00000539-200007000-00042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10866917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1Oqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2000&pages=225-229&author=T.+Yamakuraauthor=K.+Sakimuraauthor=K.+Shimoji&title=The+stereoselective+effects+of+ketamine+isomers+on+heteromeric+N-methyl-D-aspartate+receptor+channels&doi=10.1097%2F00000539-200007000-00042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The stereoselective effects of ketamine isomers on heteromeric N-methyl-D-aspartate receptor channels</span></div><div class="casAuthors">Yamakura, Tomohiro; Sakimura, Kenji; Shimoji, Koki</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia & Analgesia (Baltimore)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">225-229</span>CODEN:
                <span class="NLM_cas:coden">AACRAT</span>;
        ISSN:<span class="NLM_cas:issn">0003-2999</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The effects of S(+)- and R(-)-ketamine on heteromeric N-methyl-D-aspartate receptor channels were investigated on the ε1 / ξ1, ε2/ξ1, ε3/ξ1, and ε4/ξ1 channels expressed in Xenopus oocytes.  S(+)-ketamine inhibited all four ε/ξ channels more effectively than R(-)-ketamine.  The inhibitor concns. for half-control response for S(+)-ketamine were quite similar among the four channels with 0.44-0.56 μM.  However, the inhibitor concns. for half-control response for R(-)-ketamine varied slightly among the four channels with 1.0 μM for ε2/ξ1 and ε3/ξ1 channels and 1.9-2.0 μM for ε1/ξ1 and ε4/ξ1 channels.  Thus, the potency ratio of S(+)- and R(-)-ketamine for heteromeric channels was only slightly different among the ε/ξ channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvSYJCg0D-mbVg90H21EOLACvtfcHk0ljuRCC36A_37w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1Oqu7c%253D&md5=ea6d6b09970d7aac4ac68edfe6f0c542</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1097%2F00000539-200007000-00042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000539-200007000-00042%26sid%3Dliteratum%253Aachs%26aulast%3DYamakura%26aufirst%3DT.%26aulast%3DSakimura%26aufirst%3DK.%26aulast%3DShimoji%26aufirst%3DK.%26atitle%3DThe%2520stereoselective%2520effects%2520of%2520ketamine%2520isomers%2520on%2520heteromeric%2520N-methyl-D-aspartate%2520receptor%2520channels%26jtitle%3DAnesth.%2520Analg.%26date%3D2000%26volume%3D91%26spage%3D225%26epage%3D229%26doi%3D10.1097%2F00000539-200007000-00042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schüttler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevor, A.</span></span> <span> </span><span class="NLM_article-title">Comparative pharmacology of the ketamine isomers: studies in volunteers</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1093/bja/57.2.197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1093%2Fbja%2F57.2.197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=3970799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaL2MXktVSiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1985&pages=197-203&author=P.+Whiteauthor=J.+Sch%C3%BCttlerauthor=A.+Shaferauthor=D.+Stanskiauthor=Y.+Horaiauthor=A.+Trevor&title=Comparative+pharmacology+of+the+ketamine+isomers%3A+studies+in+volunteers&doi=10.1093%2Fbja%2F57.2.197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative pharmacology of the ketamine isomers:  studies in volunteers</span></div><div class="casAuthors">White, Paul F.; Schuttler, Jurgen; Shafer, Audrey; Stanski, Donald R.; Horai, Yukio; Trevor, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-203</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">0007-0912</span>.
    </div><div class="casAbstract">The clin. and EEG effects of the individual ketamine isomers were compared with the (±)-ketamine  [6740-88-1] mixt. in volunteers who received each drug on a sep. occasion.  Racemic ketamine 275 mg, S(+)-ketamine  [33643-49-1] 140 mg or R(-)-ketamine  [33643-46-8] 429 mg produced an anesthetic state lasting 6 min.  However, the EEG evaluation of the R(-)-isomer revealed less overall slowing, and an absence of the large slow wave complexes produced by the S(+)-isomer and the racemic mixt.  The pharmacokinetic profiles for the individual isomers of ketamine did not differ significantly from the racemic mixt.  Even though the apparent anesthetic state produced in these healthy volunteers did not differ qual. between the 3 drug groups, recovery times were consistently shorter following the individual isomers compared with the racemic mixt.  The serum ketamine concns. assocd. with regaining consciousness and orientation were consistent with an S(+)/R(-) isomer potency ratio of 4:1.  In terms of their ability to impair psychomotor function, the S(+)/R(-) potency ratio varied from 3:1 to 5:1.  After comparable degrees of central nervous system depression, it is concluded that the more potent S(+) isomer of ketamine is assocd. with a more rapid recovery of psychomotor skills that the currently used racemic mixt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmb1YMgMGE1bVg90H21EOLACvtfcHk0lg_ZnXu35l2zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXktVSiurg%253D&md5=5bb8dec8b25afacc1ac630cc68431460</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1093%2Fbja%2F57.2.197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbja%252F57.2.197%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DP.%26aulast%3DSch%25C3%25BCttler%26aufirst%3DJ.%26aulast%3DShafer%26aufirst%3DA.%26aulast%3DStanski%26aufirst%3DD.%26aulast%3DHorai%26aufirst%3DY.%26aulast%3DTrevor%26aufirst%3DA.%26atitle%3DComparative%2520pharmacology%2520of%2520the%2520ketamine%2520isomers%253A%2520studies%2520in%2520volunteers%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D1985%26volume%3D57%26spage%3D197%26epage%3D203%26doi%3D10.1093%2Fbja%2F57.2.197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leal, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandeira, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia-Melo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telles, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mello, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesus-Nunes, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerreiro-Costa, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marback, R. F.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Intravenous arketamine for treatment-resistant depression: Open-label pilot study</span>. <i>Eur. Arch. Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1007/s00406-020-01110-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2Fs00406-020-01110-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32055944" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1-6&author=G.+C.+Lealauthor=I.+D.+Bandeiraauthor=F.+S.+Correia-Meloauthor=M.+Tellesauthor=R.+P.+Melloauthor=F.+Vieiraauthor=C.+S.+Limaauthor=A.+P.+Jesus-Nunesauthor=L.+N.+Guerreiro-Costaauthor=R.+F.+Marback&title=Intravenous+arketamine+for+treatment-resistant+depression%3A+Open-label+pilot+study&doi=10.1007%2Fs00406-020-01110-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1007%2Fs00406-020-01110-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-020-01110-5%26sid%3Dliteratum%253Aachs%26aulast%3DLeal%26aufirst%3DG.%2BC.%26aulast%3DBandeira%26aufirst%3DI.%2BD.%26aulast%3DCorreia-Melo%26aufirst%3DF.%2BS.%26aulast%3DTelles%26aufirst%3DM.%26aulast%3DMello%26aufirst%3DR.%2BP.%26aulast%3DVieira%26aufirst%3DF.%26aulast%3DLima%26aufirst%3DC.%2BS.%26aulast%3DJesus-Nunes%26aufirst%3DA.%2BP.%26aulast%3DGuerreiro-Costa%26aufirst%3DL.%2BN.%26aulast%3DMarback%26aufirst%3DR.%2BF.%26atitle%3DIntravenous%2520arketamine%2520for%2520treatment-resistant%2520depression%253A%2520Open-label%2520pilot%2520study%26jtitle%3DEur.%2520Arch.%2520Psychiatry%2520Clin.%2520Neurosci.%26date%3D2020%26spage%3D1%26epage%3D6%26doi%3D10.1007%2Fs00406-020-01110-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-c.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toki, H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">AMPA receptor activation–independent antidepressant actions of ketamine metabolite (S)-Norketamine</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2018.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2018.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29945718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1SmtrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=591-600&author=C.+Yangauthor=S.+Kobayashiauthor=K.+Nakaoauthor=C.+Dongauthor=M.+Hanauthor=Y.+Quauthor=Q.+Renauthor=J.-c.+Zhangauthor=M.+Maauthor=H.+Toki&title=AMPA+receptor+activation%E2%80%93independent+antidepressant+actions+of+ketamine+metabolite+%28S%29-Norketamine&doi=10.1016%2Fj.biopsych.2018.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine</span></div><div class="casAuthors">Yang, Chun; Kobayashi, Shizuka; Nakao, Kazuhito; Dong, Chao; Han, Mei; Qu, Youge; Ren, Qian; Zhang, Ji-chun; Ma, Min; Toki, Hidetoh; Yamaguchi, Jun-ichi; Chaki, Shigeyuki; Shirayama, Yukihiko; Nakazawa, Kazu; Manabe, Toshiya; Hashimoto, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">591-600</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Ketamine, an N-methyl-D-aspartate receptor antagonist, exerts robust antidepressant effects in patients with treatment-resistant depression.  The precise mechanisms underlying ketamine's antidepressant actions remain unclear, although previous research suggests that alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) activation plays a role.  We investigated whether (S)-norketamine and (R)-norketamine, the two main metabolites of (R,S)-ketamine, also play a significant role in ketamine's antidepressant effects and whether the effects are mediated by AMPAR.  Cellular mechanisms of antidepressant action of norketamine enantiomers were examd. in mice.  (S)-Norketamine had more potent antidepressant effects than (R)-norketamine in inflammation and chronic social defeat stress models.  Furthermore, (S)-norketamine induced more beneficial effects on decreased dendritic spine d. and synaptogenesis in the prefrontal cortex and hippocampus compared with (R)-norketamine.  Unexpectedly, AMPAR antagonists did not block the antidepressant effects of (S)-norketamine.  The electrophysiol. data showed that, although (S)-norketamine inhibited N-methyl-D-aspartate receptor-mediated synaptic currents, (S)-norketamine did not enhance AMPAR-mediated neurotransmission in hippocampal neurons.  Furthermore, (S)-norketamine improved redns. in brain-derived neurotrophic factor-tropomyosin receptor kinase B signaling in the prefrontal cortex of mice susceptible to chronic social defeat stress, whereas the tropomyosin receptor kinase B antagonist and a mechanistic target of rapamycin inhibitor blocked the antidepressant effects of (S)-norketamine.  In contrast to (S)-ketamine, (S)-norketamine did not cause behavioral abnormalities, such as prepulse inhibition deficits, reward effects, loss of parvalbumin immunoreactivity in the medial prefrontal cortex, or baseline gamma-band oscillation increase.  Our data identified a novel AMPAR activation-independent mechanism underlying the antidepressant effects of (S)-norketamine.  (S)-Norketamine and its prodrugs could be novel antidepressants without the detrimental side effects of (S)-ketamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotHsV92JkpQ7Vg90H21EOLACvtfcHk0ljKuJRpha4neA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1SmtrjJ&md5=02809db36fbf74a7dae7f2e681948358</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2018.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2018.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DNakao%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.-c.%26aulast%3DMa%26aufirst%3DM.%26aulast%3DToki%26aufirst%3DH.%26atitle%3DAMPA%2520receptor%2520activation%25E2%2580%2593independent%2520antidepressant%2520actions%2520of%2520ketamine%2520metabolite%2520%2528S%2529-Norketamine%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D84%26spage%3D591%26epage%3D600%26doi%3D10.1016%2Fj.biopsych.2018.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">An update on ketamine and its two enantiomers as rapid-acting antidepressants</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1080/14737175.2019.1554434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1080%2F14737175.2019.1554434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30513009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKis7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=83-92&author=K.+Zhangauthor=K.+Hashimoto&title=An+update+on+ketamine+and+its+two+enantiomers+as+rapid-acting+antidepressants&doi=10.1080%2F14737175.2019.1554434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">An update on ketamine and its two enantiomers as rapid-acting antidepressants</span></div><div class="casAuthors">Zhang, Kai; Hashimoto, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-92</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Depression is one of the most disabling diseases worldwide.  Approx. one-third of depressed patients are treatment-resistant to the currently available antidepressants and there is a significant therapeutic time lag of weeks to months.  There is a clear unmet need for rapid-acting and more efficacious treatments.  (R,S)-ketamine, an old anesthetic drug appears now to be going through a renaissance.  This paper reviews recent literature describing the antidepressant effects of ketamine and its enantiomer (S)-ketamine in patients with major depressive disorder (MDD) and bipolar disorder (BD).  Furthermore, the authors discuss the therapeutic potential of (R)-ketamine, another enantiomer of (R,S)-ketamine, and (S)-norketamine.  A no. of clin. studies have demonstrated that (R,S)-ketamine has rapid-acting and sustained antidepressant activity in treatment-resistant patients with MDD, BD, and other psychiatric disorders.  Off-label use of ketamine for mood disorders is proving popular in the United States.  Meanwhile, preclin. data suggests that (R)-ketamine can exert longer-lasting antidepressant effects than (S)-ketamine in animal models of depression, and (R)-ketamine may have less detrimental side effects than (R,S)-ketamine and (S)-ketamine.  Addnl., (S)-norketamine exhibits rapid and sustained antidepressant effects, with a potency similar to that of (S)-ketamine.  Unlike (S)-ketamine, (S)-norketamine does not cause behavioral and biochem. abnormalities and could be a safer than (S)-ketamine too.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotO_RddKNgVrVg90H21EOLACvtfcHk0ljKuJRpha4neA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKis7zJ&md5=54ae909a31f50f5499b305a7760c214c</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1080%2F14737175.2019.1554434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737175.2019.1554434%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DAn%2520update%2520on%2520ketamine%2520and%2520its%2520two%2520enantiomers%2520as%2520rapid-acting%2520antidepressants%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2019%26volume%3D19%26spage%3D83%26epage%3D92%26doi%3D10.1080%2F14737175.2019.1554434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span> <span> </span><span class="NLM_article-title">Is (S)-norketamine an alternative antidepressant for esketamine?</span>. <i>Eur. Arch. Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">867</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1007/s00406-018-0922-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2Fs00406-018-0922-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30008119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FotF2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2019&pages=867-868&author=K.+Hashimotoauthor=C.+Yang&title=Is+%28S%29-norketamine+an+alternative+antidepressant+for+esketamine%3F&doi=10.1007%2Fs00406-018-0922-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Is (S)-norketamine an alternative antidepressant for esketamine?</span></div><div class="casAuthors">Hashimoto Kenji; Yang Chun</div><div class="citationInfo"><span class="NLM_cas:title">European archives of psychiatry and clinical neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">867-868</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTyoXrDS6dJ1m8bhe6roZYfW6udTcc2eaIZyEgdB2-E7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FotF2msA%253D%253D&md5=dd9c0c0f1cdf9db7c2055a3b509b5f3b</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs00406-018-0922-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-018-0922-2%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DC.%26atitle%3DIs%2520%2528S%2529-norketamine%2520an%2520alternative%2520antidepressant%2520for%2520esketamine%253F%26jtitle%3DEur.%2520Arch.%2520Psychiatry%2520Clin.%2520Neurosci.%26date%3D2019%26volume%3D269%26spage%3D867%26epage%3D868%26doi%3D10.1007%2Fs00406-018-0922-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defaix, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabresse, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardier, A. M.</span></span> <span> </span><span class="NLM_article-title">Common neurotransmission recruited in (R, S)-ketamine and (2R, 6R)-hydroxynorketamine–induced sustained antidepressant-like effects</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">e3</span>– <span class="NLM_lpage">e6</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2017.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2017.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29174592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFahtrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=e3-e6&author=T.+H.+Phamauthor=C.+Defaixauthor=X.+Xuauthor=S.-X.+Dengauthor=N.+Fabresseauthor=J.-C.+Alvarezauthor=D.+W.+Landryauthor=R.+A.+Brachmanauthor=C.+A.+Dennyauthor=A.+M.+Gardier&title=Common+neurotransmission+recruited+in+%28R%2C+S%29-ketamine+and+%282R%2C+6R%29-hydroxynorketamine%E2%80%93induced+sustained+antidepressant-like+effects&doi=10.1016%2Fj.biopsych.2017.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects</span></div><div class="casAuthors">Pham, Thu Ha; Defaix, Celine; Xu, Xiaoming; Deng, Shi-Xian; Fabresse, Nicolas; Alvarez, Jean-Claude; Landry, Donald W.; Brachman, Rebecca A.; Denny, Christine A.; Gardier, Alain M.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e3-e6</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this paper we discuss common neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant-like effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLsNONcnguX7Vg90H21EOLACvtfcHk0ljz9gTqSiQPzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFahtrzO&md5=208712d9d888987b99379fe51c25b7d3</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2017.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2017.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DPham%26aufirst%3DT.%2BH.%26aulast%3DDefaix%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DS.-X.%26aulast%3DFabresse%26aufirst%3DN.%26aulast%3DAlvarez%26aufirst%3DJ.-C.%26aulast%3DLandry%26aufirst%3DD.%2BW.%26aulast%3DBrachman%26aufirst%3DR.%2BA.%26aulast%3DDenny%26aufirst%3DC.%2BA.%26aulast%3DGardier%26aufirst%3DA.%2BM.%26atitle%3DCommon%2520neurotransmission%2520recruited%2520in%2520%2528R%252C%2520S%2529-ketamine%2520and%2520%25282R%252C%25206R%2529-hydroxynorketamine%25E2%2580%2593induced%2520sustained%2520antidepressant-like%2520effects%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D84%26spage%3De3%26epage%3De6%26doi%3D10.1016%2Fj.biopsych.2017.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y.-C.</span></span> <span> </span><span class="NLM_article-title">(2R, 6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2018.06.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.neuropharm.2018.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29953886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1agt7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2018&pages=1-12&author=D.+Chouauthor=H.-Y.+Pengauthor=T.-B.+Linauthor=C.-Y.+Laiauthor=M.-C.+Hsiehauthor=Y.-C.+Wenauthor=A.-S.+Leeauthor=H.-H.+Wangauthor=P.-S.+Yangauthor=G.-D.+Chenauthor=Y.-C.+Ho&title=%282R%2C+6R%29-hydroxynorketamine+rescues+chronic+stress-induced+depression-like+behavior+through+its+actions+in+the+midbrain+periaqueductal+gray&doi=10.1016%2Fj.neuropharm.2018.06.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray</span></div><div class="casAuthors">Chou, Dylan; Peng, Hsien-Yu; Lin, Tzer-Bin; Lai, Cheng-Yuan; Hsieh, Ming-Chun; Wen, Yang-Cheng; Lee, An-Sheng; Wang, Hsueh-Hsiao; Yang, Po-Sheng; Chen, Gin-Den; Ho, Yu-Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It has been widely reported that ketamine rescues chronic stress-induced depression-like behavior, but the underlying cellular mechanisms of the rapid antidepressant actions of ketamine remain largely unclear.  Both male and female Sprague-Dawley rats were used and received modified learned helplessness paradigm to induce depression-like behavior.  Depression-like behavior was assayed and manipulated using forced swim tests, sucrose preference tests and pharmacol. microinjection.  We conducted whole-cell patch-clamp electrophysiol. recordings in the midbrain ventrolateral periaqueductal gray (vlPAG) neurons.  Surface and cytosolic glutamate receptor 1 (GluR1) α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor expression were analyzed using Western blotting.  Phosphorylated GluR1 expression was quantified using Western blotting anal.  The results showed that a single systemic administration of a ketamine metabolite (2R,6R)-hydroxynorketamine (2R,6R-HNK) rapidly rescued chronic stress-induced depression-like behavior and persisted for up to 21 days.  Consistently, the chronic stress-induced diminished glutamatergic transmission and surface GluR1 expression in the vlPAG were also reversed by a single systemic injection of (2R,6R)-HNK.  Furthermore, bath application of (2R,6R)-HNK increased the frequency and amplitude of miniature excitatory postsynaptic currents (mEPSCs) in the vlPAG.  Further evidence for the antidepressant action of (2R,6R)-HNK is provided by the finding that microinjection of (2R,6R)-HNK into the vlPAG exhibited a rapid-acting and long-lasting antidepressant effect.  This antidepressant effect of (2R,6R)-HNK was prevented by the intra-vlPAG microinjection of AMPA receptor antagonist CNQX.  Together, the current results provide evidence that (2R,6R)-HNK rescues chronic stress-induced depression-like behavior with rapid-acting and long-lasting antidepressant effects through enhancement of AMPA receptor-mediated transmission in the vlPAG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVtK_JUYSLu7Vg90H21EOLACvtfcHk0ljz9gTqSiQPzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1agt7vL&md5=a4fa7174f33d0620f3e2103193fa2d8e</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2018.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2018.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DD.%26aulast%3DPeng%26aufirst%3DH.-Y.%26aulast%3DLin%26aufirst%3DT.-B.%26aulast%3DLai%26aufirst%3DC.-Y.%26aulast%3DHsieh%26aufirst%3DM.-C.%26aulast%3DWen%26aufirst%3DY.-C.%26aulast%3DLee%26aufirst%3DA.-S.%26aulast%3DWang%26aufirst%3DH.-H.%26aulast%3DYang%26aufirst%3DP.-S.%26aulast%3DChen%26aufirst%3DG.-D.%26aulast%3DHo%26aufirst%3DY.-C.%26atitle%3D%25282R%252C%25206R%2529-hydroxynorketamine%2520rescues%2520chronic%2520stress-induced%2520depression-like%2520behavior%2520through%2520its%2520actions%2520in%2520the%2520midbrain%2520periaqueductal%2520gray%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D139%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.neuropharm.2018.06.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.-H.</span></span> <span> </span><span class="NLM_article-title">Neuronal correlates of depression</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">4825</span>– <span class="NLM_lpage">4848</span>, <span class="refDoi"> DOI: 10.1007/s00018-015-2044-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2Fs00018-015-2044-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26542802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyrsLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2015&pages=4825-4848&author=D.+Chaudhuryauthor=H.+Liuauthor=M.-H.+Han&title=Neuronal+correlates+of+depression&doi=10.1007%2Fs00018-015-2044-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal correlates of depression</span></div><div class="casAuthors">Chaudhury, Dipesh; Liu, He; Han, Ming-Hu</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4825-4848</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Major depressive disorder (MDD) is a common psychiatric disorder effecting approx. 121 million people worldwide and recent reports from the World Health Organization (WHO) suggest that it will be the leading contributor to the global burden of diseases.  At present, the most commonly used treatment strategies are still based on the monoamine hypothesis that has been the predominant theory in the last 60 years.  Clin. observations show that only a subset of depressed patients exhibits full remission when treated with classical monoamine-based antidepressants together with the fact that patients exhibit multiple symptoms suggest that the pathophysiol. leading to mood disorders may differ between patients.  Accumulating evidence indicates that depression is a neural circuit disorder and that onset of depression may be located at different regions of the brain involving different transmitter systems and mol. mechanisms.  This review synthesizes findings from rodent studies from which emerges a role for different, yet interconnected, mol. systems and assocd. neural circuits to the etiol. of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdQv5HpCdBALVg90H21EOLACvtfcHk0liQudiJ8bm01g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyrsLfJ&md5=72f3fa204417b9a68175147bdd696c17</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs00018-015-2044-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-015-2044-6%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhury%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DM.-H.%26atitle%3DNeuronal%2520correlates%2520of%2520depression%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2015%26volume%3D72%26spage%3D4825%26epage%3D4848%26doi%3D10.1007%2Fs00018-015-2044-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ionescu, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felicione, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapero, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deckersbach, T.</span></span> <span> </span><span class="NLM_article-title">Ketamine-associated brain changes: a review of the neuroimaging literature</span>. <i>Harvard Rev. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">320</span>, <span class="refDoi"> DOI: 10.1097/HRP.0000000000000179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2FHRP.0000000000000179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29465479" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=320&author=D.+F.+Ionescuauthor=J.+M.+Felicioneauthor=A.+Gosaiauthor=C.+Cusinauthor=P.+Shinauthor=B.+G.+Shaperoauthor=T.+Deckersbach&title=Ketamine-associated+brain+changes%3A+a+review+of+the+neuroimaging+literature&doi=10.1097%2FHRP.0000000000000179"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1097%2FHRP.0000000000000179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FHRP.0000000000000179%26sid%3Dliteratum%253Aachs%26aulast%3DIonescu%26aufirst%3DD.%2BF.%26aulast%3DFelicione%26aufirst%3DJ.%2BM.%26aulast%3DGosai%26aufirst%3DA.%26aulast%3DCusin%26aufirst%3DC.%26aulast%3DShin%26aufirst%3DP.%26aulast%3DShapero%26aufirst%3DB.%2BG.%26aulast%3DDeckersbach%26aufirst%3DT.%26atitle%3DKetamine-associated%2520brain%2520changes%253A%2520a%2520review%2520of%2520the%2520neuroimaging%2520literature%26jtitle%3DHarvard%2520Rev.%2520Psychiatry%26date%3D2018%26volume%3D26%26spage%3D320%26doi%3D10.1097%2FHRP.0000000000000179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hare, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span> <span> </span><span class="NLM_article-title">Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1038/s41380-020-0685-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fs41380-020-0685-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32086434" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=B.+D.+Hareauthor=R.+S.+Duman&title=Prefrontal+cortex+circuits+in+depression+and+anxiety%3A+contribution+of+discrete+neuronal+populations+and+target+regions&doi=10.1038%2Fs41380-020-0685-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fs41380-020-0685-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41380-020-0685-9%26sid%3Dliteratum%253Aachs%26aulast%3DHare%26aufirst%3DB.%2BD.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DPrefrontal%2520cortex%2520circuits%2520in%2520depression%2520and%2520anxiety%253A%2520contribution%2520of%2520discrete%2520neuronal%2520populations%2520and%2520target%2520regions%26jtitle%3DMol.%2520Psychiatry%26date%3D2020%26doi%3D10.1038%2Fs41380-020-0685-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span> <span> </span><span class="NLM_article-title">Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">977</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2011.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.neuron.2011.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=22405206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsFOhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2012&pages=962-977&author=E.+Y.+Yuenauthor=J.+Weiauthor=W.+Liuauthor=P.+Zhongauthor=X.+Liauthor=Z.+Yan&title=Repeated+stress+causes+cognitive+impairment+by+suppressing+glutamate+receptor+expression+and+function+in+prefrontal+cortex&doi=10.1016%2Fj.neuron.2011.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex</span></div><div class="casAuthors">Yuen, Eunice Y.; Wei, Jing; Liu, Wenhua; Zhong, Ping; Li, Xiangning; Yan, Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">962-977</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Chronic stress could trigger maladaptive changes assocd. with stress-related mental disorders; however, the underlying mechanisms remain elusive.  In this study, we found that exposing juvenile male rats to repeated stress significantly impaired the temporal order recognition memory, a cognitive process controlled by the prefrontal cortex (PFC).  Concomitantly, significantly reduced AMPAR- and NMDAR-mediated synaptic transmission and glutamate receptor expression were found in PFC pyramidal neurons from repeatedly stressed animals.  All these effects relied on activation of glucocorticoid receptors and the subsequent enhancement of ubiquitin/proteasome-mediated degrdn. of GluR1 and NR1 subunits, which was controlled by the E3 ubiquitin ligase Nedd4-1 and Fbx2, resp.  Inhibition of proteasomes or knockdown of Nedd4-1 and Fbx2 in PFC prevented the loss of glutamatergic responses and recognition memory in stressed animals.  Our results suggest that repeated stress dampens PFC glutamatergic transmission by facilitating glutamate receptor turnover, which causes the detrimental effect on PFC-dependent cognitive processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4CR_jOqOg1rVg90H21EOLACvtfcHk0liQudiJ8bm01g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsFOhsb0%253D&md5=0bf404138e8a4179a3eb20ad9b1bea98</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2011.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2011.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DYuen%26aufirst%3DE.%2BY.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DZ.%26atitle%3DRepeated%2520stress%2520causes%2520cognitive%2520impairment%2520by%2520suppressing%2520glutamate%2520receptor%2520expression%2520and%2520function%2520in%2520prefrontal%2520cortex%26jtitle%3DNeuron%26date%3D2012%26volume%3D73%26spage%3D962%26epage%3D977%26doi%3D10.1016%2Fj.neuron.2011.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanske, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heissler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schönfelder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessa, M.</span></span> <span> </span><span class="NLM_article-title">Neural correlates of emotion regulation deficits in remitted depression: the influence of regulation strategy, habitual regulation use, and emotional valence</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">686</span>– <span class="NLM_lpage">693</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2012.03.089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.neuroimage.2012.03.089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=22613776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC38nlt1WmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=686-693&author=P.+Kanskeauthor=J.+Heisslerauthor=S.+Sch%C3%B6nfelderauthor=M.+Wessa&title=Neural+correlates+of+emotion+regulation+deficits+in+remitted+depression%3A+the+influence+of+regulation+strategy%2C+habitual+regulation+use%2C+and+emotional+valence&doi=10.1016%2Fj.neuroimage.2012.03.089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Neural correlates of emotion regulation deficits in remitted depression: the influence of regulation strategy, habitual regulation use, and emotional valence</span></div><div class="casAuthors">Kanske Philipp; Heissler Janine; Schonfelder Sandra; Wessa Michele</div><div class="citationInfo"><span class="NLM_cas:title">NeuroImage</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">686-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Regulating emotions through reappraisal has been shown to elicit abnormal neural activation patterns in currently depressed patients.  It is, however, unclear if this deficit generalizes to other emotion regulation strategies, if it persists when patients recover, and if it is related to habitual use of reappraisal strategies.  Therefore, we measured the neural responses to emotional images with functional magnetic resonance imaging in remitted patients with previous episodes of major depression and healthy controls.  While viewing the images participants regulated the elicited emotions using either a reappraisal or a distraction strategy.  Habitual reappraisal use was measured with the Cognitive Emotion Regulation Questionnaire.  Depressed patients showed a selective deficit in down-regulating amygdala responses to negative emotional stimuli using reappraisal.  This down-regulation of amygdala activity was strongest in participants high in habitual reappraisal use.  Activity in the regulating control-network including anterior cingulate and lateral orbitofrontal cortex was increased during both emotion regulation strategies.  The findings in remitted patients with previous episodes of major depression suggest that altered emotion regulation is a trait-marker for depression.  This interpretation is supported by the relation of habitual reappraisal use to amygdala down-regulation success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGc8eyF2TnHEcLvDNbOD4DfW6udTcc2ebXqAwwG0Ulkbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38nlt1WmsA%253D%253D&md5=34cc72d2862f5eff02a930fc9f1ab95d</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2012.03.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2012.03.089%26sid%3Dliteratum%253Aachs%26aulast%3DKanske%26aufirst%3DP.%26aulast%3DHeissler%26aufirst%3DJ.%26aulast%3DSch%25C3%25B6nfelder%26aufirst%3DS.%26aulast%3DWessa%26aufirst%3DM.%26atitle%3DNeural%2520correlates%2520of%2520emotion%2520regulation%2520deficits%2520in%2520remitted%2520depression%253A%2520the%2520influence%2520of%2520regulation%2520strategy%252C%2520habitual%2520regulation%2520use%252C%2520and%2520emotional%2520valence%26jtitle%3DNeuroImage%26date%3D2012%26volume%3D61%26spage%3D686%26epage%3D693%26doi%3D10.1016%2Fj.neuroimage.2012.03.089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mickey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajilore, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peciña, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikora, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Decoupling of the amygdala to other salience network regions in adolescent-onset recurrent major depressive disorder</span>. <i>Psychol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1017/S0033291715002615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1017%2FS0033291715002615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26784396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC28nhslWguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2016&pages=1055-1067&author=R.+Jacobsauthor=A.+Barbaauthor=J.+Gowinsauthor=H.+Klumppauthor=L.+Jenkinsauthor=B.+Mickeyauthor=O.+Ajiloreauthor=M.+Peci%C3%B1aauthor=M.+Sikoraauthor=K.+Ryan&title=Decoupling+of+the+amygdala+to+other+salience+network+regions+in+adolescent-onset+recurrent+major+depressive+disorder&doi=10.1017%2FS0033291715002615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Decoupling of the amygdala to other salience network regions in adolescent-onset recurrent major depressive disorder</span></div><div class="casAuthors">Jacobs R H; Barba A; Gowins J R; Klumpp H; Jenkins L M; Ajilore O; Phan K L; Langenecker S A; Mickey B J; Pecina M; Sikora M; Ryan K A; Hsu D T; Welsh R C; Zubieta J-K</div><div class="citationInfo"><span class="NLM_cas:title">Psychological medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1055-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recent meta-analyses of resting-state networks in major depressive disorder (MDD) implicate network disruptions underlying cognitive and affective features of illness.  Heterogeneity of findings to date may stem from the relative lack of data parsing clinical features of MDD such as phase of illness and the burden of multiple episodes.  METHOD:  Resting-state functional magnetic resonance imaging data were collected from 17 active MDD and 34 remitted MDD patients, and 26 healthy controls (HCs) across two sites.  Participants were medication-free and further subdivided into those with single v. multiple episodes to examine disease burden.  Seed-based connectivity using the posterior cingulate cortex (PCC) seed to probe the default mode network as well as the amygdala and subgenual anterior cingulate cortex (sgACC) seeds to probe the salience network (SN) were conducted.  RESULTS:  Young adults with remitted MDD demonstrated hyperconnectivity of the left PCC to the left inferior frontal gyrus and of the left sgACC to the right ventromedial prefrontal cortex (PFC) and left hippocampus compared with HCs.  Episode-independent effects were observed between the left PCC and the right dorsolateral PFC, as well as between the left amygdala and right insula and caudate, whereas the burden of multiple episodes was associated with hypoconnectivity of the left PCC to multiple cognitive control regions as well as hypoconnectivity of the amygdala to large portions of the SN.  CONCLUSIONS:  This is the first study of a homogeneous sample of unmedicated young adults with a history of adolescent-onset MDD illustrating brain-based episodic features of illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFmF3n8no4EUbxh97K6Vt6fW6udTcc2eYAsVZhny2jmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nhslWguw%253D%253D&md5=fc241d735e24d9818978e356d2c750bf</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1017%2FS0033291715002615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0033291715002615%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DR.%26aulast%3DBarba%26aufirst%3DA.%26aulast%3DGowins%26aufirst%3DJ.%26aulast%3DKlumpp%26aufirst%3DH.%26aulast%3DJenkins%26aufirst%3DL.%26aulast%3DMickey%26aufirst%3DB.%26aulast%3DAjilore%26aufirst%3DO.%26aulast%3DPeci%25C3%25B1a%26aufirst%3DM.%26aulast%3DSikora%26aufirst%3DM.%26aulast%3DRyan%26aufirst%3DK.%26atitle%3DDecoupling%2520of%2520the%2520amygdala%2520to%2520other%2520salience%2520network%2520regions%2520in%2520adolescent-onset%2520recurrent%2520major%2520depressive%2520disorder%26jtitle%3DPsychol.%2520Med.%26date%3D2016%26volume%3D46%26spage%3D1055%26epage%3D1067%26doi%3D10.1017%2FS0033291715002615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisendrath, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathalon, D. H.</span></span> <span> </span><span class="NLM_article-title">Blunted amygdala activity is associated with depression severity in treatment-resistant depression</span>. <i>Cog. Affect. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1231</span>, <span class="refDoi"> DOI: 10.3758/s13415-017-0544-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.3758%2Fs13415-017-0544-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29063521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC1M7jvVCisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=1221-1231&author=J.+Ferriauthor=S.+J.+Eisendrathauthor=S.+L.+Fryerauthor=E.+Gillungauthor=B.+J.+Roachauthor=D.+H.+Mathalon&title=Blunted+amygdala+activity+is+associated+with+depression+severity+in+treatment-resistant+depression&doi=10.3758%2Fs13415-017-0544-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Blunted amygdala activity is associated with depression severity in treatment-resistant depression</span></div><div class="casAuthors">Ferri Jamie; Eisendrath Stuart J; Fryer Susanna L; Gillung Erin; Mathalon Daniel H; Fryer Susanna L; Roach Brian J; Mathalon Daniel H; Mathalon Daniel H</div><div class="citationInfo"><span class="NLM_cas:title">Cognitive, affective & behavioral neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1221-1231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Up to 50% of individuals with major depressive disorder (MDD) do not recover after two antidepressant medication trials, and therefore meet the criteria for treatment-resistant depression (TRD).  Mindfulness-based cognitive therapy (MBCT) is one promising treatment; however, the extent to which MBCT influences clinical outcomes relative to baseline neural activation remains unknown.  In the present study we investigated baseline differences in amygdala activation between TRD patients and healthy controls (HCs), related amygdala activation to depression symptoms, and examined the impacts of MBCT and amygdala activation on longitudinal depression outcomes.  At baseline, TRD patients (n = 80) and HCs (n = 37) participated in a functional magnetic resonance imaging task in which they identified either the emotion (affect labeling) or the gender (gender labeling) of faces, or passively viewed faces (observing).  The TRD participants then completed eight weeks of MBCT or a health enhancement program (HEP).  Relative to HCs, the TRD patients demonstrated less amygdala activation during affect labeling, and marginally less during gender labeling.  Blunted amygdala activation in TRD patients during affect labeling was associated with greater depression severity.  MBCT was associated with greater depression reductions than was HEP directly following treatment; however, at 52 weeks the treatment effect was not significant, and baseline amygdala activation across the task conditions predicted depression severity in both groups.  TRD patients have blunted amygdala responses during affect labeling that are associated with greater concurrent depression.  Furthermore, although MBCT produced greater short-term improvements in depression than did HEP, overall baseline amygdala reactivity was predictive of long-term clinical outcomes in both groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-jPRFFm4_MisZ1x6zOs0vfW6udTcc2eZ61b3acSD2Erntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7jvVCisQ%253D%253D&md5=b4f8ece6967a5f3192b410c94f037bc3</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3758%2Fs13415-017-0544-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3758%252Fs13415-017-0544-6%26sid%3Dliteratum%253Aachs%26aulast%3DFerri%26aufirst%3DJ.%26aulast%3DEisendrath%26aufirst%3DS.%2BJ.%26aulast%3DFryer%26aufirst%3DS.%2BL.%26aulast%3DGillung%26aufirst%3DE.%26aulast%3DRoach%26aufirst%3DB.%2BJ.%26aulast%3DMathalon%26aufirst%3DD.%2BH.%26atitle%3DBlunted%2520amygdala%2520activity%2520is%2520associated%2520with%2520depression%2520severity%2520in%2520treatment-resistant%2520depression%26jtitle%3DCog.%2520Affect.%2520Behav.%2520Neurosci.%26date%3D2017%26volume%3D17%26spage%3D1221%26epage%3D1231%26doi%3D10.3758%2Fs13415-017-0544-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grueter, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothwell, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenka, R. C.</span></span> <span> </span><span class="NLM_article-title">Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>487</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1038/nature11160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnature11160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=22785313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWisrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=183-189&author=B.+K.+Limauthor=K.+W.+Huangauthor=B.+A.+Grueterauthor=P.+E.+Rothwellauthor=R.+C.+Malenka&title=Anhedonia+requires+MC4R-mediated+synaptic+adaptations+in+nucleus+accumbens&doi=10.1038%2Fnature11160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens</span></div><div class="casAuthors">Lim, Byung Kook; Huang, Kee Wui; Grueter, Brad A.; Rothwell, Patrick E.; Malenka, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">7406</span>),
    <span class="NLM_cas:pages">183-189</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic stress is a strong diathesis for depression in humans and is used to generate animal models of depression.  It commonly leads to several major symptoms of depression, including dysregulated feeding behavior, anhedonia and behavioral despair.  Although hypotheses defining the neural pathophysiol. of depression have been proposed, the crit. synaptic adaptations in key brain circuits that mediate stress-induced depressive symptoms remain poorly understood.  Here we show that chronic stress in mice decreases the strength of excitatory synapses on D1 dopamine receptor-expressing nucleus accumbens medium spiny neurons owing to activation of the melanocortin 4 receptor.  Stress-elicited increases in behavioral measurements of anhedonia, but not increases in measurements of behavioral despair, are prevented by blocking these melanocortin 4 receptor-mediated synaptic changes in vivo.  These results establish that stress-elicited anhedonia requires a neuropeptide-triggered, cell-type-specific synaptic adaptation in the nucleus accumbens and that distinct circuit adaptations mediate other major symptoms of stress-elicited depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKEc-kNRWIA7Vg90H21EOLACvtfcHk0lh-iTcMygZzYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWisrbI&md5=4dcb328d8819479b72dad30948497755</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fnature11160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11160%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DB.%2BK.%26aulast%3DHuang%26aufirst%3DK.%2BW.%26aulast%3DGrueter%26aufirst%3DB.%2BA.%26aulast%3DRothwell%26aufirst%3DP.%2BE.%26aulast%3DMalenka%26aufirst%3DR.%2BC.%26atitle%3DAnhedonia%2520requires%2520MC4R-mediated%2520synaptic%2520adaptations%2520in%2520nucleus%2520accumbens%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D183%26epage%3D189%26doi%3D10.1038%2Fnature11160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kallarackal, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kvarta, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammarata, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaberi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S. M.</span></span> <span> </span><span class="NLM_article-title">Chronic stress induces a selective decrease in AMPA receptor-mediated synaptic excitation at hippocampal temporoammonic-CA1 synapses</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">15669</span>– <span class="NLM_lpage">15674</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.2588-13.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1523%2FJNEUROSCI.2588-13.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=24089474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2lur3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=15669-15674&author=A.+J.+Kallarackalauthor=M.+D.+Kvartaauthor=E.+Cammarataauthor=L.+Jaberiauthor=X.+Caiauthor=A.+M.+Baileyauthor=S.+M.+Thompson&title=Chronic+stress+induces+a+selective+decrease+in+AMPA+receptor-mediated+synaptic+excitation+at+hippocampal+temporoammonic-CA1+synapses&doi=10.1523%2FJNEUROSCI.2588-13.2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic stress induces a selective decrease in AMPA receptor-mediated synaptic excitation at hippocampal temporoammonic-CA1 synapses</span></div><div class="casAuthors">Kallarackal, Angy J.; Kvarta, Mark D.; Cammarata, Erin; Jaberi, Leelah; Cai, Xiang; Bailey, Aileen M.; Thompson, Scott M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">15669-15674</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Chronic stress promotes depression, but how it disrupts cognition and mood remains unknown.  Chronic stress causes atrophy of pyramidal cell dendrites in the hippocampus and cortex in human and animal models, and a depressive-like behavioral state.  We now test the hypothesis that excitatory temporoammonic (TA) synapses in the distal dendrites of CA1 pyramidal cells in rats are altered by chronic unpredictable stress (CUS) and restored by chronic antidepressant treatment, in conjunction with the behavioral consequences of CUS.  We obsd. a decrease in AMPAR-mediated excitation at TA-CA1 synapses, but not Schaffer collateral-CA1 synapses, after CUS, with a corresponding layer-specific decrease in GluA1 expression.  Both changes were reversed by chronic fluoxetine.  CUS also disrupted long-term memory consolidation in the Morris water maze, a function of TA-CA1 synapses.  The decreases in TA-CA1 AMPAR-mediated excitation and performance in the consolidation test were correlated pos. with decreases in sucrose preference, a measure of anhedonia.  We conclude that chronic stress selectively decreases AMPAR no. and function at specific synapses and suggest that this underlies various depressive endophenotypes.  Our findings provide evidence that glutamatergic dysfunction is an underlying cause of depression and that current first-line antidepressant drugs act by restoring excitatory synaptic strength.  Our findings suggest novel therapeutic targets for this debilitating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh57gzYtk14LVg90H21EOLACvtfcHk0lhgJNgVJyWP5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2lur3J&md5=a0c5c4e70f4af188c00b63f4ddf9c397</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2588-13.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2588-13.2013%26sid%3Dliteratum%253Aachs%26aulast%3DKallarackal%26aufirst%3DA.%2BJ.%26aulast%3DKvarta%26aufirst%3DM.%2BD.%26aulast%3DCammarata%26aufirst%3DE.%26aulast%3DJaberi%26aufirst%3DL.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DBailey%26aufirst%3DA.%2BM.%26aulast%3DThompson%26aufirst%3DS.%2BM.%26atitle%3DChronic%2520stress%2520induces%2520a%2520selective%2520decrease%2520in%2520AMPA%2520receptor-mediated%2520synaptic%2520excitation%2520at%2520hippocampal%2520temporoammonic-CA1%2520synapses%26jtitle%3DJ.%2520Neurosci.%26date%3D2013%26volume%3D33%26spage%3D15669%26epage%3D15674%26doi%3D10.1523%2FJNEUROSCI.2588-13.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span> <span> </span><span class="NLM_article-title">Lateral habenula in the pathophysiology of depression</span>. <i>Curr. Opin. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.conb.2017.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.conb.2017.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29175713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2018&pages=90-96&author=Y.+Yangauthor=H.+Wangauthor=J.+Huauthor=H.+Hu&title=Lateral+habenula+in+the+pathophysiology+of+depression&doi=10.1016%2Fj.conb.2017.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Lateral habenula in the pathophysiology of depression</span></div><div class="casAuthors">Yang, Yan; Wang, Hao; Hu, Ji; Hu, Hailan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Neurobiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">90-96</span>CODEN:
                <span class="NLM_cas:coden">COPUEN</span>;
        ISSN:<span class="NLM_cas:issn">0959-4388</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Depression is a devastating disorder with a combination of diverse symptoms such as low self-esteem, lack of motivation, anhedonia, loss of appetite, low energy, and discomfort without a clear cause.  Depression has been suggested to be the result of maladaptive changes in specific brain circuits.  Recently, the lateral habenula (LHb) has emerged as a key brain region in the pathophysiol. of depression.  Increasing evidence from rodent, non-human primate and human studies indicates that the aberrant activity of the LHb is assocd. with depressive symptoms such as helplessness, anhedonia, and excessive neg. focus.  Revealing the mol., cellular and circuit properties of the LHb will help explain how abnormalities in LHb activity are linked to depressive disorders, and shed light on developing novel strategies for depression treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFwV1YLkSapLVg90H21EOLACvtfcHk0lh5aL6UVioNcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSitbfO&md5=4ddfadd5be1e86180eee06ca2623fc3c</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.conb.2017.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.conb.2017.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DH.%26atitle%3DLateral%2520habenula%2520in%2520the%2520pathophysiology%2520of%2520depression%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D2018%26volume%3D48%26spage%3D90%26epage%3D96%26doi%3D10.1016%2Fj.conb.2017.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drevets, W.</span></span> <span> </span><span class="NLM_article-title">Neurocircuitry of mood disorders</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.1038/npp.2009.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnpp.2009.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=19693001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD1MfivVSkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=192-216&author=J.+Priceauthor=W.+Drevets&title=Neurocircuitry+of+mood+disorders&doi=10.1038%2Fnpp.2009.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Neurocircuitry of mood disorders</span></div><div class="casAuthors">Price Joseph L; Drevets Wayne C</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">192-216</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This review begins with a brief historical overview of attempts in the first half of the 20th century to discern brain systems that underlie emotion and emotional behavior.  These early studies identified the amygdala, hippocampus, and other parts of what was termed the 'limbic' system as central parts of the emotional brain.  Detailed connectional data on this system began to be obtained in the 1970s and 1980s, as more effective neuroanatomical techniques based on axonal transport became available.  In the last 15 years these methods have been applied extensively to the limbic system and prefrontal cortex of monkeys, and much more specific circuits have been defined.  In particular, a system has been described that links the medial prefrontal cortex and a few related cortical areas to the amygdala, the ventral striatum and pallidum, the medial thalamus, the hypothalamus, and the periaqueductal gray and other parts of the brainstem.  A large body of human data from functional and structural imaging, as well as analysis of lesions and histological material indicates that this system is centrally involved in mood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcTdc2c-lnpb5XHngOXiV_fW6udTcc2eZjqRg17Gpslrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MfivVSkuw%253D%253D&md5=49a5c88147c5318509a3b994ce548e59</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2009.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2009.104%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DJ.%26aulast%3DDrevets%26aufirst%3DW.%26atitle%3DNeurocircuitry%2520of%2520mood%2520disorders%26jtitle%3DNeuropsychopharmacology%26date%3D2010%26volume%3D35%26spage%3D192%26epage%3D216%26doi%3D10.1038%2Fnpp.2009.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murrough, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacoviello, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumeister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iosifescu, D. V.</span></span> <span> </span><span class="NLM_article-title">Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies</span>. <i>Neurobiol. Learn. Mem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1016/j.nlm.2011.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.nlm.2011.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=21704176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2011&pages=553-563&author=J.+W.+Murroughauthor=B.+Iacovielloauthor=A.+Neumeisterauthor=D.+S.+Charneyauthor=D.+V.+Iosifescu&title=Cognitive+dysfunction+in+depression%3A+neurocircuitry+and+new+therapeutic+strategies&doi=10.1016%2Fj.nlm.2011.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies</span></div><div class="casAuthors">Murrough, James W.; Iacoviello, Brian; Neumeister, Alexander; Charney, Dennis S.; Iosifescu, Dan V.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Learning and Memory</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">553-563</span>CODEN:
                <span class="NLM_cas:coden">NLMEFR</span>;
        ISSN:<span class="NLM_cas:issn">1074-7427</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Major depressive disorder (MDD) is a disabling medical condition assocd. with significant morbidity, mortality and public health costs.  However, neurocircuitry abnormalities underlying depression remain incompletely understood and consequently current treatment options are unfortunately limited in efficacy.  Recent research has begun to focus specifically on cognitive aspects of depression and potential neurobiol. correlates.  Two fundamental types of cognitive dysfunction obsd. in MDD are cognitive biases, which include distorted information processing or attentional allocation toward neg. stimuli, and cognitive deficits, which include impairments in attention, short-term memory and executive functioning.  In this article, we present a selective review of current research findings in these domains and examine neuroimaging research that is beginning to characterize the neurocircuitry underlying these biases and deficits.  We propose that deficient cognitive functioning, attention biases and the sustained neg. affect characteristic of MDD can be understood as arising in part from dysfunctional prefrontal-subcortical circuitry and related disturbances in the cognitive control of emotion.  Finally, we highlight potential new pharmacol. and non-pharmacol. therapeutic strategies for MDD based on an evolving mechanistic understanding of the disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLIwSi3SXol7Vg90H21EOLACvtfcHk0lh5aL6UVioNcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsL7E&md5=928d9c8f9f216690f1399616f759900c</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.nlm.2011.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nlm.2011.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DMurrough%26aufirst%3DJ.%2BW.%26aulast%3DIacoviello%26aufirst%3DB.%26aulast%3DNeumeister%26aufirst%3DA.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DIosifescu%26aufirst%3DD.%2BV.%26atitle%3DCognitive%2520dysfunction%2520in%2520depression%253A%2520neurocircuitry%2520and%2520new%2520therapeutic%2520strategies%26jtitle%3DNeurobiol.%2520Learn.%2520Mem.%26date%3D2011%26volume%3D96%26spage%3D553%26epage%3D563%26doi%3D10.1016%2Fj.nlm.2011.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallak, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dursun, S. M.</span></span> <span> </span><span class="NLM_article-title">Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco–magnetic resonance imaging study</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1001/archgenpsychiatry.2007.37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1001%2Farchgenpsychiatry.2007.37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=18250253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FptFyksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=154-164&author=J.+W.+Deakinauthor=J.+Leesauthor=S.+McKieauthor=J.+E.+Hallakauthor=S.+R.+Williamsauthor=S.+M.+Dursun&title=Glutamate+and+the+neural+basis+of+the+subjective+effects+of+ketamine%3A+a+pharmaco%E2%80%93magnetic+resonance+imaging+study&doi=10.1001%2Farchgenpsychiatry.2007.37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study</span></div><div class="casAuthors">Deakin J F William; Lees Jane; McKie Shane; Hallak Jaime E C; Williams Steve R; Dursun Serdar M</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-64</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  Ketamine evokes psychosislike symptoms, and its primary action is to impair N-methyl-D-aspartate glutamate receptor neurotransmission, but it also induces secondary increases in glutamate release.  OBJECTIVES:  To identify the sites of action of ketamine in inducing symptoms and to determine the role of increased glutamate release using the glutamate release inhibitor lamotrigine.  DESIGN:  Two experiments with different participants were performed using a double-blind, placebo-controlled, randomized, crossover, counterbalanced-order design.  In the first experiment, the effect of intravenous ketamine hydrochloride on regional blood oxygenation level-dependent (BOLD) signal and correlated symptoms was compared with intravenous saline placebo.  In the second experiment, pretreatment with lamotrigine was compared with placebo to identify which effects of ketamine are mediated by increased glutamate release.  SETTING:  Wellcome Trust Clinical Research Facility, Manchester, England.  PARTICIPANTS:  Thirty-three healthy, right-handed men were recruited by advertisements.  INTERVENTIONS:  In experiment 1, participants were given intravenous ketamine (1-minute bolus of 0.26 mg/kg, followed by a maintenance infusion of 0.25 mg/kg/h for the remainder of the session) or placebo (0.9% saline solution).  In experiment 2, participants were pretreated with 300 mg of lamotrigine or placebo and then were given the same doses of ketamine as in experiment 1.  MAIN OUTCOME MEASURES:  Regional BOLD signal changes during ketamine or placebo infusion and Brief Psychiatric Rating Scale and Clinician-Administered Dissociative States Scale scores.  RESULTS:  Ketamine induced a rapid, focal, and unexpected decrease in ventromedial frontal cortex, including orbitofrontal cortex and subgenual cingulate, which strongly predicted its dissociative effects and increased activity in mid-posterior cingulate, thalamus, and temporal cortical regions (r = 0.90).  Activations correlated with Brief Psychiatric Rating Scale psychosis scores.  Lamotrigine pretreatment prevented many of the BOLD signal changes and the symptoms.  CONCLUSIONS:  These 2 changes may underpin 2 fundamental processes of psychosis: abnormal perceptual experiences and impaired cognitive-emotional evaluation of their significance.  The results are compatible with the theory that the neural and subjective effects of ketamine involve increased glutamate release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRE58QpfpTcutyzdcP07UmufW6udTcc2eZpclmHvr_1Mrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FptFyksg%253D%253D&md5=6e99c34faa15f1c1117740718c469622</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1001%2Farchgenpsychiatry.2007.37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchgenpsychiatry.2007.37%26sid%3Dliteratum%253Aachs%26aulast%3DDeakin%26aufirst%3DJ.%2BW.%26aulast%3DLees%26aufirst%3DJ.%26aulast%3DMcKie%26aufirst%3DS.%26aulast%3DHallak%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DS.%2BR.%26aulast%3DDursun%26aufirst%3DS.%2BM.%26atitle%3DGlutamate%2520and%2520the%2520neural%2520basis%2520of%2520the%2520subjective%2520effects%2520of%2520ketamine%253A%2520a%2520pharmaco%25E2%2580%2593magnetic%2520resonance%2520imaging%2520study%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2008%26volume%3D65%26spage%3D154%26epage%3D164%26doi%3D10.1001%2Farchgenpsychiatry.2007.37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvadore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornwell, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colon-Rosario, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppola, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manji, H. K.</span></span> <span> </span><span class="NLM_article-title">Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2008.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2008.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=18822408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFeksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2009&pages=289-295&author=G.+Salvadoreauthor=B.+R.+Cornwellauthor=V.+Colon-Rosarioauthor=R.+Coppolaauthor=C.+Grillonauthor=C.+A.+Zarateauthor=H.+K.+Manji&title=Increased+anterior+cingulate+cortical+activity+in+response+to+fearful+faces%3A+a+neurophysiological+biomarker+that+predicts+rapid+antidepressant+response+to+ketamine&doi=10.1016%2Fj.biopsych.2008.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Increased Anterior Cingulate Cortical Activity in Response to Fearful Faces: A Neurophysiological Biomarker that Predicts Rapid Antidepressant Response to Ketamine</span></div><div class="casAuthors">Salvadore, Giacomo; Cornwell, Brian R.; Colon-Rosario, Veronica; Coppola, Richard; Grillon, Christian; Zarate, Carlos A.; Manji, Husseini K.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">289-295</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Most patients with major depressive disorder (MDD) experience a period of lengthy trial and error when trying to find optimal antidepressant treatment; identifying biomarkers that could predict response to antidepressant treatment would be of enormous benefit.  We tested the hypothesis that pretreatment anterior cingulate cortex (ACC) activity could be a putative biomarker of rapid antidepressant response to ketamine, in line with previous findings that investigated the effects of conventional antidepressants.  We also investigated patterns of ACC activity to rapid presentation of fearful faces compared with the normal habituation obsd. in healthy subjects.  Methods: We elicited ACC activity in drug-free patients with MDD (n = 11) and healthy control subjects (n = 11) by rapidly presenting fearful faces, a paradigm known to activate rostral regions of the ACC.  Spatial-filtering analyses were performed on magnetoencephalog. (MEG) recordings, which offer the temporal precision necessary to est. ACC activity elicited by the rapid presentation of stimuli.  Magnetoencephalog. recordings were obtained only once for both patients and control subjects.  Patients were subsequently administered a single ketamine infusion followed by assessment of depressive symptoms 4 h later.  Results: Although healthy subjects had decreased neuromagnetic activity in the rostral ACC across repeated exposures, patients with MDD showed robust increases in pretreatment ACC activity.  Notably, this increase was pos. correlated with subsequent rapid antidepressant response to ketamine.  Exploratory analyses showed that pretreatment amygdala activity was neg. correlated with change in depressive symptoms.  Conclusions: Pretreatment rostral ACC activation may be a useful biomarker that identifies a subgroup of patients who will respond favorably to ketamine's antidepressant effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotbAnatv3btLVg90H21EOLACvtfcHk0ljqK8zgMrKmqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFeksrk%253D&md5=900e392965797d3e5c41c96f2a9740b6</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2008.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2008.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DSalvadore%26aufirst%3DG.%26aulast%3DCornwell%26aufirst%3DB.%2BR.%26aulast%3DColon-Rosario%26aufirst%3DV.%26aulast%3DCoppola%26aufirst%3DR.%26aulast%3DGrillon%26aufirst%3DC.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DManji%26aufirst%3DH.%2BK.%26atitle%3DIncreased%2520anterior%2520cingulate%2520cortical%2520activity%2520in%2520response%2520to%2520fearful%2520faces%253A%2520a%2520neurophysiological%2520biomarker%2520that%2520predicts%2520rapid%2520antidepressant%2520response%2520to%2520ketamine%26jtitle%3DBiol.%2520Psychiatry%26date%3D2009%26volume%3D65%26spage%3D289%26epage%3D295%26doi%3D10.1016%2Fj.biopsych.2008.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvadore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornwell, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambataro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colon-Rosario, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carver, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holroyd, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiazGranados, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado-Vieira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillon, C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1422</span>, <span class="refDoi"> DOI: 10.1038/npp.2010.24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnpp.2010.24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=20393460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVSntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=1415-1422&author=G.+Salvadoreauthor=B.+R.+Cornwellauthor=F.+Sambataroauthor=D.+Latovauthor=V.+Colon-Rosarioauthor=F.+Carverauthor=T.+Holroydauthor=N.+DiazGranadosauthor=R.+Machado-Vieiraauthor=C.+Grillon&title=Anterior+cingulate+desynchronization+and+functional+connectivity+with+the+amygdala+during+a+working+memory+task+predict+rapid+antidepressant+response+to+ketamine&doi=10.1038%2Fnpp.2010.24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Anterior Cingulate Desynchronization and Functional Connectivity with the Amygdala During a Working Memory Task Predict Rapid Antidepressant Response to Ketamine</span></div><div class="casAuthors">Salvadore, Giacomo; Cornwell, Brian R.; Sambataro, Fabio; Latov, David; Colon-Rosario, Veronica; Carver, Frederick; Holroyd, Tom; Diaz Granados, Nancy; Machado-Vieira, Rodrigo; Grillon, Christian; Drevets, Wayne C.; Zarate, Carlos A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1415-1422</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pregenual anterior cingulate cortex (pgACC) hyperactivity differentiates treatment responders from non-responders to various pharmacol. antidepressant interventions, including ketamine, an N-methyl-D-aspartate receptor antagonist.  Evidence of pgACC hyperactivation during non-emotional working memory tasks in patients with major depressive disorder (MDD) highlights the importance of this region for processing both emotionally salient and cognitive stimuli.  However, it is unclear whether pgACC activity might serve as a potential biomarker of antidepressant response during working memory tasks as well, in line with previous research with emotionally arousing tasks.  This study tested the hypothesis that during the N-back task, a widely used working memory paradigm, low pretreatment pgACC activity, as well as coherence between the pgACC and the amygdala, would be correlated with the clin. improvement after ketamine.  Magnetoencephalog. (MEG) recordings were obtained from 15 drug-free patients with MDD during working memory performance 1 to 3 days before receiving a single ketamine infusion.  Functional activation patterns were analyzed using advanced MEG source anal.  Source coherence analyses were conducted to quantify the degree of long-range functional connectivity between the pgACC and the amygdala.  Patients who showed the least engagement of the pgACC in response to increased working memory load showed the greatest symptomatic improvement within 4 h of ketamine administration (r=0.82, p=0.0002, false discovery rate (FDR) <0.05).  Pretreatment functional connectivity between the pgACC and the left amygdala was neg. correlated with antidepressant symptom change (r=-0.73, p=0.0021, FDR <0.05).  These data implicate the pgACC and its putative interaction with the amygdala in predicting antidepressant response to ketamine in a working memory task context.  Neuropsychopharmacol. (2010) 35, 1415-1422; doi:10.1038/npp.2010.24; published online 10 March 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJVN7J6X5SOLVg90H21EOLACvtfcHk0ljqK8zgMrKmqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVSntrc%253D&md5=43264b2667165a6e7d150b18d5d0021d</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2010.24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2010.24%26sid%3Dliteratum%253Aachs%26aulast%3DSalvadore%26aufirst%3DG.%26aulast%3DCornwell%26aufirst%3DB.%2BR.%26aulast%3DSambataro%26aufirst%3DF.%26aulast%3DLatov%26aufirst%3DD.%26aulast%3DColon-Rosario%26aufirst%3DV.%26aulast%3DCarver%26aufirst%3DF.%26aulast%3DHolroyd%26aufirst%3DT.%26aulast%3DDiazGranados%26aufirst%3DN.%26aulast%3DMachado-Vieira%26aufirst%3DR.%26aulast%3DGrillon%26aufirst%3DC.%26atitle%3DAnterior%2520cingulate%2520desynchronization%2520and%2520functional%2520connectivity%2520with%2520the%2520amygdala%2520during%2520a%2520working%2520memory%2520task%2520predict%2520rapid%2520antidepressant%2520response%2520to%2520ketamine%26jtitle%3DNeuropsychopharmacology%26date%3D2010%26volume%3D35%26spage%3D1415%26epage%3D1422%26doi%3D10.1038%2Fnpp.2010.24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Covington, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maze, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPlant, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouzon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamminga, C. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">16082</span>– <span class="NLM_lpage">16090</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.1731-10.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1523%2FJNEUROSCI.1731-10.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=21123555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SlurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=16082-16090&author=H.+E.+Covingtonauthor=M.+K.+Loboauthor=I.+Mazeauthor=V.+Vialouauthor=J.+M.+Hymanauthor=S.+Zamanauthor=Q.+LaPlantauthor=E.+Mouzonauthor=S.+Ghoseauthor=C.+A.+Tamminga&title=Antidepressant+effect+of+optogenetic+stimulation+of+the+medial+prefrontal+cortex&doi=10.1523%2FJNEUROSCI.1731-10.2010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex</span></div><div class="casAuthors">Covington, Herbert E., III; Lobo, Mary Kay; Maze, Ian; Vialou, Vincent; Hyman, James M.; Zaman, Samir; La Plant, Quincey; Mouzon, Ezekiel; Ghose, Subroto; Tamminga, Carol A.; Neve, Rachael L.; Deisseroth, Karl; Nestler, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">16082-16090</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Brain stimulation and imaging studies in humans have highlighted a key role for the prefrontal cortex in clin. depression; however, it remains unknown whether excitation or inhibition of prefrontal cortical neuronal activity is assocd. with antidepressant responses.  Here, we examd. cellular indicators of functional activity, including the immediate early genes (IEGs) zif268 (egr1), c-fos, and arc, in the prefrontal cortex of clin. depressed humans obtained postmortem.  We also examd. these genes in the ventral portion of the medial prefrontal cortex (mPFC) of mice after chronic social defeat stress, a mouse model of depression.  In addn., we used viral vectors to overexpress channel rhodopsin 2 (a light-activated cation channel) in mouse mPFC to optogenetically drive "burst" patterns of cortical firing in vivo and examine the behavioral consequences.  Prefrontal cortical tissue derived from clin. depressed humans displayed significant redns. in IEG expression, consistent with a deficit in neuronal activity within this brain region.  Mice subjected to chronic social defeat stress exhibited similar redns. in levels of IEG expression in mPFC.  Interestingly, some of these changes were not obsd. in defeated mice that escape the deleterious consequences of the stress, i.e., resilient animals.  In those mice that expressed a strong depressive-like phenotype, i.e., susceptible animals, optogenetic stimulation of mPFC exerted potent antidepressant-like effects, without affecting general locomotor activity, anxiety-like behaviors, or social memory.  These results indicate that the activity of the mPFC is a key determinant of depression-like behavior, as well as antidepressant responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzHc8rw8jgcLVg90H21EOLACvtfcHk0liafJ0uLRBKVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SlurrF&md5=f2d2161ea7771dfb2cb8ae650e58c638</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1731-10.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1731-10.2010%26sid%3Dliteratum%253Aachs%26aulast%3DCovington%26aufirst%3DH.%2BE.%26aulast%3DLobo%26aufirst%3DM.%2BK.%26aulast%3DMaze%26aufirst%3DI.%26aulast%3DVialou%26aufirst%3DV.%26aulast%3DHyman%26aufirst%3DJ.%2BM.%26aulast%3DZaman%26aufirst%3DS.%26aulast%3DLaPlant%26aufirst%3DQ.%26aulast%3DMouzon%26aufirst%3DE.%26aulast%3DGhose%26aufirst%3DS.%26aulast%3DTamminga%26aufirst%3DC.%2BA.%26atitle%3DAntidepressant%2520effect%2520of%2520optogenetic%2520stimulation%2520of%2520the%2520medial%2520prefrontal%2520cortex%26jtitle%3DJ.%2520Neurosci.%26date%3D2010%26volume%3D30%26spage%3D16082%26epage%3D16090%26doi%3D10.1523%2FJNEUROSCI.1731-10.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuchikami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohleb, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Land, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiLeone, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajanian, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span> <span> </span><span class="NLM_article-title">Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">8106</span>– <span class="NLM_lpage">8111</span>, <span class="refDoi"> DOI: 10.1073/pnas.1414728112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1073%2Fpnas.1414728112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26056286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1Cks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=8106-8111&author=M.+Fuchikamiauthor=A.+Thomasauthor=R.+Liuauthor=E.+S.+Wohlebauthor=B.+B.+Landauthor=R.+J.+DiLeoneauthor=G.+K.+Aghajanianauthor=R.+S.+Duman&title=Optogenetic+stimulation+of+infralimbic+PFC+reproduces+ketamine%E2%80%99s+rapid+and+sustained+antidepressant+actions&doi=10.1073%2Fpnas.1414728112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions</span></div><div class="casAuthors">Fuchikami, Manabu; Thomas, Alexandra; Liu, Rongjian; Wohleb, Eric S.; Land, Benjamin B.; Di Leone, Ralph J.; Aghajanian, George K.; Duman, Ronald S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">8106-8111</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Ketamine produces rapid and sustained antidepressant actions in depressed patients, but the precise cellular mechanisms underlying these effects have not been identified.  Here we detd. if modulation of neuronal activity in the infralimbic prefrontal cortex (IL-PFC) underlies the antidepressant and anxiolytic actions of ketamine.  We found that neuronal inactivation of the IL-PFC completely blocked the antidepressant and anxiolytic effects of systemic ketamine in rodent models and that ketamine microinfusion into IL-PFC reproduced these behavioral actions of systemic ketamine.  We also found that optogenetic stimulation of the IL-PFC produced rapid and long-lasting antidepressant and anxiolytic effects and that these effects are assocd. with increased no. and function of spine synapses of layer V pyramidal neurons.  The results demonstrate that ketamine infusions or optogenetic stimulation of IL-PFC are sufficient to produce long-lasting antidepressant behavioral and synaptic responses similar to the effects of systemic ketamine administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaKumbToxsFrVg90H21EOLACvtfcHk0liafJ0uLRBKVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1Cks7w%253D&md5=e1324a1064d8b4e275acffa28fe85c05</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1414728112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1414728112%26sid%3Dliteratum%253Aachs%26aulast%3DFuchikami%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DWohleb%26aufirst%3DE.%2BS.%26aulast%3DLand%26aufirst%3DB.%2BB.%26aulast%3DDiLeone%26aufirst%3DR.%2BJ.%26aulast%3DAghajanian%26aufirst%3DG.%2BK.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DOptogenetic%2520stimulation%2520of%2520infralimbic%2520PFC%2520reproduces%2520ketamine%25E2%2580%2599s%2520rapid%2520and%2520sustained%2520antidepressant%2520actions%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D8106%26epage%3D8111%26doi%3D10.1073%2Fpnas.1414728112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vollenweider, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leenders, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharfetter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angst, J.</span></span> <span> </span><span class="NLM_article-title">Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F] fluorodeoxyglucose (FDG)</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/S0924-977X(96)00039-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2FS0924-977X%2896%2900039-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=9088881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK2sXhtlyisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=9-24&author=F.+Vollenweiderauthor=K.+Leendersauthor=C.+Scharfetterauthor=A.+Antoniniauthor=P.+Maguireauthor=J.+Missimerauthor=J.+Angst&title=Metabolic+hyperfrontality+and+psychopathology+in+the+ketamine+model+of+psychosis+using+positron+emission+tomography+%28PET%29+and+%5B18F%5D+fluorodeoxyglucose+%28FDG%29&doi=10.1016%2FS0924-977X%2896%2900039-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)</span></div><div class="casAuthors">Vollenweider, F. X.; Leenders, K. L.; Scharfetter, C.; Antonini, A.; Maguire, P.; Missimer, J.; Angst, J.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-24</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">To date, the ketamine/PCP model of psychosis has been proposed to be one of the best pharmacol. models to mimic schizophrenic psychosis in healthy volunteers, since ketamine can induce both pos. and neg. symptoms of schizophrenia.  At subanesthetic doses, ketamine has been reported to primarily block N-methyl-D-aspartate (NMDA) receptor complex giving support to a glutamate deficiency hypothesis in schizophrenia.  Positron emission tomog. was used to study ketamine-induced psychotic symptom formation in relation to cerebral metabolic alterations in healthy volunteers.  This study shows that NMDA receptor blockade results in a hyperfrontal metabolic pattern.  Increased metabolic activity in the frontomedial and anterior cingulate cortex correlated pos. with psychotic symptom formation, in particular with ego pathol.  Anal. of correlations between syndrome scores and metabolic rate of glucose (CMRglu) or metabolic gradients (ratios) revealed that each psychopathol. syndrome was assocd. with a no. of metabolic alterations in cortical and subcortical brain regions, suggesting that not a single brain region, but distributed neuronal networks are involved in acute psychotic symptom formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHFpuBLa-MbVg90H21EOLACvtfcHk0liafJ0uLRBKVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtlyisrw%253D&md5=37111d5ec36dbb3cb18483b661037292</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2FS0924-977X%2896%2900039-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0924-977X%252896%252900039-9%26sid%3Dliteratum%253Aachs%26aulast%3DVollenweider%26aufirst%3DF.%26aulast%3DLeenders%26aufirst%3DK.%26aulast%3DScharfetter%26aufirst%3DC.%26aulast%3DAntonini%26aufirst%3DA.%26aulast%3DMaguire%26aufirst%3DP.%26aulast%3DMissimer%26aufirst%3DJ.%26aulast%3DAngst%26aufirst%3DJ.%26atitle%3DMetabolic%2520hyperfrontality%2520and%2520psychopathology%2520in%2520the%2520ketamine%2520model%2520of%2520psychosis%2520using%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520and%2520%255B18F%255D%2520fluorodeoxyglucose%2520%2528FDG%2529%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D1997%26volume%3D7%26spage%3D9%26epage%3D24%26doi%3D10.1016%2FS0924-977X%2896%2900039-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Långsjö, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaisti, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aalto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aantaa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikonen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipilä, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvanto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinin, H.</span></span> <span> </span><span class="NLM_article-title">Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">614</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1097/00000542-200309000-00016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2F00000542-200309000-00016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=12960545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD3svitFGisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2003&pages=614-623&author=J.+W.+L%C3%A5ngsj%C3%B6author=K.+K.+Kaistiauthor=S.+Aaltoauthor=S.+Hinkkaauthor=R.+Aantaaauthor=V.+Oikonenauthor=H.+Sipil%C3%A4author=T.+Kurkiauthor=M.+Silvantoauthor=H.+Scheinin&title=Effects+of+subanesthetic+doses+of+ketamine+on+regional+cerebral+blood+flow%2C+oxygen+consumption%2C+and+blood+volume+in+humans&doi=10.1097%2F00000542-200309000-00016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans</span></div><div class="casAuthors">Langsjo Jaakko W; Kaisti Kaike K; Aalto Sargo; Hinkka Susanna; Aantaa Riku; Oikonen Vesa; Sipila Hannu; Kurki Timo; Silvanto Martti; Scheinin Harry</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">614-23</span>
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    </div><div class="casAbstract">BACKGROUND:  Animal experiments have demonstrated neuroprotection by ketamine.  However, because of its propensity to increase cerebral blood flow, metabolism, and intracranial pressure, its use in neurosurgery or trauma patients has been questioned.  METHODS:  15O-labeled water, oxygen, and carbon monoxide were used as positron emission tomography tracers to determine quantitative regional cerebral blood flow (rCBF), metabolic rate of oxygen (rCMRO2), and blood volume (rCBV), respectively, on selected regions of interest of nine healthy male volunteers at baseline and during three escalating concentrations of ketamine (targeted to 30, 100, and 300 ng/ml).  In addition, voxel-based analysis for relative changes in rCBF and rCMRO2 was performed using statistical parametric mapping.  RESULTS:  The mean +/- SD measured ketamine serum concentrations were 37 +/- 8, 132 +/- 19, and 411 +/- 71 ng/ml.  Mean arterial pressure was slightly elevated (maximally by 15.3%, P < 0.001) during ketamine infusion.  Ketamine increased rCBF in a concentration-dependent manner.  In the region-of-interest analysis, the greatest absolute changes were detected at the highest ketamine concentration level in the anterior cingulate (38.2% increase from baseline, P < 0.001), thalamus (28.5%, P < 0.001), putamen (26.8%, P < 0.001), and frontal cortex (25.4%, P < 0.001).  Voxel-based analysis revealed marked relative rCBF increases in the anterior cingulate, frontal cortex, and insula.  Although absolute rCMRO2 was not changed in the region-of-interest analysis, subtle relative increases in the frontal, parietal, and occipital cortices and decreases predominantly in the cerebellum were detected in the voxel-based analysis. rCBV increased only in the frontal cortex (4%, P = 0.022).  CONCLUSIONS:  Subanesthetic doses of ketamine induced a global increase in rCBF but no changes in rCMRO2.  Consequently, the regional oxygen extraction fraction was decreased.  Disturbed coupling of cerebral blood flow and metabolism is, however, considered unlikely because ketamine has been previously shown to increase cerebral glucose metabolism.  Only a minor increase in rCBV was detected.  Interestingly, the most profound changes in rCBF were observed in structures related to pain processing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSfSswHFtZq-2mnZh2OgS0fW6udTcc2eY9R1dV-OoTUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svitFGisg%253D%253D&md5=5fb56ae54f786e3b0828e18dad28823f</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1097%2F00000542-200309000-00016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-200309000-00016%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25A5ngsj%25C3%25B6%26aufirst%3DJ.%2BW.%26aulast%3DKaisti%26aufirst%3DK.%2BK.%26aulast%3DAalto%26aufirst%3DS.%26aulast%3DHinkka%26aufirst%3DS.%26aulast%3DAantaa%26aufirst%3DR.%26aulast%3DOikonen%26aufirst%3DV.%26aulast%3DSipil%25C3%25A4%26aufirst%3DH.%26aulast%3DKurki%26aufirst%3DT.%26aulast%3DSilvanto%26aufirst%3DM.%26aulast%3DScheinin%26aufirst%3DH.%26atitle%3DEffects%2520of%2520subanesthetic%2520doses%2520of%2520ketamine%2520on%2520regional%2520cerebral%2520blood%2520flow%252C%2520oxygen%2520consumption%252C%2520and%2520blood%2520volume%2520in%2520humans%26jtitle%3DAnesthesiology%26date%3D2003%26volume%3D99%26spage%3D614%26epage%3D623%26doi%3D10.1097%2F00000542-200309000-00016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Långsjö, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaisti, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aalto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aantaa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikonen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viljanen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvanto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinin, H.</span></span> <span> </span><span class="NLM_article-title">Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1065</span>– <span class="NLM_lpage">1071</span>, <span class="refDoi"> DOI: 10.1097/00000542-200405000-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2F00000542-200405000-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=15114201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ivVKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2004&pages=1065-1071&author=J.+W.+L%C3%A5ngsj%C3%B6author=E.+Salmiauthor=K.+K.+Kaistiauthor=S.+Aaltoauthor=S.+Hinkkaauthor=R.+Aantaaauthor=V.+Oikonenauthor=T.+Viljanenauthor=T.+Kurkiauthor=M.+Silvantoauthor=H.+Scheinin&title=Effects+of+subanesthetic+ketamine+on+regional+cerebral+glucose+metabolism+in+humans&doi=10.1097%2F00000542-200405000-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans</span></div><div class="casAuthors">Langsjo Jaakko W; Salmi Elina; Kaisti Kaike K; Aalto Sargo; Hinkka Susanna; Aantaa Riku; Oikonen Vesa; Viljanen Tapio; Kurki Timo; Silvanto Martti; Scheinin Harry</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1065-71</span>
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    </div><div class="casAbstract">BACKGROUND:  The authors have recently shown with positron emission tomography that subanesthetic doses of racemic ketamine increase cerebral blood flow but do not affect oxygen consumption significantly.  In this study, the authors wanted to assess the effects of racemic ketamine on regional glucose metabolic rate (rGMR) in similar conditions to establish whether ketamine truly induces disturbed coupling between cerebral blood flow and metabolism.  METHODS:  18F-labeled fluorodeoxyglucose was used as a positron emission tomography tracer to quantify rGMR on 12 brain regions of interest of nine healthy male volunteers at baseline and during a 300-ng/ml ketamine target concentration level.  In addition, voxel-based analysis was performed for the relative changes in rGMR using statistical parametric mapping.  RESULTS:  The mean +/- SD measured ketamine serum concentration was 326.4+/-86.3 ng/ml.  The mean arterial pressure was slightly increased (maximally by 16.4%) during ketamine infusion (P < 0.001).  Ketamine increased absolute rGMR significantly in most regions of interest studied.  The greatest increases were detected in the thalamus (14.6+/-15.9%; P = 0.029) and in the frontal (13.6+/-13.1%; P = 0.011) and parietal cortices (13.1+/-11.2%; P = 0.007).  Absolute rGMR was not decreased anywhere in the brain.  The voxel-based analysis revealed relative rGMR increases in the frontal, temporal, and parietal cortices.  CONCLUSIONS:  Global increases in rGMR seem to parallel ketamine-induced increases in cerebral blood flow detected in the authors' earlier study.  Therefore, ketamine-induced disturbance of coupling between cerebral blood flow and metabolism is highly unlikely.  The previously observed decrease in oxygen extraction fraction may be due to nonoxidative glucose metabolism during ketamine-induced increase in glutamate release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ87ax4Qk7-gpNiNltV31zlfW6udTcc2eY9R1dV-OoTUbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ivVKjsA%253D%253D&md5=8ee9d5b6502d0f769b8b1319c8cab205</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1097%2F00000542-200405000-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-200405000-00006%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25A5ngsj%25C3%25B6%26aufirst%3DJ.%2BW.%26aulast%3DSalmi%26aufirst%3DE.%26aulast%3DKaisti%26aufirst%3DK.%2BK.%26aulast%3DAalto%26aufirst%3DS.%26aulast%3DHinkka%26aufirst%3DS.%26aulast%3DAantaa%26aufirst%3DR.%26aulast%3DOikonen%26aufirst%3DV.%26aulast%3DViljanen%26aufirst%3DT.%26aulast%3DKurki%26aufirst%3DT.%26aulast%3DSilvanto%26aufirst%3DM.%26aulast%3DScheinin%26aufirst%3DH.%26atitle%3DEffects%2520of%2520subanesthetic%2520ketamine%2520on%2520regional%2520cerebral%2520glucose%2520metabolism%2520in%2520humans%26jtitle%3DAnesthesiology%26date%3D2004%26volume%3D100%26spage%3D1065%26epage%3D1071%26doi%3D10.1097%2F00000542-200405000-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dranovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hen, R.</span></span> <span> </span><span class="NLM_article-title">Hippocampal neurogenesis: regulation by stress and antidepressants</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1143</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2006.03.082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2006.03.082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=16797263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVOitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=1136-1143&author=A.+Dranovskyauthor=R.+Hen&title=Hippocampal+neurogenesis%3A+regulation+by+stress+and+antidepressants&doi=10.1016%2Fj.biopsych.2006.03.082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Hippocampal Neurogenesis: Regulation by Stress and Antidepressants</span></div><div class="casAuthors">Dranovsky, Alex; Hen, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1136-1143</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence implicates hippocampal neurogenesis in the pathophysiol. of depression.  Psychosocial stress reduces neurogenesis in rodents, whereas chronic treatment with antidepressants increases neurogenesis and blocks the effects of stress.  The effects of stress and antidepressant treatment on hippocampal neurogenesis parallel behavioral changes in animal models.  Moreover, ablating hippocampal neurogenesis renders antidepressants inactive in behavioral paradigms used to model antidepressant response and anxiety-like behavior in mice.  In humans, monoamine-modulating antidepressants demonstrate clin. efficacy in treating depression and anxiety, which are often pptd. by psychosocial stress.  This review examines the mounting evidence that stress and antidepressant treatment regulate neurogenesis in animals.  Special attention is paid to the cellular and mol. mechanisms by which this regulation takes place.  An anal. of current animal models used to study response to stress and antidepressants indicates the importance of modeling chronic treatment, which reflects both changes in neurogenesis and clin. response.  Exploring responses of hippocampal neurogenesis to exptl. challenges in appropriate animal models should delineate the role of adult-born neurons in hippocampal physiol.  Focusing on neurogenic response to exptl. paradigms of stress and antidepressant treatment is particularly interesting for understanding the pathophysiol. of major depressive disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdL0eOUELZLbVg90H21EOLACvtfcHk0lieaDLq2WYz2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVOitr0%253D&md5=2b7ca0bbd44242c38db77bc63b76ab77</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2006.03.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2006.03.082%26sid%3Dliteratum%253Aachs%26aulast%3DDranovsky%26aufirst%3DA.%26aulast%3DHen%26aufirst%3DR.%26atitle%3DHippocampal%2520neurogenesis%253A%2520regulation%2520by%2520stress%2520and%2520antidepressants%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D59%26spage%3D1136%26epage%3D1143%26doi%3D10.1016%2Fj.biopsych.2006.03.082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteggia, L. M.</span></span> <span> </span><span class="NLM_article-title">A neurotrophic model for stress-related mood disorders</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2006.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2006.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=16631126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVOisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=1116-1127&author=R.+S.+Dumanauthor=L.+M.+Monteggia&title=A+neurotrophic+model+for+stress-related+mood+disorders&doi=10.1016%2Fj.biopsych.2006.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">A Neurotrophic Model for Stress-Related Mood Disorders</span></div><div class="casAuthors">Duman, Ronald S.; Monteggia, Lisa M.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1116-1127</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  There is a growing body of evidence demonstrating that stress decreases the expression of brain-derived neurotrophic factor (BDNF) in limbic structures that control mood and that antidepressant treatment reverses or blocks the effects of stress.  Decreased levels of BDNF, as well as other neruotrophic factors, could contribute to the atrophy of certain limbic structures, including the hippocampus and prefrontal cortex that has been obsd. in depressed subjects.  Conversely, the neurotrophic actions of antidepressants could reverse neuronal atrophy and cell loss and thereby contribute to the therapeutic actions of these treatments.  This review provides a crit. examn. of the neurotrophic hypothesis of depression that has evolved from this work, including anal. of preclin. cellular (adult neurogenesis) and behavioral models of depression and antidepressant actions, as well as clin. neuroimaging and postmortem studies.  Although there are some limitations, the results of these studies are consistent with the hypothesis that decreased expression of BDNF and possibly other growth factors contributes to depression and that upregulation of BDNF plays a role in the actions of antidepressant treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozqx3V7lrUJLVg90H21EOLACvtfcHk0lgmcb5ZQ_3l_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVOisbc%253D&md5=8fe1fca7e53b3002346c030243a595a5</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2006.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2006.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DDuman%26aufirst%3DR.%2BS.%26aulast%3DMonteggia%26aufirst%3DL.%2BM.%26atitle%3DA%2520neurotrophic%2520model%2520for%2520stress-related%2520mood%2520disorders%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D59%26spage%3D1116%26epage%3D1127%26doi%3D10.1016%2Fj.biopsych.2006.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span> <span> </span><span class="NLM_article-title">Disrupted reward circuits is associated with cognitive deficits and depression severity in major depressive disorder</span>. <i>J. Psychiatr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1016/j.jpsychires.2016.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.jpsychires.2016.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27673704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC2svktV2quw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2017&pages=9-17&author=L.+Gongauthor=Y.+Yinauthor=C.+Heauthor=Q.+Yeauthor=F.+Baiauthor=Y.+Yuanauthor=H.+Zhangauthor=L.+Lvauthor=H.+Zhangauthor=C.+Xieauthor=Z.+Zhang&title=Disrupted+reward+circuits+is+associated+with+cognitive+deficits+and+depression+severity+in+major+depressive+disorder&doi=10.1016%2Fj.jpsychires.2016.09.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Disrupted reward circuits is associated with cognitive deficits and depression severity in major depressive disorder</span></div><div class="casAuthors">Gong Liang; He Cancan; Ye Qing; Yin Yingying; Yuan Yonggui; Bai Feng; Zhang Zhijun; Zhang Haisan; Lv Luxian; Zhang Hongxing; Xie Chunming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neuroimaging studies have demonstrated that major depressive disorder (MDD) patients show blunted activity responses to reward-related tasks.  However, whether abnormal reward circuits affect cognition and depression in MDD patients remains unclear.  Seventy-five drug-naive MDD patients and 42 cognitively normal (CN) subjects underwent a resting-state functional magnetic resonance imaging scan.  The bilateral nucleus accumbens (NAc) were selected as seeds to construct reward circuits across all subjects.  A multivariate linear regression analysis was employed to investigate the neural substrates of cognitive function and depression severity on the reward circuits in MDD patients.  The common pathway underlying cognitive deficits and depression was identified with conjunction analysis.  Compared with CN subjects, MDD patients showed decreased reward network connectivity that was primarily located in the prefrontal-striatal regions.  Importantly, distinct and common neural pathways underlying cognition and depression were identified, implying the independent and synergistic effects of cognitive deficits and depression severity on reward circuits.  This study demonstrated that disrupted topological organization within reward circuits was significantly associated with cognitive deficits and depression severity in MDD patients.  These findings suggest that in addition to antidepressant treatment, normalized reward circuits should be a focus and a target for improving depression and cognitive deficits in MDD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSPV-njIIuiOxsqfvU0ziafW6udTcc2eZ75-xf0xMMIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svktV2quw%253D%253D&md5=ef1f437945be250901d3c8678ab68dd5</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2016.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2016.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DL.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLv%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DZ.%26atitle%3DDisrupted%2520reward%2520circuits%2520is%2520associated%2520with%2520cognitive%2520deficits%2520and%2520depression%2520severity%2520in%2520major%2520depressive%2520disorder%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2017%26volume%3D84%26spage%3D9%26epage%3D17%26doi%3D10.1016%2Fj.jpsychires.2016.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-c.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">Comparison of ketamine, 7, 8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression</span>. <i>Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">4325</span>– <span class="NLM_lpage">4335</span>, <span class="refDoi"> DOI: 10.1007/s00213-015-4062-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2Fs00213-015-4062-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGnsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2015&pages=4325-4335&author=J.-c.+Zhangauthor=W.+Yaoauthor=C.+Dongauthor=C.+Yangauthor=Q.+Renauthor=M.+Maauthor=M.+Hanauthor=K.+Hashimoto&title=Comparison+of+ketamine%2C+7%2C+8-dihydroxyflavone%2C+and+ANA-12+antidepressant+effects+in+the+social+defeat+stress+model+of+depression&doi=10.1007%2Fs00213-015-4062-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression</span></div><div class="casAuthors">Zhang, Ji-chun; Yao, Wei; Dong, Chao; Yang, Chun; Ren, Qian; Ma, Min; Han, Mei; Hashimoto, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4325-4335</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Brain-derived neurotrophic factor (BDNF) and signaling at its receptor, tropomyosin-related kinase B (TrkB), are implicated in the rapid and long-lasting antidepressant effects of ketamine.  Moreover, a TrkB agonist, 7,8-dihydroxyflavone (7,8-DHF), and/or TrkB antagonist, ANA-12, shows antidepressant effects in animal models of depression.  Objective: The objective of this study is to compare the influence of ketamine, 7,8-DHF, and ANA-12 on antidepressant activity in the social defeat stress model.  Results: In the tail suspension and forced swimming tests, ketamine, 7,8-DHF, or ANA-12 markedly attenuated the increased immobility time in depressed mice compared with the vehicle-treated group.  In the sucrose preference test, all drugs significantly improved the reduced preference in depressed mice at both 1 and 3 days after a single dose.  Antidepressant effect of ketamine, but not 7,8-DHF or ANA-12, was still detectable 7 days after a single dose.  Western blot analyses showed that ketamine, but not 7,8-DHF or ANA-12, markedly attenuated reduced levels of BDNF and postsynaptic d. protein 95 (PSD-95) in the prefrontal cortex (PFC), dentate gyrus (DG), and CA3 of the hippocampus in depressed mice 8 days after a single dose.  Furthermore, ketamine markedly increased reduced levels of GluA1 in the PFC and DG of depressed mice.  In contrast, ketamine showed no effect against increased levels of BDNF, PSD-95, and GluA1 obsd. in the nucleus accumbens of depressed mice.  Conclusions: Compared with 7,8-DHF and ANA-12, ketamine is a longer-lasting antidepressant in the social defeat stress model, and synaptogenesis may be required for the mechanisms that promote sustained antidepressant effects of ketamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw85FFINDI-rVg90H21EOLACvtfcHk0lgmcb5ZQ_3l_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGnsbbO&md5=1d933f735f89f53ed50741eea09f672c</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1007%2Fs00213-015-4062-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-015-4062-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.-c.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DComparison%2520of%2520ketamine%252C%25207%252C%25208-dihydroxyflavone%252C%2520and%2520ANA-12%2520antidepressant%2520effects%2520in%2520the%2520social%2520defeat%2520stress%2520model%2520of%2520depression%26jtitle%3DPsychopharmacol.%26date%3D2015%26volume%3D232%26spage%3D4325%26epage%3D4335%26doi%3D10.1007%2Fs00213-015-4062-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-c.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">Rapid and sustained antidepressant action of the mGlu2/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyw089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1093%2Fijnp%2Fpyw089" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=228-236&author=C.+Dongauthor=J.-c.+Zhangauthor=W.+Yaoauthor=Q.+Renauthor=M.+Maauthor=C.+Yangauthor=S.+Chakiauthor=K.+Hashimoto&title=Rapid+and+sustained+antidepressant+action+of+the+mGlu2%2F3+receptor+antagonist+MGS0039+in+the+social+defeat+stress+model%3A+comparison+with+ketamine&doi=10.1093%2Fijnp%2Fpyw089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyw089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyw089%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.-c.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DChaki%26aufirst%3DS.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DRapid%2520and%2520sustained%2520antidepressant%2520action%2520of%2520the%2520mGlu2%252F3%2520receptor%2520antagonist%2520MGS0039%2520in%2520the%2520social%2520defeat%2520stress%2520model%253A%2520comparison%2520with%2520ketamine%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2016%26volume%3D20%26spage%3D228%26epage%3D236%26doi%3D10.1093%2Fijnp%2Fpyw089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotlib, I. H.</span></span> <span> </span><span class="NLM_article-title">Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">1000</span>, <span class="refDoi"> DOI: 10.1038/mp.2008.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fmp.2008.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=18504424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Knur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=993-1000&author=J.+P.+Hamiltonauthor=M.+Siemerauthor=I.+H.+Gotlib&title=Amygdala+volume+in+major+depressive+disorder%3A+a+meta-analysis+of+magnetic+resonance+imaging+studies&doi=10.1038%2Fmp.2008.57"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies</span></div><div class="casAuthors">Hamilton, J. P.; Siemer, M.; Gotlib, I. H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-1000</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Major depressive disorder has been assocd. with volumetric abnormality in the amygdala.  In this meta-anal. we examine results from magnetic resonance imaging volumetry studies of the amygdala in depression in order to assess both the nature of the relationship between depression and amygdala vol. as well as the influence of extraexperimental factors that may account for significant variability in reported findings.  We searched PubMed and ISI Web of Knowledge databases for articles published from 1985 to 2008 that used the wildcard terms Depress*' and Amygdal*' in the title, keywords or abstr.  From the 13 studies that met inclusion criteria for our meta-anal., we calcd. aggregate effect size and heterogeneity ests. from amygdala volumetric data; we then used meta-regression to det. whether variability in specific extraexperimental factors accounted for variability in findings.  The lack of a reliable difference in amygdala vol. between depressed and never-depressed individuals was accounted for by a pos. correlation between amygdala vol. differences and the proportion of medicated depressed persons in study samples: whereas the aggregate effect size calcd. from studies that included only medicated individuals indicated that amygdala vol. was significantly increased in depressed relative to healthy persons, studies with only unmedicated depressed individuals showed a reliable decrease in amygdala vol. in depression.  These findings are consistent with a formulation in which an antidepressant-mediated increase in levels of brain-derived neurotrophic factor promotes neurogenesis and protects against glucocorticoid toxicity in the amygdala in medicated but not in unmedicated depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNJXr9JjL0T7Vg90H21EOLACvtfcHk0lg4OSuW1Qj-hQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Knur3O&md5=5e476f3dff204af5ed74fec701483b84</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fmp.2008.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2008.57%26sid%3Dliteratum%253Aachs%26aulast%3DHamilton%26aufirst%3DJ.%2BP.%26aulast%3DSiemer%26aufirst%3DM.%26aulast%3DGotlib%26aufirst%3DI.%2BH.%26atitle%3DAmygdala%2520volume%2520in%2520major%2520depressive%2520disorder%253A%2520a%2520meta-analysis%2520of%2520magnetic%2520resonance%2520imaging%2520studies%26jtitle%3DMol.%2520Psychiatry%26date%3D2008%26volume%3D13%26spage%3D993%26epage%3D1000%26doi%3D10.1038%2Fmp.2008.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheidegger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henning, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraehenmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifritz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, S.</span></span> <span> </span><span class="NLM_article-title">Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation</span>. <i>Hum. Brain Mapp.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1941</span>– <span class="NLM_lpage">1952</span>, <span class="refDoi"> DOI: 10.1002/hbm.23148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1002%2Fhbm.23148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26915535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC28jksVOqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=1941-1952&author=M.+Scheideggerauthor=A.+Henningauthor=M.+Walterauthor=M.+Lehmannauthor=R.+Kraehenmannauthor=H.+Boekerauthor=E.+Seifritzauthor=S.+Grimm&title=Ketamine+administration+reduces+amygdalo-hippocampal+reactivity+to+emotional+stimulation&doi=10.1002%2Fhbm.23148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation</span></div><div class="casAuthors">Scheidegger Milan; Lehmann Mick; Kraehenmann Rainer; Boeker Heinz; Seifritz Erich; Grimm Simone; Scheidegger Milan; Henning Anke; Henning Anke; Henning Anke; Seifritz Erich; Walter Martin; Kraehenmann Rainer; Grimm Simone</div><div class="citationInfo"><span class="NLM_cas:title">Human brain mapping</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1941-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increased amygdala reactivity might lead to negative bias during emotional processing that can be reversed by antidepressant drug treatment.  However, little is known on how N-methyl-d-aspartate (NMDA) receptor antagonism with ketamine as a novel antidepressant drug target might modulate amygdala reactivity to emotional stimulation.  Using functional magnetic resonance imaging (fMRI) and resting-state fMRI (rsfMRI), we assessed amygdalo-hippocampal reactivity at baseline and during pharmacological stimulation with ketamine (intravenous bolus of 0.12 mg/kg, followed by a continuous infusion of 0.25 mg/kg/h) in 23 healthy subjects that were presented with stimuli from the International Affective Picture System (IAPS).  We found that ketamine reduced neural reactivity in the bilateral amygdalo-hippocampal complex during emotional stimulation.  Reduced amygdala reactivity to negative pictures was correlated to resting-state connectivity to the pregenual anterior cingulate cortex.  Interestingly, subjects experienced intensity of psychedelic alterations of consciousness during ketamine infusion predicted the reduction in neural responsivity to negative but not to positive or neutral stimuli.  Our findings suggest that the pharmacological modulation of glutamate-responsive cerebral circuits, which is associated with a shift in emotional bias and a reduction of amygdalo-hippocampal reactivity to emotional stimuli, represents an early biomechanism to restore parts of the disrupted neurobehavioral homeostasis in MDD patients.  Hum Brain Mapp 37:1941-1952, 2016. © 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNtjQKGMVmwv69nzq6467DfW6udTcc2eZGVTrCy6uI6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jksVOqtg%253D%253D&md5=a3688908b69d0e85256429fbd4a545d9</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fhbm.23148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhbm.23148%26sid%3Dliteratum%253Aachs%26aulast%3DScheidegger%26aufirst%3DM.%26aulast%3DHenning%26aufirst%3DA.%26aulast%3DWalter%26aufirst%3DM.%26aulast%3DLehmann%26aufirst%3DM.%26aulast%3DKraehenmann%26aufirst%3DR.%26aulast%3DBoeker%26aufirst%3DH.%26aulast%3DSeifritz%26aufirst%3DE.%26aulast%3DGrimm%26aufirst%3DS.%26atitle%3DKetamine%2520administration%2520reduces%2520amygdalo-hippocampal%2520reactivity%2520to%2520emotional%2520stimulation%26jtitle%3DHum.%2520Brain%2520Mapp.%26date%3D2016%26volume%3D37%26spage%3D1941%26epage%3D1952%26doi%3D10.1002%2Fhbm.23148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study</span>. <i>Hum. Brain Mapp.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1080</span>– <span class="NLM_lpage">1090</span>, <span class="refDoi"> DOI: 10.1002/hbm.23085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1002%2Fhbm.23085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26821769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC28nltlCguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=1080-1090&author=C.+T.+Liauthor=M.+H.+Chenauthor=W.+C.+Linauthor=C.+J.+Hongauthor=B.+H.+Yangauthor=R.+S.+Liuauthor=P.+C.+Tuauthor=T.+P.+Su&title=The+effects+of+low-dose+ketamine+on+the+prefrontal+cortex+and+amygdala+in+treatment-resistant+depression%3A+A+randomized+controlled+study&doi=10.1002%2Fhbm.23085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study</span></div><div class="casAuthors">Li Cheng-Ta; Chen Mu-Hong; Lin Wei-Chen; Hong Chen-Jee; Tu Pei-Chi; Su Tung-Ping; Li Cheng-Ta; Chen Mu-Hong; Lin Wei-Chen; Hong Chen-Jee; Tu Pei-Chi; Su Tung-Ping; Yang Bang-Hung; Liu Ren-Shyan; Su Tung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Human brain mapping</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1080-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Low-dose ketamine has been found to have robust and rapid antidepressant effects.  A hypoactive prefrontal cortex (PFC) and a hyperactive amygdala have been suggested to be associated with treatment-resistant depression (TRD).  However, it is unclear whether the rapid antidepressant mechanisms of ketamine on TRD involve changes in glutamatergic neurotransmission in the PFC and the amygdala.  METHODS:  A group of 48 TRD patients were recruited and equally randomized into three groups (A: 0.5 kg/mg-ketamine; B: 0.2 kg/mg-ketamine; and C: normal saline [NS]).  Standardized uptake values (SUV) of glucose metabolism measured by (18) F-FDG positron-emission-tomography before and immediately after a 40-min ketamine or NS infusion were used for subsequent region-of-interest (ROI) analyses (a priori regions: PFC and amygdala) and whole-brain voxel-wise analyses and were correlated with antidepressant responses, as defined by the Hamilton depression rating scale score.  The (18) F-FDG signals were used as a proxy measure of glutamate neurotransmission.  RESULTS:  The ROI analysis indicated that Group A and Group B, but not Group C, had increases in the SUV of the PFC (group-by-time interaction: F = 7.373, P = 0.002), whereas decreases in the SUV of the amygdala were observed in all three groups (main effect of time, P < 0.001).  The voxel-wise analysis further confirmed a significant group effect on the PFC (corrected for family-wise errors, P < 0.05; post hoc analysis: Group A<Group C, Group B<Group C).  The SUV differences in the PFC predicted the antidepressant responses at 40 and 240 min post-treatment.  The PFC changes did not differ between those with and without side effects.  CONCLUSION:  Ketamine's rapid antidepressant effects involved the facilitation of glutamatergic neurotransmission in the PFC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkiTiBcoX5VhLDWw4HIq2sfW6udTcc2eZGVTrCy6uI6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nltlCguw%253D%253D&md5=18ee8d99e65e80d75260aedaedd29049</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1002%2Fhbm.23085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhbm.23085%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%2BT.%26aulast%3DChen%26aufirst%3DM.%2BH.%26aulast%3DLin%26aufirst%3DW.%2BC.%26aulast%3DHong%26aufirst%3DC.%2BJ.%26aulast%3DYang%26aufirst%3DB.%2BH.%26aulast%3DLiu%26aufirst%3DR.%2BS.%26aulast%3DTu%26aufirst%3DP.%2BC.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DThe%2520effects%2520of%2520low-dose%2520ketamine%2520on%2520the%2520prefrontal%2520cortex%2520and%2520amygdala%2520in%2520treatment-resistant%2520depression%253A%2520A%2520randomized%2520controlled%2520study%26jtitle%3DHum.%2520Brain%2520Mapp.%26date%3D2016%26volume%3D37%26spage%3D1080%26epage%3D1090%26doi%3D10.1002%2Fhbm.23085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al Shweiki, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeckl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinacker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barschke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorner-Ciossek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schönfeldt-Lecuona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengerer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, M.</span></span> <span> </span><span class="NLM_article-title">S-ketamine induces acute changes in the proteome of the mouse amygdala</span>. <i>J. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">103679</span>, <span class="refDoi"> DOI: 10.1016/j.jprot.2020.103679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.jprot.2020.103679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32032757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFSqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2020&pages=103679&author=M.+R.+Al+Shweikiauthor=P.+Oecklauthor=P.+Steinackerauthor=P.+Barschkeauthor=C.+Pryceauthor=C.+Dorner-Ciossekauthor=C.+Sch%C3%B6nfeldt-Lecuonaauthor=B.+Hengererauthor=M.+Otto&title=S-ketamine+induces+acute+changes+in+the+proteome+of+the+mouse+amygdala&doi=10.1016%2Fj.jprot.2020.103679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">S-ketamine induces acute changes in the proteome of the mouse amygdala</span></div><div class="casAuthors">Al Shweiki, Mhd rami; Oeckl, Patrick; Steinacker, Petra; Barschke, Peggy; Pryce, Christopher; Dorner-Ciossek, Cornelia; Schoenfeldt-Lecuona, Carlos; Hengerer, Bastian; Otto, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">216</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103679</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study in mice aimed to investigate acute proteomic changes after ketamine administration in various brain regions including amygdala and hippocampus.  One hour after administration of s-ketamine, the brain-region tissues of interest were dissected out and analyzed using label-free shotgun proteomics.  The deep proteomic anal. of amygdala and hippocampus identified 89,526 peptides corresponding to 8000 proteins.  The anal. revealed a pronounced proteomic signature of the acute ketamine effect in the amygdala.  We anticipate that this proteomic dataset will improve understanding of the mechanism of action of ketamine and identification of new drug targets.  Major depressive disorder (MDD) is the leading cause of global disability and it presents a significant challenge to human health.  S-ketamine has been proposed as a rapid acting antidepressant and, indeed, the FDA recently approved it for treatment of resistant MDD.  However, the mechanism of action of s-ketamine as an antidepressant is still elusive.  In this context, we investigated the short-term proteomic changes after ketamine administration in mouse brain regions previously related to ketamine effects such as amygdala and hippocampus.  We anticipate that this proteomic dataset will provide highly useful information to improve our understanding of the mechanism of action of ketamine and identification of new drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLpc2uIQmOubVg90H21EOLACvtfcHk0lg1Okr_QdJl3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFSqsrc%253D&md5=3194e35b6df72c85d0b61cef98408362</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2020.103679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2020.103679%26sid%3Dliteratum%253Aachs%26aulast%3DAl%2BShweiki%26aufirst%3DM.%2BR.%26aulast%3DOeckl%26aufirst%3DP.%26aulast%3DSteinacker%26aufirst%3DP.%26aulast%3DBarschke%26aufirst%3DP.%26aulast%3DPryce%26aufirst%3DC.%26aulast%3DDorner-Ciossek%26aufirst%3DC.%26aulast%3DSch%25C3%25B6nfeldt-Lecuona%26aufirst%3DC.%26aulast%3DHengerer%26aufirst%3DB.%26aulast%3DOtto%26aufirst%3DM.%26atitle%3DS-ketamine%2520induces%2520acute%2520changes%2520in%2520the%2520proteome%2520of%2520the%2520mouse%2520amygdala%26jtitle%3DJ.%2520Proteomics%26date%3D2020%26volume%3D216%26spage%3D103679%26doi%3D10.1016%2Fj.jprot.2020.103679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nestler, E. J.</span></span> <span> </span><span class="NLM_article-title">Role of the brain’s reward circuitry in depression: transcriptional mechanisms</span>. <i>Int. Rev. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/bs.irn.2015.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fbs.irn.2015.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26472529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlWrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2015&pages=151-170&author=E.+J.+Nestler&title=Role+of+the+brain%E2%80%99s+reward+circuitry+in+depression%3A+transcriptional+mechanisms&doi=10.1016%2Fbs.irn.2015.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the brain's reward circuitry in depression: transcriptional mechanisms</span></div><div class="casAuthors">Nestler, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Neurobiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">Nicotine Use in Mental Illness and Neurological Disorders</span>),
    <span class="NLM_cas:pages">151-170</span>CODEN:
                <span class="NLM_cas:coden">IRNEAE</span>;
        ISSN:<span class="NLM_cas:issn">0074-7742</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Increasing evidence supports an important role for the brain's reward circuitry in controlling mood under normal conditions and contributing importantly to the pathophysiol. and symptomatol. of a range of mood disorders, such as depression.  Here we focus on the nucleus accumbens (NAc), a crit. component of the brain's reward circuitry, in depression and other stress-related disorders.  The prominence of anhedonia, reduced motivation, and decreased energy level in most individuals with depression supports the involvement of the NAc in these conditions.  We conc. on several transcription factors (CREB, ΔFosB, SRF, NFκB, and β-catenin), which are altered in the NAc in rodent depression models - and in some cases in the NAc of depressed humans, and which produce robust depression- or antidepressant-like effects when manipulated in the NAc in animal models.  These studies of the NAc have established novel approaches toward modeling key symptoms of depression in animals and could enable the development of antidepressant medications with fundamentally new mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfsfNT6DKNB7Vg90H21EOLACvtfcHk0lg1Okr_QdJl3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlWrtLY%253D&md5=3f5c6c1e1e225f23dd3ff1fe6fc3be84</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fbs.irn.2015.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.irn.2015.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DNestler%26aufirst%3DE.%2BJ.%26atitle%3DRole%2520of%2520the%2520brain%25E2%2580%2599s%2520reward%2520circuitry%2520in%2520depression%253A%2520transcriptional%2520mechanisms%26jtitle%3DInt.%2520Rev.%2520Neurobiol.%26date%3D2015%26volume%3D124%26spage%3D151%26epage%3D170%26doi%3D10.1016%2Fbs.irn.2015.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bessa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morais, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palha, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, N.</span></span> <span> </span><span class="NLM_article-title">Stress-induced anhedonia is associated with hypertrophy of medium spiny neurons of the nucleus accumbens</span>. <i>Transl. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e266</span>– <span class="NLM_lpage">e266</span>, <span class="refDoi"> DOI: 10.1038/tp.2013.39</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Ftp.2013.39" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=23736119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSqsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=e266-e266&author=J.+Bessaauthor=M.+Moraisauthor=F.+Marquesauthor=L.+Pintoauthor=J.+A.+Palhaauthor=O.+Almeidaauthor=N.+Sousa&title=Stress-induced+anhedonia+is+associated+with+hypertrophy+of+medium+spiny+neurons+of+the+nucleus+accumbens&doi=10.1038%2Ftp.2013.39"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Stress-induced anhedonia is associated with hypertrophy of medium spiny neurons of the nucleus accumbens</span></div><div class="casAuthors">Bessa, J. M.; Morais, M.; Marques, F.; Pinto, L.; Palha, J. A.; Almeida, O. F. X.; Sousa, N.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">June</span>),
    <span class="NLM_cas:pages">e266</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">There is accumulating evidence that the nucleus accumbens (NAc) has an important role in the pathophysiol. of depression.  As the NAc is a key component in the neural circuitry of reward, it has been hypothesized that anhedonia, a core symptom of depression, might be related to dysfunction of this brain region.  Neuronal morphol. and expression of plasticity-related mols. were examd. in the NAc of rats displaying anhedonic behavior (measured in the sucrose-consumption test) in response to chronic mild stress.  To demonstrate the relevance of our measurements to depression, we tested whether the obsd. changes were sensitive to reversal with antidepressants (imipramine and fluoxetine).  Data show that animals displaying anhedonic behavior display an hypertrophy of medium spiny neurons in the NAc and, in parallel, have increased expression of the genes encoding for brain-derived neurotrophic factor, neural cell adhesion mol. and synaptic protein synapsin 1.  Importantly, the reversal of stress-induced anhedonia by antidepressants is linked to a restoration of gene-expression patterns and dendritic morphol. in the NAc.  Using an animal model of depression, we show that stress induces anhedonic behavior that is assocd. with specific changes in the neuronal morphol. and in the gene-expression profile of the NAc that are effectively reversed after treatment with antidepressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUk0qbR2_HQbVg90H21EOLACvtfcHk0lg1Okr_QdJl3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSqsL%252FK&md5=8122d3671ddd70b7189ad24fa9f77696</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1038%2Ftp.2013.39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2013.39%26sid%3Dliteratum%253Aachs%26aulast%3DBessa%26aufirst%3DJ.%26aulast%3DMorais%26aufirst%3DM.%26aulast%3DMarques%26aufirst%3DF.%26aulast%3DPinto%26aufirst%3DL.%26aulast%3DPalha%26aufirst%3DJ.%2BA.%26aulast%3DAlmeida%26aufirst%3DO.%26aulast%3DSousa%26aufirst%3DN.%26atitle%3DStress-induced%2520anhedonia%2520is%2520associated%2520with%2520hypertrophy%2520of%2520medium%2520spiny%2520neurons%2520of%2520the%2520nucleus%2520accumbens%26jtitle%3DTransl.%2520Psychiatry%26date%3D2013%26volume%3D3%26spage%3De266%26epage%3De266%26doi%3D10.1038%2Ftp.2013.39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdallah, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coplan, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shungu, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S. J.</span></span> <span> </span><span class="NLM_article-title">The nucleus accumbens and ketamine treatment in major depressive disorder</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1739</span>– <span class="NLM_lpage">1746</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnpp.2017.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=28272497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlt1Srtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=1739-1746&author=C.+G.+Abdallahauthor=A.+Jackowskiauthor=R.+Salasauthor=S.+Guptaauthor=J.+R.+Satoauthor=X.+Maoauthor=J.+D.+Coplanauthor=D.+C.+Shunguauthor=S.+J.+Mathew&title=The+nucleus+accumbens+and+ketamine+treatment+in+major+depressive+disorder&doi=10.1038%2Fnpp.2017.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder</span></div><div class="casAuthors">Abdallah, Chadi G.; Jackowski, Andrea; Salas, Ramiro; Gupta, Swapnil; Sato, Joao R.; Mao, Xiangling; Coplan, Jeremy D.; Shungu, Dikoma C.; Mathew, Sanjay J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1739-1746</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Animal models of depression repeatedly showed stress-induced nucleus accumbens (NAc) hypertrophy.  Recently, ketamine was found to normalize this stress-induced NAc structural growth.  Here, we investigated NAc structural abnormalities in major depressive disorder (MDD) in two cohorts.  Cohort A included a cross-sectional sample of 34 MDD and 26 healthy control (HC) subjects, with high-resoln. magnetic resonance imaging (MRI) to est. NAc vols.  Proton MR spectroscopy (1H MRS) was used to divide MDD subjects into two subgroups: glutamate-based depression (GBD) and non-GBD.  A sep. longitudinal sample (cohort B) included 16 MDD patients who underwent MRI at baseline then 24 h following i.v. infusion of ketamine (0.5 mg/kg).  In cohort A, we found larger left NAc vol. in MDD compared to controls (Cohen's d=1.05), but no significant enlargement in the right NAc (d=0.44).  Follow-up analyses revealed significant subgrouping effects on the left (d≥1.48) and right NAc (d≥0.95) with larger bilateral NAc in non-GBD compared to GBD and HC.  NAc vols. were not different between GBD and HC.  In cohort B, ketamine treatment reduced left NAc, but increased left hippocampal, vols. in patients achieving remission.  The cross-sectional data provided the first evidence of enlarged NAc in patients with MDD.  These NAc abnormalities were limited to patients with non-GBD.  The pilot longitudinal data revealed a pattern of normalization of left NAc and hippocampal vols. particularly in patients who achieved remission following ketamine treatment, an intriguing preliminary finding that awaits replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg-D1Z91MdLLVg90H21EOLACvtfcHk0lgrQAeLndLUow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlt1Srtb4%253D&md5=679fe574d648d99060b3947886425776</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.49%26sid%3Dliteratum%253Aachs%26aulast%3DAbdallah%26aufirst%3DC.%2BG.%26aulast%3DJackowski%26aufirst%3DA.%26aulast%3DSalas%26aufirst%3DR.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DSato%26aufirst%3DJ.%2BR.%26aulast%3DMao%26aufirst%3DX.%26aulast%3DCoplan%26aufirst%3DJ.%2BD.%26aulast%3DShungu%26aufirst%3DD.%2BC.%26aulast%3DMathew%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520nucleus%2520accumbens%2520and%2520ketamine%2520treatment%2520in%2520major%2520depressive%2520disorder%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D1739%26epage%3D1746%26doi%3D10.1038%2Fnpp.2017.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokras, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventura-Silva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pêgo, J.</span></span> <span> </span><span class="NLM_article-title">The positive effect on ketamine as a priming adjuvant in antidepressant treatment</span>. <i>Transl. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e573</span>– <span class="NLM_lpage">e573</span>, <span class="refDoi"> DOI: 10.1038/tp.2015.66</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Ftp.2015.66" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26080090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOku73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=e573-e573&author=A.+Meloauthor=N.+Kokrasauthor=C.+Dallaauthor=C.+Ferreiraauthor=A.+Ventura-Silvaauthor=N.+Sousaauthor=J.+P%C3%AAgo&title=The+positive+effect+on+ketamine+as+a+priming+adjuvant+in+antidepressant+treatment&doi=10.1038%2Ftp.2015.66"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The positive effect on ketamine as a priming adjuvant in antidepressant treatment</span></div><div class="casAuthors">Melo, A.; Kokras, N.; Dalla, C.; Ferreira, C.; Ventura-Silva, A. P.; Sousa, N.; Pego, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e573</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ketamine is an anesthetic with antidepressant properties.  The rapid and lasting effect of ketamine obsd. in preclin. and clin. research makes it a promising therapeutic to improve current major depression (MD) treatment.  Our work intended to evaluate whether the combined use of classic antidepressants (imipramine or fluoxetine) and ketamine would improve the antidepressant response.  Using an animal model of depressive-like behavior, we show that the addn. of ketamine to antidepressants anticipates the behavioral response and accelerates the neuroplastic events when compared with the use of antidepressants alone.  In conclusion, our results suggest the need for a reappraisal of the current pharmacol. treatment of MD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIOYJR_IDgMrVg90H21EOLACvtfcHk0lgrQAeLndLUow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOku73E&md5=c10f4952e4250a8c39bf5db42334cd29</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Ftp.2015.66&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2015.66%26sid%3Dliteratum%253Aachs%26aulast%3DMelo%26aufirst%3DA.%26aulast%3DKokras%26aufirst%3DN.%26aulast%3DDalla%26aufirst%3DC.%26aulast%3DFerreira%26aufirst%3DC.%26aulast%3DVentura-Silva%26aufirst%3DA.%26aulast%3DSousa%26aufirst%3DN.%26aulast%3DP%25C3%25AAgo%26aufirst%3DJ.%26atitle%3DThe%2520positive%2520effect%2520on%2520ketamine%2520as%2520a%2520priming%2520adjuvant%2520in%2520antidepressant%2520treatment%26jtitle%3DTransl.%2520Psychiatry%26date%3D2015%26volume%3D5%26spage%3De573%26epage%3De573%26doi%3D10.1038%2Ftp.2015.66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Circuits and functions of the lateral habenula in health and in disease</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">277</span>, <span class="refDoi"> DOI: 10.1038/s41583-020-0292-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fs41583-020-0292-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32269316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmslejtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=277&author=H.+Huauthor=Y.+Cuiauthor=Y.+Yang&title=Circuits+and+functions+of+the+lateral+habenula+in+health+and+in+disease&doi=10.1038%2Fs41583-020-0292-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Circuits and functions of the lateral habenula in health and in disease</span></div><div class="casAuthors">Hu, Hailan; Cui, Yihui; Yang, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">277-295</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The past decade has witnessed exponentially growing interest in the lateral habenula (LHb) owing to new discoveries relating to its crit. role in regulating neg. motivated behavior and its implication in major depression.  The LHb, sometimes referred to as the brain's 'antireward center', receives inputs from diverse limbic forebrain and basal ganglia structures, and targets essentially all midbrain neuromodulatory systems, including the noradrenergic, serotonergic and dopaminergic systems.  Its unique anatomical position enables the LHb to act as a hub that integrates value-based, sensory and experience-dependent information to regulate various motivational, cognitive and motor processes.  Dysfunction of the LHb may contribute to the pathophysiol. of several psychiatric disorders, esp. major depression.  Recently, exciting progress has been made in identifying the mol. and cellular mechanisms in the LHb that underlie neg. emotional state in animal models of drug withdrawal and major depression.  A future challenge is to translate these advances into effective clin. treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBr-Nvh01I6rVg90H21EOLACvtfcHk0lgrQAeLndLUow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmslejtbY%253D&md5=15553af7487f9556aa380288ecab5567</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fs41583-020-0292-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41583-020-0292-4%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DH.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DCircuits%2520and%2520functions%2520of%2520the%2520lateral%2520habenula%2520in%2520health%2520and%2520in%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2020%26volume%3D21%26spage%3D277%26doi%3D10.1038%2Fs41583-020-0292-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piriz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirrione, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henn, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinow, R.</span></span> <span> </span><span class="NLM_article-title">Synaptic potentiation onto habenula neurons in the learned helplessness model of depression</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>470</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1038/nature09742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnature09742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=21350486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVagtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=470&publication_year=2011&pages=535-539&author=B.+Liauthor=J.+Pirizauthor=M.+Mirrioneauthor=C.+Chungauthor=C.+D.+Proulxauthor=D.+Schulzauthor=F.+Hennauthor=R.+Malinow&title=Synaptic+potentiation+onto+habenula+neurons+in+the+learned+helplessness+model+of+depression&doi=10.1038%2Fnature09742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Synaptic potentiation onto habenula neurons in the learned helplessness model of depression</span></div><div class="casAuthors">Li, Bo; Piriz, Joaquin; Mirrione, Martine; Chung, Chi Hye; Proulx, Christophe D.; Schulz, Daniela; Henn, Fritz; Malinow, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">470</span>
        (<span class="NLM_cas:issue">7335</span>),
    <span class="NLM_cas:pages">535-539</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The cellular basis of depressive disorders is poorly understood.  Recent studies in monkeys indicate that neurons in the lateral habenula (LHb), a nucleus that mediates communication between forebrain and midbrain structures, can increase their activity when an animal fails to receive an expected pos. reward or receives a stimulus that predicts aversive conditions (i.e., disappointment or anticipation of a neg. outcome).  LHb neurons project to, and modulate, dopamine-rich regions, such as the ventral tegmental area (VTA), that control reward-seeking behavior and participate in depressive disorders.  Here we show that in two learned helplessness models of depression, excitatory synapses onto LHb neurons projecting to the VTA are potentiated.  Synaptic potentiation correlates with an animal's helplessness behavior and is due to an enhanced presynaptic release probability.  Depleting transmitter release by repeated elec. stimulation of LHb afferents, using a protocol that can be effective for patients who are depressed, markedly suppresses synaptic drive onto VTA-projecting LHb neurons in brain slices and can significantly reduce learned helplessness behavior in rats.  Our results indicate that increased presynaptic action onto LHb neurons contributes to the rodent learned helplessness model of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYrvQS3-PHAbVg90H21EOLACvtfcHk0lgrQAeLndLUow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVagtbo%253D&md5=7eb3ff7d5da8ee4d70921875fd1c65dc</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fnature09742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09742%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DPiriz%26aufirst%3DJ.%26aulast%3DMirrione%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DC.%26aulast%3DProulx%26aufirst%3DC.%2BD.%26aulast%3DSchulz%26aufirst%3DD.%26aulast%3DHenn%26aufirst%3DF.%26aulast%3DMalinow%26aufirst%3DR.%26atitle%3DSynaptic%2520potentiation%2520onto%2520habenula%2520neurons%2520in%2520the%2520learned%2520helplessness%2520model%2520of%2520depression%26jtitle%3DNature%26date%3D2011%26volume%3D470%26spage%3D535%26epage%3D539%26doi%3D10.1038%2Fnature09742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span> <span> </span><span class="NLM_article-title">Ketamine blocks bursting in the lateral habenula to rapidly relieve depression</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>554</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1038/nature25509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnature25509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29446381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisl2kuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=554&publication_year=2018&pages=317-322&author=Y.+Yangauthor=Y.+Cuiauthor=K.+Sangauthor=Y.+Dongauthor=Z.+Niauthor=S.+Maauthor=H.+Hu&title=Ketamine+blocks+bursting+in+the+lateral+habenula+to+rapidly+relieve+depression&doi=10.1038%2Fnature25509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine blocks bursting in the lateral habenula to rapidly relieve depression</span></div><div class="casAuthors">Yang, Yan; Cui, Yihui; Sang, Kangning; Dong, Yiyan; Ni, Zheyi; Ma, Shuangshuang; Hu, Hailan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">554</span>
        (<span class="NLM_cas:issue">7692</span>),
    <span class="NLM_cas:pages">317-322</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine has attracted enormous interest in mental health research owing to its rapid antidepressant actions, but its mechanism of action has remained elusive.  Here the authors show that blockade of NMDAR-dependent bursting activity in the 'antireward center', the lateral habenula (LHb), mediates the rapid antidepressant actions of ketamine in rat and mouse models of depression.  LHb neurons show a significant increase in burst activity and theta-band synchronization in depressive-like animals, which is reversed by ketamine.  Burst-evoking photostimulation of LHb drives behavioral despair and anhedonia.  Pharmacol. and modeling expts. reveal that LHb bursting requires both NMDARs and low-voltage-sensitive T-type calcium channels (T-VSCCs).  Furthermore, local blockade of NMDAR or T-VSCCs in the LHb is sufficient to induce rapid antidepressant effects.  The results suggest a simple model whereby ketamine quickly elevates mood by blocking NMDAR-dependent bursting activity of LHb neurons to disinhibit downstream monoaminergic reward centers, and provide a framework for developing new rapid-acting antidepressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXd9LBRBR0nbVg90H21EOLACvtfcHk0lgYi6Vm4LDnsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisl2kuro%253D&md5=0f81f4413d5eec5a5fe5e0f81c860a78</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fnature25509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25509%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DSang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DH.%26atitle%3DKetamine%2520blocks%2520bursting%2520in%2520the%2520lateral%2520habenula%2520to%2520rapidly%2520relieve%2520depression%26jtitle%3DNature%26date%3D2018%26volume%3D554%26spage%3D317%26epage%3D322%26doi%3D10.1038%2Fnature25509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pittenger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span> <span> </span><span class="NLM_article-title">Stress, depression, and neuroplasticity: a convergence of mechanisms</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1301574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fsj.npp.1301574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=17851537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKltb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=88-109&author=C.+Pittengerauthor=R.+S.+Duman&title=Stress%2C+depression%2C+and+neuroplasticity%3A+a+convergence+of+mechanisms&doi=10.1038%2Fsj.npp.1301574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms</span></div><div class="casAuthors">Pittenger, Christopher; Duman, Ronald S.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-109</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Increasing evidence demonstrates that neuroplasticity, a fundamental mechanism of neuronal adaptation, is disrupted in mood disorders and in animal models of stress.  Here we provide an overview of the evidence that chronic stress, which can ppt. or exacerbate depression, disrupts neuroplasticity, while antidepressant treatment produces opposing effects and can enhance neuroplasticity.  We discuss neuroplasticity at different levels: structural plasticity (such as plastic changes in spine and dendrite morphol. as well as adult neurogenesis), functional synaptic plasticity, and the mol. and cellular mechanisms accompanying such changes.  Together, these studies elucidate mechanisms that may contribute to the pathophysiol. of depression.  Greater appreciation of the convergence of mechanisms between stress, depression, and neuroplasticity is likely to lead to the identification of novel targets for more efficacious treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-fTJjJ9kw07Vg90H21EOLACvtfcHk0lgYi6Vm4LDnsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKltb%252FL&md5=55728b3984de6deef40e4df161f619b3</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301574%26sid%3Dliteratum%253Aachs%26aulast%3DPittenger%26aufirst%3DC.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DStress%252C%2520depression%252C%2520and%2520neuroplasticity%253A%2520a%2520convergence%2520of%2520mechanisms%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26spage%3D88%26epage%3D109%26doi%3D10.1038%2Fsj.npp.1301574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardier, A. M.</span></span> <span> </span><span class="NLM_article-title">Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2019.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.pharmthera.2019.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30851296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltVSgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2019&pages=58-90&author=T.+H.+Phamauthor=A.+M.+Gardier&title=Fast-acting+antidepressant+activity+of+ketamine%3A+highlights+on+brain+serotonin%2C+glutamate%2C+and+GABA+neurotransmission+in+preclinical+studies&doi=10.1016%2Fj.pharmthera.2019.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies</span></div><div class="casAuthors">Pham, Thu Ha; Gardier, Alain M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-90</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays a fast antidepressant activity in treatment-resistant depression and in rodent models of anxiety/depression.  A large body of evidence concerning the cellular and mol. mechanisms underlying its fast antidepressant-like activity comes from animal studies.  Although structural remodeling of frontocortical/hippocampal neurons has been proposed as crit., the role of excitatory/inhibitory neurotransmitters in this behavioral effect is unclear.  Neurochem. and behavioral changes are maintained 24h after ketamine administration, well beyond its plasma elimination half-life.  Thus, ketamine is believed to initiate a cascade of cellular mechanisms supporting its fast antidepressant-like activity.  To date, the underlying mechanism involves glutamate release, then downstream activation of AMPA receptors, which trigger mammalian target of rapamycin (mTOR)-dependent structural plasticity via brain-derived neurotrophic factor (BDNF) and protein neo-synthesis in the medial prefrontal cortex (mPFC), a brain region strongly involved in ketamine therapeutic effects.  However, these mPFC effects are not restricted to glutamatergic pyramidal cells, but extend to other neurotransmitters (GABA, serotonin), glial cells, and brain circuits (mPFC/dorsal raphe nucleus-DRN).  It could be also mediated by one or several ketamine metabolites (e.g., (2R,6R)-HNK).  The present review focuses on evidence for mPFC neurotransmission abnormalities in major depressive disorder (MDD) and their potential impact on neural circuits (mPFC/DRN).  We will integrate these considerations with results from recent preclin. studies showing that ketamine, at antidepressant-relevant doses, induces neuronal adaptations that involve the glutamate-excitatory/GABA-inhibitory balance.  Our analyses will help direct future studies to further elucidate the mechanism of action of fast-acting antidepressant drugs, and to inform development of novel, more efficacious therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSlrIAPlq7PbVg90H21EOLACvtfcHk0lgYi6Vm4LDnsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltVSgu7s%253D&md5=7e501b0e6491aa594c06322cfa121f9e</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2019.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2019.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DPham%26aufirst%3DT.%2BH.%26aulast%3DGardier%26aufirst%3DA.%2BM.%26atitle%3DFast-acting%2520antidepressant%2520activity%2520of%2520ketamine%253A%2520highlights%2520on%2520brain%2520serotonin%252C%2520glutamate%252C%2520and%2520GABA%2520neurotransmission%2520in%2520preclinical%2520studies%26jtitle%3DPharmacol.%2520Ther.%26date%3D2019%26volume%3D199%26spage%3D58%26epage%3D90%26doi%3D10.1016%2Fj.pharmthera.2019.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, D. a.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercier, M.</span></span> <span> </span><span class="NLM_article-title">Ketamine and phencyclidine: the good, the bad and the unexpected</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">4254</span>– <span class="NLM_lpage">4276</span>, <span class="refDoi"> DOI: 10.1111/bph.13222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1111%2Fbph.13222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26075331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ent73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=4254-4276&author=D.+a.+Lodgeauthor=M.+Mercier&title=Ketamine+and+phencyclidine%3A+the+good%2C+the+bad+and+the+unexpected&doi=10.1111%2Fbph.13222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine and phencyclidine: the good, the bad and the unexpected</span></div><div class="casAuthors">Lodge, D.; Mercier, M. S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4254-4276</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The history of ketamine and phencyclidine from their development as potential clin. anesthetics through drugs of abuse and animal models of schizophrenia to potential rapidly acting antidepressants is reviewed.  The discovery in 1983 of the NMDA receptor antagonist property of ketamine and phencyclidine was a key step to understanding their pharmacol., including their psychotomimetic effects in man.  This review describes the historical context and the course of that discovery and its expansion into other hallucinatory drugs.  The relevance of these findings to modern hypotheses of schizophrenia and the implications for drug discovery are reviewed.  The findings of the rapidly acting antidepressant effects of ketamine in man are discussed in relation to other glutamatergic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcDQQWyFfaSrVg90H21EOLACvtfcHk0lggCuesryzG7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ent73F&md5=fc1b6f9b5ba8b1760681ac5bce12d7d7</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1111%2Fbph.13222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13222%26sid%3Dliteratum%253Aachs%26aulast%3DLodge%26aufirst%3DD.%2Ba.%26aulast%3DMercier%26aufirst%3DM.%26atitle%3DKetamine%2520and%2520phencyclidine%253A%2520the%2520good%252C%2520the%2520bad%2520and%2520the%2520unexpected%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D4254%26epage%3D4276%26doi%3D10.1111%2Fbph.13222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span> <span> </span><span class="NLM_article-title">Ketamine abuse potential and use disorder</span>. <i>Brain Res. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.brainresbull.2016.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.brainresbull.2016.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27261367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvFehtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2016&pages=68-73&author=Y.+Liuauthor=D.+Linauthor=B.+Wuauthor=W.+Zhou&title=Ketamine+abuse+potential+and+use+disorder&doi=10.1016%2Fj.brainresbull.2016.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine abuse potential and use disorder</span></div><div class="casAuthors">Liu, Yu; Lin, Deyong; Wu, Boliang; Zhou, Wenhua</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">Part_1</span>),
    <span class="NLM_cas:pages">68-73</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Ketamine is a noncompetitive antagonist of N-methyl-D-asparate (NMDA) receptor and has been long used as an anesthetic agent in humans and veterinary medicine.  The present article reviews the epidemiol., pharmacol., neurochem., and treatment of ketamine abuse.  Ketamine has a unique mood controlling property and a no. of studies have demonstrated a significant and rapid antidepressant effect of ketamine.  However, the therapeutic value of ketamine to treat psychiatric disorders faces a major challenge that ketamine also owns significant reinforcing and toxic effects.  Its abuse has posted severe harms on individuals and society.  Disrupted learning and memory processing has long been related with ketamine use.  It is hypothesized that ketamine blocks NMDA receptors on gamma-aminobutyric acid (GABA) neurons inside the thalamic reticular nucleus, which leads to disinhibition of dopaminergic neurons and increased release of dopamine.  Currently, there is no specific treatment for treating every ketamine patient presenting peripheral toxicity.  Interestingly, ketamine psychotherapy has been suggested to be a promising approach to treat addiction of other drugs.  Future research can continue to develop creative ways to investigate potential mechanism and treatments related to ketamine abuse that have posted severe individual and social harms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLfMHEo19ttLVg90H21EOLACvtfcHk0lggCuesryzG7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvFehtbw%253D&md5=7820f78cc85a789ab72433fce29a48dd</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresbull.2016.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresbull.2016.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DW.%26atitle%3DKetamine%2520abuse%2520potential%2520and%2520use%2520disorder%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2016%26volume%3D126%26spage%3D68%26epage%3D73%26doi%3D10.1016%2Fj.brainresbull.2016.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipsky, R. H.</span></span> <span> </span><span class="NLM_article-title">Repeated ketamine administration alters N-methyl-D-aspartic acid receptor subunit gene expression: implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans</span>. <i>Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1177/1535370214549531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1177%2F1535370214549531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktl2qtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=2015&pages=145-155&author=K.+Xuauthor=R.+H.+Lipsky&title=Repeated+ketamine+administration+alters+N-methyl-D-aspartic+acid+receptor+subunit+gene+expression%3A+implication+of+genetic+vulnerability+for+ketamine+abuse+and+ketamine+psychosis+in+humans&doi=10.1177%2F1535370214549531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Repeated ketamine administration alters N-methyl-D-aspartic acid receptor subunit gene expression: implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans</span></div><div class="casAuthors">Xu, Ke; Lipsky, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-155</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3699</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  For more than 40 years following its approval by the Food and Drug Administration (FDA) as an anesthetic, ketamine, a noncompetitive N-methyl-D-aspartic acid (NMDA) receptor antagonist, has been used as a tool of psychiatric research.  As a psychedelic drug, ketamine induces psychotic symptoms, cognitive impairment, and mood elevation, which resemble some symptoms of schizophrenia.  Recreational use of ketamine has been increasing in recent years.  However, little is known of the underlying mol. mechanisms responsible for ketamine-assocd. psychosis.  Recent animal studies have shown that repeated ketamine administration significantly increases NMDA receptor subunit gene expression, in particular subunit 1 (NR1 or GluN1) levels.  This results in neurodegeneration, supporting a potential mechanism where up-regulation of NMDA receptors could produce cognitive deficits in chronic ketamine abuse patients.  In other studies, NMDA receptor gene variants are assocd. with addictive behavior.  Here, we focus on the roles of NMDA receptor gene subunits in ketamine abuse and ketamine psychosis and propose that full sequencing of NMDA receptor genes may help explain individual vulnerability to ketamine abuse and ketamine-assocd. psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0TPUOBfX_xLVg90H21EOLACvtfcHk0lggCuesryzG7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktl2qtLw%253D&md5=3371142f300e7c443b1e0b66f3816967</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1177%2F1535370214549531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1535370214549531%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLipsky%26aufirst%3DR.%2BH.%26atitle%3DRepeated%2520ketamine%2520administration%2520alters%2520N-methyl-D-aspartic%2520acid%2520receptor%2520subunit%2520gene%2520expression%253A%2520implication%2520of%2520genetic%2520vulnerability%2520for%2520ketamine%2520abuse%2520and%2520ketamine%2520psychosis%2520in%2520humans%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2015%26volume%3D240%26spage%3D145%26epage%3D155%26doi%3D10.1177%2F1535370214549531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span> <span> </span><span class="NLM_article-title">Repurposing potential of ketamine: Opportunities and challenges</span>. <i>Ind. J. Psychol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.4103/IJPSYM.IJPSYM_228_19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.4103%2FIJPSYM.IJPSYM_228_19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=31997862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FmtFSmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2020&pages=22&author=C.+Gautamauthor=S.+S.+Mahajanauthor=J.+Sharmaauthor=H.+Singhauthor=J.+Singh&title=Repurposing+potential+of+ketamine%3A+Opportunities+and+challenges&doi=10.4103%2FIJPSYM.IJPSYM_228_19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing Potential of Ketamine: Opportunities and Challenges</span></div><div class="casAuthors">Gautam C S; Mahajan Sonia S; Sharma Jatin; Singh Harmanjit; Singh Jagjit</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of psychological medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-29</span>
        ISSN:<span class="NLM_cas:issn">0253-7176</span>.
    </div><div class="casAbstract">Ketamine is a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor which also interacts with various other receptors that account for its myriad actions.  Originally approved as a general anesthetic, it is being explored to be repurposed for numerous other indications such as depressive disorders, suicidal ideation, substance-use disorders, anxiety disorders, chronic pain, refractory status epilepticus, and bronchial asthma exacerbations.  Numerous trials are ongoing for the same.  The nasal spray of esketamine, a more potent S (+) enantiomer of ketamine, has been approved by the United States Food and Drug Administration (USFDA) for treatment-resistant depression along with the oral antidepressants.  However, there are concerns about its safety on long term use, given its psychedelic effects and potential abuse.  In this review, we discuss repurposing ketamine for potential therapeutic use and about the safety concerns related to ketamine and esketamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbNOcjfUVimZNiNltV31zlfW6udTcc2eYKPSqopIaCN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FmtFSmsg%253D%253D&md5=56495360ebea692ca8626e5aa056ecb5</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.4103%2FIJPSYM.IJPSYM_228_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252FIJPSYM.IJPSYM_228_19%26sid%3Dliteratum%253Aachs%26aulast%3DGautam%26aufirst%3DC.%26aulast%3DMahajan%26aufirst%3DS.%2BS.%26aulast%3DSharma%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DRepurposing%2520potential%2520of%2520ketamine%253A%2520Opportunities%2520and%2520challenges%26jtitle%3DInd.%2520J.%2520Psychol.%2520Med.%26date%3D2020%26volume%3D42%26spage%3D22%26doi%3D10.4103%2FIJPSYM.IJPSYM_228_19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokane, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armant, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolaños-Guzmán, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrotti, L. I.</span></span> <span> </span><span class="NLM_article-title">Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>384</i></span>,  <span class="NLM_fpage">112548</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2020.112548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.bbr.2020.112548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32061748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1amsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2020&pages=112548&author=S.+S.+Kokaneauthor=R.+J.+Armantauthor=C.+A.+Bola%C3%B1os-Guzm%C3%A1nauthor=L.+I.+Perrotti&title=Overlap+in+the+neural+circuitry+and+molecular+mechanisms+underlying+ketamine+abuse+and+its+use+as+an+antidepressant&doi=10.1016%2Fj.bbr.2020.112548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant</span></div><div class="casAuthors">Kokane, Saurabh S.; Armant, Ross J.; Bolanos-Guzman, Carlos A.; Perrotti, Linda I.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112548</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Ketamine, a dissociative anesthetic and psychedelic compd., has revolutionized the field of psychopharmacol. by showing robust, and rapid-acting antidepressant activity in patients suffering from major depressive disorder (MDD), suicidal tendencies, and treatment-resistant depression (TRD).  Ketamine's efficacy, however, is transient, and patients must return to the clinic for repeated treatment as they experience relapse.  This is cause for concern because ketamine is known for its abuse liability, and repeated exposure to drugs of abuse often leads to drug abuse/dependence.  Though the mechanism(s) underlying its antidepressant activity is an area of current intense research, both clin. and preclin. evidence shows that ketamine's effects are mediated, at least in part, by mol. adaptations resulting in long-lasting synaptic changes in mesolimbic brain regions known to regulate natural and drug reward.  This review outlines our limited knowledge of ketamine's neurobiol. and biochem. underpinnings mediating its antidepressant effects and correlates them to its abuse potential.  Depression and addiction share overlapping neural circuitry and mol. mechanisms, and though speculative, repeated use of ketamine for the treatment of depression could lead to the development of substance use disorder/addiction, and thus should be tempered with caution.  There is much that remains to be known about the long-term effects of ketamine, and our lack of understanding of neurobiol. mechanisms underlying its antidepressant effects is a clear limiting factor that needs to be addressed systematically before using repeated ketamine in the treatment of depressed patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6ZwmRuUnbTLVg90H21EOLACvtfcHk0liATtZx1fcNAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1amsbc%253D&md5=919879a81ef28509d119f283db4048f1</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2020.112548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2020.112548%26sid%3Dliteratum%253Aachs%26aulast%3DKokane%26aufirst%3DS.%2BS.%26aulast%3DArmant%26aufirst%3DR.%2BJ.%26aulast%3DBola%25C3%25B1os-Guzm%25C3%25A1n%26aufirst%3DC.%2BA.%26aulast%3DPerrotti%26aufirst%3DL.%2BI.%26atitle%3DOverlap%2520in%2520the%2520neural%2520circuitry%2520and%2520molecular%2520mechanisms%2520underlying%2520ketamine%2520abuse%2520and%2520its%2520use%2520as%2520an%2520antidepressant%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2020%26volume%3D384%26spage%3D112548%26doi%3D10.1016%2Fj.bbr.2020.112548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fox, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, M. K.</span></span> <span> </span><span class="NLM_article-title">The molecular and cellular mechanisms of depression: a focus on reward circuitry</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1798</span>, <span class="refDoi"> DOI: 10.1038/s41380-019-0415-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fs41380-019-0415-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30967681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FjsleitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1798&author=M.+E.+Foxauthor=M.+K.+Lobo&title=The+molecular+and+cellular+mechanisms+of+depression%3A+a+focus+on+reward+circuitry&doi=10.1038%2Fs41380-019-0415-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular and cellular mechanisms of depression: a focus on reward circuitry</span></div><div class="casAuthors">Fox Megan E; Lobo Mary Kay</div><div class="citationInfo"><span class="NLM_cas:title">Molecular psychiatry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1798-1815</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Depression is a complex disorder that takes an enormous toll on individual health.  As affected individuals display a wide variation in their clinical symptoms, the precise neural mechanisms underlying the development of depression remain elusive.  Although it is impossible to phenocopy every symptom of human depression in rodents, the preclinical field has had great success in modeling some of the core affective and neurovegetative depressive symptoms, including social withdrawal, anhedonia, and weight loss.  Adaptations in select cell populations may underlie these individual depressive symptoms and new tools have expanded our ability to monitor and manipulate specific cell types.  This review outlines some of the most recent preclinical discoveries on the molecular and neurophysiological mechanisms in reward circuitry that underlie the expression of behavioral constructs relevant to depressive symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCCVnFOX46mEGy1nwu7K2mfW6udTcc2eYASo-fWlNDgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FjsleitQ%253D%253D&md5=ae1b49ef4844340646eb9f70cbc0647a</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2Fs41380-019-0415-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41380-019-0415-3%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DM.%2BE.%26aulast%3DLobo%26aufirst%3DM.%2BK.%26atitle%3DThe%2520molecular%2520and%2520cellular%2520mechanisms%2520of%2520depression%253A%2520a%2520focus%2520on%2520reward%2520circuitry%26jtitle%3DMol.%2520Psychiatry%26date%3D2019%26volume%3D24%26spage%3D1798%26doi%3D10.1038%2Fs41380-019-0415-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikonomidou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miksa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittigau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vöckler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikranian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenkova, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefovska, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olney, J. W.</span></span> <span> </span><span class="NLM_article-title">Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1126/science.283.5398.70</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1126%2Fscience.283.5398.70" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=9872743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK1MXktFSitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1999&pages=70-74&author=C.+Ikonomidouauthor=F.+Boschauthor=M.+Miksaauthor=P.+Bittigauauthor=J.+V%C3%B6cklerauthor=K.+Dikranianauthor=T.+I.+Tenkovaauthor=V.+Stefovskaauthor=L.+Turskiauthor=J.+W.+Olney&title=Blockade+of+NMDA+receptors+and+apoptotic+neurodegeneration+in+the+developing+brain&doi=10.1126%2Fscience.283.5398.70"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain</span></div><div class="casAuthors">Ikonomidou, Chrysanthy; Bosch, Friederike; Miksa, Michael; Bittigau, Petra; Vockler, Jessica; Dikranian, Krikor; Tenkova, Tanya I.; Stefovska, Vanya; Turski, Lechoslaw; Olney, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">5398</span>),
    <span class="NLM_cas:pages">70-74</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Programmed cell death (apoptosis) occurs during normal development of the central nervous system.  However, the mechanisms that det. which neurons will succumb to apoptosis are poorly understood.  Blockade of N-methyl-D-aspartate (NMDA) glutamate receptors for only a few hours during late fetal or early neonatal life triggered widespread apoptotic neurodegeneration in the developing rat brain, suggesting that the excitatory neurotransmitter glutamate, acting at NMDA receptors, controls neuronal survival.  These findings may have relevance to human neurodevelopmental disorders involving prenatal (drug-abusing mothers) or postnatal (pediatric anesthesia) exposure to drugs that block NMDA receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9KhLG5igGBbVg90H21EOLACvtfcHk0liATtZx1fcNAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktFSitA%253D%253D&md5=ba2750c3a0894b313353327ffa958398</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1126%2Fscience.283.5398.70&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.283.5398.70%26sid%3Dliteratum%253Aachs%26aulast%3DIkonomidou%26aufirst%3DC.%26aulast%3DBosch%26aufirst%3DF.%26aulast%3DMiksa%26aufirst%3DM.%26aulast%3DBittigau%26aufirst%3DP.%26aulast%3DV%25C3%25B6ckler%26aufirst%3DJ.%26aulast%3DDikranian%26aufirst%3DK.%26aulast%3DTenkova%26aufirst%3DT.%2BI.%26aulast%3DStefovska%26aufirst%3DV.%26aulast%3DTurski%26aufirst%3DL.%26aulast%3DOlney%26aufirst%3DJ.%2BW.%26atitle%3DBlockade%2520of%2520NMDA%2520receptors%2520and%2520apoptotic%2520neurodegeneration%2520in%2520the%2520developing%2520brain%26jtitle%3DScience%26date%3D1999%26volume%3D283%26spage%3D70%26epage%3D74%26doi%3D10.1126%2Fscience.283.5398.70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Effects of ketamine on levels of inflammatory cytokines IL-6, IL-1β, and TNF-α in the hippocampus of mice following acute or chronic administration</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">139</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.3389%2Ffphar.2017.00139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=28373844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVKmsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=139&author=Y.+Liauthor=R.+Shenauthor=G.+Wenauthor=R.+Dingauthor=A.+Duauthor=J.+Zhouauthor=Z.+Dongauthor=X.+Renauthor=H.+Yaoauthor=R.+Zhao&title=Effects+of+ketamine+on+levels+of+inflammatory+cytokines+IL-6%2C+IL-1%CE%B2%2C+and+TNF-%CE%B1+in+the+hippocampus+of+mice+following+acute+or+chronic+administration&doi=10.3389%2Ffphar.2017.00139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of ketamine on levels of inflammatory cytokines IL-6, IL-1β, and TNF-α in the hippocampus of mice following acute or chronic administration</span></div><div class="casAuthors">Li, Yanning; Shen, Ruipeng; Wen, Gehua; Ding, Runtao; Du, Ao; Zhou, Jichuan; Dong, Zhibin; Ren, Xinghua; Yao, Hui; Zhao, Rui; Zhang, Guohua; Lu, Yan; Wu, Xu</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">139/1-139/14</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Ketamine is an injectable anesthetic and recreational drug of abuse commonly used worldwide.  Many exptl. studies have shown that ketamine can impair cognitive function and induce psychotic states.  Neuroinflammation has been suggested to play an important role in neurodegeneration.  Meanwhile, ketamine has been shown to modulate the levels of inflammatory cytokines.  We hypothesized that the effects of ketamine on the central nervous system are assocd. with inflammatory cytokines.  Therefore, we set out to establish acute and chronic ketamine administration models in C57BL/6 mice, to evaluate spatial recognition memory and emotional response, to analyze the changes in the levels of the inflammatory cytokines interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) in the mouse hippocampus, employing behavioral tests, Western blot, quant. reverse transcriptase-polymerase chain reaction (qRT-PCR) and immunohistochem.  Our results showed that ketamine at the dose of 60 mg/kg induced spatial recognition memory deficit and reduced anxietylike behaviors in mice after chronic administration.  Moreover, we found that ketamine increased the hippocampal levels of IL-6 and IL-1β after single, multiple and long-term administration in a dose-dependent manner.  However, the expression level of TNF-α differed in the mouse hippocampus under different conditions.  Single administration of ketamine increased the level of TNF-α, whereas multiple and long-term administration decreased it significantly.  We considered that TNF-α expression could be controlled by a bi-directional regulatory pathway, which was assocd. with the dose and duration of ketamine administration.  Our results suggest that the alterations in the levels of inflammatory cytokines IL-6, IL-1β, and TNF-α may be involved in the neurotoxicity of ketamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquYGobwrzgWLVg90H21EOLACvtfcHk0ljodWGSNa3d-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVKmsb4%253D&md5=a1501fccc6e446a4e33b316f8df3d14b</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00139%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWen%26aufirst%3DG.%26aulast%3DDing%26aufirst%3DR.%26aulast%3DDu%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DR.%26atitle%3DEffects%2520of%2520ketamine%2520on%2520levels%2520of%2520inflammatory%2520cytokines%2520IL-6%252C%2520IL-1%25CE%25B2%252C%2520and%2520TNF-%25CE%25B1%2520in%2520the%2520hippocampus%2520of%2520mice%2520following%2520acute%2520or%2520chronic%2520administration%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D139%26doi%3D10.3389%2Ffphar.2017.00139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pomarol-Clotet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corlett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Absalom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullmore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, P.</span></span> <span> </span><span class="NLM_article-title">Psychological effects of ketamine in healthy volunteers: phenomenological study</span>. <i>Br. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1192/bjp.bp.105.015263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1192%2Fbjp.bp.105.015263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=16880489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD28vls1aisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2006&pages=173-179&author=E.+Pomarol-Clotetauthor=G.+Honeyauthor=G.+Murrayauthor=P.+Corlettauthor=A.+Absalomauthor=M.+Leeauthor=P.+McKennaauthor=E.+Bullmoreauthor=P.+Fletcher&title=Psychological+effects+of+ketamine+in+healthy+volunteers%3A+phenomenological+study&doi=10.1192%2Fbjp.bp.105.015263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Psychological effects of ketamine in healthy volunteers. Phenomenological study</span></div><div class="casAuthors">Pomarol-Clotet E; Honey G D; Murray G K; Corlett P R; Absalom A R; Lee M; McKenna P J; Bullmore E T; Fletcher P C</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of psychiatry : the journal of mental science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">173-9</span>
        ISSN:<span class="NLM_cas:issn">0007-1250</span>.
    </div><div class="casAbstract">BACKGROUND:  The psychosis-inducing effect of ketamine is important evidence supporting the glutamate hypothesis of schizophrenia.  However, the symptoms the drug produces have not been described systematically.  AIM:  To examine the effects of ketamine in healthy people using a structured psychiatric interview.  METHOD:  Ketamine (200 ng/ml) or placebo was administered by continuous infusion to 15 healthy volunteers.  Symptoms were rated using the Present State Examination, the Thought, Language and Communication Scale and the Scale for Assessment of Negative Symptoms.  RESULTS:  Ketamine induced a range of perceptual distortions, but not hallucinations.  Referential ideas were seen in nearly half the sample.  There were only mild and infrequent ratings on the thought disorder scale.  Affective flattening and alogia were seen in some volunteers.  CONCLUSIONS:  Ketamine does not reproduce the full picture of schizophrenia.  The main point of similarity concerns referential thinking.  Phenomena resembling negative symptoms are also seen, but the distinction of these from the drug's sedative effects requires further elucidation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpNGPgVkzx2hFwe7cAcrfPfW6udTcc2eYFqVMsHyOEfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vls1aisQ%253D%253D&md5=06dcc502462b6c7faed99af971964312</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1192%2Fbjp.bp.105.015263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fbjp.bp.105.015263%26sid%3Dliteratum%253Aachs%26aulast%3DPomarol-Clotet%26aufirst%3DE.%26aulast%3DHoney%26aufirst%3DG.%26aulast%3DMurray%26aufirst%3DG.%26aulast%3DCorlett%26aufirst%3DP.%26aulast%3DAbsalom%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DMcKenna%26aufirst%3DP.%26aulast%3DBullmore%26aufirst%3DE.%26aulast%3DFletcher%26aufirst%3DP.%26atitle%3DPsychological%2520effects%2520of%2520ketamine%2520in%2520healthy%2520volunteers%253A%2520phenomenological%2520study%26jtitle%3DBr.%2520J.%2520Psychiatry%26date%3D2006%26volume%3D189%26spage%3D173%26epage%3D179%26doi%3D10.1192%2Fbjp.bp.105.015263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbrock, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorner-Ciossek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rast, G.</span></span> <span> </span><span class="NLM_article-title">Effects of specific nicotinic acetylcholine receptor agonists on hippocampal long-term potentiation</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">S116</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2011.05.295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.jalz.2011.05.295" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=S116&author=H.+Rosenbrockauthor=C.+Dorner-Ciossekauthor=K.+Krokerauthor=G.+Rast&title=Effects+of+specific+nicotinic+acetylcholine+receptor+agonists+on+hippocampal+long-term+potentiation&doi=10.1016%2Fj.jalz.2011.05.295"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2011.05.295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2011.05.295%26sid%3Dliteratum%253Aachs%26aulast%3DRosenbrock%26aufirst%3DH.%26aulast%3DDorner-Ciossek%26aufirst%3DC.%26aulast%3DKroker%26aufirst%3DK.%26aulast%3DRast%26aufirst%3DG.%26atitle%3DEffects%2520of%2520specific%2520nicotinic%2520acetylcholine%2520receptor%2520agonists%2520on%2520hippocampal%2520long-term%2520potentiation%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2011%26volume%3D7%26spage%3DS116%26doi%3D10.1016%2Fj.jalz.2011.05.295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Myers, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluth, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, W. W.</span></span> <span> </span><span class="NLM_article-title">Ketamine: a cause of urinary tract dysfunction</span>. <i>Clin. Lab. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1016/j.cll.2016.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.cll.2016.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27842789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC2snlvFKiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=721-744&author=F.+A.+Myersauthor=M.+H.+Bluthauthor=W.+W.+Cheung&title=Ketamine%3A+a+cause+of+urinary+tract+dysfunction&doi=10.1016%2Fj.cll.2016.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: A Cause of Urinary Tract Dysfunction</span></div><div class="casAuthors">Myers Frank Anthony Jr; Bluth Martin H; Cheung Wellman W</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in laboratory medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">721-744</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug addiction as a result of improper use of prescribed and illicit use has been on the increase globally.  The effects of such use have implications in the urologic disease space.  To this end, Ketamine has been reported to affect urologic function, causing a number of voiding symptoms.  It may also confound the differential diagnosis of urologic diseases, such as interstitial cystitis, among others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuNhWGuJIGbCnGiHuhFGv8fW6udTcc2eYFqVMsHyOEfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snlvFKiug%253D%253D&md5=d094eb8e30f35f319e70d8086ea2e56b</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.cll.2016.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cll.2016.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DF.%2BA.%26aulast%3DBluth%26aufirst%3DM.%2BH.%26aulast%3DCheung%26aufirst%3DW.%2BW.%26atitle%3DKetamine%253A%2520a%2520cause%2520of%2520urinary%2520tract%2520dysfunction%26jtitle%3DClin.%2520Lab.%2520Med.%26date%3D2016%26volume%3D36%26spage%3D721%26epage%3D744%26doi%3D10.1016%2Fj.cll.2016.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Acevedo-Diaz, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanaugh, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadriu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, L. T.</span></span> <span> </span><span class="NLM_article-title">Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression</span>. <i>J. Affective Disord.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">568</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1016/j.jad.2019.11.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.jad.2019.11.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=31791675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlWktLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=2020&pages=568-575&author=E.+E.+Acevedo-Diazauthor=G.+W.+Cavanaughauthor=D.+Greensteinauthor=C.+Krausauthor=B.+Kadriuauthor=C.+A.+Zarateauthor=L.+T.+Park&title=Comprehensive+assessment+of+side+effects+associated+with+a+single+dose+of+ketamine+in+treatment-resistant+depression&doi=10.1016%2Fj.jad.2019.11.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression</span></div><div class="casAuthors">Acevedo-Diaz, Elia E.; Cavanaugh, Grace W.; Greenstein, Dede; Kraus, Christoph; Kadriu, Bashkim; Zarate, Carlos A.; Park, Lawrence T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Affective Disorders</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">568-575</span>CODEN:
                <span class="NLM_cas:coden">JADID7</span>;
        ISSN:<span class="NLM_cas:issn">0165-0327</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Concerns about ketamine for treating depression include abuse potential and the occurrence of psychotomimetic effects.  This study sought to comprehensively assess side effects (SEs) assocd. with a single subanesthetic-dose i.v. ketamine infusion.  A secondary aim was to examine the relationship between Clinician-Administered Dissociative States Scale (CADSS) scores and dissociative symptoms reported on a comprehensive, clinician-administered SE questionnaire.  Data from 188 participants were pooled from four placebo-controlled, crossover ketamine trials and one open-label study (n = 163 with either treatment-resistant major depressive disorder or bipolar disorder and 25 healthy controls).  SEs were actively solicited in a standardized fashion and monitored over the time-course of each study.  Statistical analyses assessed the effect of drug (ketamine, placebo) on SEs and measured the relationship between CADSS total score and SEs contemporaneously endorsed during structured interviews.  Forty-four of 120 SEs occurred in at least 5% of participants over all trials.  Thirty-three of these 44 SEs were significantly assocd. with active drug administration (vs. placebo).  The most common SE was feeling strange/weird/loopy.  Most SEs peaked within an hour of ketamine administration and resolved completely by two hours post-infusion.  No serious drug-related adverse events or increased ketamine craving/abuse post-administration were obsd.  A pos. correlation was found between dissociative SEs and total CADSS score.  The post-hoc nature of the anal.; the limited generalizability of a single subanesthetic-dose ketamine infusion; and the lack of formal measures to assess ketamine's cognitive, urol., or addictive potential.  No long-lasting significant SEs occurred over the approx. three-month follow-up period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocM-t8h_mvrbVg90H21EOLACvtfcHk0lgfBSk-BQFAIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlWktLfP&md5=0cbdb90cc86e441c2aa114211532191e</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.jad.2019.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jad.2019.11.028%26sid%3Dliteratum%253Aachs%26aulast%3DAcevedo-Diaz%26aufirst%3DE.%2BE.%26aulast%3DCavanaugh%26aufirst%3DG.%2BW.%26aulast%3DGreenstein%26aufirst%3DD.%26aulast%3DKraus%26aufirst%3DC.%26aulast%3DKadriu%26aufirst%3DB.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DPark%26aufirst%3DL.%2BT.%26atitle%3DComprehensive%2520assessment%2520of%2520side%2520effects%2520associated%2520with%2520a%2520single%2520dose%2520of%2520ketamine%2520in%2520treatment-resistant%2520depression%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2020%26volume%3D263%26spage%3D568%26epage%3D575%26doi%3D10.1016%2Fj.jad.2019.11.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzucco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hough, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, R. C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2019.19020172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1176%2Fappi.ajp.2019.19020172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=31109201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BB3M7nvVSjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=428-438&author=V.+Popovaauthor=E.+J.+Dalyauthor=M.+Trivediauthor=K.+Cooperauthor=R.+Laneauthor=P.+Limauthor=C.+Mazzuccoauthor=D.+Houghauthor=M.+E.+Thaseauthor=R.+C.+Shelton&title=Efficacy+and+safety+of+flexibly+dosed+esketamine+nasal+spray+combined+with+a+newly+initiated+oral+antidepressant+in+treatment-resistant+depression%3A+a+randomized+double-blind+active-controlled+study&doi=10.1176%2Fappi.ajp.2019.19020172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study</span></div><div class="casAuthors">Popova Vanina; Daly Ella J; Trivedi Madhukar; Cooper Kimberly; Lane Rosanne; Lim Pilar; Mazzucco Christine; Hough David; Thase Michael E; Shelton Richard C; Molero Patricio; Vieta Eduard; Bajbouj Malek; Manji Husseini; Drevets Wayne C; Singh Jaskaran B</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">428-438</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants.  This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active comparator) plus placebo nasal spray.  METHODS:  This was a phase 3, double-blind, active-controlled, multicenter study conducted at 39 outpatient referral centers.  The study enrolled adults with moderate to severe nonpsychotic depression and a history of nonresponse to at least two antidepressants in the current episode, with one antidepressant assessed prospectively.  Confirmed nonresponders were randomly assigned to treatment with esketamine nasal spray (56 or 84 mg twice weekly) and an antidepressant or antidepressant and placebo nasal spray.  The primary efficacy endpoint, change from baseline to day 28 in Montgomery-ÅAsberg Depression Rating Scale (MADRS) score, was assessed by a mixed-effects model using repeated measures.  RESULTS:  Of 435 patients screened, 227 underwent randomization and 197 completed the 28-day double-blind treatment phase.  Change in MADRS score with esketamine plus antidepressant was significantly greater than with antidepressant plus placebo at day 28 (difference of least square means=-4.0, SE=1.69, 95% CI=-7.31, -0.64); likewise, clinically meaningful improvement was observed in the esketamine plus antidepressant arm at earlier time points.  The five most common adverse events (dissociation, nausea, vertigo, dysgeusia, and dizziness) all were observed more frequently in the esketamine plus antidepressant arm than in the antidepressant plus placebo arm; 7% and 0.9% of patients in the respective treatment groups discontinued study drug because of an adverse event.  Adverse events in the esketamine plus antidepressant arm generally appeared shortly after dosing and resolved by 1.5 hours after dosing.  CONCLUSIONS:  Current treatment options for treatment-resistant depression have considerable limitations in terms of efficacy and patient acceptability.  Esketamine is expected to address an unmet medical need in this population through its novel mechanism of action and rapid onset of antidepressant efficacy.  The study supports the efficacy and safety of esketamine nasal spray as a rapidly acting antidepressant for patients with treatment-resistant depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjG6m4HxP7vLrIbt-tGZmxfW6udTcc2eavrGJ7gwV-8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7nvVSjsA%253D%253D&md5=29fccbe859b33f8ced55216a5ca06aa9</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2019.19020172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2019.19020172%26sid%3Dliteratum%253Aachs%26aulast%3DPopova%26aufirst%3DV.%26aulast%3DDaly%26aufirst%3DE.%2BJ.%26aulast%3DTrivedi%26aufirst%3DM.%26aulast%3DCooper%26aufirst%3DK.%26aulast%3DLane%26aufirst%3DR.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DMazzucco%26aufirst%3DC.%26aulast%3DHough%26aufirst%3DD.%26aulast%3DThase%26aufirst%3DM.%2BE.%26aulast%3DShelton%26aufirst%3DR.%2BC.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520flexibly%2520dosed%2520esketamine%2520nasal%2520spray%2520combined%2520with%2520a%2520newly%2520initiated%2520oral%2520antidepressant%2520in%2520treatment-resistant%2520depression%253A%2520a%2520randomized%2520double-blind%2520active-controlled%2520study%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2019%26volume%3D176%26spage%3D428%26epage%3D438%26doi%3D10.1176%2Fappi.ajp.2019.19020172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Potter, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhury, M.</span></span> <span> </span><span class="NLM_article-title">Ketamine: repurposing and redefining a multifaceted drug</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1854</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.drudis.2014.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=25224017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SqtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1848-1854&author=D.+E.+Potterauthor=M.+Choudhury&title=Ketamine%3A+repurposing+and+redefining+a+multifaceted+drug&doi=10.1016%2Fj.drudis.2014.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: repurposing and redefining a multifaceted drug</span></div><div class="casAuthors">Potter, David E.; Choudhury, Mahua</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1848-1854</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">This short review will highlight recent clin. and basic research that supports the therapeutic utility of ketamine as a rapid-acting, life-saving antidepressant and a versatile analgesic.  After 50 years of use as a dissociative anesthetic and misuse as a street drug, ketamine has re-emerged as a useful off-label agent for ameliorating various types of pain and resistant depression.  In addn. to its ability to inhibit N-methyl-D-aspartate (NMDA) receptors, the diverse actions of ketamine might involve epigenetic mechanisms such as microRNA regulation.  Thus, ketamine is transitioning from being the pharmacologist's nightmare to one of the most interesting developments in the pharmacol. of depression and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLqKHY-SNpN7Vg90H21EOLACvtfcHk0lgfBSk-BQFAIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SqtbfK&md5=4c337cd5187299b2bf5e7116f7248fb2</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DPotter%26aufirst%3DD.%2BE.%26aulast%3DChoudhury%26aufirst%3DM.%26atitle%3DKetamine%253A%2520repurposing%2520and%2520redefining%2520a%2520multifaceted%2520drug%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1848%26epage%3D1854%26doi%3D10.1016%2Fj.drudis.2014.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rüschoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietmaier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brockhoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstädter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishel, R.</span></span> <span> </span><span class="NLM_article-title">Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">11301</span>– <span class="NLM_lpage">11306</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.19.11301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1073%2Fpnas.95.19.11301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=9736731" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=11301-11306&author=J.+R%C3%BCschoffauthor=S.+Wallingerauthor=W.+Dietmaierauthor=T.+Bockerauthor=G.+Brockhoffauthor=F.+Hofst%C3%A4dterauthor=R.+Fishel&title=Aspirin+suppresses+the+mutator+phenotype+associated+with+hereditary+nonpolyposis+colorectal+cancer+by+genetic+selection&doi=10.1073%2Fpnas.95.19.11301"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.19.11301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.19.11301%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25BCschoff%26aufirst%3DJ.%26aulast%3DWallinger%26aufirst%3DS.%26aulast%3DDietmaier%26aufirst%3DW.%26aulast%3DBocker%26aufirst%3DT.%26aulast%3DBrockhoff%26aufirst%3DG.%26aulast%3DHofst%25C3%25A4dter%26aufirst%3DF.%26aulast%3DFishel%26aufirst%3DR.%26atitle%3DAspirin%2520suppresses%2520the%2520mutator%2520phenotype%2520associated%2520with%2520hereditary%2520nonpolyposis%2520colorectal%2520cancer%2520by%2520genetic%2520selection%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D11301%26epage%3D11306%26doi%3D10.1073%2Fpnas.95.19.11301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeBusk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepine, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glasser, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shpilsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRiesthal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1016/j.amjcard.2003.09.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.amjcard.2003.09.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=14715338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=147-153&author=R.+F.+DeBuskauthor=C.+J.+Pepineauthor=D.+B.+Glasserauthor=A.+Shpilskyauthor=H.+DeRiesthalauthor=M.+Sweeney&title=Efficacy+and+safety+of+sildenafil+citrate+in+men+with+erectile+dysfunction+and+stable+coronary+artery+disease&doi=10.1016%2Fj.amjcard.2003.09.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease</span></div><div class="casAuthors">DeBusk, Robert F.; Pepine, Carl J.; Glasser, Dale B.; Shpilsky, Arkady; DeRiesthal, Herb; Sweeney, Michael</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-153</span>CODEN:
                <span class="NLM_cas:coden">AJCDAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">This was a double-blind, placebo-controlled, flexible-dose study of the efficacy and safety of sildenafil in men with erectile dysfunction (ED) and clin. stable coronary artery disease (CAD).  Patients were randomized to receive sildenafil or placebo for 12 wk.  Primary outcomes were questions 3 and 4 of the International Index of Erectile Function (IIEF).  Secondary outcomes included the other IIEF questions and functional domains, the Life Satisfaction Checklist, the Erectile Dysfunction Inventory of Treatment Satisfaction, 2 global efficacy assessment questions, and intercourse success rate.  By week 12, sildenafil-treated patients (n = 70) showed significant improvements on questions 3 and 4 compared with placebo-treated patients (n = 72; p <0.01).  Larger percentages of sildenafil-treated patients reported improved erections (64%) and improved intercourse (65%) compared with placebo-treated patients (21% and 19%, resp.).  Sildenafil-treated patients were highly satisfied with treatment and their sexual life compared with placebo-treated patients.  Forty-seven percent of sildenafil- and 32% of placebo-treated patients experienced adverse events, including transient headache, hypertension, flushing, and dyspepsia.  There were no serious drug-related cardiovascular effects.  Thus, sildenafil is an effective and well-tolerated treatment for ED in men with CAD.  Sildenafil was not assocd. with addnl. safety risks in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBnCWMLPT17LVg90H21EOLACvtfcHk0lh6XbqEafvyHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSquw%253D%253D&md5=3042796c98ddc503fe006c505d62f7df</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.amjcard.2003.09.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjcard.2003.09.030%26sid%3Dliteratum%253Aachs%26aulast%3DDeBusk%26aufirst%3DR.%2BF.%26aulast%3DPepine%26aufirst%3DC.%2BJ.%26aulast%3DGlasser%26aufirst%3DD.%2BB.%26aulast%3DShpilsky%26aufirst%3DA.%26aulast%3DDeRiesthal%26aufirst%3DH.%26aulast%3DSweeney%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520sildenafil%2520citrate%2520in%2520men%2520with%2520erectile%2520dysfunction%2520and%2520stable%2520coronary%2520artery%2520disease%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2004%26volume%3D93%26spage%3D147%26epage%3D153%26doi%3D10.1016%2Fj.amjcard.2003.09.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elena V.  Filatova</span>, <span class="hlFld-ContribAuthor ">Maria I.  Shadrina</span>, <span class="hlFld-ContribAuthor ">Petr A.  Slominsky</span>. </span><span class="cited-content_cbyCitation_article-title">Major Depression: One Brain, One Disease, One Set of Intertwined Processes. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2021,</strong> <em>10 </em>
                                    (6)
                                     , 1283. <a href="https://doi.org/10.3390/cells10061283" title="DOI URL">https://doi.org/10.3390/cells10061283</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells10061283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells10061283%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DMajor%252BDepression%25253A%252BOne%252BBrain%25252C%252BOne%252BDisease%25252C%252BOne%252BSet%252Bof%252BIntertwined%252BProcesses%26aulast%3DFilatova%26aufirst%3DElena%2BV.%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D6%26spage%3D1283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of phencyclidine (PCP), ketamine, and its isomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Ketamine binding site in the NMDA receptor. NMDA receptors are tetrameric ionotropic glutamate receptors composed of two NR1 and two NR2 subunits. Ketamine binds within the channel and acts as a noncompetitive antagonist of the NMDA receptor. By blocking the channel, ketamine prevents the influx of Ca<sup>2+</sup> or Na<sup>+</sup> ions and depolarization of the neuronal membrane, leading to decreased neurotransmitter release or downstream signaling. The figure is modeled after Pham and Gardier (ref <a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Major metabolic pathways of (<i>S</i>)-ketamine and (<i>R</i>)-ketamine. In the presence of specific cytochrome P450 isoforms, ketamine is <i>N</i>-demethylated to generate corresponding norketamine and then hydroxylated to the corresponding hydroxynorketamine. Hydroxylation can occur at different positions of the cyclohexane ring. Some of the hydroxylated compounds can form glucuronides. The hydroxynorketamine can also eliminate a water molecule nonenzymatically to generate dehydronorketamine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structure of some clinically important antidepressants: MAOIs (monoamine oxidase inhibitors), TCAs (tricyclic antidepressants), SSRIs (selective serotonin reuptake inhibitors), and SNRIs (serotonin–norepinephrine reuptake inhibitors).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Simplified diagram showing the sites of action of antidepressants. TCAs, SSRIs, and SNRIs increase noradrenergic or serotonergic neurotransmission by blocking corresponding reuptake transporters (NET or SERT). MAOIs inhibit monoamine oxidases that inactivate the monoamine neurotransmitter. Antidepressants produce long-lasting changes in monoaminergic neurotransmission by modulating both presynaptic and postsynaptic receptors. Postsynaptic GPCRs, such as βAR, αAR, 5HTR<sub>1–7</sub> are known to participate in this mechanism. SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin–norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; MAOI, monoamine oxidase inhibitor; AR, adrenergic receptor; HT, hydroxytryptamine; NE, norepinephrine; GPCR, G-protein coupled receptor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Simplified diagram showing the mechanism associated with ketamine’s rapid antidepressant action. Ketamine may preferentially block NMDA receptors located at the GABAergic interneurons and reduce inhibition of glutamate release that stimulates the AMPA receptors, which then activates a signaling cascade that raises BDNF levels. Local release of BDNF stimulates TrkB receptors, resulting in the activation of ERK/MAPK, AKT, and the mTORC1 pathways and suppression of eEF2. These processes activate local protein synthesis and restore dendritic spine formation and synaptic connectivity. Ketamine can also activate cellular plasticity cascade by inhibiting extrasynaptic NMDA receptor. AKT, protein kinase B; AMPAR, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; BDNF, brain-derived neurotrophic factor; eEF2, eukaryotic elongation factor 2; ERK/MAPK, extracellular signal-regulated kinase/mitogen-activated kinase; GABA, γ-aminobutyric acid; mTORC1, mechanistic target of rapamycin complex 1; NMDAR, <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor; TrkB, tropomyosin receptor kinase B.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/medium/jm0c01193_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Neurocircuits implicated in the rapid antidepressant action of ketamine. Projections for glutamatergic neurons (blue), GABAergic neurons (green), and dopaminergic neurons (red) are shown. The reward pathway in the corticomesolimibic structure, consisting of the VTA, HPC, NAc, and mPFC, is primarily involved in ketamine’s antidepressant action by increasing dopamine output. An aversive stimuli decreases dopamine output as the result of glutamatergic projections from the LHb to the VTA. The figure is modeled after Gould et al. (ref <a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a>) and Kokane et al. (ref <a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a>). GABA, γ-aminobutyric acid; HPC, hippocampus; LHb, lateral habenula; mPFC, medial prefrontal cortex; NAc, nucleus accumbens; VTA, ventral tegmental area.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c01193/20201120/images/large/jm0c01193_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01193&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i17">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40688" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40688" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 137 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reardon, S.</span></span> <span> </span><span class="NLM_article-title">Antidepressant based on party drug gets backing from FDA advisory group</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_fpage">10</span>, <span class="refDoi"> DOI: 10.1038/d41586-019-00559-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fd41586-019-00559-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=10&author=S.+Reardon&title=Antidepressant+based+on+party+drug+gets+backing+from+FDA+advisory+group&doi=10.1038%2Fd41586-019-00559-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fd41586-019-00559-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41586-019-00559-2%26sid%3Dliteratum%253Aachs%26aulast%3DReardon%26aufirst%3DS.%26atitle%3DAntidepressant%2520based%2520on%2520party%2520drug%2520gets%2520backing%2520from%2520FDA%2520advisory%2520group%26jtitle%3DNature%26date%3D2019%26spage%3D10%26doi%3D10.1038%2Fd41586-019-00559-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span>US Food
and Drug Administration press release FDA Approves New Nasal Spray
Medication for Treatment-Resistant Depression; Available Only at a
Certified Doctor’s Office or Clinic, March 05, <span class="NLM_year">2019</span>. <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified" class="extLink">https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=US+Food%0Aand+Drug+Administration+press+release+FDA+Approves+New+Nasal+Spray%0AMedication+for+Treatment-Resistant+Depression%3B+Available+Only+at+a%0ACertified+Doctor%E2%80%99s+Office+or+Clinic%2C+March+05%2C+2019.+https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span>Depression
and Other Common Mental Disorders: Global Health Estimates; World
Health Organization, 2017. WHO reference number: WHO/MSD/MER/2017.2.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Depression%0Aand+Other+Common+Mental+Disorders%3A+Global+Health+Estimates%3B+World%0AHealth+Organization%2C+2017.+WHO+reference+number%3A+WHO%2FMSD%2FMER%2F2017.2."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rush, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nierenberg, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warden, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niederehe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavori, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, B. D.</span></span> <span> </span><span class="NLM_article-title">Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">1905</span>– <span class="NLM_lpage">1917</span>, <span class="refDoi"> DOI: 10.1176/ajp.2006.163.11.1905</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1176%2Fajp.2006.163.11.1905" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=17074942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD28njslKgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2006&pages=1905-1917&author=A.+J.+Rushauthor=M.+H.+Trivediauthor=S.+R.+Wisniewskiauthor=A.+A.+Nierenbergauthor=J.+W.+Stewartauthor=D.+Wardenauthor=G.+Niedereheauthor=M.+E.+Thaseauthor=P.+W.+Lavoriauthor=B.+D.+Lebowitz&title=Acute+and+longer-term+outcomes+in+depressed+outpatients+requiring+one+or+several+treatment+steps%3A+a+STAR*+D+report&doi=10.1176%2Fajp.2006.163.11.1905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report</span></div><div class="casAuthors">Rush A John; Trivedi Madhukar H; Wisniewski Stephen R; Nierenberg Andrew A; Stewart Jonathan W; Warden Diane; Niederehe George; Thase Michael E; Lavori Philip W; Lebowitz Barry D; McGrath Patrick J; Rosenbaum Jerrold F; Sackeim Harold A; Kupfer David J; Luther James; Fava Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1905-17</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.  METHOD:  A broadly representative adult outpatient sample with nonpsychotic major depressive disorder received one (N=3,671) to four (N=123) successive acute treatment steps.  Those not achieving remission with or unable to tolerate a treatment step were encouraged to move to the next step.  Those with an acceptable benefit, preferably symptom remission, from any particular step could enter a 12-month naturalistic follow-up phase.  A score of <or=5 on the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR(16)) (equivalent to <or=7 on the 17-item Hamilton Rating Scale for Depression [HRSD(17)]) defined remission; a QIDS-SR(16) total score of >or=11 (HRSD(17)>or=14) defined relapse.  RESULTS:  The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively.  The overall cumulative remission rate was 67%.  Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.  In addition, lower relapse rates were found among participants who were in remission at follow-up entry than for those who were not after the first three treatment steps.  CONCLUSIONS:  When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.  Studies to identify the best multistep treatment sequences for individual patients and the development of more broadly effective treatments are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4B4LcnXBaZ-2mnZh2OgS0fW6udTcc2eYxRipFzRvHe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28njslKgug%253D%253D&md5=56cee0c64d3d97549fe77b36aeab6ebd</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1176%2Fajp.2006.163.11.1905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fajp.2006.163.11.1905%26sid%3Dliteratum%253Aachs%26aulast%3DRush%26aufirst%3DA.%2BJ.%26aulast%3DTrivedi%26aufirst%3DM.%2BH.%26aulast%3DWisniewski%26aufirst%3DS.%2BR.%26aulast%3DNierenberg%26aufirst%3DA.%2BA.%26aulast%3DStewart%26aufirst%3DJ.%2BW.%26aulast%3DWarden%26aufirst%3DD.%26aulast%3DNiederehe%26aufirst%3DG.%26aulast%3DThase%26aufirst%3DM.%2BE.%26aulast%3DLavori%26aufirst%3DP.%2BW.%26aulast%3DLebowitz%26aufirst%3DB.%2BD.%26atitle%3DAcute%2520and%2520longer-term%2520outcomes%2520in%2520depressed%2520outpatients%2520requiring%2520one%2520or%2520several%2520treatment%2520steps%253A%2520a%2520STAR%252A%2520D%2520report%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2006%26volume%3D163%26spage%3D1905%26epage%3D1917%26doi%3D10.1176%2Fajp.2006.163.11.1905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nock, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S. J.</span></span> <span> </span><span class="NLM_article-title">Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">522</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2009.04.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2009.04.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=19545857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsFyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=522-526&author=R.+B.+Priceauthor=M.+K.+Nockauthor=D.+S.+Charneyauthor=S.+J.+Mathew&title=Effects+of+intravenous+ketamine+on+explicit+and+implicit+measures+of+suicidality+in+treatment-resistant+depression&doi=10.1016%2Fj.biopsych.2009.04.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression</span></div><div class="casAuthors">Price, Rebecca B.; Nock, Matthew K.; Charney, Dennis S.; Mathew, Sanjay J.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">522-526</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">I.v. ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide.  The Implicit Assocn. Test (IAT), a performance-based measure of assocn. between concepts, may have utility in suicide assessment.  Twenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 h before and 24 h following a single subanesthetic dose of i.v. ketamine.  Ten patients also completed IATs assessing implicit suicidal assocns. at comparable time points.  In a second study, nine patients received three times-weekly ketamine infusions over a 12-day period.  Twenty-four hours after a single infusion, MADRS-SI scores were reduced on av. by 2.08 points on a 0 to 6 scale (p < .001; d = 1.37), and 81% of patients received a rating of 0 or 1 postinfusion.  Implicit suicidal assocns. were also reduced following ketamine (p = .003; d = 1.36), with redns. correlated across implicit and explicit measures.  MADRS-SI redns. were sustained for 12 days by repeated-dose ketamine (p < .001; d = 2.42).  These preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9Fx48ILoJsbVg90H21EOLACvtfcHk0lgyGixVqNLGOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsFyhsLY%253D&md5=ebe4a33be519795ccbd0fb0c318c5d96</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2009.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2009.04.029%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DR.%2BB.%26aulast%3DNock%26aufirst%3DM.%2BK.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DMathew%26aufirst%3DS.%2BJ.%26atitle%3DEffects%2520of%2520intravenous%2520ketamine%2520on%2520explicit%2520and%2520implicit%2520measures%2520of%2520suicidality%2520in%2520treatment-resistant%2520depression%26jtitle%3DBiol.%2520Psychiatry%26date%3D2009%26volume%3D66%26spage%3D522%26epage%3D526%26doi%3D10.1016%2Fj.biopsych.2009.04.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iosifescu, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murrough, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Jurdi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soleimani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foulkes, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S. J.</span></span> <span> </span><span class="NLM_article-title">Effects of ketamine on explicit and implicit suicidal cognition: A randomized controlled trial in treatment-resistant depression</span>. <i>Depression Anxiety</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1002/da.22253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1002%2Fda.22253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=24668760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Sgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=335-343&author=R.+B.+Priceauthor=D.+V.+Iosifescuauthor=J.+W.+Murroughauthor=L.+C.+Changauthor=R.+K.+Al+Jurdiauthor=S.+Z.+Iqbalauthor=L.+Soleimaniauthor=D.+S.+Charneyauthor=A.+L.+Foulkesauthor=S.+J.+Mathew&title=Effects+of+ketamine+on+explicit+and+implicit+suicidal+cognition%3A+A+randomized+controlled+trial+in+treatment-resistant+depression&doi=10.1002%2Fda.22253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT-RESISTANT DEPRESSION</span></div><div class="casAuthors">Price, Rebecca B.; Iosifescu, Dan V.; Murrough, James W.; Chang, Lee C.; Al Jurdi, Rayan K.; Iqbal, Syed Z.; Soleimani, Laili; Charney, Dennis S.; Foulkes, Alexandra L.; Mathew, Sanjay J.</div><div class="citationInfo"><span class="NLM_cas:title">Depression and Anxiety</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">335-343</span>CODEN:
                <span class="NLM_cas:coden">DEANF5</span>;
        ISSN:<span class="NLM_cas:issn">1091-4269</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Preliminary evidence suggests i.v. ketamine has rapid effects on suicidal cognition, making it an attractive candidate for depressed patients at imminent risk of suicide.  In the first randomized controlled trial of ketamine using an anesthetic control condition, we tested ketamine's acute effects on explicit suicidal cognition and a performance-based index of implicit suicidal cognition (Implicit Assocn. Test; IAT) previously linked to suicidal behavior.  Method : Symptomatic patients with treatment-resistant unipolar major depression (inadequate response to ≥3 antidepressants) were assessed using a composite index of explicit suicidal ideation (Beck Scale for Suicidal Ideation, Montgomery-Asberg Rating Scale suicide item, Quick Inventory of Depressive Symptoms suicide item) and the IAT to assess suicidality implicitly.  Measures were taken at baseline and 24 h following a single subanesthetic dose of ketamine (n = 36) or midazolam (n = 21), a psychoactive placebo agent selected for its similar, rapid anesthetic effects.  Twenty four hours postinfusion, explicit suicidal cognition was significantly reduced in the ketamine but not the midazolam group.  Results : Fifty three percent of ketamine-treated patients scored zero on all three explicit suicide measures at 24 h, compared with 24% of the midazolam group (χ2 = 4.6; P = .03).  Implicit assocns. between self- and escape-related words were reduced following ketamine (P = .01; d = .58) but not midazolam (P = .68; d = .09).  Ketamine-specific decreases in explicit suicidal cognition were largest in patients with elevated suicidal cognition at baseline, and were mediated by decreases in nonsuicide-related depressive symptoms.  Conclusions : I.v. ketamine produces rapid redns. in suicidal cognition over and above active placebo.  Further study is warranted to test ketamine's antisuicidal effects in higher-risk samples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNV--LTDcJXrVg90H21EOLACvtfcHk0lh0CQ-DG3QpzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Sgtrc%253D&md5=11433330ff6633720429f72d33bbf817</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fda.22253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fda.22253%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DR.%2BB.%26aulast%3DIosifescu%26aufirst%3DD.%2BV.%26aulast%3DMurrough%26aufirst%3DJ.%2BW.%26aulast%3DChang%26aufirst%3DL.%2BC.%26aulast%3DAl%2BJurdi%26aufirst%3DR.%2BK.%26aulast%3DIqbal%26aufirst%3DS.%2BZ.%26aulast%3DSoleimani%26aufirst%3DL.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DFoulkes%26aufirst%3DA.%2BL.%26aulast%3DMathew%26aufirst%3DS.%2BJ.%26atitle%3DEffects%2520of%2520ketamine%2520on%2520explicit%2520and%2520implicit%2520suicidal%2520cognition%253A%2520A%2520randomized%2520controlled%2520trial%2520in%2520treatment-resistant%2520depression%26jtitle%3DDepression%2520Anxiety%26date%3D2014%26volume%3D31%26spage%3D335%26epage%3D343%26doi%3D10.1002%2Fda.22253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murrough, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soleimani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWilde, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacoviello, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lener, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kautz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial</span>. <i>Psychol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3571</span>– <span class="NLM_lpage">3580</span>, <span class="refDoi"> DOI: 10.1017/S0033291715001506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1017%2FS0033291715001506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26266877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC287itVaqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=3571-3580&author=J.+W.+Murroughauthor=L.+Soleimaniauthor=K.+DeWildeauthor=K.+Collinsauthor=K.+Lapidusauthor=B.+Iacovielloauthor=M.+Lenerauthor=M.+Kautzauthor=J.+Kimauthor=J.+Stern&title=Ketamine+for+rapid+reduction+of+suicidal+ideation%3A+a+randomized+controlled+trial&doi=10.1017%2FS0033291715001506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial</span></div><div class="casAuthors">Murrough J W; Soleimani L; DeWilde K E; Collins K A; Iacoviello B M; Lener M; Kautz M; Iosifescu D V; Charney D S; Lapidus K A; Kim J; Stern J B; Price R B; Perez A M; Brallier J W; Rodriguez G J; Goodman W K</div><div class="citationInfo"><span class="NLM_cas:title">Psychological medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3571-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Suicide is a devastating public health problem and very few biological treatments have been found to be effective for quickly reducing the intensity of suicidal ideation (SI).  We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression.  METHOD:  We conducted a randomized, controlled trial of ketamine in patients with mood and anxiety spectrum disorders who presented with clinically significant SI (n = 24).  Patients received a single infusion of ketamine or midazolam (as an active placebo) in addition to standard of care.  SI measured using the Beck Scale for Suicidal Ideation (BSI) 24 h post-treatment represented the primary outcome.  Secondary outcomes included the Montgomery-Asberg Depression Rating Scale--Suicidal Ideation (MADRS-SI) score at 24 h and additional measures beyond the 24-h time-point.  RESULTS:  The intervention was well tolerated and no dropouts occurred during the primary 7-day assessment period.  BSI score was not different between the treatment groups at 24 h (p = 0.32); however, a significant difference emerged at 48 h (p = 0.047).  MADRS-SI score was lower in the ketamine group compared to midazolam group at 24 h (p = 0.05).  The treatment effect was no longer significant at the end of the 7-day assessment period.  CONCLUSIONS:  The current findings provide initial support for the safety and tolerability of ketamine as an intervention for SI in patients who are at elevated risk for suicidal behavior.  Larger, well-powered studies are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyrVioJTA195Pq5LRczm8ffW6udTcc2eZKAETWsF_v9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287itVaqsw%253D%253D&md5=c9eb9a5c60ebce2066430b1229d24609</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1017%2FS0033291715001506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0033291715001506%26sid%3Dliteratum%253Aachs%26aulast%3DMurrough%26aufirst%3DJ.%2BW.%26aulast%3DSoleimani%26aufirst%3DL.%26aulast%3DDeWilde%26aufirst%3DK.%26aulast%3DCollins%26aufirst%3DK.%26aulast%3DLapidus%26aufirst%3DK.%26aulast%3DIacoviello%26aufirst%3DB.%26aulast%3DLener%26aufirst%3DM.%26aulast%3DKautz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DStern%26aufirst%3DJ.%26atitle%3DKetamine%2520for%2520rapid%2520reduction%2520of%2520suicidal%2520ideation%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DPsychol.%2520Med.%26date%3D2015%26volume%3D45%26spage%3D3571%26epage%3D3580%26doi%3D10.1017%2FS0033291715001506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pushpakom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iorio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escott, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilliams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamee, C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Drug repurposing: progress, challenges and recommendations</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">58</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnrd.2018.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30310233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvV2gtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=41-58&author=S.+Pushpakomauthor=F.+Iorioauthor=P.+A.+Eyersauthor=K.+J.+Escottauthor=S.+Hopperauthor=A.+Wellsauthor=A.+Doigauthor=T.+Guilliamsauthor=J.+Latimerauthor=C.+McNamee&title=Drug+repurposing%3A+progress%2C+challenges+and+recommendations&doi=10.1038%2Fnrd.2018.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repurposing: progress, challenges and recommendations</span></div><div class="casAuthors">Pushpakom, Sudeep; Iorio, Francesco; Eyers, Patrick A.; Escott, K. Jane; Hopper, Shirley; Wells, Andrew; Doig, Andrew; Guilliams, Tim; Latimer, Joanna; McNamee, Christine; Norris, Alan; Sanseau, Philippe; Cavalla, David; Pirmohamed, Munir</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-58</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old' drugs to treat both common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked compds., with potentially lower overall development costs and shorter development timelines.  Various data-driven and exptl. approaches have been suggested for the identification of repurposable drug candidates; however, there are also major technol. and regulatory challenges that need to be addressed.  In this Review, we present approaches used for drug repurposing (also known as drug repositioning), discuss the challenges faced by the repurposing community and recommend innovative ways by which these challenges could be addressed to help realize the full potential of drug repurposing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUl_N5c2iDerVg90H21EOLACvtfcHk0lh0CQ-DG3QpzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvV2gtr7I&md5=6bcc8f26828414de02564494fb4d3296</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.168%26sid%3Dliteratum%253Aachs%26aulast%3DPushpakom%26aufirst%3DS.%26aulast%3DIorio%26aufirst%3DF.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26aulast%3DEscott%26aufirst%3DK.%2BJ.%26aulast%3DHopper%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DA.%26aulast%3DDoig%26aufirst%3DA.%26aulast%3DGuilliams%26aufirst%3DT.%26aulast%3DLatimer%26aufirst%3DJ.%26aulast%3DMcNamee%26aufirst%3DC.%26atitle%3DDrug%2520repurposing%253A%2520progress%252C%2520challenges%2520and%2520recommendations%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D41%26epage%3D58%26doi%3D10.1038%2Fnrd.2018.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nowak-Sliwinska, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scapozza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz i Altaba, A.</span></span> <span> </span><span class="NLM_article-title">Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer</span>. <i>Biochim. Biophys. Acta, Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1871</i></span>,  <span class="NLM_fpage">434</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1016/j.bbcan.2019.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.bbcan.2019.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=31034926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFent7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1871&publication_year=2019&pages=434-454&author=P.+Nowak-Sliwinskaauthor=L.+Scapozzaauthor=A.+Ruiz+i+Altaba&title=Drug+repurposing+in+oncology%3A+Compounds%2C+pathways%2C+phenotypes+and+computational+approaches+for+colorectal+cancer&doi=10.1016%2Fj.bbcan.2019.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer</span></div><div class="casAuthors">Nowak-Sliwinska, Patrycja; Scapozza, Leonardo; Altaba, Ariel Ruiz i</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1871</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">434-454</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields.  Such drug repurposing promises faster access of drugs to patients while reducing costs in the long and difficult process of drug development.  However, the no. of existing drugs and diseases, together with the heterogeneity of patients and diseases, notably including cancers, can make repurposing time consuming and inefficient.  The key question we address is how to efficiently repurpose an existing drug to treat a given indication.  As drug efficacy remains the main bottleneck for overall success, we discuss the need for machine-learning computational methods in combination with specific phenotypic studies along with mechanistic studies, chem. genetics and omics assays to successfully predict disease-drug pairs.  Such a pipeline could be particularly important to cancer patients who face heterogeneous, recurrent and metastatic disease and need fast and personalized treatments.  Here we focus on drug repurposing for colorectal cancer and describe selected therapeutics already repositioned for its prevention and/or treatment as well as potential candidates.  We consider this review as a selective compilation of approaches and methodologies, and argue how, taken together, they could bring drug repurposing to the next level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDgG6Bc5SoMLVg90H21EOLACvtfcHk0lj6ah7j7A-RXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFent7o%253D&md5=70957ccf92ba748d6cb564fd1f3de533</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bbcan.2019.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbcan.2019.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DNowak-Sliwinska%26aufirst%3DP.%26aulast%3DScapozza%26aufirst%3DL.%26aulast%3DRuiz%2Bi%2BAltaba%26aufirst%3DA.%26atitle%3DDrug%2520repurposing%2520in%2520oncology%253A%2520Compounds%252C%2520pathways%252C%2520phenotypes%2520and%2520computational%2520approaches%2520for%2520colorectal%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2019%26volume%3D1871%26spage%3D434%26epage%3D454%26doi%3D10.1016%2Fj.bbcan.2019.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jourdan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bureau, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochais, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallemagne, P.</span></span> <span> </span><span class="NLM_article-title">Drug repositioning: a brief overview</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1145</span>– <span class="NLM_lpage">1151</span>, <span class="refDoi"> DOI: 10.1111/jphp.13273</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1111%2Fjphp.13273" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32301512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFynsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=1145-1151&author=J.+P.+Jourdanauthor=R.+Bureauauthor=C.+Rochaisauthor=P.+Dallemagne&title=Drug+repositioning%3A+a+brief+overview&doi=10.1111%2Fjphp.13273"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repositioning: a brief overview</span></div><div class="casAuthors">Jourdan, Jean-Pierre; Bureau, Ronan; Rochais, Christophe; Dallemagne, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1145-1151</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Objectives : Drug repositioning, i.e., the use of a drug in an indication other than the one for which it was initially marketed, is a growing trend.  Its origins lie mainly in the attrition experienced in recent years in the field of new drug discovery.  Key findings : Despite some regulatory and economic challenges, drug repositioning offers many advantages, and a no. of recent successes have confirmed both its public health benefits and its com. value.  The first examples of successful drug repositioning mainly came about through serendipity like acetylsalicylic acid, thalidomide, sildenafil or dimethylfumarate.  Conclusion : The history of great-repositioned drugs has given some solns. to various pathologies.  Serendipity is not yet useful to find repositioning drugs.  Drug repositioning is of growing interest.  Nowadays, a more rational approach to the identification of drug candidates for repositioning is possible, esp. using data mining.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKhYOs_wF60LVg90H21EOLACvtfcHk0lj6ah7j7A-RXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFynsb4%253D&md5=d524624854fda65d7b411afb37638c76</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fjphp.13273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjphp.13273%26sid%3Dliteratum%253Aachs%26aulast%3DJourdan%26aufirst%3DJ.%2BP.%26aulast%3DBureau%26aufirst%3DR.%26aulast%3DRochais%26aufirst%3DC.%26aulast%3DDallemagne%26aufirst%3DP.%26atitle%3DDrug%2520repositioning%253A%2520a%2520brief%2520overview%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2020%26volume%3D72%26spage%3D1145%26epage%3D1151%26doi%3D10.1111%2Fjphp.13273" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desborough, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, D. M.</span></span> <span> </span><span class="NLM_article-title">The aspirin story–from willow to wonder drug</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">674</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.1111/bjh.14520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1111%2Fbjh.14520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=28106908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ns1yruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2017&pages=674-683&author=M.+J.+Desboroughauthor=D.+M.+Keeling&title=The+aspirin+story%E2%80%93from+willow+to+wonder+drug&doi=10.1111%2Fbjh.14520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The aspirin story - from willow to wonder drug</span></div><div class="casAuthors">Desborough Michael J R; Desborough Michael J R; Keeling David M</div><div class="citationInfo"><span class="NLM_cas:title">British journal of haematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">674-683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The story of the discovery of aspirin stretches back more than 3500 years to when bark from the willow tree was used as a pain reliever and antipyretic.  It involves an Oxfordshire clergyman, scientists at a German dye manufacturer, a Nobel Prize-winning discovery and a series of pivotal clinical trials.  Aspirin is now the most commonly used drug in the world.  Its role in preventing cardiovascular and cerebrovascular disease has been revolutionary and one of the biggest pharmaceutical success stories of the last century.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTb-EOs4b09frJzI8owOhpDfW6udTcc2eY4Getc6yTNULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ns1yruw%253D%253D&md5=1fa9f7b773a87120df07e4c7de7ff5cb</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fbjh.14520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.14520%26sid%3Dliteratum%253Aachs%26aulast%3DDesborough%26aufirst%3DM.%2BJ.%26aulast%3DKeeling%26aufirst%3DD.%2BM.%26atitle%3DThe%2520aspirin%2520story%25E2%2580%2593from%2520willow%2520to%2520wonder%2520drug%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2017%26volume%3D177%26spage%3D674%26epage%3D683%26doi%3D10.1111%2Fbjh.14520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montinari, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Caterina, R.</span></span> <span> </span><span class="NLM_article-title">The first 3500 years of aspirin history from its roots–A concise summary</span>. <i>Vasc. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.vph.2018.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.vph.2018.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30391545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ymsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2019&pages=1-8&author=M.+R.+Montinariauthor=S.+Minelliauthor=R.+De+Caterina&title=The+first+3500+years+of+aspirin+history+from+its+roots%E2%80%93A+concise+summary&doi=10.1016%2Fj.vph.2018.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The first 3500 years of aspirin history from its roots - A concise summary</span></div><div class="casAuthors">Montinari, Maria Rosa; Minelli, Sergio; De Caterina, Raffaele</div><div class="citationInfo"><span class="NLM_cas:title">Vascular Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">VPAHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1537-1891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Aspirin is currently the most widely used drug worldwide, and has been clearly one of the most important pharmacol. achievements of the twentieth century.  Historians of medicine have traced its birth in 1897, but the fascinating history of aspirin actually dates back >3500 years, when willow bark was used as a painkiller and antipyretic by Sumerians and Egyptians, and then by great physicians from ancient Greece and Rome.  The modern history of aspirin precursors, salicylates, began in 1763 with Reverend Stone - who first described their antipyretic effects - and continued in the 19th century with many researchers involved in their extn. and chem. synthesis.  Bayer chemist Felix Hoffmann synthesized aspirin in 1897, and 70 years later the pharmacologist John Vane elucidated its mechanism of action in inhibiting prostaglandin prodn.  Originally used as an antipyretic and anti-inflammatory drug, aspirin then became, for its antiplatelet properties, a milestone in preventing cardiovascular and cerebrovascular diseases.  The aspirin story continues today with the growing evidence of its chemopreventive effect against colorectal and other types of cancer, now awaiting the results of ongoing primary prevention trials in this setting.  This concise review revisits the history of aspirin with a focus on its most remote origins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Kfy_hlJnD7Vg90H21EOLACvtfcHk0ljUfIHXsGI5bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ymsL%252FE&md5=e4f1102998af42a5c6851495e9359979</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.vph.2018.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vph.2018.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DMontinari%26aufirst%3DM.%2BR.%26aulast%3DMinelli%26aufirst%3DS.%26aulast%3DDe%2BCaterina%26aufirst%3DR.%26atitle%3DThe%2520first%25203500%2520years%2520of%2520aspirin%2520history%2520from%2520its%2520roots%25E2%2580%2593A%2520concise%2520summary%26jtitle%3DVasc.%2520Pharmacol.%26date%3D2019%26volume%3D113%26spage%3D1%26epage%3D8%26doi%3D10.1016%2Fj.vph.2018.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osterloh, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span> <span> </span><span class="NLM_article-title">Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">702</span>, <span class="refDoi"> DOI: 10.1038/nrd2030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnrd2030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=16883306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFCkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=689-702&author=H.+A.+Ghofraniauthor=I.+H.+Osterlohauthor=F.+Grimminger&title=Sildenafil%3A+from+angina+to+erectile+dysfunction+to+pulmonary+hypertension+and+beyond&doi=10.1038%2Fnrd2030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond</span></div><div class="casAuthors">Ghofrani, Hossein A.; Osterloh, Ian H.; Grimminger, Friedrich</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">689-702</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In less than 20 years, the first selective type 5 phosphodiesterase inhibitor, sildenafil, has evolved from a potential anti-angina drug to an on-demand oral treatment for erectile dysfunction (Viagra), and more recently to a new orally active treatment for pulmonary hypertension (Revatio).  Here we describe the key milestones in the development of sildenafil for these diverse medical conditions, discuss the advances in science and clin. medicine that have accompanied this journey and consider possible future indications for this versatile drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0RYuF_xCiO7Vg90H21EOLACvtfcHk0ljUfIHXsGI5bA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFCkuro%253D&md5=efe63ba98a0914f1a9e4a0b9257cfeba</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrd2030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2030%26sid%3Dliteratum%253Aachs%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DOsterloh%26aufirst%3DI.%2BH.%26aulast%3DGrimminger%26aufirst%3DF.%26atitle%3DSildenafil%253A%2520from%2520angina%2520to%2520erectile%2520dysfunction%2520to%2520pulmonary%2520hypertension%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D689%26epage%3D702%26doi%3D10.1038%2Fnrd2030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">World Health Organization</span>. World
Health Organization Model List of Essential Medicines: 21st list 2019. <span class="NLM_publisher-name">World Health Organization</span>. <a href="https://apps.who.int/iris/handle/10665/325771" class="extLink">https://apps.who.int/iris/handle/10665/325771</a>. License: CC BY-NC-SA 3.0 IGO, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=World+Health+Organization.+World%0AHealth+Organization+Model+List+of+Essential+Medicines%3A+21st+list+2019.+World+Health+Organization.+https%3A%2F%2Fapps.who.int%2Firis%2Fhandle%2F10665%2F325771.+License%3A+CC+BY-NC-SA+3.0+IGO%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26pub%3DWorld%2520Health%2520Organization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domino, E. F.</span></span> <span> </span><span class="NLM_article-title">Taming the ketamine tiger</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">678</span>– <span class="NLM_lpage">684</span>, <span class="refDoi"> DOI: 10.1097/ALN.0b013e3181ed09a2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2FALN.0b013e3181ed09a2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=20693870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC3cjnslSjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2010&pages=678-684&author=E.+F.+Domino&title=Taming+the+ketamine+tiger&doi=10.1097%2FALN.0b013e3181ed09a2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Taming the ketamine tiger. 1965</span></div><div class="casAuthors">Domino Edward F</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">678-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Pharmacologic actions of CI-581, a chemical derivative of phencyclidine, were determined in 20 volunteers from a prison population.  The results indicate that this drug is an effective analgesic and anesthetic agent in doses of 1.0 to 2.0 mg per kilogram.  With intravenous administration the onset of action is within 1 min and the effects last for about 5 to 10 min, depending on dosage level and individual variation.  No tachyphylaxis was evident on repeat doses.  Respiratory depression was slight and transient.  Hypertension, tachycardia, and psychic changes are undesirable characteristics of the drug.  Whether these can be modified by preanesthetic medication was not determined in this study.  Recovery from analgesia and coma usually took place within 10 min, although from electroencephalographic evidence it may be assumed that subjects were not completely normal until after 1 to 2 h.  No evidence of liver or kidney toxicity was obtained.  CI-581 produces pharmacologic effects similar to those reported for phencyclidine, but of shorter duration.  The drug deserves further pharmacologic and clinical trials.  It is proposed that the words "dissociative anesthetic" be used to describe the mental state produced by this drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTrRg8-SzzmV0PI-fCgwosgfW6udTcc2ebu-IF9s2WOLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjnslSjtQ%253D%253D&md5=e037b14d9d90569965b2ff687f13dc47</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1097%2FALN.0b013e3181ed09a2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FALN.0b013e3181ed09a2%26sid%3Dliteratum%253Aachs%26aulast%3DDomino%26aufirst%3DE.%2BF.%26atitle%3DTaming%2520the%2520ketamine%2520tiger%26jtitle%3DAnesthesiology%26date%3D2010%26volume%3D113%26spage%3D678%26epage%3D684%26doi%3D10.1097%2FALN.0b013e3181ed09a2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domino, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chodoff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corssen, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic effects of CI-581, a new dissociative anesthetic, in man</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1002/cpt196563279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1002%2Fcpt196563279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=14296024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADyaF2M7gtVKgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1965&pages=279-291&author=E.+F.+Dominoauthor=P.+Chodoffauthor=G.+Corssen&title=Pharmacologic+effects+of+CI-581%2C+a+new+dissociative+anesthetic%2C+in+man&doi=10.1002%2Fcpt196563279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">PHARMACOLOGIC EFFECTS OF CI-581, A NEW DISSOCIATIVE ANESTHETIC, IN MAN</span></div><div class="casAuthors">DOMINO E F; CHODOFF P; CORSSEN G</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">279-91</span>
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuQWQYmYA2eX6HPRus0rAafW6udTcc2eaKSLoscHCTn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF2M7gtVKgsw%253D%253D&md5=664315adbde3f2f7c64edcc5388ac28e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fcpt196563279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt196563279%26sid%3Dliteratum%253Aachs%26aulast%3DDomino%26aufirst%3DE.%2BF.%26aulast%3DChodoff%26aufirst%3DP.%26aulast%3DCorssen%26aufirst%3DG.%26atitle%3DPharmacologic%2520effects%2520of%2520CI-581%252C%2520a%2520new%2520dissociative%2520anesthetic%252C%2520in%2520man%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D1965%26volume%3D6%26spage%3D279%26epage%3D291%26doi%3D10.1002%2Fcpt196563279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corssen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domino, E. F.</span></span> <span> </span><span class="NLM_article-title">Dissociative anesthesia: Further pharmacologic studies and first clinical experience with the phencyclidine derivative Cl-581</span>. <i>Anesth. Analg.</i> <span class="NLM_year" style="font-weight: bold;">1966</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">40</span>, <span class="refDoi"> DOI: 10.1213/00000539-196601000-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1213%2F00000539-196601000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=5325977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaF28XhtVyntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=1966&pages=29-40&author=G.+Corssenauthor=E.+F.+Domino&title=Dissociative+anesthesia%3A+Further+pharmacologic+studies+and+first+clinical+experience+with+the+phencyclidine+derivative+Cl-581&doi=10.1213%2F00000539-196601000-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative, CI-581</span></div><div class="casAuthors">Corssen, Guenter; Domino, Edward F.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia & Analgesia (Hagerstown, MD, United States)</span>
        (<span class="NLM_cas:date">1966</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-40</span>CODEN:
                <span class="NLM_cas:coden">AACRAT</span>;
        ISSN:<span class="NLM_cas:issn">0003-2999</span>.
    </div><div class="casAbstract">I.v. 2-(O-chlorophenyl)-2-methylaminocyclohexanone-HCl (CI-581) produced profound analgesia assocd. with a peculiar state of altered consciousness.  Respiratory function was transiently reduced at the onset of anesthesia and returned to normal within 1-3 min.  In adults, i.v. administration sometime elevated both systolic and diastolic blood pressures to undesirable levels.  CI-581 had no discernible toxic effects on humans.  CI-581 is a potent anesthetic agent with a fast onset of action and limited duration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9J6zoN-HzwLVg90H21EOLACvtfcHk0liQTMrcFefSow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF28XhtVyntr8%253D&md5=a6db146429a940227efb723faff63af4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1213%2F00000539-196601000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1213%252F00000539-196601000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DCorssen%26aufirst%3DG.%26aulast%3DDomino%26aufirst%3DE.%2BF.%26atitle%3DDissociative%2520anesthesia%253A%2520Further%2520pharmacologic%2520studies%2520and%2520first%2520clinical%2520experience%2520with%2520the%2520phencyclidine%2520derivative%2520Cl-581%26jtitle%3DAnesth.%2520Analg.%26date%3D1966%26volume%3D45%26spage%3D29%26epage%3D40%26doi%3D10.1213%2F00000539-196601000-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, J. R.</span>; <span class="NLM_string-name">Hedges, J. R.</span></span> <i>Roberts and Hedges’ Clinical Procedures in Emergency Medicine E-Book</i>; <span class="NLM_publisher-name">Elsevier Health Sciences</span>: <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+R.+Roberts&author=J.+R.+Hedges&title=Roberts+and+Hedges%E2%80%99+Clinical+Procedures+in+Emergency+Medicine+E-Book"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DJ.%2BR.%26btitle%3DRoberts%2520and%2520Hedges%25E2%2580%2599%2520Clinical%2520Procedures%2520in%2520Emergency%2520Medicine%2520E-Book%26pub%3DElsevier%2520Health%2520Sciences%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Way, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevor, a. J.</span></span> <span> </span><span class="NLM_article-title">Ketamine—its pharmacology and therapeutic uses</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1097/00000542-198202000-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2F00000542-198202000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=6892475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaL38XhsleltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1982&pages=119-136&author=P.+F.+Whiteauthor=W.+L.+Wayauthor=a.+J.+Trevor&title=Ketamine%E2%80%94its+pharmacology+and+therapeutic+uses&doi=10.1097%2F00000542-198202000-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine - its pharmacology and therapeutic uses</span></div><div class="casAuthors">White, Paul F.; Way, Walter L.; Trevor, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-36</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    </div><div class="casAbstract">A review with 255 refs. of the pharmacol. of ketamine (I)  [6740-88-1].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr53dU39Epv97Vg90H21EOLACvtfcHk0liQTMrcFefSow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XhsleltL4%253D&md5=969f9a0021526ce2975b06549d899a86</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1097%2F00000542-198202000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-198202000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DP.%2BF.%26aulast%3DWay%26aufirst%3DW.%2BL.%26aulast%3DTrevor%26aufirst%3Da.%2BJ.%26atitle%3DKetamine%25E2%2580%2594its%2520pharmacology%2520and%2520therapeutic%2520uses%26jtitle%3DAnesthesiology%26date%3D1982%26volume%3D56%26spage%3D119%26epage%3D136%26doi%3D10.1097%2F00000542-198202000-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">A historical review of antidepressant effects of ketamine and its enantiomers</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">172870</span>, <span class="refDoi"> DOI: 10.1016/j.pbb.2020.172870</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.pbb.2020.172870" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32035078" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsVOlt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=172870&author=Y.+Weiauthor=L.+Changauthor=K.+Hashimoto&title=A+historical+review+of+antidepressant+effects+of+ketamine+and+its+enantiomers&doi=10.1016%2Fj.pbb.2020.172870"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A historical review of antidepressant effects of ketamine and its enantiomers</span></div><div class="casAuthors">Wei, Yan; Chang, Lijia; Hashimoto, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">172870</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The robust antidepressant effects of (R,S)-ketamine are among the most important discoveries in mood research over the last half century.  Off-label use of (R,S)-ketamine, which is an equal mixt. of (R)-ketamine and (S)-ketamine, has become esp. popular in the United States (US) for treatment-resistant depression.  On March 5, 2019, the US Food and Drug Administration approved an (S)-ketamine nasal spray for use in treatment-resistant depression, though its use has been limited to certified medical offices or clinics.  On Dec. 19, 2019, (S)-ketamine nasal spray was approved for the same indication in Europe.  However, despite its potential for benefit, there are several concerns about the efficacy of (S)-ketamine nasal spray.  Accumulating evidence from preclin. studies show that (R)-ketamine has greater potency and longer lasting antidepressant effects than (S)-ketamine in animal models of depression, and that (R)-ketamine has fewer detrimental side effects than either (R,S)-ketamine or (S)-ketamine.  As such, clin. studies of (R)-ketamine in humans are now underway by Perception Neuroscience Ltd.  In this article, we review the brief history of (R,S)-ketamine and its two enantiomers as novel antidepressants.  We also discuss the mechanisms of ketamine's antidepressant actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKVy8HLcOtC7Vg90H21EOLACvtfcHk0lj5KkSbPhYYHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsVOlt74%253D&md5=d9988745234ff150632b74708e6cdb79</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2020.172870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2020.172870%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DA%2520historical%2520review%2520of%2520antidepressant%2520effects%2520of%2520ketamine%2520and%2520its%2520enantiomers%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2020%26volume%3D190%26spage%3D172870%26doi%3D10.1016%2Fj.pbb.2020.172870" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmotsu, O.</span></span> <span> </span><span class="NLM_article-title">Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor?</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">704</span>– <span class="NLM_lpage">710</span>, <span class="refDoi"> DOI: 10.1097/00000542-199004000-00021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2F00000542-199004000-00021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1969718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK3cXitFSru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1990&pages=704-710&author=T.+Yamamuraauthor=K.+Haradaauthor=A.+Okamuraauthor=O.+Kemmotsu&title=Is+the+site+of+action+of+ketamine+anesthesia+the+N-methyl-D-aspartate+receptor%3F&doi=10.1097%2F00000542-199004000-00021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Is the site of action of ketamine anesthesia the N-methyl-D-aspartate receptor?</span></div><div class="casAuthors">Yamamura, Takeyasu; Harada, Kohji; Okamura, Atsushi; Kemmotsu, Osamu</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">704-10</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    </div><div class="casAbstract">Synaptic mechanisms underlying ketamine anesthesia were studied using in vitro prepns. of the lamprey CNS.  Axonal conduction, transmitter release from the presynaptic terminal, postsynaptic response to the putative neurotransmitters, and resting and activated membrane properties were studied in the absence and the presence of various concns. of ketamine.  Ketamine markedly reduced N-methyl-D-aspartate (NMDA)-activated responses, such as depolarizations to bath-applied NMDA and bursting rhythm during "fictive locomotion.".  The 50% block of the responses took place in the presence of 10-20 μM ketamine, whereas those induced by kainate and quisqualate (the other two subclasses of L-glutamate/L-aspartate agonists) were spared at concns. > 600-800 μM.  None of the other neuronal events tested were suppressed in the presence of still higher concns. of ketamine.  The results support the hypothesis that ketamine might exert its anesthetic effect by a pharmacol. specific interaction with the NMDA receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgbDmPsofTYbVg90H21EOLACvtfcHk0lj5KkSbPhYYHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXitFSru7Y%253D&md5=97405a4571126a128e31f76c2e4ea8fa</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1097%2F00000542-199004000-00021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-199004000-00021%26sid%3Dliteratum%253Aachs%26aulast%3DYamamura%26aufirst%3DT.%26aulast%3DHarada%26aufirst%3DK.%26aulast%3DOkamura%26aufirst%3DA.%26aulast%3DKemmotsu%26aufirst%3DO.%26atitle%3DIs%2520the%2520site%2520of%2520action%2520of%2520ketamine%2520anesthesia%2520the%2520N-methyl-D-aspartate%2520receptor%253F%26jtitle%3DAnesthesiology%26date%3D1990%26volume%3D72%26spage%3D704%26epage%3D710%26doi%3D10.1097%2F00000542-199004000-00021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, D.</span></span> <span> </span><span class="NLM_article-title">The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1983.tb11031.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1111%2Fj.1476-5381.1983.tb11031.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=6317114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaL3sXkvF2itbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1983&pages=565-575&author=N.+Anisauthor=S.+Berryauthor=N.+Burtonauthor=D.+Lodge&title=The+dissociative+anaesthetics%2C+ketamine+and+phencyclidine%2C+selectively+reduce+excitation+of+central+mammalian+neurones+by+N-methyl-aspartate&doi=10.1111%2Fj.1476-5381.1983.tb11031.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The dissociative anesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate</span></div><div class="casAuthors">Anis, N. A.; Berry, S. C.; Burton, N. R.; Lodge, D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">565-75</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">The interaction of 2 dissociative anesthetics, ketamine (I)  [6740-88-1] and phencyclidine (II)  [77-10-1], with the responses of spinal neurons to the electrophoretic administration of amino acids and acetylcholine  [51-84-3] was studied in decerebrate or pentobarbitone-anesthetized cats and rats.  Both ketamine and phencyclidine selectively blocked excitation by N-methyl-D-aspartate (NMA)  [6384-92-5], with little effect on excitation by quisqualate  [52809-07-1] or kainate  [487-79-6].  Ketamine reduced responses to L-aspartate  [56-84-8] somewhat more than those to L-glutamate  [56-86-0]; the sensitivity of responses to these 2 putative transmitters was between that to NMA on one hand and that to quisqualate or kainate on the other.  In Renshaw cells, ketamine and phencyclidine reduced responses to acetylcholine less than those to NMA, but more than those to quisqualate or kainate.  Dorsal root-evoked synaptic excitation of Renshaw cells was reduced to a greater extent than that following ventral root excitation.  I.v. ketamine, 2.5-20 mg/kg, and phencyclidine, 0.2-0.5 mg/kg, also selectively blocked excitation of neurons by NMA.  Ketamine showed no consistent or selective effect on inhibition of spinal neurons by electrophoretically administered glycine  [56-40-6] or γ-aminobutyric acid (GABA)  [56-12-2].  The results suggest that redn. of synaptic excitation mediated via NMA receptors contributes to the anesthetic analgesic properties of these 2 dissociative anesthetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp29LbcqvL2YLVg90H21EOLACvtfcHk0lj5KkSbPhYYHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXkvF2itbw%253D&md5=6465c36de28c2096ef223618ef09fe8c</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1983.tb11031.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1983.tb11031.x%26sid%3Dliteratum%253Aachs%26aulast%3DAnis%26aufirst%3DN.%26aulast%3DBerry%26aufirst%3DS.%26aulast%3DBurton%26aufirst%3DN.%26aulast%3DLodge%26aufirst%3DD.%26atitle%3DThe%2520dissociative%2520anaesthetics%252C%2520ketamine%2520and%2520phencyclidine%252C%2520selectively%2520reduce%2520excitation%2520of%2520central%2520mammalian%2520neurones%2520by%2520N-methyl-aspartate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1983%26volume%3D79%26spage%3D565%26epage%3D575%26doi%3D10.1111%2Fj.1476-5381.1983.tb11031.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, K. B.</span>; <span class="NLM_string-name">Yi, F.</span>; <span class="NLM_string-name">Perszyk, R. E.</span>; <span class="NLM_string-name">Menniti, F. S.</span>; <span class="NLM_string-name">Traynelis, S. F.</span></span> <span> </span><span class="NLM_article-title">NMDA Receptors in the Central Nervous System</span>. In  <i>NMDA Receptors</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnashev, N.</span>, <span class="NLM_string-name">Szepetowski, P.</span></span>, Eds.; <span class="NLM_series">Methods in Molecular Biology</span>; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">1677</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2F978-1-4939-7321-7_1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.+B.+Hansen&author=F.+Yi&author=R.+E.+Perszyk&author=F.+S.+Menniti&author=S.+F.+Traynelisauthor=N.+Burnashev&author=P.+Szepetowski&title=NMDA+Receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-7321-7_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-7321-7_1%26sid%3Dliteratum%253Aachs%26aulast%3DHansen%26aufirst%3DK.%2BB.%26atitle%3DNMDA%2520Receptors%2520in%2520the%2520Central%2520Nervous%2520System%26btitle%3DNMDA%2520Receptors%26aulast%3DBurnashev%26aufirst%3DN.%26pub%3DHumana%2520Press%26date%3D2017%26volume%3D1677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moaddel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riggs, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Highland, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albuquerque, E. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, T. D.</span></span> <span> </span><span class="NLM_article-title">Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">621</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1124/pr.117.015198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1124%2Fpr.117.015198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29945898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkvVKnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2018&pages=621-660&author=P.+Zanosauthor=R.+Moaddelauthor=P.+J.+Morrisauthor=L.+M.+Riggsauthor=J.+N.+Highlandauthor=P.+Georgiouauthor=E.+F.+Pereiraauthor=E.+X.+Albuquerqueauthor=C.+J.+Thomasauthor=C.+A.+Zarateauthor=T.+D.+Gould&title=Ketamine+and+ketamine+metabolite+pharmacology%3A+insights+into+therapeutic+mechanisms&doi=10.1124%2Fpr.117.015198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms</span></div><div class="casAuthors">Zanos, Panos; Moaddel, Ruin; Morris, Patrick J.; Riggs, Lace M.; Highland, Jaclyn N.; Georgiou, Polymnia; Pereira, Edna F. R.; Albuquerque, Edson X.; Thomas, Craig J.; Zarate, Carlos A.; Gould, Todd D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">621-660</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Ketamine, a racemic mixt. consisting of (S)- and (R)-ketamine, has been in clin. use since 1970.  Although best characterized for its dissociative anesthetic properties, ketamine also exerts analgesic, anti-inflammatory, and antidepressant actions.  We provide a comprehensive review of these therapeutic uses, emphasizing drug dose, route of administration, and the time course of these effects.  Dissociative, psychotomimetic, cognitive, and peripheral side effects assocd. with short-term or prolonged exposure, as well as recreational ketamine use, are also discussed.  We further describe ketamine's pharmacokinetics, including its rapid and extensive metab. to norketamine, dehydronorketamine, hydroxyketamine, and hydroxynorketamine (HNK) metabolites.  Whereas the anesthetic and analgesic properties of ketamine are generally attributed to direct ketamine-induced inhibition of N-methyl-D-aspartate receptors, other putative lower-affinity pharmacol. targets of ketamine include, but are not limited to, γ-amynobutyric acid (GABA), dopamine, serotonin, sigma, opioid, and cholinergic receptors, as well as voltage-gated sodium and hyperpolarization-activated cyclic nucleotide-gated channels.  We examine the evidence supporting the relevance of these targets of ketamine and its metabolites to the clin. effects of the drug.  Ketamine metabolites may have broader clin. relevance than was previously considered, given that HNK metabolites have antidepressant efficacy in preclin. studies.  Overall, pharmacol. target deconvolution of ketamine and its metabolites will provide insight crit. to the development of new pharmacotherapies that possess the desirable clin. effects of ketamine, but limit undesirable side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYhDD-d6NivLVg90H21EOLACvtfcHk0li-JpTUO-o4nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkvVKnsbo%253D&md5=b7a464be9a74eeead29c6fe3eecf115d</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1124%2Fpr.117.015198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.117.015198%26sid%3Dliteratum%253Aachs%26aulast%3DZanos%26aufirst%3DP.%26aulast%3DMoaddel%26aufirst%3DR.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26aulast%3DRiggs%26aufirst%3DL.%2BM.%26aulast%3DHighland%26aufirst%3DJ.%2BN.%26aulast%3DGeorgiou%26aufirst%3DP.%26aulast%3DPereira%26aufirst%3DE.%2BF.%26aulast%3DAlbuquerque%26aufirst%3DE.%2BX.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DGould%26aufirst%3DT.%2BD.%26atitle%3DKetamine%2520and%2520ketamine%2520metabolite%2520pharmacology%253A%2520insights%2520into%2520therapeutic%2520mechanisms%26jtitle%3DPharmacol.%2520Rev.%26date%3D2018%26volume%3D70%26spage%3D621%26epage%3D660%26doi%3D10.1124%2Fpr.117.015198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lü, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goehring, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM structures of the triheteromeric NMDA receptor and its allosteric modulation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">eaal3729</span>, <span class="refDoi"> DOI: 10.1126/science.aal3729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1126%2Fscience.aal3729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=28232581" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2017&pages=eaal3729&author=W.+L%C3%BCauthor=J.+Duauthor=A.+Goehringauthor=E.+Gouaux&title=Cryo-EM+structures+of+the+triheteromeric+NMDA+receptor+and+its+allosteric+modulation&doi=10.1126%2Fscience.aal3729"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1126%2Fscience.aal3729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aal3729%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25BC%26aufirst%3DW.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DGoehring%26aufirst%3DA.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DCryo-EM%2520structures%2520of%2520the%2520triheteromeric%2520NMDA%2520receptor%2520and%2520its%2520allosteric%2520modulation%26jtitle%3DScience%26date%3D2017%26volume%3D355%26spage%3Deaal3729%26doi%3D10.1126%2Fscience.aal3729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, M. Ø.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jogini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mchaourab, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouaux, E.</span></span> <span> </span><span class="NLM_article-title">Mechanism of NMDA receptor channel block by MK-801 and memantine</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>556</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">519</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0039-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fs41586-018-0039-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29670280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=556&publication_year=2018&pages=515-519&author=X.+Songauthor=M.+%C3%98.+Jensenauthor=V.+Joginiauthor=R.+A.+Steinauthor=C.-H.+Leeauthor=H.+S.+Mchaourabauthor=D.+E.+Shawauthor=E.+Gouaux&title=Mechanism+of+NMDA+receptor+channel+block+by+MK-801+and+memantine&doi=10.1038%2Fs41586-018-0039-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of NMDA receptor channel block by MK-801 and memantine</span></div><div class="casAuthors">Song, Xianqiang; Jensen, Morten Oe.; Jogini, Vishwanath; Stein, Richard A.; Lee, Chia-Hsueh; Mchaourab, Hassane S.; Shaw, David E.; Gouaux, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">556</span>
        (<span class="NLM_cas:issue">7702</span>),
    <span class="NLM_cas:pages">515-519</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The NMDA (N-methyl-D-aspartate) receptor transduces the binding of glutamate and glycine, coupling it to the opening of a Ca2+-permeable ion channel.  Owing to the lack of high-resoln. structural studies of the NMDA receptor, the mechanism by which ion-channel blockers occlude ion permeation is not well understood.  Here, we show that removal of the N-terminal domains from the GluN1-GluN2B NMDA receptor yields a functional receptor and crystals with good diffraction properties, allowing us to map the binding site of NMDA receptor blocker MK-801.  This crystal structure, together with long-timescale mol. dynamics simulations, shows how MK-801 and memantine (a drug approved for the treatment of Alzheimer's disease) bind within the vestibule of the ion channel, promote closure of the ion channel gate and lodge between the M3-helix-bundle crossing and the M2-pore loops, phys. blocking ion permeation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoObAwT_zZL77Vg90H21EOLACvtfcHk0li-JpTUO-o4nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgurs%253D&md5=999ad75bd573b0120b425b9fd451b5ae</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0039-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0039-9%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DX.%26aulast%3DJensen%26aufirst%3DM.%2B%25C3%2598.%26aulast%3DJogini%26aufirst%3DV.%26aulast%3DStein%26aufirst%3DR.%2BA.%26aulast%3DLee%26aufirst%3DC.-H.%26aulast%3DMchaourab%26aufirst%3DH.%2BS.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DGouaux%26aufirst%3DE.%26atitle%3DMechanism%2520of%2520NMDA%2520receptor%2520channel%2520block%2520by%2520MK-801%2520and%2520memantine%26jtitle%3DNature%26date%3D2018%26volume%3D556%26spage%3D515%26epage%3D519%26doi%3D10.1038%2Fs41586-018-0039-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kotermanski, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. W.</span></span> <span> </span><span class="NLM_article-title">Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer’s drug memantine</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2774</span>– <span class="NLM_lpage">2779</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.3703-08.2009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1523%2FJNEUROSCI.3703-08.2009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=19261873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1Wmurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=2774-2779&author=S.+E.+Kotermanskiauthor=J.+W.+Johnson&title=Mg2%2B+imparts+NMDA+receptor+subtype+selectivity+to+the+Alzheimer%E2%80%99s+drug+memantine&doi=10.1523%2FJNEUROSCI.3703-08.2009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine</span></div><div class="casAuthors">Kotermanski, Shawn E.; Johnson, Jon W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2774-2779</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">N-Methyl-D-aspartate receptors (NMDARs) mediate interneuronal communication and are broadly involved in nervous system physiol. and pathol. (Dingledine et al., 1999).  Memantine, a drug that blocks the ion channel formed by NMDARs, is a widely prescribed treatment of Alzheimer's disease (Schmitt, 2005; Lipton, 2006; Parsons et al., 2007).  Research on memantine's mechanism of action has focused on the NMDAR subtypes most highly expressed in adult cerebral cortex, NR1/2A and NR1/2B receptors (Cull-Candy and Leszkiewicz, 2004), and has largely ignored interactions with extracellular Mg2+ (Mg2+o).  Mg2+o is an endogenous NMDAR channel blocker that binds near memantine's binding site (Kashiwagi et al., 2002; Chen and Lipton, 2005).  We report that a physiol. concn. (1 mM) of Mg2+o decreased memantine inhibition of NR1/2A and NR1/2B receptors nearly 20-fold at a membrane voltage near rest.  In contrast, memantine inhibition of the other principal NMDAR subtypes, NR1/2C and NR1/2D receptors, was decreased only ∼3-fold.  As a result, therapeutic memantine concns. should have negligible effects on NR1/2A or NR1/2B receptor activity but pronounced effects on NR1/2C and NR1/2D receptors.  Quant. modeling showed that the voltage dependence of memantine inhibition also is altered by 1 mM Mg2+o.  We report similar results with the NMDAR channel blocker ketamine, a drug used to model schizophrenia (Krystal et al., 2003).  These results suggest that currently hypothesized mechanisms of memantine and ketamine action should be reconsidered and that NR1/2C and/or NR1/2D receptors play a more important role in cortical physiol. and pathol. than previously appreciated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzuamppfCmt7Vg90H21EOLACvtfcHk0li-JpTUO-o4nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1Wmurc%253D&md5=a89ad44a47ec6d46992814cc130c99d6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3703-08.2009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3703-08.2009%26sid%3Dliteratum%253Aachs%26aulast%3DKotermanski%26aufirst%3DS.%2BE.%26aulast%3DJohnson%26aufirst%3DJ.%2BW.%26atitle%3DMg2%252B%2520imparts%2520NMDA%2520receptor%2520subtype%2520selectivity%2520to%2520the%2520Alzheimer%25E2%2580%2599s%2520drug%2520memantine%26jtitle%3DJ.%2520Neurosci.%26date%3D2009%26volume%3D29%26spage%3D2774%26epage%3D2779%26doi%3D10.1523%2FJNEUROSCI.3703-08.2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dravid, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erreger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyuboslavsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almonte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>581</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1113/jphysiol.2006.124958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1113%2Fjphysiol.2006.124958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=17303642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD2s3ovVyguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=581&publication_year=2007&pages=107-128&author=S.+M.+Dravidauthor=K.+Erregerauthor=H.+Yuanauthor=K.+Nicholsonauthor=P.+Leauthor=P.+Lyuboslavskyauthor=A.+Almonteauthor=E.+Murrayauthor=C.+Mosleyauthor=J.+Barber&title=Subunit-specific+mechanisms+and+proton+sensitivity+of+NMDA+receptor+channel+block&doi=10.1113%2Fjphysiol.2006.124958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block</span></div><div class="casAuthors">Dravid Shashank M; Erreger Kevin; Yuan Hongjie; Nicholson Katherine; Le Phuong; Lyuboslavsky Polina; Almonte Antoine; Murray Ernest; Mosely Cara; Barber Jeremy; French Adam; Balster Robert; Murray Thomas F; Traynelis Stephen F</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of physiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">581</span>
        (<span class="NLM_cas:issue">Pt 1</span>),
    <span class="NLM_cas:pages">107-28</span>
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    </div><div class="casAbstract">We have compared the potencies of structurally distinct channel blockers at recombinant NR1/NR2A, NR1/NR2B, NR1/NR2C and NR1/NR2D receptors.  The IC50 values varied with stereochemistry and subunit composition, suggesting that it may be possible to design subunit-selective channel blockers.  For dizocilpine (MK-801), the differential potency of MK-801 stereoisomers determined at recombinant NMDA receptors was confirmed at native receptors in vitro and in vivo.  Since the proton sensor is tightly linked both structurally and functionally to channel gating, we examined whether blocking molecules that interact in the channel pore with the gating machinery can differentially sense protonation of the receptor.  Blockers capable of remaining trapped in the pore during agonist unbinding showed the strongest dependence on extracellular pH, appearing more potent at acidic pH values that promote channel closure.  Determination of pK(a) values for channel blockers suggests that the ionization of ketamine but not of other blockers can influence its pH-dependent potency.  Kinetic modelling and single channel studies suggest that the pH-dependent block of NR1/NR2A by (-)MK-801 but not (+)MK-801 reflects an increase in the MK-801 association rate even though protons reduce channel open probability and thus MK-801 access to its binding site.  Allosteric modulators that alter pH sensitivity alter the potency of MK-801, supporting the interpretation that the pH sensitivity of MK-801 binding reflects the changes at the proton sensor rather than a secondary effect of pH.  These data suggest a tight coupling between the proton sensor and the ion channel gate as well as unique subunit-specific mechanisms of channel block.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcStu9_z3ViyDvIW7hznt0zpfW6udTcc2eYVa5AHh5kiurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s3ovVyguw%253D%253D&md5=925d12d73740bf616173011163f9945b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.2006.124958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.2006.124958%26sid%3Dliteratum%253Aachs%26aulast%3DDravid%26aufirst%3DS.%2BM.%26aulast%3DErreger%26aufirst%3DK.%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DNicholson%26aufirst%3DK.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DLyuboslavsky%26aufirst%3DP.%26aulast%3DAlmonte%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DE.%26aulast%3DMosley%26aufirst%3DC.%26aulast%3DBarber%26aufirst%3DJ.%26atitle%3DSubunit-specific%2520mechanisms%2520and%2520proton%2520sensitivity%2520of%2520NMDA%2520receptor%2520channel%2520block%26jtitle%3DJ.%2520Physiol.%26date%3D2007%26volume%3D581%26spage%3D107%26epage%3D128%26doi%3D10.1113%2Fjphysiol.2006.124958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamakura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, M.</span></span> <span> </span><span class="NLM_article-title">Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists</span>. <i>NeuroReport</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">687</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1097/00001756-199306000-00021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2F00001756-199306000-00021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=8347808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK3sXlslCjsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1993&pages=687-690&author=T.+Yamakuraauthor=H.+Moriauthor=H.+Masakiauthor=K.+Shimojiauthor=M.+Mishina&title=Different+sensitivities+of+NMDA+receptor+channel+subtypes+to+non-competitive+antagonists&doi=10.1097%2F00001756-199306000-00021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists</span></div><div class="casAuthors">Yamakura, Tomohiro; Mori, Hisashi; Masaki, Hisashi; Shimoji, Koki; Mishina, Masayoshi</div><div class="citationInfo"><span class="NLM_cas:title">NeuroReport</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">687-90</span>CODEN:
                <span class="NLM_cas:coden">NERPEZ</span>;
        ISSN:<span class="NLM_cas:issn">0959-4965</span>.
    </div><div class="casAbstract">Four kinds of heteromeric N-methyl-D-aspartate (NMDA) receptor channels, the ε1/ζ1, ε2/ζ1, ε3/ζ1 and ε4/ζ1 channels, were expressed in Xenopus oocytes and their sensitivities to various non-competitive antagonists were examd.  The ε1/ζ1 and ε2/ζ1 channels were more sensitive to (+)MK-801 (dizocilpine) than the ε3/ζ1 and ε4/ζ1 channels, whereas the sensitivities to phencyclidine (PCP), ketamine and N-allylnormetazocine (SKF-10,047) were only slightly variable among the four ε/ζ channels.  Furthermore, the replacement by glutamine or arginine of the conserved asparagine residue in segment M2 of the ε2 and ζ1 NMDA receptor channel subunits reduced the sensitivities to PCP, ketamine and SKF-10,047, though to different extents.  These results, together with previous findings, suggest that these non-competitive antagonists as well as (+)MK-801 and Mg2+ act on a common site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxjm7lee0_SrVg90H21EOLACvtfcHk0lj7OE_fzrX3dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlslCjsb0%253D&md5=dd0c9e2a34022b418ef601d3146ac9f3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1097%2F00001756-199306000-00021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001756-199306000-00021%26sid%3Dliteratum%253Aachs%26aulast%3DYamakura%26aufirst%3DT.%26aulast%3DMori%26aufirst%3DH.%26aulast%3DMasaki%26aufirst%3DH.%26aulast%3DShimoji%26aufirst%3DK.%26aulast%3DMishina%26aufirst%3DM.%26atitle%3DDifferent%2520sensitivities%2520of%2520NMDA%2520receptor%2520channel%2520subtypes%2520to%2520non-competitive%2520antagonists%26jtitle%3DNeuroReport%26date%3D1993%26volume%3D4%26spage%3D687%26epage%3D690%26doi%3D10.1097%2F00001756-199306000-00021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hansch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Björkroth, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, A.</span></span> <span> </span><span class="NLM_article-title">Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">663</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1002/jps.2600760902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1002%2Fjps.2600760902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=11002801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaL2sXmt1yhur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1987&pages=663-687&author=C.+Hanschauthor=J.+Bj%C3%B6rkrothauthor=A.+Leo&title=Hydrophobicity+and+central+nervous+system+agents%3A+on+the+principle+of+minimal+hydrophobicity+in+drug+design&doi=10.1002%2Fjps.2600760902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Hydrophobicity and central nervous system agents:  on the principle of minimal hydrophobicity in drug design</span></div><div class="casAuthors">Hansch, Corwin; Bjoerkroth, J. P.; Leo, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">663-87</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    </div><div class="casAbstract">A review with 110 refs. of hydrophobicity of central nervous system drugs in relation to their desired or undesired penetration through the blood-brain barrier.  A method is presented for detn. of optimal drug hydrophobicity and lipophilicity based on evaluation of the partition coeffs. on the octanol-water hydrophobic scale.  A large no. of drugs are evaluated as examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvoksnH-zmbrVg90H21EOLACvtfcHk0lj7OE_fzrX3dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXmt1yhur0%253D&md5=601e31e52a18871eac3e95bb264f21bf</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fjps.2600760902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.2600760902%26sid%3Dliteratum%253Aachs%26aulast%3DHansch%26aufirst%3DC.%26aulast%3DBj%25C3%25B6rkroth%26aufirst%3DJ.%26aulast%3DLeo%26aufirst%3DA.%26atitle%3DHydrophobicity%2520and%2520central%2520nervous%2520system%2520agents%253A%2520on%2520the%2520principle%2520of%2520minimal%2520hydrophobicity%2520in%2520drug%2520design%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D1987%26volume%3D76%26spage%3D663%26epage%3D687%26doi%3D10.1002%2Fjps.2600760902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlisides, P. E.</span></span> <span> </span><span class="NLM_article-title">Ketamine: 50 years of modulating the mind</span>. <i>Front. Hum. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">612</span>, <span class="refDoi"> DOI: 10.3389/fnhum.2016.00612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.3389%2Ffnhum.2016.00612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27965560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtV2itrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=612&author=L.+Liauthor=P.+E.+Vlisides&title=Ketamine%3A+50+years+of+modulating+the+mind&doi=10.3389%2Ffnhum.2016.00612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: 50 years of modulating the mind</span></div><div class="casAuthors">Li, Linda; Vlisides, Phillip E.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Human Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">612/1-612/15</span>CODEN:
                <span class="NLM_cas:coden">FHNRAI</span>;
        ISSN:<span class="NLM_cas:issn">1662-5161</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Ketamine was introduced into clin. practice in the 1960s and continues to be both clin. useful and scientifically fascinating.  With considerably diverse mol. targets and neurophysiol. properties, ketamine's effects on the central nervous system remain incompletely understood.  Investigators have leveraged the unique characteristics of ketamine to explore the invariant, fundamental mechanisms of anesthetic action.  Emerging evidence indicates that ketamine-mediated anesthesia may occur via disruption of corticocortical information transfer in a frontal-to-parietal ("top down") distribution.  This proposed mechanism of general anesthesia has since been demonstrated with anesthetics in other pharmacol. classes as well.  Ketamine remains invaluable to the fields of anesthesiol. and crit. care medicine, in large part due to its ability to maintain cardiorespiratory stability while providing effective sedation and analgesia.  Furthermore, there may be an emerging role for ketamine in treatment of refractory depression and Post-Traumatic Stress Disorder.  In this article, we review the history of ketamine, its pharmacol., putative mechanisms of action and current clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokopoVkR3447Vg90H21EOLACvtfcHk0lj7OE_fzrX3dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtV2itrjE&md5=b7df8f181691f0a4469e41551e82b4ab</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3389%2Ffnhum.2016.00612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnhum.2016.00612%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DVlisides%26aufirst%3DP.%2BE.%26atitle%3DKetamine%253A%252050%2520years%2520of%2520modulating%2520the%2520mind%26jtitle%3DFront.%2520Hum.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D612%26doi%3D10.3389%2Ffnhum.2016.00612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peltoniemi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagelberg, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olkkola, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saari, T. I.</span></span> <span> </span><span class="NLM_article-title">Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1059</span>– <span class="NLM_lpage">1077</span>, <span class="refDoi"> DOI: 10.1007/s40262-016-0383-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2Fs40262-016-0383-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27028535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsF2iurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=1059-1077&author=M.+A.+Peltoniemiauthor=N.+M.+Hagelbergauthor=K.+T.+Olkkolaauthor=T.+I.+Saari&title=Ketamine%3A+a+review+of+clinical+pharmacokinetics+and+pharmacodynamics+in+anesthesia+and+pain+therapy&doi=10.1007%2Fs40262-016-0383-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy</span></div><div class="casAuthors">Peltoniemi, Marko A.; Hagelberg, Nora M.; Olkkola, Klaus T.; Saari, Teijo I.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1059-1077</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Ketamine is a phencyclidine deriv., which functions primarily as an antagonist of the N-methyl-D-aspartate receptor.  It has no affinity for gamma-aminobutyric acid receptors in the central nervous system.  Ketamine shows a chiral structure consisting of two optical isomers.  It undergoes oxidative metab., mainly to norketamine by cytochrome P 450 (CYP) 3A and CYP2B6 enzymes.  The use of S-ketamine is increasing worldwide, since the S(+)-enantiomer has been postulated to be a four times more potent anesthetic and analgesic than the R(-)-enantiomer and approx. two times more effective than the racemic mixt. of ketamine.  Because of extensive first-pass metab., oral bioavailability is poor and ketamine is vulnerable to pharmacokinetic drug interactions.  Sublingual and nasal formulations of ketamine are being developed, and esp. nasal administration produces rapid max. plasma ketamine concns. with relatively high bioavailability.  Ketamine produces hemodynamically stable anesthesia via central sympathetic stimulation without affecting respiratory function.  Animal studies have shown that ketamine has neuroprotective properties, and there is no evidence of elevated intracranial pressure after ketamine dosing in humans.  Low-dose perioperative ketamine may reduce opioid consumption and chronic postsurgical pain after specific surgical procedures.  However, long-term analgesic effects of ketamine in chronic pain patients have not been demonstrated.  Besides analgesic properties, ketamine has rapid-acting antidepressant effects, which may be useful in treating therapy-resistant depressive patients.  Well-known psychotomimetic and cognitive adverse effects restrict the clin. usefulness of ketamine, even though fewer psychomimetic adverse effects have been reported with S-ketamine in comparison with the racemate.  Safety issues in long-term use are yet to be resolved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLqyI74DCcnbVg90H21EOLACvtfcHk0lj6oEcnjFS1gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsF2iurw%253D&md5=92bb0dcd7d034220f58418af4cee164c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs40262-016-0383-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-016-0383-6%26sid%3Dliteratum%253Aachs%26aulast%3DPeltoniemi%26aufirst%3DM.%2BA.%26aulast%3DHagelberg%26aufirst%3DN.%2BM.%26aulast%3DOlkkola%26aufirst%3DK.%2BT.%26aulast%3DSaari%26aufirst%3DT.%2BI.%26atitle%3DKetamine%253A%2520a%2520review%2520of%2520clinical%2520pharmacokinetics%2520and%2520pharmacodynamics%2520in%2520anesthesia%2520and%2520pain%2520therapy%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2016%26volume%3D55%26spage%3D1059%26epage%3D1077%26doi%3D10.1007%2Fs40262-016-0383-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rejaei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Ketamine use in current clinical practice</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1038/aps.2016.5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Faps.2016.5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27018176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2iu7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=865-872&author=M.+Gaoauthor=D.+Rejaeiauthor=H.+Liu&title=Ketamine+use+in+current+clinical+practice&doi=10.1038%2Faps.2016.5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine use in current clinical practice</span></div><div class="casAuthors">Gao, Mei; Rejaei, Damoon; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">865-872</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">After nearly half a century on the market, ketamine still occupies a unique corner in the medical armamentarium of anesthesiologists or clinicians treating pain.  Over the last two decades, much research has been conducted highlighting the drug's mechanisms of action, specifically those of its enantiomers.  Nowadays, ketamine is also being utilized for pediatric pain control in emergency department, with its anti-hyperalgesic and anti-inflammatory effects being revealed in acute and chronic pain management.  Recently, new insights have been gained on ketamine's potential anti-depressive and antisuicidal effects.  This article provides an overview of the drug's pharmacokinetics and pharmacodynamics while also discussing the potential benefits and risks of ketamine administration in various clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprxv2CkTeEJ7Vg90H21EOLACvtfcHk0lj6oEcnjFS1gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2iu7jP&md5=29b44ebb7b25d9c2a41a04d7b8f6bf10</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Faps.2016.5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2016.5%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DRejaei%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DKetamine%2520use%2520in%2520current%2520clinical%2520practice%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2016%26volume%3D37%26spage%3D865%26epage%3D872%26doi%3D10.1038%2Faps.2016.5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsze, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machan, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhlaghi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linakis, J. G.</span></span> <span> </span><span class="NLM_article-title">Intranasal ketamine for procedural sedation in pediatric laceration repair: a preliminary report</span>. <i>Pediatr. Emerg. Care</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1097/PEC.0b013e3182624935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2FPEC.0b013e3182624935" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=22858745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC38fltFOlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2012&pages=767-770&author=D.+S.+Tszeauthor=D.+W.+Steeleauthor=J.+T.+Machanauthor=F.+Akhlaghiauthor=J.+G.+Linakis&title=Intranasal+ketamine+for+procedural+sedation+in+pediatric+laceration+repair%3A+a+preliminary+report&doi=10.1097%2FPEC.0b013e3182624935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Intranasal ketamine for procedural sedation in pediatric laceration repair: a preliminary report</span></div><div class="casAuthors">Tsze Daniel S; Steele Dale W; Machan Jason T; Akhlaghi Fatemeh; Linakis James G</div><div class="citationInfo"><span class="NLM_cas:title">Pediatric emergency care</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">767-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  The objective of this study was to compare the efficacy of 3 doses of intranasal ketamine (INK) for sedation of children from 1 to 7 years old requiring laceration repair.  METHODS:  This was a randomized, prospective, double-blind trial of children requiring sedation for laceration repair.  Patients with simple lacerations were randomized by age to receive 3, 6, or 9 mg/kg INK.  Adequacy and efficacy of sedation were measured with the Ramsay sedation score and the Observational Scale of Behavioral Distress-Revised.  Serum ketamine and norketamine levels were drawn during the procedure.  Sedation duration and adverse events were recorded.  RESULTS:  Of the 12 patients enrolled, 3 patients achieved adequate sedation, all at the 9-mg/kg dose.  The study was suspended at that time as per predetermined criteria.  CONCLUSIONS:  Nine milligrams of INK per kilogram produced a significantly higher proportion of successful sedations than the 3- and 6-mg/kg doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSa-KaX86UKAGPgL4LrC-0VfW6udTcc2ea4Oje3C6Z2Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fltFOlsQ%253D%253D&md5=76b8092fd39c0939eea697ff35fe3bc5</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1097%2FPEC.0b013e3182624935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FPEC.0b013e3182624935%26sid%3Dliteratum%253Aachs%26aulast%3DTsze%26aufirst%3DD.%2BS.%26aulast%3DSteele%26aufirst%3DD.%2BW.%26aulast%3DMachan%26aufirst%3DJ.%2BT.%26aulast%3DAkhlaghi%26aufirst%3DF.%26aulast%3DLinakis%26aufirst%3DJ.%2BG.%26atitle%3DIntranasal%2520ketamine%2520for%2520procedural%2520sedation%2520in%2520pediatric%2520laceration%2520repair%253A%2520a%2520preliminary%2520report%26jtitle%3DPediatr.%2520Emerg.%2520Care%26date%3D2012%26volume%3D28%26spage%3D767%26epage%3D770%26doi%3D10.1097%2FPEC.0b013e3182624935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sinner, B.</span>; <span class="NLM_string-name">Graf, B.</span></span> <span> </span><span class="NLM_article-title">Ketamine</span>. In  <i>Modern Anesthetics</i>; <span class="NLM_publisher-name">Springer</span>, <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2008</span>; pp  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">333</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2F978-3-540-74806-9_15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=313-333&author=B.+Sinner&author=B.+Graf&title=Modern+Anesthetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1007%2F978-3-540-74806-9_15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-540-74806-9_15%26sid%3Dliteratum%253Aachs%26aulast%3DSinner%26aufirst%3DB.%26atitle%3DKetamine%26btitle%3DModern%2520Anesthetics%26pub%3DSpringer%26date%3D2008%26spage%3D313%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quibell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prommer, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihalyo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twycross, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcock, A.</span></span> <span> </span><span class="NLM_article-title">Ketamine</span>. <i>J. Pain Symptom Manage.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1016/j.jpainsymman.2011.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.jpainsymman.2011.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=21419322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs12hsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=640-649&author=R.+Quibellauthor=E.+E.+Prommerauthor=M.+Mihalyoauthor=R.+Twycrossauthor=A.+Wilcock&title=Ketamine&doi=10.1016%2Fj.jpainsymman.2011.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine*</span></div><div class="casAuthors">Quibell, Rachel; Prommer, Eric E.; Mihalyo, Mary; Twycross, Robert; Wilcock, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pain and Symptom Management</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">640-649</span>CODEN:
                <span class="NLM_cas:coden">JPSMEU</span>;
        ISSN:<span class="NLM_cas:issn">0885-3924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Therapeutic Reviews aim to provide essential independent information for health professionals about drugs used in palliative and hospice care.  Addnl. content is available on www.palliativedrugs.com.  Country-specific books (Hospice and Palliative Care Formulary USA, and Palliative Care Formulary, British and Canadian editions) are also available and can be ordered from www.palliativebooks.com.  The series editors welcome feedback on the articles (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="1179605161707d7d78706578677475636476623f727e7c">[email protected]</a>).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHNpCOGO1hjrVg90H21EOLACvtfcHk0liMIXwR3it-bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs12hsro%253D&md5=45b7b2fc655b69b4ee17b7b472b25f74</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.jpainsymman.2011.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpainsymman.2011.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DQuibell%26aufirst%3DR.%26aulast%3DPrommer%26aufirst%3DE.%2BE.%26aulast%3DMihalyo%26aufirst%3DM.%26aulast%3DTwycross%26aufirst%3DR.%26aulast%3DWilcock%26aufirst%3DA.%26atitle%3DKetamine%26jtitle%3DJ.%2520Pain%2520Symptom%2520Manage.%26date%3D2011%26volume%3D41%26spage%3D640%26epage%3D649%26doi%3D10.1016%2Fj.jpainsymman.2011.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cromhout, A.</span></span> <span> </span><span class="NLM_article-title">Ketamine: its use in the emergency department</span>. <i>Emerg. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1046/j.1442-2026.2003.00433.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1046%2Fj.1442-2026.2003.00433.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=12675625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD3s7lvFKitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2003&pages=155-159&author=A.+Cromhout&title=Ketamine%3A+its+use+in+the+emergency+department&doi=10.1046%2Fj.1442-2026.2003.00433.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: its use in the emergency department</span></div><div class="casAuthors">Cromhout Andries</div><div class="citationInfo"><span class="NLM_cas:title">Emergency medicine (Fremantle, W.A.)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-9</span>
        ISSN:<span class="NLM_cas:issn">1035-6851</span>.
    </div><div class="casAbstract">Ketamine has been known to the medical world for over 30 years, yet is not widely used to its full potential.  It is often considered to be a 'third world' drug only.  In light of a recent increase in interest in its use in the developed world, this review is for emergency physicians to use as a quick reference.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJPSIGyUS4OrmQt-ICR3qNfW6udTcc2eZbIUc6FxWfkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s7lvFKitQ%253D%253D&md5=dc37c1746eb691bf4bbabd1e9b8e08ce</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1046%2Fj.1442-2026.2003.00433.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1442-2026.2003.00433.x%26sid%3Dliteratum%253Aachs%26aulast%3DCromhout%26aufirst%3DA.%26atitle%3DKetamine%253A%2520its%2520use%2520in%2520the%2520emergency%2520department%26jtitle%3DEmerg.%2520Med.%26date%3D2003%26volume%3D15%26spage%3D155%26epage%3D159%26doi%3D10.1046%2Fj.1442-2026.2003.00433.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aroni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacovidou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dontas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourzitaki, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xanthos, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1177/0091270009337941</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1177%2F0091270009337941" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=19546251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVSqur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=957-964&author=F.+Aroniauthor=N.+Iacovidouauthor=I.+Dontasauthor=C.+Pourzitakiauthor=T.+Xanthos&title=Pharmacological+aspects+and+potential+new+clinical+applications+of+ketamine%3A+reevaluation+of+an+old+drug&doi=10.1177%2F0091270009337941"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug</span></div><div class="casAuthors">Aroni, Filippia; Iacovidou, Nicoletta; Dontas, Ismene; Pourzitaki, Chryssa; Xanthos, Theodoros</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">957-964</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Ketamine, the phencyclidine deriv. described in 1965, is an i.v. anesthetic with a variety of applications.  The enthusiasm following its initial release subsided due to side effects from the central nervous system.  New anesthetics limited the role of ketamine in anesthetic practice.  However, its hemodynamically stable profile, along with its beneficial respiratory properties and analgesic potency, rendered the drug invaluable in battlefield medicine, sedation of the uncooperative child, analgesia, and sedation in burn units.  Reevaluation, though, of analgesic properties of ketamine resulted in new interest regarding its use in perioperative and chronic pain management.  Moreover, recent studies in the effects of the substance on intracranial pressure and cerebral blood flow led to revising the recommendation against its use in brain injury.  Furthermore, the bronchodilating effects of the substance led to increasing interest for potential use in asthma treatment.  In addn., sepn. of the 2 enantiomers and subsequent sep. studies indicated beneficial results of the S(+) one.  Thus, new controlled multicentered clin. trials are to be conducted to justify approval for new uses of ketamine and take advantage of its unique range of applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP4ry9lXzq0bVg90H21EOLACvtfcHk0liMIXwR3it-bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVSqur%252FL&md5=4d74fed4e68a393e9809fe9020d5bfe8</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1177%2F0091270009337941&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009337941%26sid%3Dliteratum%253Aachs%26aulast%3DAroni%26aufirst%3DF.%26aulast%3DIacovidou%26aufirst%3DN.%26aulast%3DDontas%26aufirst%3DI.%26aulast%3DPourzitaki%26aufirst%3DC.%26aulast%3DXanthos%26aufirst%3DT.%26atitle%3DPharmacological%2520aspects%2520and%2520potential%2520new%2520clinical%2520applications%2520of%2520ketamine%253A%2520reevaluation%2520of%2520an%2520old%2520drug%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D957%26epage%3D964%26doi%3D10.1177%2F0091270009337941" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, D. G.</span></span> <span> </span><span class="NLM_article-title">Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia</span>. <i>Anesth. Prog.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">61</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1308374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADyaK3szntVKqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1992&pages=61&author=D.+A.+Haasauthor=D.+G.+Harper&title=Ketamine%3A+a+review+of+its+pharmacologic+properties+and+use+in+ambulatory+anesthesia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia</span></div><div class="casAuthors">Haas D A; Harper D G</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia progress</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">61-8</span>
        ISSN:<span class="NLM_cas:issn">0003-3006</span>.
    </div><div class="casAbstract">The administration of intravenous agents is the most commonly used method in Canada and the United States to produce sedation or general anesthesia for dental procedures.  Ketamine, a dissociative anesthetic, has several advantageous physical, pharmacokinetic, and pharmacodynamic properties.  It can be used to induce anesthesia, sedation, analgesia, and amnesia.  Ketamine can maintain functional residual capacity, induce bronchodilation, and avoid cardiovascular depression.  However, adverse effects have been demonstrated, such as cardiovascular stimulation and unpleasant emergence phenomena, both of which may be modulated by supplementation with benzodiazepines.  An increase in the use of ketamine for ambulatory anesthesia has recently been advocated.  This review of the literature supports the use of ketamine as an effective agent for selected anesthetic procedures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnipagfkjBp_tos8R3JUhXfW6udTcc2eb1_bef1ZnmFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3szntVKqtQ%253D%253D&md5=d99781724220188faa8554931134310f</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaas%26aufirst%3DD.%2BA.%26aulast%3DHarper%26aufirst%3DD.%2BG.%26atitle%3DKetamine%253A%2520a%2520review%2520of%2520its%2520pharmacologic%2520properties%2520and%2520use%2520in%2520ambulatory%2520anesthesia%26jtitle%3DAnesth.%2520Prog.%26date%3D1992%26volume%3D39%26spage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasinather, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, Y.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nurhidayat, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarlais, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schottenfeld, R.</span></span> <span> </span><span class="NLM_article-title">To use or not to use: an update on licit and illicit ketamine use</span>. <i>Subst Abuse Rehabil.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">11</span>, <span class="refDoi"> DOI: 10.2147/SAR.S15458</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.2147%2FSAR.S15458" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=24474851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsFyqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=11&author=J.-H.+Liauthor=V.+Kasinatherauthor=Y.-w.+Cheungauthor=W.+Zhouauthor=A.+W.+Nurhidayatauthor=D.+C.+Jarlaisauthor=R.+Schottenfeld&title=To+use+or+not+to+use%3A+an+update+on+licit+and+illicit+ketamine+use&doi=10.2147%2FSAR.S15458"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">To use or not to use: an update on licit and illicit ketamine use</span></div><div class="casAuthors">Li Jih-Heng; Vicknasingam Balasingam; Cheung Yuet-Wah; Zhou Wang; Nurhidayat Adhi Wibowo; Jarlais Don C Des; Schottenfeld Richard</div><div class="citationInfo"><span class="NLM_cas:title">Substance abuse and rehabilitation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11-20</span>
        ISSN:<span class="NLM_cas:issn">1179-8467</span>.
    </div><div class="casAbstract">Ketamine, a derivative of phencyclidine that was developed in the 1960s, is an anesthetic and analgesic with hallucinogenic effects.  In this paper, the pharmacological and toxicological effects of ketamine are briefly reviewed.  Ketamine possesses a wide safety margin but such a therapeutic benefit is somewhat offset by its emergence phenomenon (mind-body dissociation and delirium) and hallucinogenic effects.  The increasing abuse of ketamine, initially predominantly in recreational scenes to experience a "k-hole" and other hallucinatory effects but more recently also as a drug abused during the workday or at home, has further pushed governments to confine its usage in many countries.  Recently, urinary tract dysfunction has been associated with long-term ketamine use.  In some long-term ketamine users, such damage can be irreversible and could result in renal failure and dialysis.  Although ketamine has not yet been scheduled in the United Nations Conventions, previous studies using different assessment parameters to score the overall harms of drugs indicated that ketamine may cause more harm than some of the United Nations scheduled drugs.  Some countries in Southeast and East Asia have reported an escalating situation of ketamine abuse.  Dependence, lower urinary tract dysfunction, and sexual impulse or violence were the most notable among the ketamine-associated symptoms in these countries.  These results implied that the danger of ketamine may have been underestimated previously.  Therefore, the severity levels of the ketamine-associated problems should be scrutinized more carefully and objectively.  To prevent ketamine from being improperly used and evolving into an epidemic, a thorough survey on the prevalence and characteristics of illicit ketamine use is imperative so that suitable policy and measures can be taken.  On the other hand, recent findings that ketamine could be useful for treating major depressive disorder has given this old drug a new impetus.  If ketamine is indeed a remedy for treating depression, more research on the risks and benefits of its clinical use will be indispensable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0KN9U3mPo0I3yKPtYViAGfW6udTcc2eb1_bef1ZnmFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsFyqtQ%253D%253D&md5=be1f7d17db8ced43f2da251357f4beb7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.2147%2FSAR.S15458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FSAR.S15458%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.-H.%26aulast%3DKasinather%26aufirst%3DV.%26aulast%3DCheung%26aufirst%3DY.-w.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DNurhidayat%26aufirst%3DA.%2BW.%26aulast%3DJarlais%26aufirst%3DD.%2BC.%26aulast%3DSchottenfeld%26aufirst%3DR.%26atitle%3DTo%2520use%2520or%2520not%2520to%2520use%253A%2520an%2520update%2520on%2520licit%2520and%2520illicit%2520ketamine%2520use%26jtitle%3DSubst%2520Abuse%2520Rehabil.%26date%3D2011%26volume%3D2%26spage%3D11%26doi%3D10.2147%2FSAR.S15458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moaddel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanghvi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dossou, K. S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bupp, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swezey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Loughlin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span> <span> </span><span class="NLM_article-title">The distribution and clearance of (2S, 6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e00157</span>, <span class="refDoi"> DOI: 10.1002/prp2.157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1002%2Fprp2.157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26171236" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=e00157&author=R.+Moaddelauthor=M.+Sanghviauthor=K.+S.+S.+Dossouauthor=A.+Ramamoorthyauthor=C.+Greenauthor=J.+Buppauthor=R.+Swezeyauthor=K.+O%E2%80%99Loughlinauthor=I.+W.+Wainer&title=The+distribution+and+clearance+of+%282S%2C+6S%29-hydroxynorketamine%2C+an+active+ketamine+metabolite%2C+in+Wistar+rats&doi=10.1002%2Fprp2.157"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fprp2.157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.157%26sid%3Dliteratum%253Aachs%26aulast%3DMoaddel%26aufirst%3DR.%26aulast%3DSanghvi%26aufirst%3DM.%26aulast%3DDossou%26aufirst%3DK.%2BS.%2BS.%26aulast%3DRamamoorthy%26aufirst%3DA.%26aulast%3DGreen%26aufirst%3DC.%26aulast%3DBupp%26aufirst%3DJ.%26aulast%3DSwezey%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Loughlin%26aufirst%3DK.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26atitle%3DThe%2520distribution%2520and%2520clearance%2520of%2520%25282S%252C%25206S%2529-hydroxynorketamine%252C%2520an%2520active%2520ketamine%2520metabolite%252C%2520in%2520Wistar%2520rats%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2015%26volume%3D3%26spage%3De00157%26doi%3D10.1002%2Fprp2.157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boku, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hishimoto, A.</span></span> <span> </span><span class="NLM_article-title">Neural basis of major depressive disorder: beyond monoamine hypothesis</span>. <i>Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1111/pcn.12604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1111%2Fpcn.12604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=28926161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlvVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2018&pages=3-12&author=S.+Bokuauthor=S.+Nakagawaauthor=H.+Todaauthor=A.+Hishimoto&title=Neural+basis+of+major+depressive+disorder%3A+beyond+monoamine+hypothesis&doi=10.1111%2Fpcn.12604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Neural basis of major depressive disorder: Beyond monoamine hypothesis</span></div><div class="casAuthors">Boku, Shuken; Nakagawa, Shin; Toda, Hiroyuki; Hishimoto, Akitoyo</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry and Clinical Neurosciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-12</span>CODEN:
                <span class="NLM_cas:coden">PCNEFP</span>;
        ISSN:<span class="NLM_cas:issn">1323-1316</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The monoamine hypothesis has been accepted as the most common hypothesis of major depressive disorder (MDD) for a long period because of its simplicity and understandability.  Actually, most currently used antidepressants have been considered to act based on the monoamine hypothesis.  However, an important problem of the monoamine hypothesis has been pointed out as follows: it fails to explain the latency of response to antidepressants.  In addn., many patients with MDD have remained refractory to currently used antidepressants.  Therefore, monoamine-alternate hypotheses are required to explain the latency of response to antidepressants.  Such hypotheses have been expected to contribute to identifying hopeful new therapeutic targets for MDD.  Past studies have revealed that the vol. of the hippocampus is decreased in patients with MDD, which is likely caused by the failure of the hypothalamic-pituitary-adrenal axis and following elevation of glucocorticoids.  Two hypotheses have been proposed to explain the vol. of the hippocampus: (i) the neuroplasticity hypothesis; and (ii) the neurogenesis hypothesis.  The neuroplasticity hypothesis explains how the hippocampal vol. is decreased by the morphol. changes of hippocampal neurons, such as the shortening length of dendrites and the decreased no. and d. of spines.  The neurogenesis hypothesis explains how the hippocampal vol. is decreased by the decrease of neurogenesis in the hippocampal dentate gyrus.  These hypotheses are able to explain the latency of response to antidepressants.  In this review, we first overview how the neuroplasticity and neurogenesis hypotheses have been developed.  We then describe the details of these hypotheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ-o-pmwi-M7Vg90H21EOLACvtfcHk0lhgACzVHbwHAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlvVehsg%253D%253D&md5=36b5009c7c8c80dd123cfd1a862fc85b</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fpcn.12604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpcn.12604%26sid%3Dliteratum%253Aachs%26aulast%3DBoku%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DS.%26aulast%3DToda%26aufirst%3DH.%26aulast%3DHishimoto%26aufirst%3DA.%26atitle%3DNeural%2520basis%2520of%2520major%2520depressive%2520disorder%253A%2520beyond%2520monoamine%2520hypothesis%26jtitle%3DPsychiatry%2520Clin.%2520Neurosci.%26date%3D2018%26volume%3D72%26spage%3D3%26epage%3D12%26doi%3D10.1111%2Fpcn.12604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aulakh, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolozin, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolliver, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D. L.</span></span> <span> </span><span class="NLM_article-title">Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants</span>. <i>Mol. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/0169-328X(93)90069-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2F0169-328X%2893%2990069-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=8381906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK3sXpsVajsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1993&pages=31-35&author=K.+P.+Leschauthor=C.+S.+Aulakhauthor=B.+L.+Wolozinauthor=T.+J.+Tolliverauthor=J.+L.+Hillauthor=D.+L.+Murphy&title=Regional+brain+expression+of+serotonin+transporter+mRNA+and+its+regulation+by+reuptake+inhibiting+antidepressants&doi=10.1016%2F0169-328X%2893%2990069-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants</span></div><div class="casAuthors">Lesch, K. Peter; Aulakh, Charanjit S.; Wolozin, Benjamin L.; Tolliver, Teresa J.; Hill, James L.; Murphy, Dennis L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Brain Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">31-5</span>CODEN:
                <span class="NLM_cas:coden">MBREE4</span>;
        ISSN:<span class="NLM_cas:issn">0169-328X</span>.
    </div><div class="casAbstract">Regional expression and antidepressant drug-induced regulation of mRNA encoding the serotonin (5-HT) transporter were studied in rat brain.  While 5-HT transporter mRNA is abundantly expressed in the midbrain raphe complex, lower concns. were also found in frontal cortex, hippocampus, and neostriatum using a combination of reverse transcriptase-polymerase chain reaction (RT-PCR), Southern hybridization, and sequence anal.  Long-term administration of antidepressants which inhibit 5-HT reuptake, but not monoamine oxidase inhibitors or 5-HT receptor agonists, decrease 5-HT transporter mRNA steady-state concns.  Based on these observations, we conclude that (1) mRNA coding for the 5-HT transporter is present in several brain areas assocd. with ascending HT pathways, and (2) chronic treatment with reuptake inhibiting antidepressants may be assocd. with regulation of the 5-HT transporter at the level of gene expression which may contribute to the neuroadaptive mechanisms that likely underlie their therapeutic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5vDCJu2GApLVg90H21EOLACvtfcHk0lgFxUYbBGnb0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXpsVajsg%253D%253D&md5=34eb78f79ed46ce897a49fca297a82c8</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2F0169-328X%2893%2990069-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0169-328X%252893%252990069-2%26sid%3Dliteratum%253Aachs%26aulast%3DLesch%26aufirst%3DK.%2BP.%26aulast%3DAulakh%26aufirst%3DC.%2BS.%26aulast%3DWolozin%26aufirst%3DB.%2BL.%26aulast%3DTolliver%26aufirst%3DT.%2BJ.%26aulast%3DHill%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DD.%2BL.%26atitle%3DRegional%2520brain%2520expression%2520of%2520serotonin%2520transporter%2520mRNA%2520and%2520its%2520regulation%2520by%2520reuptake%2520inhibiting%2520antidepressants%26jtitle%3DMol.%2520Brain%2520Res.%26date%3D1993%26volume%3D17%26spage%3D31%26epage%3D35%26doi%3D10.1016%2F0169-328X%2893%2990069-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J. M.</span>; <span class="NLM_string-name">Bies, R. R.</span>; <span class="NLM_string-name">Shelton, R. C.</span></span> <span> </span><span class="NLM_article-title">Drug Therapy of Depression and Anxiety Disorders</span>. In  <i>Goodman & Gilman’s: The Pharmacological Basis of Therapeutics</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunton, L. L.</span>, <span class="NLM_string-name">Hilal-Dandan, R.</span>, <span class="NLM_string-name">Knollmann, B. C.</span></span>, Eds.; <span class="NLM_publisher-name">McGraw-Hill</span>, <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2017</span>; Vol.  <span class="NLM_volume">13e</span>. <a href="https://accesspharmacy.mhmedical.com/content.aspx?bookid=2189&amp;sectionid=169518711" class="extLink">https://accesspharmacy.mhmedical.com/content.aspx?bookid=2189&sectionid=169518711</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=J.+M.+O%E2%80%99Donnell&author=R.+R.+Bies&author=R.+C.+Sheltonauthor=L.+L.+Brunton&author=R.+Hilal-Dandan&author=B.+C.+Knollmann&title=Goodman+%26+Gilman%E2%80%99s%3A+The+Pharmacological+Basis+of+Therapeutics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%2BM.%26atitle%3DDrug%2520Therapy%2520of%2520Depression%2520and%2520Anxiety%2520Disorders%26btitle%3DGoodman%2520%2526%2520Gilman%25E2%2580%2599s%253A%2520The%2520Pharmacological%2520Basis%2520of%2520Therapeutics%26aulast%3DBrunton%26aufirst%3DL.%2BL.%26pub%3DMcGraw-Hill%26date%3D2017%26volume%3D13e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappiello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oren, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heninger, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span> <span> </span><span class="NLM_article-title">Antidepressant effects of ketamine in depressed patients</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1016/S0006-3223(99)00230-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2FS0006-3223%2899%2900230-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10686270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD3cXht1KqtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2000&pages=351-354&author=R.+M.+Bermanauthor=A.+Cappielloauthor=A.+Anandauthor=D.+A.+Orenauthor=G.+R.+Heningerauthor=D.+S.+Charneyauthor=J.+H.+Krystal&title=Antidepressant+effects+of+ketamine+in+depressed+patients&doi=10.1016%2FS0006-3223%2899%2900230-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant effects of ketamine in depressed patients</span></div><div class="casAuthors">Berman, R. M.; Cappiello, A.; Anand, A.; Oren, D. A.; Heninger, G. R.; Charney, D. S.; Krystal, J. H.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">351-354</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">Subjects with major depression completed 2 test days that involved i.v. treatment with ketamine-HCl [an N-methyl-D-aspartate (NMDA) receptor antagonist] (0.5 mg/kg) or saline solns. under randomized, double-blind conditions. The subjects evidenced significant improvement in depressive symptoms within 72 h after ketamine but not placebo infusion. These results suggest a potential role for NMDA receptor-modulating drugs in the treatment of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe9INO5Rp16bVg90H21EOLACvtfcHk0lgFxUYbBGnb0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXht1KqtrY%253D&md5=45ef4a17496654912e0bf515ba3fce2a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2FS0006-3223%2899%2900230-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-3223%252899%252900230-9%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DR.%2BM.%26aulast%3DCappiello%26aufirst%3DA.%26aulast%3DAnand%26aufirst%3DA.%26aulast%3DOren%26aufirst%3DD.%2BA.%26aulast%3DHeninger%26aufirst%3DG.%2BR.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26atitle%3DAntidepressant%2520effects%2520of%2520ketamine%2520in%2520depressed%2520patients%26jtitle%3DBiol.%2520Psychiatry%26date%3D2000%26volume%3D47%26spage%3D351%26epage%3D354%26doi%3D10.1016%2FS0006-3223%2899%2900230-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harakal, J.</span></span> <span> </span><span class="NLM_article-title">Evaluation of ketamine HCl for anti-depressant activity</span>. <i>Arch Int. Pharmacodyn. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">74</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1156026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaE2MXksFemtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=1975&pages=68-74&author=R.+Sofiaauthor=J.+Harakal&title=Evaluation+of+ketamine+HCl+for+anti-depressant+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of ketamine hydrochloride for antidepressant activity</span></div><div class="casAuthors">Sofia, R. D.; Harakal, J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Archives Internationales de Pharmacodynamie et de Therapie</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">68-74</span>CODEN:
                <span class="NLM_cas:coden">AIPTAK</span>;
        ISSN:<span class="NLM_cas:issn">0003-9780</span>.
    </div><div class="casAbstract">Ketamine-HCl (I-HCl) [1867-66-9] had significant antidepressant activities in mice and rats over a wide range of oral doses.  The tests used were (1) reversal of tetrabenazine-induced ptosis in mice, (2) reversal of reserpine-induced hypothermia in rats, (3) enhancement of yohimbine toxicity in mice, and (4) inhibition of oxotremorine-induced tremors in mice.  In general, the antidepressant potency of I was less than that of imipramine-HCl [113-52-0].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_u_EETY_DPrVg90H21EOLACvtfcHk0lgFxUYbBGnb0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXksFemtro%253D&md5=192f63e5fc42a0f3fddaa5f01c0d89fb</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DR.%26aulast%3DHarakal%26aufirst%3DJ.%26atitle%3DEvaluation%2520of%2520ketamine%2520HCl%2520for%2520anti-depressant%2520activity%26jtitle%3DArch%2520Int.%2520Pharmacodyn.%2520Ther.%26date%3D1975%26volume%3D214%26spage%3D68%26epage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trullas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span> <span> </span><span class="NLM_article-title">Functional antagonists at the NMDA receptor complex exhibit antidepressant actions</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(90)90204-J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2F0014-2999%2890%2990204-J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=2171955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK3cXls1Gqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=1990&pages=1-10&author=R.+Trullasauthor=P.+Skolnick&title=Functional+antagonists+at+the+NMDA+receptor+complex+exhibit+antidepressant+actions&doi=10.1016%2F0014-2999%2890%2990204-J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Functional antagonists at the NMDA receptor complex exhibit antidepressant actions</span></div><div class="casAuthors">Trullas, Ramon; Skolnick, Phil</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">Inescapable, but not escapable, stress inhibits the induction of long-term potentiation (LTP) in the CA1 region of hippocampus, a process that is dependent upon activation of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.  Since inescapable stress also produces a syndrome of behavioral depression sensitive to clin. effective antidepressants, the actions of functional antagonists were examd. at the NMDA receptor complex in animal models commonly used to evaluate potential antidepressants.  A competitive NMDA antagonist 2-amino-7-phosphonoheptanoic acid (AP 7), a noncompetitive NMDA antagonist Dizolcipine (MK 801), and a partial agonist at strychnine-insensitive glycine receptors 1-aminocyclopropanecarboxylic acid (ACPC) mimicked the effects of clin. effective antidepressants in these models.  These findings indicate that the NMDA receptor complex may be involved in the behavioral deficits induced by inescapable stress, and that substances capable of reducing neurotransmission at the NMDA receptor complex may represent a new class of antidepressants.  Based on these findings, the hypothesis that pathways subserved by the NMDA subtype of glutamate receptors are involved in the pathophysiol. of affective disorders may have heuristic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofvVFlsLw007Vg90H21EOLACvtfcHk0lgklsMGgXaV6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXls1Gqtbk%253D&md5=cf9c6c36e42862e7f6a093a79e5f6817</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2890%2990204-J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252890%252990204-J%26sid%3Dliteratum%253Aachs%26aulast%3DTrullas%26aufirst%3DR.%26aulast%3DSkolnick%26aufirst%3DP.%26atitle%3DFunctional%2520antagonists%2520at%2520the%2520NMDA%2520receptor%2520complex%2520exhibit%2520antidepressant%2520actions%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1990%26volume%3D185%26spage%3D1%26epage%3D10%26doi%3D10.1016%2F0014-2999%2890%2990204-J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brutsche, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ameli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckenbaugh, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manji, H. K.</span></span> <span> </span><span class="NLM_article-title">A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">856</span>– <span class="NLM_lpage">864</span>, <span class="refDoi"> DOI: 10.1001/archpsyc.63.8.856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1001%2Farchpsyc.63.8.856" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=16894061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD28XovF2lsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2006&pages=856-864&author=C.+A.+Zarateauthor=J.+B.+Singhauthor=P.+J.+Carlsonauthor=N.+E.+Brutscheauthor=R.+Ameliauthor=D.+A.+Luckenbaughauthor=D.+S.+Charneyauthor=H.+K.+Manji&title=A+randomized+trial+of+an+N-methyl-D-aspartate+antagonist+in+treatment-resistant+major+depression&doi=10.1001%2Farchpsyc.63.8.856"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression</span></div><div class="casAuthors">Zarate, Carlos A., Jr.; Singh, Jaskaran B.; Carlson, Paul J.; Brutsche, Nancy E.; Ameli, Rezvan; Luckenbaugh, David A.; Charney, Dennis S.; Manji, Husseini K.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of General Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">856-864</span>CODEN:
                <span class="NLM_cas:coden">ARGPAQ</span>;
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity.  Exploring pharmacol. strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care.  Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiol. and treatment of mood disorders.  To det. whether a rapid antidepressant effect can be achieved with an antagonist at the N-methyl-D-aspartate receptor in subjects with major depression.  A randomized, placebo-controlled, double-blind crossover study from Nov. 2004 to Sept. 2005.  Setting: Mood Disorders Research Unit at the National Institute of Mental Health.  Eighteen subjects with DSM-IV major depression (treatment resistant).  After a 2-wk drug-free period, subjects were given an i.v. infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart.  Subjects were rated at baseline and at 40, 80, 110, and 230 min and 1, 2, 3, and 7 days postinfusion.  Changes in scores on the primary efficacy measure, the 21-item Hamilton Depression Rating Scale.  Subjects receiving ketamine showed significant improvement in depression compared with subjects receiving placebo within 110 min after injection, which remained significant throughout the following week.  The effect size for the drug difference was very large (d=1.46 [95% confidence interval, 0.91-2.01]) after 24 h and moderate to large (d=0.68 [95% confidence interval, 0.13-1.23]) after 1 wk.  Of the 17 subjects treated with ketamine, 71% met response and 29% met remission criteria the day following ketamine infusion.  Thirty-five percent of subjects maintained response for at least 1 wk.  Robust and rapid antidepressant effects resulted from a single i.v. dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 h postinfusion and continued to remain significant for 1 wk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG5iDWz2z98LVg90H21EOLACvtfcHk0lgklsMGgXaV6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovF2lsLo%253D&md5=dc1c435252fa602a404e35a260fa5ef1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.63.8.856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.63.8.856%26sid%3Dliteratum%253Aachs%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DSingh%26aufirst%3DJ.%2BB.%26aulast%3DCarlson%26aufirst%3DP.%2BJ.%26aulast%3DBrutsche%26aufirst%3DN.%2BE.%26aulast%3DAmeli%26aufirst%3DR.%26aulast%3DLuckenbaugh%26aufirst%3DD.%2BA.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DManji%26aufirst%3DH.%2BK.%26atitle%3DA%2520randomized%2520trial%2520of%2520an%2520N-methyl-D-aspartate%2520antagonist%2520in%2520treatment-resistant%2520major%2520depression%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2006%26volume%3D63%26spage%3D856%26epage%3D864%26doi%3D10.1001%2Farchpsyc.63.8.856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective</span>. <i>Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">613</span>– <span class="NLM_lpage">627</span>, <span class="refDoi"> DOI: 10.1111/pcn.12902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1111%2Fpcn.12902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=31215725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCjurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2019&pages=613-627&author=K.+Hashimoto&title=Rapid-acting+antidepressant+ketamine%2C+its+metabolites+and+other+candidates%3A+A+historical+overview+and+future+perspective&doi=10.1111%2Fpcn.12902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective</span></div><div class="casAuthors">Hashimoto, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Psychiatry and Clinical Neurosciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">613-627</span>CODEN:
                <span class="NLM_cas:coden">PCNEFP</span>;
        ISSN:<span class="NLM_cas:issn">1323-1316</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence suggests that the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine produces rapid and sustained antidepressant effects in treatment-resistant patients with MDD or BD.  Ketamine is a racemic mixt. comprising equal parts of (R)-ketamine (or arketamine) and (S)-ketamine (or esketamine).  Because (S)-ketamine has higher affinity for NMDAR than (R)-ketamine, esketamine was developed as an antidepressant.  On 5 March 2019, esketamine nasal spray was approved by the US Food and Drug Administration.  However, preclin. data suggest that (R)-ketamine exerts greater potency and longer-lasting antidepressant effects than (S)-ketamine in animal models of depression and that (R)-ketamine has less detrimental side-effects than (R,S)-ketamine or (S)-ketamine.  In this article, the author reviews the historical overview of the antidepressant actions of enantiomers of ketamine and its major metabolites norketamine and hydroxynorketamine.  Furthermore, the author discusses the other potential rapid-acting antidepressant candidates (i.e., NMDAR antagonists and modulators, low-voltage-sensitive T-type calcium channel inhibitor, potassium channel Kir4.1 inhibitor, neg. modulators of γ-aminobutyric acid, and type A [GABAA] receptors) to compare them with ketamine.  Moreover, the mol. and cellular mechanisms of ketamine s antidepressant effects are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJMfLuDM80E7Vg90H21EOLACvtfcHk0lgklsMGgXaV6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCjurzL&md5=c332c590edd834e5f38b8675c482020a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fpcn.12902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpcn.12902%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DRapid-acting%2520antidepressant%2520ketamine%252C%2520its%2520metabolites%2520and%2520other%2520candidates%253A%2520A%2520historical%2520overview%2520and%2520future%2520perspective%26jtitle%3DPsychiatry%2520Clin.%2520Neurosci.%26date%3D2019%26volume%3D73%26spage%3D613%26epage%3D627%26doi%3D10.1111%2Fpcn.12902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gould, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S. M.</span></span> <span> </span><span class="NLM_article-title">Molecular pharmacology and neurobiology of rapid-acting antidepressants</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1146/annurev-pharmtox-010617-052811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1146%2Fannurev-pharmtox-010617-052811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30296896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOjtLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=213-236&author=T.+D.+Gouldauthor=C.+A.+Zarateauthor=S.+M.+Thompson&title=Molecular+pharmacology+and+neurobiology+of+rapid-acting+antidepressants&doi=10.1146%2Fannurev-pharmtox-010617-052811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants</span></div><div class="casAuthors">Gould, Todd D.; Zarate, Carlos A.; Thompson, Scott M.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">213-236</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  For decades, symptoms of depression have been treated primarily with medications that directly target the monoaminergic brain systems, which typically take weeks to exert measurable effects and months to exert remission of symptoms.  Low, subanesthetic doses of (R,S)-ketamine (ketamine) result in the rapid improvement of core depressive symptoms, including mood, anhedonia, and suicidal ideation, occurring within hours following a single administration, with relief from symptoms typically lasting up to a week.  The discovery of these actions of ketamine has resulted in a reconceptualization of how depression could be more effectively treated in the future.  In this review, we discuss clin. data pertaining to ketamine and other rapid-acting antidepressant drugs, as well as the current state of pharmacol. knowledge regarding their mechanism of action.  Addnl., we discuss the neurobiol. circuits that are engaged by this drug class and that may be targeted by a future generation of medications, for example, hydroxynorketamine; metabotropic glutamate receptor 2/3 antagonists; and N-methyl-d-aspartate, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, and γ-aminobutyric acid receptor modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgU_1LWtV2xLVg90H21EOLACvtfcHk0lgklsMGgXaV6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOjtLbO&md5=5cb69da4e6e99fdf5134e9a81235de71</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010617-052811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010617-052811%26sid%3Dliteratum%253Aachs%26aulast%3DGould%26aufirst%3DT.%2BD.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DThompson%26aufirst%3DS.%2BM.%26atitle%3DMolecular%2520pharmacology%2520and%2520neurobiology%2520of%2520rapid-acting%2520antidepressants%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2019%26volume%3D59%26spage%3D213%26epage%3D236%26doi%3D10.1146%2Fannurev-pharmtox-010617-052811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beautrais, A. L.</span></span> <span> </span><span class="NLM_article-title">A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1127</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1017/S1461145711000629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1017%2FS1461145711000629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=21557878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1eitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=1127-1131&author=G.+L.+Larkinauthor=A.+L.+Beautrais&title=A+preliminary+naturalistic+study+of+low-dose+ketamine+for+depression+and+suicide+ideation+in+the+emergency+department&doi=10.1017%2FS1461145711000629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department</span></div><div class="casAuthors">Larkin, Gregory Luke; Beautrais, Annette L.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1127-1131</span>CODEN:
                <span class="NLM_cas:coden">IJNUFB</span>;
        ISSN:<span class="NLM_cas:issn">1461-1457</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">We examd. the preliminary feasibility, tolerability and efficacy of single-dose, i.v. ketamine in depressed emergency department (ED) patients with suicide ideation (SI).  Fourteen depressed ED patients with SI received a single i.v. bolus of ketamine (0.2 mg/kg) over 1-2 min.  Patients were monitored for 4 h, then re-contacted daily for 10 d.  Treatment response and time to remission were evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS) and Kaplan-Meier survival anal., resp.  Mean MADRS scores fell significantly from 40.4 (s.e.m. = 1.8) at baseline to 11.5 (s.e.m. = 2.2) at 240 min.  Median time to MADRS score ≤10 was 80 min (interquartile range 0.67-24 h).  SI scores (MADRS item 10) decreased significantly from 3.9 (s.e.m. = 0.4) at baseline to 0.6 (s.e.m. = 0.2) after 40 min post-administration; SI improvements were sustained over 10 d.  These data provide preliminary, open-label support for the feasibility and efficacy of ketamine as a rapid-onset antidepressant in the ED.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3n1-ulQFRRLVg90H21EOLACvtfcHk0lh-8w8vtMAnbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1eitb4%253D&md5=baa32d2ac03c9ed00a6884ec7e57fb0f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1017%2FS1461145711000629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1461145711000629%26sid%3Dliteratum%253Aachs%26aulast%3DLarkin%26aufirst%3DG.%2BL.%26aulast%3DBeautrais%26aufirst%3DA.%2BL.%26atitle%3DA%2520preliminary%2520naturalistic%2520study%2520of%2520low-dose%2520ketamine%2520for%2520depression%2520and%2520suicide%2520ideation%2520in%2520the%2520emergency%2520department%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2011%26volume%3D14%26spage%3D1127%26epage%3D1131%26doi%3D10.1017%2FS1461145711000629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gueorguieva, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, J. H.</span></span> <span> </span><span class="NLM_article-title">Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">2482</span>– <span class="NLM_lpage">2492</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.94</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnpp.2017.94" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=28492279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFGhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=2482-2492&author=T.-P.+Suauthor=M.-H.+Chenauthor=C.-T.+Liauthor=W.-C.+Linauthor=C.-J.+Hongauthor=R.+Gueorguievaauthor=P.-C.+Tuauthor=Y.-M.+Baiauthor=C.-M.+Chengauthor=J.+H.+Krystal&title=Dose-related+effects+of+adjunctive+ketamine+in+Taiwanese+patients+with+treatment-resistant+depression&doi=10.1038%2Fnpp.2017.94"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression</span></div><div class="casAuthors">Su, Tung-Ping; Chen, Mu-Hong; Li, Cheng-Ta; Lin, Wei-Chen; Hong, Chen-Jee; Gueorguieva, Ralitza; Tu, Pei-Chi; Bai, Ya-Mei; Cheng, Chih-Ming; Krystal, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2482-2492</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The antidepressant effects of ketamine are thought to depend on brain-derived neurotrophic factor (BDNF) genotype and dose.  The purpose of this study was to characterize the dose-related antidepressant effects of ketamine in patients with treatment-resistant depression drawn from a Chinese population predominately possessing lower activity BDNF genotypes (Val/Met, Met/Met).  We conducted a double-blind, randomized, parallel-group, placebo-controlled trial of a single ketamine infusion (saline, 0.2 mg/kg, 0.5 mg/kg).  Patients (N=71; BDNF genotype: Val/Val (N=12, 17%), Val/Met (N=40, 56.3%), and Met/Met (N=19, 26.8%)) received mood ratings before infusion, after infusion, and for the subsequent 14 days.  Plasma ketamine levels and BDNF genotypes were assessed.  This study found a significant dose-related ketamine effect on scores on the Hamilton Depression Rating Scale (HAMD).  The responder anal. (>50% redn. from baseline HAMD on at least 2 days between days 2 and 5) also revealed a significant dose-related effect (saline: 12.5%, 0.2 mg/kg: 39.1%; 0.5 mg/kg: 45.8%).  This is the first report to our knowledge to demonstrate the dose-related efficacy of R/S-ketamine for treatment-resistant depression and the first to characterize ketamine effects in a genotyped Chinese population in which most (83%) patients possessed at least one copy of the lower functioning Met allele of the BDNF gene.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCoQDDPQblILVg90H21EOLACvtfcHk0lh-8w8vtMAnbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFGhu74%253D&md5=38c9f0256aa7c7ee7f0d5aa61e3adec4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.94&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.94%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DT.-P.%26aulast%3DChen%26aufirst%3DM.-H.%26aulast%3DLi%26aufirst%3DC.-T.%26aulast%3DLin%26aufirst%3DW.-C.%26aulast%3DHong%26aufirst%3DC.-J.%26aulast%3DGueorguieva%26aufirst%3DR.%26aulast%3DTu%26aufirst%3DP.-C.%26aulast%3DBai%26aufirst%3DY.-M.%26aulast%3DCheng%26aufirst%3DC.-M.%26aulast%3DKrystal%26aufirst%3DJ.%2BH.%26atitle%3DDose-related%2520effects%2520of%2520adjunctive%2520ketamine%2520in%2520Taiwanese%2520patients%2520with%2520treatment-resistant%2520depression%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D2482%26epage%3D2492%26doi%3D10.1038%2Fnpp.2017.94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murrough, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iosifescu, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Jurdi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillemer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foulkes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>170</i></span>,  <span class="NLM_fpage">1134</span>– <span class="NLM_lpage">1142</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2013.13030392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1176%2Fappi.ajp.2013.13030392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=23982301" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC3sbivVeluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=170&publication_year=2013&pages=1134-1142&author=J.+W.+Murroughauthor=D.+V.+Iosifescuauthor=L.+C.+Changauthor=R.+K.+Al+Jurdiauthor=C.+E.+Greenauthor=A.+M.+Perezauthor=S.+Iqbalauthor=S.+Pillemerauthor=A.+Foulkesauthor=A.+Shah&title=Antidepressant+efficacy+of+ketamine+in+treatment-resistant+major+depression%3A+a+two-site+randomized+controlled+trial&doi=10.1176%2Fappi.ajp.2013.13030392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial</span></div><div class="casAuthors">Murrough James W; Iosifescu Dan V; Chang Lee C; Al Jurdi Rayan K; Green Charles E; Perez Andrew M; Iqbal Syed; Pillemer Sarah; Foulkes Alexandra; Shah Asim; Charney Dennis S; Mathew Sanjay J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">170</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1134-42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has shown rapid antidepressant effects, but small study groups and inadequate control conditions in prior studies have precluded a definitive conclusion.  The authors evaluated the rapid antidepressant efficacy of ketamine in a large group of patients with treatment-resistant major depression.  METHOD:  This was a two-site, parallel-arm, randomized controlled trial of a single infusion of ketamine compared to an active placebo control condition, the anesthetic midazolam.  Patients with treatment-resistant major depression experiencing a major depressive episode were randomly assigned under double-blind conditions to receive a single intravenous infusion of ketamine or midazolam in a 2:1 ratio (N=73).  The primary outcome was change in depression severity 24 hours after drug administration, as assessed by the Montgomery-ÅAsberg Depression Rating Scale (MADRS).  RESULTS:  The ketamine group had greater improvement in the MADRS score than the midazolam group 24 hours after treatment.  After adjustment for baseline scores and site, the MADRS score was lower in the ketamine group than in the midazolam group by 7.95 points (95% confidence interval [CI], 3.20 to 12.71).  The likelihood of response at 24 hours was greater with ketamine than with midazolam (odds ratio, 2.18; 95% CI, 1.21 to 4.14), with response rates of 64% and 28%, respectively.  CONCLUSIONS:  Ketamine demonstrated rapid antidepressant effects in an optimized study design, further supporting NMDA receptor modulation as a novel mechanism for accelerated improvement in severe and chronic forms of depression.  More information on response durability and safety is required before implementation in clinical practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTK3l9x7dQJ9DEwO064Z95rfW6udTcc2eZL2PX58hmLOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbivVeluw%253D%253D&md5=69bb383250da1e7a6824a593541aa214</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2013.13030392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2013.13030392%26sid%3Dliteratum%253Aachs%26aulast%3DMurrough%26aufirst%3DJ.%2BW.%26aulast%3DIosifescu%26aufirst%3DD.%2BV.%26aulast%3DChang%26aufirst%3DL.%2BC.%26aulast%3DAl%2BJurdi%26aufirst%3DR.%2BK.%26aulast%3DGreen%26aufirst%3DC.%2BE.%26aulast%3DPerez%26aufirst%3DA.%2BM.%26aulast%3DIqbal%26aufirst%3DS.%26aulast%3DPillemer%26aufirst%3DS.%26aulast%3DFoulkes%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DA.%26atitle%3DAntidepressant%2520efficacy%2520of%2520ketamine%2520in%2520treatment-resistant%2520major%2520depression%253A%2520a%2520two-site%2520randomized%2520controlled%2520trial%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2013%26volume%3D170%26spage%3D1134%26epage%3D1142%26doi%3D10.1176%2Fappi.ajp.2013.13030392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murrough, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soleimani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWilde, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapidus, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacoviello, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lener, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kautz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stern, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial</span>. <i>Psychol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3571</span>, <span class="refDoi"> DOI: 10.1017/S0033291715001506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1017%2FS0033291715001506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26266877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC287itVaqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=3571&author=J.+W.+Murroughauthor=L.+Soleimaniauthor=K.+DeWildeauthor=K.+Collinsauthor=K.+Lapidusauthor=B.+Iacovielloauthor=M.+Lenerauthor=M.+Kautzauthor=J.+Kimauthor=J.+Stern&title=Ketamine+for+rapid+reduction+of+suicidal+ideation%3A+a+randomized+controlled+trial&doi=10.1017%2FS0033291715001506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial</span></div><div class="casAuthors">Murrough J W; Soleimani L; DeWilde K E; Collins K A; Iacoviello B M; Lener M; Kautz M; Iosifescu D V; Charney D S; Lapidus K A; Kim J; Stern J B; Price R B; Perez A M; Brallier J W; Rodriguez G J; Goodman W K</div><div class="citationInfo"><span class="NLM_cas:title">Psychological medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3571-80</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Suicide is a devastating public health problem and very few biological treatments have been found to be effective for quickly reducing the intensity of suicidal ideation (SI).  We have previously shown that a single dose of ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, is associated with a rapid reduction in depressive symptom severity and SI in patients with treatment-resistant depression.  METHOD:  We conducted a randomized, controlled trial of ketamine in patients with mood and anxiety spectrum disorders who presented with clinically significant SI (n = 24).  Patients received a single infusion of ketamine or midazolam (as an active placebo) in addition to standard of care.  SI measured using the Beck Scale for Suicidal Ideation (BSI) 24 h post-treatment represented the primary outcome.  Secondary outcomes included the Montgomery-Asberg Depression Rating Scale--Suicidal Ideation (MADRS-SI) score at 24 h and additional measures beyond the 24-h time-point.  RESULTS:  The intervention was well tolerated and no dropouts occurred during the primary 7-day assessment period.  BSI score was not different between the treatment groups at 24 h (p = 0.32); however, a significant difference emerged at 48 h (p = 0.047).  MADRS-SI score was lower in the ketamine group compared to midazolam group at 24 h (p = 0.05).  The treatment effect was no longer significant at the end of the 7-day assessment period.  CONCLUSIONS:  The current findings provide initial support for the safety and tolerability of ketamine as an intervention for SI in patients who are at elevated risk for suicidal behavior.  Larger, well-powered studies are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyrVioJTA195Pq5LRczm8ffW6udTcc2eY7PtqzHWBx6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287itVaqsw%253D%253D&md5=c9eb9a5c60ebce2066430b1229d24609</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1017%2FS0033291715001506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0033291715001506%26sid%3Dliteratum%253Aachs%26aulast%3DMurrough%26aufirst%3DJ.%2BW.%26aulast%3DSoleimani%26aufirst%3DL.%26aulast%3DDeWilde%26aufirst%3DK.%26aulast%3DCollins%26aufirst%3DK.%26aulast%3DLapidus%26aufirst%3DK.%26aulast%3DIacoviello%26aufirst%3DB.%26aulast%3DLener%26aufirst%3DM.%26aulast%3DKautz%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DStern%26aufirst%3DJ.%26atitle%3DKetamine%2520for%2520rapid%2520reduction%2520of%2520suicidal%2520ideation%253A%2520a%2520randomized%2520controlled%2520trial%26jtitle%3DPsychol.%2520Med.%26date%3D2015%26volume%3D45%26spage%3D3571%26doi%3D10.1017%2FS0033291715001506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grunebaum, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galfalvy, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, T.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keilp, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moitra, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parris, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marver, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milak, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sublette, M. E.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2017.17060647</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1176%2Fappi.ajp.2017.17060647" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29202655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ns12htw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=327-335&author=M.+F.+Grunebaumauthor=H.+C.+Galfalvyauthor=T.-H.+Chooauthor=J.+G.+Keilpauthor=V.+K.+Moitraauthor=M.+S.+Parrisauthor=J.+E.+Marverauthor=A.+K.+Burkeauthor=M.+S.+Milakauthor=M.+E.+Sublette&title=Ketamine+for+rapid+reduction+of+suicidal+thoughts+in+major+depression%3A+a+midazolam-controlled+randomized+clinical+trial&doi=10.1176%2Fappi.ajp.2017.17060647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial</span></div><div class="casAuthors">Grunebaum Michael F; Galfalvy Hanga C; Choo Tse-Hwei; Keilp John G; Moitra Vivek K; Parris Michelle S; Marver Julia E; Burke Ainsley K; Milak Matthew S; Sublette M Elizabeth; Oquendo Maria A; Mann J John</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">327-335</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce suicide risk.  Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation.  The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major depressive disorder.  METHOD:  In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score ≥4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion.  The primary outcome measure was SSI score 24 hours after infusion (at day 1).  RESULTS:  The reduction in SSI score at day 1 was 4.96 points greater for the ketamine group compared with the midazolam group (95% CI=2.33, 7.59; Cohen's d=0.75).  The proportion of responders (defined as having a reduction ≥50% in SSI score) at day 1 was 55% for the ketamine group and 30% for the midazolam group (odds ratio=2.85, 95% CI=1.14, 7.15; number needed to treat=4.0).  Improvement in the Profile of Mood States depression subscale was greater at day 1 for the ketamine group compared with the midazolam group (estimate=7.65, 95% CI=1.36, 13.94), and this effect mediated 33.6% of ketamine's effect on SSI score.  Side effects were short-lived, and clinical improvement was maintained for up to 6 weeks with additional optimized standard pharmacotherapy in an uncontrolled follow-up.  CONCLUSIONS:  Adjunctive ketamine demonstrated a greater reduction in clinically significant suicidal ideation in depressed patients within 24 hours compared with midazolam, partially independently of antidepressant effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQh8z9TZaL7U2gRQsDqrjW_fW6udTcc2eZxkbU2HQP39Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ns12htw%253D%253D&md5=6d562a138b50baab953a6e22267bc73e</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2017.17060647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2017.17060647%26sid%3Dliteratum%253Aachs%26aulast%3DGrunebaum%26aufirst%3DM.%2BF.%26aulast%3DGalfalvy%26aufirst%3DH.%2BC.%26aulast%3DChoo%26aufirst%3DT.-H.%26aulast%3DKeilp%26aufirst%3DJ.%2BG.%26aulast%3DMoitra%26aufirst%3DV.%2BK.%26aulast%3DParris%26aufirst%3DM.%2BS.%26aulast%3DMarver%26aufirst%3DJ.%2BE.%26aulast%3DBurke%26aufirst%3DA.%2BK.%26aulast%3DMilak%26aufirst%3DM.%2BS.%26aulast%3DSublette%26aufirst%3DM.%2BE.%26atitle%3DKetamine%2520for%2520rapid%2520reduction%2520of%2520suicidal%2520thoughts%2520in%2520major%2520depression%253A%2520a%2520midazolam-controlled%2520randomized%2520clinical%2520trial%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2018%26volume%3D175%26spage%3D327%26epage%3D335%26doi%3D10.1176%2Fappi.ajp.2017.17060647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zorumski, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennerick, S.</span></span> <span> </span><span class="NLM_article-title">Ketamine: NMDA receptors and beyond</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">11158</span>– <span class="NLM_lpage">11164</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.1547-16.2016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1523%2FJNEUROSCI.1547-16.2016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27807158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Ohuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=11158-11164&author=C.+F.+Zorumskiauthor=Y.+Izumiauthor=S.+Mennerick&title=Ketamine%3A+NMDA+receptors+and+beyond&doi=10.1523%2FJNEUROSCI.1547-16.2016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: NMDA receptors and beyond</span></div><div class="casAuthors">Zorumski, Charles F.; Izumi, Yukitoshi; Mennerick, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">11158-11164</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Human studies examg. the effects of the dissociative anesthetic ketamine as a model for psychosis and as a rapidly acting antidepressant have spurred great interest in understanding ketamine's actions at mol., cellular, and network levels.  Although ketamine has unequivocal uncompetitive inhibitory effects on N-methyl-d-aspartate receptors (NMDARs) and may preferentially alter the function of NMDARs on interneurons, recent work has questioned whether block of NMDARs is crit. for its mood enhancing actions.  In this viewpoint, we examine the evolving literature on ketamine supporting NMDARs as important triggers for certain psychiatric effects and the possibility that the antidepressant trigger is unrelated to NMDARs.  The rapidly evolving story of ketamine offers great hope for untangling and treating the biol. of both depressive and psychotic illnesses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZHmks6tBEArVg90H21EOLACvtfcHk0lhR593gmdnV9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Ohuro%253D&md5=c01604b55dcce286edcfa5add52f82f2</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1547-16.2016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1547-16.2016%26sid%3Dliteratum%253Aachs%26aulast%3DZorumski%26aufirst%3DC.%2BF.%26aulast%3DIzumi%26aufirst%3DY.%26aulast%3DMennerick%26aufirst%3DS.%26atitle%3DKetamine%253A%2520NMDA%2520receptors%2520and%2520beyond%26jtitle%3DJ.%2520Neurosci.%26date%3D2016%26volume%3D36%26spage%3D11158%26epage%3D11164%26doi%3D10.1523%2FJNEUROSCI.1547-16.2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, T. D.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of ketamine action as an antidepressant</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">801</span>– <span class="NLM_lpage">811</span>, <span class="refDoi"> DOI: 10.1038/mp.2017.255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fmp.2017.255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29532791" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGqtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=801-811&author=P.+Zanosauthor=T.+D.+Gould&title=Mechanisms+of+ketamine+action+as+an+antidepressant&doi=10.1038%2Fmp.2017.255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of ketamine action as an antidepressant</span></div><div class="casAuthors">Zanos, P.; Gould, T. D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">801-811</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Clin. studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions.  Although this finding has been met with enthusiasm, ketamine's widespread use is limited by its abuse potential and dissociative properties.  Recent preclin. research has focused on unraveling the mol. mechanisms underlying the antidepressant actions of ketamine in an effort to develop novel pharmacotherapies, which will mimic ketamine's antidepressant actions but lack its undesirable effects.  Here we review hypotheses for the mechanism of action of ketamine as an antidepressant, including synaptic or GluN2B-selective extra-synaptic N-methyl-D-aspartate receptor (NMDAR) inhibition, inhibition of NMDARs localized on GABAergic interneurons, inhibition of NMDAR-dependent burst firing of lateral habenula neurons, and the role of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor activation.  We also discuss links between ketamine's antidepressant actions and downstream mechanisms regulating synaptic plasticity, including brain-derived neurotrophic factor (BDNF), eukaryotic elongation factor 2 (eEF2), mechanistic target of rapamycin (mTOR) and glycogen synthase kinase-3 (GSK-3).  Mechanisms that do not involve direct inhibition of the NMDAR, including a role for ketamine's (R)-ketamine enantiomer and hydroxynorketamine (HNK) metabolites, specifically (2R,6R)-HNK, are also discussed.  Proposed mechanisms of ketamine's action are not mutually exclusive and may act in a complementary manner to exert acute changes in synaptic plasticity, leading to sustained strengthening of excitatory synapses, which are necessary for antidepressant behavioral actions.  Understanding the mol. mechanisms underpinning ketamine's antidepressant actions will be invaluable for the identification of targets, which will drive the development of novel, effective, next-generation pharmacotherapies for the treatment of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2Tp-KuHNxHbVg90H21EOLACvtfcHk0lhR593gmdnV9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGqtLo%253D&md5=4ad9b04daba1abb6f408b976c8d75463</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fmp.2017.255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2017.255%26sid%3Dliteratum%253Aachs%26aulast%3DZanos%26aufirst%3DP.%26aulast%3DGould%26aufirst%3DT.%2BD.%26atitle%3DMechanisms%2520of%2520ketamine%2520action%2520as%2520an%2520antidepressant%26jtitle%3DMol.%2520Psychiatry%26date%3D2018%26volume%3D23%26spage%3D801%26epage%3D811%26doi%3D10.1038%2Fmp.2017.255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, D.</span></span> <span> </span><span class="NLM_article-title">Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2921</span>– <span class="NLM_lpage">2927</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.17-08-02921.1997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1523%2FJNEUROSCI.17-08-02921.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=9092613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK2sXisValurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=2921-2927&author=B.+Moghaddamauthor=B.+Adamsauthor=A.+Vermaauthor=D.+Daly&title=Activation+of+glutamatergic+neurotransmission+by+ketamine%3A+a+novel+step+in+the+pathway+from+NMDA+receptor+blockade+to+dopaminergic+and+cognitive+disruptions+associated+with+the+prefrontal+cortex&doi=10.1523%2FJNEUROSCI.17-08-02921.1997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex</span></div><div class="casAuthors">Moghaddam, Bita; Adams, Barbara; Verma, Anita; Daly, Darron</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2921-2927</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Subanesthetic doses of ketamine, a noncompetitive NMDA receptor antagonist, impair prefrontal cortex (PFC) function in the rat and produce symptoms in humans similar to those obsd. in schizophrenia and dissociative states, including impaired performance of frontal lobe-sensitive tests.  Several lines of evidence suggest that ketamine may impair PFC function in part by interacting with dopamine neurotransmission in this region.  This study sought to det. the mechanism by which ketamine may disrupt dopaminergic neurotransmission in, and cognitive functions assocd. with, the PFC.  A thorough dose-response study using microdialysis in conscious rats indicated that low doses of ketamine (10, 20, and 30 mg/kg) increase glutamate outflow in the PFC, suggesting that at these doses ketamine may increase glutamatergic neurotransmission in the PFC at non-NMDA glutamate receptors.  An anesthetic dose of ketamine (200 mg/kg) decreased, and an intermediate dose of 50 mg/kg did not affect, glutamate levels.  Ketamine, at 30 mg/kg, also increased the release of dopamine in the PFC.  This increase was blocked by intra-PFC application of the AMPA/kainate receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione CNQX.  Furthermore, ketamine-induced activation of dopamine release and impairment of spatial delayed alternation in the rodent, a PFC-sensitive cognitive task, was ameliorated by systemic pretreatment with AMPA/kainate receptor antagonist LY293558.  These findings suggest that ketamine may disrupt dopaminergic neurotransmission in the PFC as well as cognitive functions assocd. with this region, in part, by increasing the release of glutamate, thereby stimulating postsynaptic non-NMDA glutamate receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKNWCBwx_sLVg90H21EOLACvtfcHk0lg8fsQ728VVow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXisValurk%253D&md5=74f7a1696b2c30f0a38e34963334eb0b</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.17-08-02921.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.17-08-02921.1997%26sid%3Dliteratum%253Aachs%26aulast%3DMoghaddam%26aufirst%3DB.%26aulast%3DAdams%26aufirst%3DB.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DDaly%26aufirst%3DD.%26atitle%3DActivation%2520of%2520glutamatergic%2520neurotransmission%2520by%2520ketamine%253A%2520a%2520novel%2520step%2520in%2520the%2520pathway%2520from%2520NMDA%2520receptor%2520blockade%2520to%2520dopaminergic%2520and%2520cognitive%2520disruptions%2520associated%2520with%2520the%2520prefrontal%2520cortex%26jtitle%3DJ.%2520Neurosci.%26date%3D1997%26volume%3D17%26spage%3D2921%26epage%3D2927%26doi%3D10.1523%2FJNEUROSCI.17-08-02921.1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Homayoun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, B.</span></span> <span> </span><span class="NLM_article-title">NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">11496</span>– <span class="NLM_lpage">11500</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.2213-07.2007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1523%2FJNEUROSCI.2213-07.2007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=17959792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1Kms7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=11496-11500&author=H.+Homayounauthor=B.+Moghaddam&title=NMDA+receptor+hypofunction+produces+opposite+effects+on+prefrontal+cortex+interneurons+and+pyramidal+neurons&doi=10.1523%2FJNEUROSCI.2213-07.2007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons</span></div><div class="casAuthors">Homayoun, Houman; Moghaddam, Bita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">11496-11500</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">NMDA receptors mediate excitatory postsynaptic potentials throughout the brain but, paradoxically, NMDA receptor antagonists produce cortical excitation in humans and behaving rodents.  To elucidate a mechanism for these diverging effects, we examd. the effect of use-dependent inhibition of NMDA receptors on the spontaneous activity of putative GABA interneurons and pyramidal neurons in the prefrontal cortex of awake rats.  We find that inhibition of NMDA receptors predominately decreases the activity of putative GABA interneurons but, at a delayed rate, increases the firing rate of the majority of pyramidal neurons.  Thus, NMDA receptors preferentially drive the activity of cortical inhibitory interneurons suggesting that NMDA receptor inhibition causes cortical excitation by disinhibition of pyramidal neurons.  These findings support the hypothesis that NMDA receptor hypofunction, which has been implicated in the pathophysiol. of schizophrenia, diminishes the inhibitory control of PFC output neurons.  Reducing this effect may be crit. for treatment of schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphTQMv9YbXkrVg90H21EOLACvtfcHk0lg8fsQ728VVow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1Kms7zK&md5=bb02a5b8f8b33e213c1a87f8e42530ff</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2213-07.2007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2213-07.2007%26sid%3Dliteratum%253Aachs%26aulast%3DHomayoun%26aufirst%3DH.%26aulast%3DMoghaddam%26aufirst%3DB.%26atitle%3DNMDA%2520receptor%2520hypofunction%2520produces%2520opposite%2520effects%2520on%2520prefrontal%2520cortex%2520interneurons%2520and%2520pyramidal%2520neurons%26jtitle%3DJ.%2520Neurosci.%26date%3D2007%26volume%3D27%26spage%3D11496%26epage%3D11500%26doi%3D10.1523%2FJNEUROSCI.2213-07.2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banasr, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dwyer, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajanian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span> <span> </span><span class="NLM_article-title">mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>329</i></span>,  <span class="NLM_fpage">959</span>– <span class="NLM_lpage">964</span>, <span class="refDoi"> DOI: 10.1126/science.1190287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1126%2Fscience.1190287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=20724638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVaqurzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=329&publication_year=2010&pages=959-964&author=N.+Liauthor=B.+Leeauthor=R.-J.+Liuauthor=M.+Banasrauthor=J.+M.+Dwyerauthor=M.+Iwataauthor=X.-Y.+Liauthor=G.+Aghajanianauthor=R.+S.+Duman&title=mTOR-dependent+synapse+formation+underlies+the+rapid+antidepressant+effects+of+NMDA+antagonists&doi=10.1126%2Fscience.1190287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists</span></div><div class="casAuthors">Li, Nanxin; Lee, Boyoung; Liu, Rong-Jian; Banasr, Mounira; Dwyer, Jason M.; Iwata, Masaaki; Li, Xiao-Yuan; Aghajanian, George; Duman, Ronald S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">329</span>
        (<span class="NLM_cas:issue">5994</span>),
    <span class="NLM_cas:pages">959-964</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The rapid antidepressant response after ketamine administration in treatment-resistant depressed patients suggests a possible new approach for treating mood disorders compared to the weeks or months required for std. medications.  However, the mechanisms underlying this action of ketamine [a glutamate N-methyl-D-aspartic acid (NMDA) receptor antagonist] have not been identified.  We obsd. that ketamine rapidly activated the mammalian target of rapamycin (mTOR) pathway, leading to increased synaptic signaling proteins and increased no. and function of new spine synapses in the prefrontal cortex of rats.  Moreover, blockade of mTOR signaling completely blocked ketamine induction of synaptogenesis and behavioral responses in models of depression.  Our results demonstrate that these effects of ketamine are opposite to the synaptic deficits that result from exposure to stress and could contribute to the fast antidepressant actions of ketamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpup6dg0BLy6bVg90H21EOLACvtfcHk0lg8fsQ728VVow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVaqurzI&md5=10e346a65ae3aa8eb30f16fccbda28b3</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1126%2Fscience.1190287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1190287%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DR.-J.%26aulast%3DBanasr%26aufirst%3DM.%26aulast%3DDwyer%26aufirst%3DJ.%2BM.%26aulast%3DIwata%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.-Y.%26aulast%3DAghajanian%26aufirst%3DG.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DmTOR-dependent%2520synapse%2520formation%2520underlies%2520the%2520rapid%2520antidepressant%2520effects%2520of%2520NMDA%2520antagonists%26jtitle%3DScience%26date%3D2010%26volume%3D329%26spage%3D959%26epage%3D964%26doi%3D10.1126%2Fscience.1190287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Monteggia, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gideons, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavalali, E. T.</span></span> <span> </span><span class="NLM_article-title">The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2012.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2012.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=23062356" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSnsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1199-1203&author=L.+M.+Monteggiaauthor=E.+Gideonsauthor=E.+T.+Kavalali&title=The+role+of+eukaryotic+elongation+factor+2+kinase+in+rapid+antidepressant+action+of+ketamine&doi=10.1016%2Fj.biopsych.2012.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Eukaryotic Elongation Factor 2 Kinase in Rapid Antidepressant Action of Ketamine</span></div><div class="casAuthors">Monteggia, Lisa M.; Gideons, Erinn; Kavalali, Ege T.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1199-1203</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Major depressive disorder is a devastating mental disorder.  Current antidepressant medications can be effective for some patients with depression; however, these drugs exert mood-elevating effects only after prolonged administration, and a sizable fraction of the patient population fails to respond to treatment.  There is an urgent need for faster-acting antidepressants with reliable treatment outcomes and sustained efficacy for individuals with depression, in particular those contemplating suicide.  Recent clin. studies report that ketamine, an ionotropic glutamatergic N-methyl-D-aspartate (NMDA) receptor blocker, shows fast-acting antidepressant action, thus bringing fresh perspective into preclin. studies investigating novel antidepressant targets and treatments.  Our recent studies show that the effects of ketamine are dependent on brain-derived neurotrophic factor (BDNF) and subsequent activation of the high-affinity BDNF receptor, TrkB.  Our findings also suggest that the fast-acting antidepressant effects of ketamine require rapid protein translation, but not transcription, resulting in robust increases in dendritic BDNF protein levels that are important for the behavioral effect.  These findings also uncover eukaryotic elongation factor 2 kinase (eEF2K), a Ca2+/calmodulin dependent serine/threonine kinase that phosphorylates eEF2 and regulates the elongation step of protein translation, as a major mol. substrate mediating the rapid antidepressant effect of ketamine.  Our results show that ketamine-mediated suppression of resting NMDA receptor activity leads to inhibition of eEF2 kinase and subsequent dephosphorylation of eEF2 and augmentation of BDNF synthesis.  This article outlines our recent studies on the synaptic mechanisms that underlie ketamine action, in particular the properties of eEF2K as a potential antidepressant target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMxq-boIeY5rVg90H21EOLACvtfcHk0lgh_0pN3qp4Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSnsbjE&md5=d8c874fa212e2dca424474e5224f1a7e</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2012.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2012.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DMonteggia%26aufirst%3DL.%2BM.%26aulast%3DGideons%26aufirst%3DE.%26aulast%3DKavalali%26aufirst%3DE.%2BT.%26atitle%3DThe%2520role%2520of%2520eukaryotic%2520elongation%2520factor%25202%2520kinase%2520in%2520rapid%2520antidepressant%2520action%2520of%2520ketamine%26jtitle%3DBiol.%2520Psychiatry%26date%3D2013%26volume%3D73%26spage%3D1199%26epage%3D1203%26doi%3D10.1016%2Fj.biopsych.2012.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Autry, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adachi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nosyreva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Na, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, P.-f.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavalali, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteggia, L. M.</span></span> <span> </span><span class="NLM_article-title">NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>475</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1038/nature10130</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnature10130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=21677641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsFOktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=475&publication_year=2011&pages=91-95&author=A.+E.+Autryauthor=M.+Adachiauthor=E.+Nosyrevaauthor=E.+S.+Naauthor=M.+F.+Losauthor=P.-f.+Chengauthor=E.+T.+Kavalaliauthor=L.+M.+Monteggia&title=NMDA+receptor+blockade+at+rest+triggers+rapid+behavioural+antidepressant+responses&doi=10.1038%2Fnature10130"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses</span></div><div class="casAuthors">Autry, Anita E.; Adachi, Megumi; Nosyreva, Elena; Na, Elisa S.; Los, Maarten F.; Cheng, Peng-fei; Kavalali, Ege T.; Monteggia, Lisa M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">475</span>
        (<span class="NLM_cas:issue">7354</span>),
    <span class="NLM_cas:pages">91-95</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Clin. studies consistently demonstrate that a single sub-psychomimetic dose of ketamine, an ionotropic glutamatergic NMDAR (N-methyl-D-aspartate receptor) antagonist, produces fast-acting antidepressant responses in patients suffering from major depressive disorder, although the underlying mechanism is unclear.  Depressed patients report the alleviation of major depressive disorder symptoms within two hours of a single, low-dose i.v. infusion of ketamine, with effects lasting up to two weeks, unlike traditional antidepressants (serotonin re-uptake inhibitors), which take weeks to reach efficacy.  This delay is a major drawback to current therapies for major depressive disorder and faster-acting antidepressants are needed, particularly for suicide-risk patients.  The ability of ketamine to produce rapidly acting, long-lasting antidepressant responses in depressed patients provides a unique opportunity to investigate underlying cellular mechanisms.  Here we show that ketamine and other NMDAR antagonists produce fast-acting behavioral antidepressant-like effects in mouse models, and that these effects depend on the rapid synthesis of brain-derived neurotrophic factor.  We find that the ketamine-mediated blockade of NMDAR at rest deactivates eukaryotic elongation factor 2 (eEF2) kinase (also called CaMKIII), resulting in reduced eEF2 phosphorylation and de-suppression of translation of brain-derived neurotrophic factor.  Furthermore, we find that inhibitors of eEF2 kinase induce fast-acting behavioral antidepressant-like effects.  Our findings indicate that the regulation of protein synthesis by spontaneous neurotransmission may serve as a viable therapeutic target for the development of fast-acting antidepressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxV9Fl5NiW-rVg90H21EOLACvtfcHk0lgh_0pN3qp4Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsFOktbw%253D&md5=4f3aadd45b6e5fbd2f26ddd36939321b</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnature10130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10130%26sid%3Dliteratum%253Aachs%26aulast%3DAutry%26aufirst%3DA.%2BE.%26aulast%3DAdachi%26aufirst%3DM.%26aulast%3DNosyreva%26aufirst%3DE.%26aulast%3DNa%26aufirst%3DE.%2BS.%26aulast%3DLos%26aufirst%3DM.%2BF.%26aulast%3DCheng%26aufirst%3DP.-f.%26aulast%3DKavalali%26aufirst%3DE.%2BT.%26aulast%3DMonteggia%26aufirst%3DL.%2BM.%26atitle%3DNMDA%2520receptor%2520blockade%2520at%2520rest%2520triggers%2520rapid%2520behavioural%2520antidepressant%2520responses%26jtitle%3DNature%26date%3D2011%26volume%3D475%26spage%3D91%26epage%3D95%26doi%3D10.1038%2Fnature10130" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargroder, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delpire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, B. J.</span></span> <span> </span><span class="NLM_article-title">GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e03581</span>, <span class="refDoi"> DOI: 10.7554/eLife.03581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.7554%2FeLife.03581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=25340958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOmtr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=e03581&author=O.+H.+Millerauthor=L.+Yangauthor=C.-C.+Wangauthor=E.+A.+Hargroderauthor=Y.+Zhangauthor=E.+Delpireauthor=B.+J.+Hall&title=GluN2B-containing+NMDA+receptors+regulate+depression-like+behavior+and+are+critical+for+the+rapid+antidepressant+actions+of+ketamine&doi=10.7554%2FeLife.03581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine</span></div><div class="casAuthors">Miller, Oliver H.; Yang, Lingling; Wang, Chih-Chieh; Hargroder, Elizabeth A.; Zhang, Yihui; Delpire, Eric; Hall, Benjamin J.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">03581/1-03581/37, 37 pp.</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">A single, low dose of the NMDA receptor antagonist ketamine produces rapid antidepressant actions in treatment-resistant depressed patients.  Understanding the cellular mechanisms underlying this will lead to new therapies for treating major depression.  NMDARs are heteromultimeric complexes formed through assocn. of two GluN1 and two GluN2 subunits.  We show that in vivo deletion of GluN2B, only from principal cortical neurons, mimics and occludes ketamine's actions on depression-like behavior and excitatory synaptic transmission.  Furthermore, ketamine-induced increases in mTOR activation and synaptic protein synthesis were mimicked and occluded in 2BΔCtx mice.  We show here that cortical GluN2B-contg. NMDARs are uniquely activated by ambient glutamate to regulate levels of excitatory synaptic transmission.  Together these data predict a novel cellular mechanism that explains ketamine's rapid antidepressant actions.  In this model, basal glutamatergic neurotransmission sensed by cortical GluN2B-contg. NMDARs regulates excitatory synaptic strength in PFC detg. basal levels of depression-like behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJjqjA7UWBebVg90H21EOLACvtfcHk0lgh_0pN3qp4Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOmtr%252FI&md5=2f630879bb1868d45b831b333afe61d8</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.7554%2FeLife.03581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.03581%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DO.%2BH.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DC.-C.%26aulast%3DHargroder%26aufirst%3DE.%2BA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDelpire%26aufirst%3DE.%26aulast%3DHall%26aufirst%3DB.%2BJ.%26atitle%3DGluN2B-containing%2520NMDA%2520receptors%2520regulate%2520depression-like%2520behavior%2520and%2520are%2520critical%2520for%2520the%2520rapid%2520antidepressant%2520actions%2520of%2520ketamine%26jtitle%3DeLife%26date%3D2014%26volume%3D3%26spage%3De03581%26doi%3D10.7554%2FeLife.03581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, B. J.</span></span> <span> </span><span class="NLM_article-title">Two cellular hypotheses explaining the initiation of ketamine’s antidepressant actions: Direct inhibition and disinhibition</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2015.07.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.neuropharm.2015.07.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26211972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVajsL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2016&pages=17-26&author=O.+H.+Millerauthor=J.+T.+Moranauthor=B.+J.+Hall&title=Two+cellular+hypotheses+explaining+the+initiation+of+ketamine%E2%80%99s+antidepressant+actions%3A+Direct+inhibition+and+disinhibition&doi=10.1016%2Fj.neuropharm.2015.07.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition</span></div><div class="casAuthors">Miller, Oliver H.; Moran, Jacqueline T.; Hall, Benjamin J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-26</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A single, low dose of ketamine evokes antidepressant actions in depressed patients and in patients with treatment-resistant depression (TRD).  Unlike classic antidepressants, which regulate monoamine neurotransmitter systems, ketamine is an antagonist of the N-methyl-D-aspartate (NMDA) family of glutamate receptors.  The effectiveness of NMDAR antagonists in TRD unveils a new set of targets for therapeutic intervention in major depressive disorder (MDD) and TRD.  However, a better understanding of the cellular mechanisms underlying these effects is required for guiding future therapeutic strategies, in order to minimize side effects and prolong duration of efficacy.  Here we review the evidence for and against two hypotheses that have been proposed to explain how NMDAR antagonism initiates protein synthesis and increases excitatory synaptic drive in corticolimbic brain regions, either through selective antagonism of inhibitory interneurons and cortical disinhibition, or by direct inhibition of cortical pyramidal neurons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSOVd93pk9PbVg90H21EOLACvtfcHk0lgNJiJnnFbAig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVajsL3J&md5=66b7f60bcc70f977955cfe49d2831798</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2015.07.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2015.07.028%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DO.%2BH.%26aulast%3DMoran%26aufirst%3DJ.%2BT.%26aulast%3DHall%26aufirst%3DB.%2BJ.%26atitle%3DTwo%2520cellular%2520hypotheses%2520explaining%2520the%2520initiation%2520of%2520ketamine%25E2%2580%2599s%2520antidepressant%2520actions%253A%2520Direct%2520inhibition%2520and%2520disinhibition%26jtitle%3DNeuropharmacology%26date%3D2016%26volume%3D100%26spage%3D17%26epage%3D26%26doi%3D10.1016%2Fj.neuropharm.2015.07.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallarackal, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kvarta, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeGates, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span> <span> </span><span class="NLM_article-title">An excitatory synapse hypothesis of depression</span>. <i>Trends Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1016/j.tins.2015.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.tins.2015.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=25887240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvFWmtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=279-294&author=S.+M.+Thompsonauthor=A.+J.+Kallarackalauthor=M.+D.+Kvartaauthor=A.+M.+Van+Dykeauthor=T.+A.+LeGatesauthor=X.+Cai&title=An+excitatory+synapse+hypothesis+of+depression&doi=10.1016%2Fj.tins.2015.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">An excitatory synapse hypothesis of depression</span></div><div class="casAuthors">Thompson, Scott M.; Kallarackal, Angy J.; Kvarta, Mark D.; Van Dyke, Adam M.; LeGates, Tara A.; Cai, Xiang</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Neurosciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">279-294</span>CODEN:
                <span class="NLM_cas:coden">TNSCDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-2236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Depression is a common cause of mortality and morbidity, but the biol. bases of the deficits in emotional and cognitive processing remain incompletely understood.  Current antidepressant therapies are effective in only some patients and act slowly.  Here, we propose an excitatory synapse hypothesis of depression in which chronic stress and genetic susceptibility cause changes in the strength of subsets of glutamatergic synapses at multiple locations, including the prefrontal cortex (PFC), hippocampus, and nucleus accumbens (NAc), leading to a dysfunction of corticomesolimbic reward circuitry that underlies many of the symptoms of depression.  This hypothesis accounts for current depression treatments and suggests an updated framework for the development of better therapeutic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDTca5CsMw3bVg90H21EOLACvtfcHk0lgNJiJnnFbAig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvFWmtro%253D&md5=ea8be597fe6fad3e14f5d108f24c7b0c</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.tins.2015.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tins.2015.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DS.%2BM.%26aulast%3DKallarackal%26aufirst%3DA.%2BJ.%26aulast%3DKvarta%26aufirst%3DM.%2BD.%26aulast%3DVan%2BDyke%26aufirst%3DA.%2BM.%26aulast%3DLeGates%26aufirst%3DT.%2BA.%26aulast%3DCai%26aufirst%3DX.%26atitle%3DAn%2520excitatory%2520synapse%2520hypothesis%2520of%2520depression%26jtitle%3DTrends%2520Neurosci.%26date%3D2015%26volume%3D38%26spage%3D279%26epage%3D294%26doi%3D10.1016%2Fj.tins.2015.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schloesser, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCammon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manji, H. K.</span></span> <span> </span><span class="NLM_article-title">Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2007.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2007.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=17643398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVShs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=349-352&author=S.+Maengauthor=C.+A.+Zarateauthor=J.+Duauthor=R.+J.+Schloesserauthor=J.+McCammonauthor=G.+Chenauthor=H.+K.+Manji&title=Cellular+mechanisms+underlying+the+antidepressant+effects+of+ketamine%3A+role+of+%CE%B1-amino-3-hydroxy-5-methylisoxazole-4-propionic+acid+receptors&doi=10.1016%2Fj.biopsych.2007.05.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors</span></div><div class="casAuthors">Maeng, Sungho; Zarate, Carlos A., Jr.; Du, Jing; Schloesser, Robert J.; McCammon, Joseph; Chen, Guang; Manji, Husseini K.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">349-352</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Ketamine exerts a robust, rapid, and relatively sustained antidepressant effect in patients with major depression.  Understanding the mechanisms underlying the intriguing effects of N-Me d-aspartate (NMDA) antagonists could lead to novel treatments with a rapid onset of action.  Methods: The learned helplessness, forced swim, and passive avoidance tests were used to investigate ketamine's behavioral effects in mice.  Addnl. biochem. and behavioral expts. were undertaken to det. whether the antidepressant-like properties of ketamine and other NMDA antagonists involve α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor throughput.  Results: Subanesthetic doses of ketamine treatment caused acute and sustained antidepressant-like effects.  At these doses, ketamine did not impair fear memory retention.  MK-801 (dizocilpine) and Ro25-6981, an NR2B selective antagonist, also exerted antidepressant-like effects; these effects, however, were not sustained as long as those of ketamine.  Pre-treatment with NBQX, an AMPA receptor antagonist, attenuated both ketamine-induced antidepressant-like behavior and regulation of hippocampal phosphorylated GluR1 AMPA receptors.  Conclusions: NMDA antagonists might exert rapid antidepressant-like effects by enhancing AMPA relative to NMDA throughput in crit. neuronal circuits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot035lK7LpJbVg90H21EOLACvtfcHk0lgNJiJnnFbAig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVShs7g%253D&md5=c2da1986b50b509c01d840f6348f6ce2</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2007.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2007.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DMaeng%26aufirst%3DS.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DSchloesser%26aufirst%3DR.%2BJ.%26aulast%3DMcCammon%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DManji%26aufirst%3DH.%2BK.%26atitle%3DCellular%2520mechanisms%2520underlying%2520the%2520antidepressant%2520effects%2520of%2520ketamine%253A%2520role%2520of%2520%25CE%25B1-amino-3-hydroxy-5-methylisoxazole-4-propionic%2520acid%2520receptors%26jtitle%3DBiol.%2520Psychiatry%26date%3D2008%26volume%3D63%26spage%3D349%26epage%3D352%26doi%3D10.1016%2Fj.biopsych.2007.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">Antidepressant effects of (+)-MK-801 and (−)-MK-801 in the social defeat stress model</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">pyw080</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyw080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1093%2Fijnp%2Fpyw080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27608811" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2016&pages=pyw080&author=B.+Yangauthor=Q.+Renauthor=M.+Maauthor=Q.-X.+Chenauthor=K.+Hashimoto&title=Antidepressant+effects+of+%28%2B%29-MK-801+and+%28%E2%88%92%29-MK-801+in+the+social+defeat+stress+model&doi=10.1093%2Fijnp%2Fpyw080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyw080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyw080%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DB.%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DQ.-X.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DAntidepressant%2520effects%2520of%2520%2528%252B%2529-MK-801%2520and%2520%2528%25E2%2588%2592%2529-MK-801%2520in%2520the%2520social%2520defeat%2520stress%2520model%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2016%26volume%3D19%26spage%3Dpyw080%26doi%3D10.1093%2Fijnp%2Fpyw080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moaddel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elmer, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alkondon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pribut, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, N. S.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">NMDAR inhibition-independent antidepressant actions of ketamine metabolites</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>533</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1038/nature17998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnature17998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27144355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnt1Ogs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=533&publication_year=2016&pages=481-486&author=P.+Zanosauthor=R.+Moaddelauthor=P.+J.+Morrisauthor=P.+Georgiouauthor=J.+Fischellauthor=G.+I.+Elmerauthor=M.+Alkondonauthor=P.+Yuanauthor=H.+J.+Pributauthor=N.+S.+Singh&title=NMDAR+inhibition-independent+antidepressant+actions+of+ketamine+metabolites&doi=10.1038%2Fnature17998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">NMDAR inhibition-independent antidepressant actions of ketamine metabolites</span></div><div class="casAuthors">Zanos, Panos; Moaddel, Ruin; Morris, Patrick J.; Georgiou, Polymnia; Fischell, Jonathan; Elmer, Greg I.; Alkondon, Manickavasagom; Yuan, Peixiong; Pribut, Heather J.; Singh, Nagendra S.; Dossou, Katina S. S.; Fang, Yuhong; Huang, Xi-Ping; Mayo, Cheryl L.; Wainer, Irving W.; Albuquerque, Edson X.; Thompson, Scott M.; Thomas, Craig J.; Zarate, Carlos A., Jr; Gould, Todd D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">533</span>
        (<span class="NLM_cas:issue">7604</span>),
    <span class="NLM_cas:pages">481-486</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Major depressive disorder affects around 16% of the world population at some point in their lives.  Despite the availability of numerous monoaminergic-based antidepressants, most patients require several weeks, if not months, to respond to these treatments, and many patients never attain sustained remission of their symptoms.  The noncompetitive, glutamatergic NMDAR (N-methyl-D-aspartate receptor) antagonist (R,S)-ketamine exerts rapid and sustained antidepressant effects after a single dose in patients with depression, but its use is assocd. with undesirable side effects.  Here the authors show that the metab. of (R,S)-ketamine to (2S,6S;2R,6R)-hydroxynorketamine (HNK) is essential for its antidepressant effects, and that the (2R,6R)-HNK enantiomer exerts behavioral, electroencephalog., electrophysiol. and cellular antidepressant-related actions in mice.  These antidepressant actions are independent of NMDAR inhibition but involve early and sustained activation of AMPARs (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors).  The authors also establish that (2R,6R)-HNK lacks ketamine-related side effects.  The data implicate a novel mechanism underlying the antidepressant properties of (R,S)-ketamine and have relevance for the development of next-generation, rapid-acting antidepressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzu3ydujHJ37Vg90H21EOLACvtfcHk0lhozXTRtThYAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnt1Ogs70%253D&md5=fcb8479079696cf3dc0ee89f5fadd72a</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1038%2Fnature17998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17998%26sid%3Dliteratum%253Aachs%26aulast%3DZanos%26aufirst%3DP.%26aulast%3DMoaddel%26aufirst%3DR.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26aulast%3DGeorgiou%26aufirst%3DP.%26aulast%3DFischell%26aufirst%3DJ.%26aulast%3DElmer%26aufirst%3DG.%2BI.%26aulast%3DAlkondon%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DP.%26aulast%3DPribut%26aufirst%3DH.%2BJ.%26aulast%3DSingh%26aufirst%3DN.%2BS.%26atitle%3DNMDAR%2520inhibition-independent%2520antidepressant%2520actions%2520of%2520ketamine%2520metabolites%26jtitle%3DNature%26date%3D2016%26volume%3D533%26spage%3D481%26epage%3D486%26doi%3D10.1038%2Fnature17998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zanos, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Highland, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Georgiou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenne, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moaddel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, T. D.</span></span> <span> </span><span class="NLM_article-title">(2R, 6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">6441</span>– <span class="NLM_lpage">6450</span>, <span class="refDoi"> DOI: 10.1073/pnas.1819540116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1073%2Fpnas.1819540116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30867285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFentbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=6441-6450&author=P.+Zanosauthor=J.+N.+Highlandauthor=B.+W.+Stewartauthor=P.+Georgiouauthor=C.+E.+Jenneauthor=J.+Lovettauthor=P.+J.+Morrisauthor=C.+J.+Thomasauthor=R.+Moaddelauthor=C.+A.+Zarateauthor=T.+D.+Gould&title=%282R%2C+6R%29-hydroxynorketamine+exerts+mGlu2+receptor-dependent+antidepressant+actions&doi=10.1073%2Fpnas.1819540116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions</span></div><div class="casAuthors">Zanos, Panos; Highland, Jaclyn N.; Stewart, Brent W.; Georgiou, Polymnia; Jenne, Carleigh E.; Lovett, Jacqueline; Morris, Patrick J.; Thomas, Craig J.; Moaddel, Ruin; Zarate, Carlos A. Jr.; Gould, Todd D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6441-6450</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Currently approved antidepressant drugs often take months to take full effect, and a$$Hat$$ 1/430% of depressed patients remain treatment resistant.  In contrast, ketamine, when administered as a single subanesthetic dose, exerts rapid and sustained antidepressant actions.  Preclin. studies indicate that the ketamine metabolite (2R,6R)-hydroxynorketamine [(2R,6R)-HNK] is a rapid-acting antidepressant drug candidate with limited dissocn. properties and abuse potential.  We assessed the role of group II metabotropic glutamate receptor subtypes 2 (mGlu2) and 3 (mGlu3) in the antidepressant-relevant actions of (2R,6R)-HNK using behavioral, genetic, and pharmacol. approaches as well as cortical quant. EEG (qEEG) measurements in mice.  Both ketamine and (2R,6R)-HNK prevented mGlu2/3 receptor agonist (LY379268)-induced body temp. increases in mice lacking the Grm3, but not Grm2, gene.  This action was not replicated by NMDA receptor antagonists or a chem. variant of ketamine that limits metab. to (2R,6R)-HNK.  The antidepressant-relevant behavioral effects and 30- to 80-Hz qEEG oscillation (gamma-range) increases resultant from (2R,6R)-HNK administration were prevented by pretreatment with an mGlu2/3 receptor agonist and absent in mice lacking the Grm2, but not Grm3a$$Hat$$  /a$$Hat$$  , gene.  Combined subeffective doses of the mGlu2/3 receptor antagonist LY341495 and (2R,6R)-HNK exerted synergistic increases on gamma oscillations and antidepressant-relevant behavioral actions.  These findings highlight that (2R,6R)-HNK exerts antidepressant-relevant actions via a mechanism converging with mGlu2 receptor signaling and suggest enhanced cortical gamma oscillations as a marker of target engagement relevant to antidepressant efficacy.  Moreover, these results support the use of (2R,6R)-HNK and inhibitors of mGlu2 receptor function in clin. trials for treatment-resistant depression either alone or in combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVpuD2LnUuJLVg90H21EOLACvtfcHk0lhozXTRtThYAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFentbo%253D&md5=42b259f71d373730a466a335d27663b0</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1819540116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1819540116%26sid%3Dliteratum%253Aachs%26aulast%3DZanos%26aufirst%3DP.%26aulast%3DHighland%26aufirst%3DJ.%2BN.%26aulast%3DStewart%26aufirst%3DB.%2BW.%26aulast%3DGeorgiou%26aufirst%3DP.%26aulast%3DJenne%26aufirst%3DC.%2BE.%26aulast%3DLovett%26aufirst%3DJ.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DMoaddel%26aufirst%3DR.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DGould%26aufirst%3DT.%2BD.%26atitle%3D%25282R%252C%25206R%2529-hydroxynorketamine%2520exerts%2520mGlu2%2520receptor-dependent%2520antidepressant%2520actions%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2019%26volume%3D116%26spage%3D6441%26epage%3D6450%26doi%3D10.1073%2Fpnas.1819540116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heifets, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudheimer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pankow, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatzberg, A. F.</span></span> <span> </span><span class="NLM_article-title">Attenuation of antidepressant effects of ketamine by opioid receptor antagonism</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">1205</span>– <span class="NLM_lpage">1215</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2018.18020138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1176%2Fappi.ajp.2018.18020138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30153752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BB3c3is1yjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=1205-1215&author=N.+R.+Williamsauthor=B.+D.+Heifetsauthor=C.+Blaseyauthor=K.+Sudheimerauthor=J.+Pannuauthor=H.+Pankowauthor=J.+Hawkinsauthor=J.+Birnbaumauthor=D.+M.+Lyonsauthor=C.+I.+Rodriguezauthor=A.+F.+Schatzberg&title=Attenuation+of+antidepressant+effects+of+ketamine+by+opioid+receptor+antagonism&doi=10.1176%2Fappi.ajp.2018.18020138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism</span></div><div class="casAuthors">Williams Nolan R; Heifets Boris D; Blasey Christine; Sudheimer Keith; Pannu Jaspreet; Pankow Heather; Hawkins Jessica; Birnbaum Justin; Lyons David M; Rodriguez Carolyn I; Schatzberg Alan F</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1205-1215</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  In addition to N-methyl-d-aspartate receptor antagonism, ketamine produces opioid system activation.  The objective of this study was to determine whether opioid receptor antagonism prior to administration of intravenous ketamine attenuates its acute antidepressant or dissociative effects.  METHOD:  In a proposed double-blind crossover study of 30 adults with treatment-resistant depression, the authors performed a planned interim analysis after studying 14 participants, 12 of whom completed both conditions in randomized order: placebo or 50 mg of naltrexone preceding intravenous infusion of 0.5 mg/kg of ketamine.  Response was defined as a reduction ≥50% in score on the 17-item Hamilton Depression Rating Scale (HAM-D) score on postinfusion day 1.  RESULTS:  In the interim analysis, seven of 12 adults with treatment-resistant depression met the response criterion during the ketamine plus placebo condition.  Reductions in 6-item and 17-item HAM-D scores among participants in the ketamine plus naltrexone condition were significantly lower than those of participants in the ketamine plus placebo condition on postinfusion days 1 and 3.  Secondary analysis of all participants who completed the placebo and naltrexone conditions, regardless of the robustness of response to ketamine, showed similar results.  There were no differences in ketamine-induced dissociation between conditions.  Because naltrexone dramatically blocked the antidepressant but not the dissociative effects of ketamine, the trial was halted at the interim analysis.  CONCLUSIONS:  The findings suggest that ketamine's acute antidepressant effect requires opioid system activation.  The dissociative effects of ketamine are not mediated by the opioid system, and they do not appear sufficient without the opioid effect to produce the acute antidepressant effects of ketamine in adults with treatment-resistant depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgjMyxF1SfVs-crCu0nI_sfW6udTcc2eY0n43y4OElS7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3is1yjsw%253D%253D&md5=b1d6ebff5c84be9e6ac2021490cc77c0</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2018.18020138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2018.18020138%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DN.%2BR.%26aulast%3DHeifets%26aufirst%3DB.%2BD.%26aulast%3DBlasey%26aufirst%3DC.%26aulast%3DSudheimer%26aufirst%3DK.%26aulast%3DPannu%26aufirst%3DJ.%26aulast%3DPankow%26aufirst%3DH.%26aulast%3DHawkins%26aufirst%3DJ.%26aulast%3DBirnbaum%26aufirst%3DJ.%26aulast%3DLyons%26aufirst%3DD.%2BM.%26aulast%3DRodriguez%26aufirst%3DC.%2BI.%26aulast%3DSchatzberg%26aufirst%3DA.%2BF.%26atitle%3DAttenuation%2520of%2520antidepressant%2520effects%2520of%2520ketamine%2520by%2520opioid%2520receptor%2520antagonism%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2018%26volume%3D175%26spage%3D1205%26epage%3D1215%26doi%3D10.1176%2Fappi.ajp.2018.18020138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nisenbaum, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bleakman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkin, J. M.</span></span> <span> </span><span class="NLM_article-title">A role for AMPA receptors in mood disorders</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1273</span>– <span class="NLM_lpage">1288</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2005.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.bcp.2005.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=16442080" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD28XivVOjsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=1273-1288&author=A.+Altauthor=E.+S.+Nisenbaumauthor=D.+Bleakmanauthor=J.+M.+Witkin&title=A+role+for+AMPA+receptors+in+mood+disorders&doi=10.1016%2Fj.bcp.2005.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">A role for AMPA receptors in mood disorders</span></div><div class="casAuthors">Alt, Andrew; Nisenbaum, Eric S.; Bleakman, David; Witkin, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1273-1288</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Major antidepressant agents increase synaptic levels of monoamines.  Although the monoamine hypothesis of depression remains a cornerstone of our understanding of the pathophysiol. of depression, emerging data has suggested that the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subtype of glutamate receptor may also play a pivotal role in depression.  Pos. allosteric modulators of AMPA receptors increase brain levels of brain-derived neurotrophic factor (BDNF) that impacts the viability and generation of neurons in key brain structures.  AMPA receptor potentiators are active in rodent models predictive of antidepressant efficacy.  The mechanisms by which AMPA receptor potentiators produce these biol. effects, however, are uncertain.  Current evidence points to an antidepressant mechanism that is independent of monoaminergic facilitation that is driven by neurogenesis, a process facilitated by increased BDNF expression.  However, alternative hypotheses need to be considered given uncertainties in the relation between BDNF increases and the effects of conventional antidepressant medications.  Electrophysiol. and protein conformational data indicate that structural variants of AMPA receptor potentiators can differentially modulate AMPA receptor-mediated currents, although the manner in which this impacts antidepressant efficacy is yet to be understood.  Conventional antidepressants such as fluoxetine pos. modulate AMPA receptors.  This potentiation is engendered by specific phosphorylation pathways activated through the dopamine- and cAMP-regulated phosphoprotein of Mr 32,000 (DARPP-32).  Other novel compds. with antidepressant-like effects in rodents may also produce their in vivo effects through potentiation of AMPA receptors.  Thus, AMPA receptor potentiation might be a general mechanism through which the clin. outcome of antidepressant efficacy is achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-Px6E2FH8K7Vg90H21EOLACvtfcHk0lgzq9pCUSDMcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XivVOjsbs%253D&md5=4887a0f9871c6371c535ded7c5ae6693</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2005.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2005.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DAlt%26aufirst%3DA.%26aulast%3DNisenbaum%26aufirst%3DE.%2BS.%26aulast%3DBleakman%26aufirst%3DD.%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26atitle%3DA%2520role%2520for%2520AMPA%2520receptors%2520in%2520mood%2520disorders%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2006%26volume%3D71%26spage%3D1273%26epage%3D1288%26doi%3D10.1016%2Fj.bcp.2005.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Skolnick, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trullas, R.</span></span> <span> </span><span class="NLM_article-title">Glutamate-based antidepressants: 20 years on</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">569</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2009.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.tips.2009.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=19837463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCku7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=563-569&author=P.+Skolnickauthor=P.+Popikauthor=R.+Trullas&title=Glutamate-based+antidepressants%3A+20+years+on&doi=10.1016%2Fj.tips.2009.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate-based antidepressants: 20 years on</span></div><div class="casAuthors">Skolnick, Phil; Popik, Piotr; Trullas, Ramon</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">563-569</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Depression is a chronic recurring illness that affects more than 120 million people worldwide.  Drugs increasing the synaptic availability of serotonin and norepinephrine (biogenic amine-based agents) have been used to treat depression for more than 50 years.  However, significant symptom improvement requires ≥2-4 wk of treatment and a first course of therapy provides symptom relief to only 60-65% of patients.  Roche and Evotec recently announced plans to develop N-methyl-D-aspartate (NMDA) receptor antagonists targeting the NR2B subtype for treatment-resistant depression.  This announcement closely follows a report that another NR2B antagonist, traxoprodil (CP 101 606), has antidepressant effects in patients unresponsive to a serotonin selective reuptake inhibitor, as well as reports of rapid and sustained antidepressant effects following a single injection of the NMDA antagonist ketamine.  Here we describe evidence that glutamate-based therapies might represent an effective alternative to biogenic-amine-based agents for depression and provide perspectives on the development of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruh_p71UySDrVg90H21EOLACvtfcHk0lgzq9pCUSDMcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCku7zN&md5=516f9bbbbb71fbbe02933ca90eb90410</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2009.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2009.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DSkolnick%26aufirst%3DP.%26aulast%3DPopik%26aufirst%3DP.%26aulast%3DTrullas%26aufirst%3DR.%26atitle%3DGlutamate-based%2520antidepressants%253A%252020%2520years%2520on%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D563%26epage%3D569%26doi%3D10.1016%2Fj.tips.2009.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Witkin, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golani, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, N. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. L.</span></span> <span> </span><span class="NLM_article-title">Rapid-acting antidepressants</span>. <i>Adv. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/bs.apha.2019.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fbs.apha.2019.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=31378256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Oit7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2019&pages=47-96&author=J.+M.+Witkinauthor=A.+E.+Martinauthor=L.+K.+Golaniauthor=N.+Z.+Xuauthor=J.+L.+Smith&title=Rapid-acting+antidepressants&doi=10.1016%2Fbs.apha.2019.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid-acting antidepressants</span></div><div class="casAuthors">Witkin, Jeffrey M.; Martin, Anna E.; Golani, Lalit K.; Xu, Nina Z.; Smith, Jodi L.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Pharmacology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">Neuropsychotherapeutics</span>),
    <span class="NLM_cas:pages">47-96</span>CODEN:
                <span class="NLM_cas:coden">ADPHEL</span>;
        ISSN:<span class="NLM_cas:issn">1054-3589</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Mechanisms of action of rapid-acting antidepressants for treatment of refractory patients with anhedonia.  Rapid-acting antidepressant drug action has been demonstrated in controlled clin. studies for ketamine, a few other NMDA receptor antagonists and scopolamine.  Less clin. data are currently available for psychedelic drugs such as psilocybin, lysergic acid diethylamide, and ayahuasca.  A general triggering mechanism appears to involve potentiation of AMPA receptor function.  Although the durability of antidepressant effects of ketamine and scopolamine is limited, psychedelic drugs have been reported to produce effects for many months.  The primary impediment to generating a medicine of this type for depressed patients is side effects and the lack of methods to ensure enduring antidepressant effects.  Thus, further exploration of drug possibilities continues.  Esketamine ((S)-ketamine) was recently FDA approved.  Compds. currently in clin. development include the NMDA receptor antagonist (R)-ketamine, the NMDA receptor modulator, GLYX-13 (Rapastinel), and the AMPA receptor potentiator TAK-653.  Addnl. pharmacol. classes have produced effects in the preclin. lab. to suggest their potential as rapid-acting agents.  These include mGlu2/3 receptor antagonists, AMPA receptor potentiators, and neg. allosteric modulators of GABAA(α5) receptors.  In all cases, mols. exist that could be used to provide clin. proof of concept testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnh42zms7d37Vg90H21EOLACvtfcHk0lgzq9pCUSDMcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Oit7%252FF&md5=82daa8c215b13a74170a80664ec1fff9</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fbs.apha.2019.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.apha.2019.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DWitkin%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DA.%2BE.%26aulast%3DGolani%26aufirst%3DL.%2BK.%26aulast%3DXu%26aufirst%3DN.%2BZ.%26aulast%3DSmith%26aufirst%3DJ.%2BL.%26atitle%3DRapid-acting%2520antidepressants%26jtitle%3DAdv.%2520Pharmacol.%26date%3D2019%26volume%3D86%26spage%3D47%26epage%3D96%26doi%3D10.1016%2Fbs.apha.2019.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikkelsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorkildsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgbjerg, F. M.</span></span> <span> </span><span class="NLM_article-title">Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">104</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(97)01116-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2FS0014-2999%2897%2901116-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=9311667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK2sXltVCqs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=1997&pages=99-104&author=B.+Ebertauthor=S.+Mikkelsenauthor=C.+Thorkildsenauthor=F.+M.+Borgbjerg&title=Norketamine%2C+the+main+metabolite+of+ketamine%2C+is+a+non-competitive+NMDA+receptor+antagonist+in+the+rat+cortex+and+spinal+cord&doi=10.1016%2FS0014-2999%2897%2901116-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord</span></div><div class="casAuthors">Ebert, Bjarke; Mikkelsen, Soren; Thorkildsen, Christian; Borgbjerg, Finn Molke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">99-104</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The enantiomers of the potent non-competitive NMDA receptor antagonist ketamine and its major metabolite, norketamine were evaluated as NMDA receptor antagonists using the rat cortical wedge prepn. and the neonatal rat spinal cord prepn., resp., for electrophysiol. studies and [3H](RS)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine ([3H]MK-801) in homogenate binding expts.  In agreement with earlier studies (S)-ketamine (Ki 0.3 μM) was found to possess a 5 times higher affinity for the NMDA receptor complex than (R)-ketamine (Ki 1.4 μM).  (S)-Norketamine (Ki 1.7 μM) had approx. an 8 times higher affinity than (R)-norketamine (Ki 13 μM) in the inhibition of [3H]MK-801 binding.  All compds. inhibited responses to NMDA in the rat cortical wedge prepn. and the hemisected neonatal rat spinal cord, being approx. four times more potent in the cortex than in the spinal cord except for (R)-norketamine being only twice as potent.  In light of the clin. obtained concns. of norketamine after oral administration of ketamine, these data strongly suggest that (S)-norketamine may contribute significantly to the clin. activity of (S)-ketamine, esp. when given orally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMBlstfg5EGLVg90H21EOLACvtfcHk0lgzq9pCUSDMcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXltVCqs7k%253D&md5=79dd6350eff094489159bea845e152f0</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2901116-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252901116-3%26sid%3Dliteratum%253Aachs%26aulast%3DEbert%26aufirst%3DB.%26aulast%3DMikkelsen%26aufirst%3DS.%26aulast%3DThorkildsen%26aufirst%3DC.%26aulast%3DBorgbjerg%26aufirst%3DF.%2BM.%26atitle%3DNorketamine%252C%2520the%2520main%2520metabolite%2520of%2520ketamine%252C%2520is%2520a%2520non-competitive%2520NMDA%2520receptor%2520antagonist%2520in%2520the%2520rat%2520cortex%2520and%2520spinal%2520cord%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1997%26volume%3D333%26spage%3D99%26epage%3D104%26doi%3D10.1016%2FS0014-2999%2897%2901116-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moaddel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdrakhmanova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jozwiak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wainer, I. W.</span></span> <span> </span><span class="NLM_article-title">Sub-anesthetic concentrations of (R, S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>698</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2012.11.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.ejphar.2012.11.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=23183107" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCktL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=698&publication_year=2013&pages=228-234&author=R.+Moaddelauthor=G.+Abdrakhmanovaauthor=J.+Kozakauthor=K.+Jozwiakauthor=L.+Tollauthor=L.+Jimenezauthor=A.+Rosenbergauthor=T.+Tranauthor=Y.+Xiaoauthor=C.+A.+Zarateauthor=I.+W.+Wainer&title=Sub-anesthetic+concentrations+of+%28R%2C+S%29-ketamine+metabolites+inhibit+acetylcholine-evoked+currents+in+%CE%B17+nicotinic+acetylcholine+receptors&doi=10.1016%2Fj.ejphar.2012.11.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors</span></div><div class="casAuthors">Moaddel, Ruin; Abdrakhmanova, Galia; Kozak, Joanna; Jozwiak, Krzysztof; Toll, Lawrence; Jimenez, Lucita; Rosenberg, Avraham; Tran, Thao; Xiao, Yingxian; Zarate, Carlos A.; Wainer, Irving W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">698</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">228-234</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The effect of the (R,S)-ketamine metabolites (R,S)-norketamine, (R,S)-dehydronorketamine, (2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine on the activity of α7 and α3β4 neuronal nicotinic acetylcholine receptors was investigated using patch-clamp techniques.  The data indicated that (R,S)-dehydronorketamine inhibited acetylcholine-evoked currents in α7-nicotinic acetylcholine receptor, IC50=55±6 nM, and that (2S,6S)-hydroxynorketamine, (2R,6R)-hydroxynorketamine and (R,S)-norketamine also inhibited α7-nicotinic acetylcholine receptor function at concns. ≤1 μM, while (R,S)-ketamine was inactive at these concns.  The inhibitory effect of (R,S)-dehydronorketamine was voltage-independent and the compd. did not competitively displace selective α7-nicotinic acetylcholine receptor ligands [125I]-α-bungarotoxin and [3H]-epibatidine indicating that (R,S)-dehydronorketamine is a neg. allosteric modulator of the α7-nicotinic acetylcholine receptor. (R,S)-Ketamine and (R,S)-norketamine inhibited (S)-nicotine-induced whole-cell currents in cells expressing α3β4-nicotinic acetylcholine receptor, IC50 3.1 and 9.1 μM, resp., while (R,S)-dehydronorketamine, (2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine were weak inhibitors, IC50 >100 μM.  The binding affinities of (R,S)-dehydronorketamine, (2S,6S)-hydroxynorketamine and (2R,6R)-hydroxynorketamine at the NMDA receptor were also detd. using rat brain membranes and the selective NMDA receptor antagonist [3H]-MK-801.  The calcd. Ki values were 38.95 μM for (S)-dehydronorketamine, 21.19 μM for (2S,6S)-hydroxynorketamine and>100 μM for (2R,6R)-hydroxynorketamine.  The results suggest that the inhibitory activity of ketamine metabolites at the α7-nicotinic acetylcholine receptor may contribute to the clin. effect of the drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGiMWFqBpCUrVg90H21EOLACvtfcHk0lhEbNYB7SBbBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCktL%252FL&md5=4e42dd4e84025dfd2e703ecd3d4d5352</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.11.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.11.023%26sid%3Dliteratum%253Aachs%26aulast%3DMoaddel%26aufirst%3DR.%26aulast%3DAbdrakhmanova%26aufirst%3DG.%26aulast%3DKozak%26aufirst%3DJ.%26aulast%3DJozwiak%26aufirst%3DK.%26aulast%3DToll%26aufirst%3DL.%26aulast%3DJimenez%26aufirst%3DL.%26aulast%3DRosenberg%26aufirst%3DA.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DWainer%26aufirst%3DI.%2BW.%26atitle%3DSub-anesthetic%2520concentrations%2520of%2520%2528R%252C%2520S%2529-ketamine%2520metabolites%2520inhibit%2520acetylcholine-evoked%2520currents%2520in%2520%25CE%25B17%2520nicotinic%2520acetylcholine%2520receptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D698%26spage%3D228%26epage%3D234%26doi%3D10.1016%2Fj.ejphar.2012.11.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamakura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakimura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoji, K.</span></span> <span> </span><span class="NLM_article-title">The stereoselective effects of ketamine isomers on heteromeric N-methyl-D-aspartate receptor channels</span>. <i>Anesth. Analg.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1097/00000539-200007000-00042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2F00000539-200007000-00042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10866917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1Oqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2000&pages=225-229&author=T.+Yamakuraauthor=K.+Sakimuraauthor=K.+Shimoji&title=The+stereoselective+effects+of+ketamine+isomers+on+heteromeric+N-methyl-D-aspartate+receptor+channels&doi=10.1097%2F00000539-200007000-00042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The stereoselective effects of ketamine isomers on heteromeric N-methyl-D-aspartate receptor channels</span></div><div class="casAuthors">Yamakura, Tomohiro; Sakimura, Kenji; Shimoji, Koki</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia & Analgesia (Baltimore)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">225-229</span>CODEN:
                <span class="NLM_cas:coden">AACRAT</span>;
        ISSN:<span class="NLM_cas:issn">0003-2999</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">The effects of S(+)- and R(-)-ketamine on heteromeric N-methyl-D-aspartate receptor channels were investigated on the ε1 / ξ1, ε2/ξ1, ε3/ξ1, and ε4/ξ1 channels expressed in Xenopus oocytes.  S(+)-ketamine inhibited all four ε/ξ channels more effectively than R(-)-ketamine.  The inhibitor concns. for half-control response for S(+)-ketamine were quite similar among the four channels with 0.44-0.56 μM.  However, the inhibitor concns. for half-control response for R(-)-ketamine varied slightly among the four channels with 1.0 μM for ε2/ξ1 and ε3/ξ1 channels and 1.9-2.0 μM for ε1/ξ1 and ε4/ξ1 channels.  Thus, the potency ratio of S(+)- and R(-)-ketamine for heteromeric channels was only slightly different among the ε/ξ channels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvSYJCg0D-mbVg90H21EOLACvtfcHk0lhEbNYB7SBbBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1Oqu7c%253D&md5=ea6d6b09970d7aac4ac68edfe6f0c542</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1097%2F00000539-200007000-00042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000539-200007000-00042%26sid%3Dliteratum%253Aachs%26aulast%3DYamakura%26aufirst%3DT.%26aulast%3DSakimura%26aufirst%3DK.%26aulast%3DShimoji%26aufirst%3DK.%26atitle%3DThe%2520stereoselective%2520effects%2520of%2520ketamine%2520isomers%2520on%2520heteromeric%2520N-methyl-D-aspartate%2520receptor%2520channels%26jtitle%3DAnesth.%2520Analg.%26date%3D2000%26volume%3D91%26spage%3D225%26epage%3D229%26doi%3D10.1097%2F00000539-200007000-00042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schüttler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shafer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stanski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trevor, A.</span></span> <span> </span><span class="NLM_article-title">Comparative pharmacology of the ketamine isomers: studies in volunteers</span>. <i>Br. J. Anaesth.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1093/bja/57.2.197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1093%2Fbja%2F57.2.197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=3970799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaL2MXktVSiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1985&pages=197-203&author=P.+Whiteauthor=J.+Sch%C3%BCttlerauthor=A.+Shaferauthor=D.+Stanskiauthor=Y.+Horaiauthor=A.+Trevor&title=Comparative+pharmacology+of+the+ketamine+isomers%3A+studies+in+volunteers&doi=10.1093%2Fbja%2F57.2.197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative pharmacology of the ketamine isomers:  studies in volunteers</span></div><div class="casAuthors">White, Paul F.; Schuttler, Jurgen; Shafer, Audrey; Stanski, Donald R.; Horai, Yukio; Trevor, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-203</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">0007-0912</span>.
    </div><div class="casAbstract">The clin. and EEG effects of the individual ketamine isomers were compared with the (±)-ketamine  [6740-88-1] mixt. in volunteers who received each drug on a sep. occasion.  Racemic ketamine 275 mg, S(+)-ketamine  [33643-49-1] 140 mg or R(-)-ketamine  [33643-46-8] 429 mg produced an anesthetic state lasting 6 min.  However, the EEG evaluation of the R(-)-isomer revealed less overall slowing, and an absence of the large slow wave complexes produced by the S(+)-isomer and the racemic mixt.  The pharmacokinetic profiles for the individual isomers of ketamine did not differ significantly from the racemic mixt.  Even though the apparent anesthetic state produced in these healthy volunteers did not differ qual. between the 3 drug groups, recovery times were consistently shorter following the individual isomers compared with the racemic mixt.  The serum ketamine concns. assocd. with regaining consciousness and orientation were consistent with an S(+)/R(-) isomer potency ratio of 4:1.  In terms of their ability to impair psychomotor function, the S(+)/R(-) potency ratio varied from 3:1 to 5:1.  After comparable degrees of central nervous system depression, it is concluded that the more potent S(+) isomer of ketamine is assocd. with a more rapid recovery of psychomotor skills that the currently used racemic mixt.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmb1YMgMGE1bVg90H21EOLACvtfcHk0lhEbNYB7SBbBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXktVSiurg%253D&md5=5bb8dec8b25afacc1ac630cc68431460</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1093%2Fbja%2F57.2.197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbja%252F57.2.197%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DP.%26aulast%3DSch%25C3%25BCttler%26aufirst%3DJ.%26aulast%3DShafer%26aufirst%3DA.%26aulast%3DStanski%26aufirst%3DD.%26aulast%3DHorai%26aufirst%3DY.%26aulast%3DTrevor%26aufirst%3DA.%26atitle%3DComparative%2520pharmacology%2520of%2520the%2520ketamine%2520isomers%253A%2520studies%2520in%2520volunteers%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D1985%26volume%3D57%26spage%3D197%26epage%3D203%26doi%3D10.1093%2Fbja%2F57.2.197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leal, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandeira, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia-Melo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telles, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mello, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesus-Nunes, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerreiro-Costa, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marback, R. F.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Intravenous arketamine for treatment-resistant depression: Open-label pilot study</span>. <i>Eur. Arch. Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">6</span>, <span class="refDoi"> DOI: 10.1007/s00406-020-01110-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2Fs00406-020-01110-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32055944" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=1-6&author=G.+C.+Lealauthor=I.+D.+Bandeiraauthor=F.+S.+Correia-Meloauthor=M.+Tellesauthor=R.+P.+Melloauthor=F.+Vieiraauthor=C.+S.+Limaauthor=A.+P.+Jesus-Nunesauthor=L.+N.+Guerreiro-Costaauthor=R.+F.+Marback&title=Intravenous+arketamine+for+treatment-resistant+depression%3A+Open-label+pilot+study&doi=10.1007%2Fs00406-020-01110-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1007%2Fs00406-020-01110-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-020-01110-5%26sid%3Dliteratum%253Aachs%26aulast%3DLeal%26aufirst%3DG.%2BC.%26aulast%3DBandeira%26aufirst%3DI.%2BD.%26aulast%3DCorreia-Melo%26aufirst%3DF.%2BS.%26aulast%3DTelles%26aufirst%3DM.%26aulast%3DMello%26aufirst%3DR.%2BP.%26aulast%3DVieira%26aufirst%3DF.%26aulast%3DLima%26aufirst%3DC.%2BS.%26aulast%3DJesus-Nunes%26aufirst%3DA.%2BP.%26aulast%3DGuerreiro-Costa%26aufirst%3DL.%2BN.%26aulast%3DMarback%26aufirst%3DR.%2BF.%26atitle%3DIntravenous%2520arketamine%2520for%2520treatment-resistant%2520depression%253A%2520Open-label%2520pilot%2520study%26jtitle%3DEur.%2520Arch.%2520Psychiatry%2520Clin.%2520Neurosci.%26date%3D2020%26spage%3D1%26epage%3D6%26doi%3D10.1007%2Fs00406-020-01110-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-c.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toki, H.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">AMPA receptor activation–independent antidepressant actions of ketamine metabolite (S)-Norketamine</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2018.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2018.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29945718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1SmtrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=591-600&author=C.+Yangauthor=S.+Kobayashiauthor=K.+Nakaoauthor=C.+Dongauthor=M.+Hanauthor=Y.+Quauthor=Q.+Renauthor=J.-c.+Zhangauthor=M.+Maauthor=H.+Toki&title=AMPA+receptor+activation%E2%80%93independent+antidepressant+actions+of+ketamine+metabolite+%28S%29-Norketamine&doi=10.1016%2Fj.biopsych.2018.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine</span></div><div class="casAuthors">Yang, Chun; Kobayashi, Shizuka; Nakao, Kazuhito; Dong, Chao; Han, Mei; Qu, Youge; Ren, Qian; Zhang, Ji-chun; Ma, Min; Toki, Hidetoh; Yamaguchi, Jun-ichi; Chaki, Shigeyuki; Shirayama, Yukihiko; Nakazawa, Kazu; Manabe, Toshiya; Hashimoto, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">591-600</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Ketamine, an N-methyl-D-aspartate receptor antagonist, exerts robust antidepressant effects in patients with treatment-resistant depression.  The precise mechanisms underlying ketamine's antidepressant actions remain unclear, although previous research suggests that alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) activation plays a role.  We investigated whether (S)-norketamine and (R)-norketamine, the two main metabolites of (R,S)-ketamine, also play a significant role in ketamine's antidepressant effects and whether the effects are mediated by AMPAR.  Cellular mechanisms of antidepressant action of norketamine enantiomers were examd. in mice.  (S)-Norketamine had more potent antidepressant effects than (R)-norketamine in inflammation and chronic social defeat stress models.  Furthermore, (S)-norketamine induced more beneficial effects on decreased dendritic spine d. and synaptogenesis in the prefrontal cortex and hippocampus compared with (R)-norketamine.  Unexpectedly, AMPAR antagonists did not block the antidepressant effects of (S)-norketamine.  The electrophysiol. data showed that, although (S)-norketamine inhibited N-methyl-D-aspartate receptor-mediated synaptic currents, (S)-norketamine did not enhance AMPAR-mediated neurotransmission in hippocampal neurons.  Furthermore, (S)-norketamine improved redns. in brain-derived neurotrophic factor-tropomyosin receptor kinase B signaling in the prefrontal cortex of mice susceptible to chronic social defeat stress, whereas the tropomyosin receptor kinase B antagonist and a mechanistic target of rapamycin inhibitor blocked the antidepressant effects of (S)-norketamine.  In contrast to (S)-ketamine, (S)-norketamine did not cause behavioral abnormalities, such as prepulse inhibition deficits, reward effects, loss of parvalbumin immunoreactivity in the medial prefrontal cortex, or baseline gamma-band oscillation increase.  Our data identified a novel AMPAR activation-independent mechanism underlying the antidepressant effects of (S)-norketamine.  (S)-Norketamine and its prodrugs could be novel antidepressants without the detrimental side effects of (S)-ketamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotHsV92JkpQ7Vg90H21EOLACvtfcHk0liFiliwFOs2WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1SmtrjJ&md5=02809db36fbf74a7dae7f2e681948358</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2018.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2018.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DNakao%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DQu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.-c.%26aulast%3DMa%26aufirst%3DM.%26aulast%3DToki%26aufirst%3DH.%26atitle%3DAMPA%2520receptor%2520activation%25E2%2580%2593independent%2520antidepressant%2520actions%2520of%2520ketamine%2520metabolite%2520%2528S%2529-Norketamine%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D84%26spage%3D591%26epage%3D600%26doi%3D10.1016%2Fj.biopsych.2018.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">An update on ketamine and its two enantiomers as rapid-acting antidepressants</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1080/14737175.2019.1554434</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1080%2F14737175.2019.1554434" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30513009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKis7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=83-92&author=K.+Zhangauthor=K.+Hashimoto&title=An+update+on+ketamine+and+its+two+enantiomers+as+rapid-acting+antidepressants&doi=10.1080%2F14737175.2019.1554434"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">An update on ketamine and its two enantiomers as rapid-acting antidepressants</span></div><div class="casAuthors">Zhang, Kai; Hashimoto, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-92</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Depression is one of the most disabling diseases worldwide.  Approx. one-third of depressed patients are treatment-resistant to the currently available antidepressants and there is a significant therapeutic time lag of weeks to months.  There is a clear unmet need for rapid-acting and more efficacious treatments.  (R,S)-ketamine, an old anesthetic drug appears now to be going through a renaissance.  This paper reviews recent literature describing the antidepressant effects of ketamine and its enantiomer (S)-ketamine in patients with major depressive disorder (MDD) and bipolar disorder (BD).  Furthermore, the authors discuss the therapeutic potential of (R)-ketamine, another enantiomer of (R,S)-ketamine, and (S)-norketamine.  A no. of clin. studies have demonstrated that (R,S)-ketamine has rapid-acting and sustained antidepressant activity in treatment-resistant patients with MDD, BD, and other psychiatric disorders.  Off-label use of ketamine for mood disorders is proving popular in the United States.  Meanwhile, preclin. data suggests that (R)-ketamine can exert longer-lasting antidepressant effects than (S)-ketamine in animal models of depression, and (R)-ketamine may have less detrimental side effects than (R,S)-ketamine and (S)-ketamine.  Addnl., (S)-norketamine exhibits rapid and sustained antidepressant effects, with a potency similar to that of (S)-ketamine.  Unlike (S)-ketamine, (S)-norketamine does not cause behavioral and biochem. abnormalities and could be a safer than (S)-ketamine too.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotO_RddKNgVrVg90H21EOLACvtfcHk0liFiliwFOs2WA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKis7zJ&md5=54ae909a31f50f5499b305a7760c214c</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1080%2F14737175.2019.1554434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737175.2019.1554434%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DAn%2520update%2520on%2520ketamine%2520and%2520its%2520two%2520enantiomers%2520as%2520rapid-acting%2520antidepressants%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2019%26volume%3D19%26spage%3D83%26epage%3D92%26doi%3D10.1080%2F14737175.2019.1554434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span> <span> </span><span class="NLM_article-title">Is (S)-norketamine an alternative antidepressant for esketamine?</span>. <i>Eur. Arch. Psychiatry Clin. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">867</span>– <span class="NLM_lpage">868</span>, <span class="refDoi"> DOI: 10.1007/s00406-018-0922-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2Fs00406-018-0922-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30008119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FotF2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=2019&pages=867-868&author=K.+Hashimotoauthor=C.+Yang&title=Is+%28S%29-norketamine+an+alternative+antidepressant+for+esketamine%3F&doi=10.1007%2Fs00406-018-0922-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Is (S)-norketamine an alternative antidepressant for esketamine?</span></div><div class="casAuthors">Hashimoto Kenji; Yang Chun</div><div class="citationInfo"><span class="NLM_cas:title">European archives of psychiatry and clinical neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">867-868</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTyoXrDS6dJ1m8bhe6roZYfW6udTcc2eZsmUKbT6p6Ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FotF2msA%253D%253D&md5=dd9c0c0f1cdf9db7c2055a3b509b5f3b</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs00406-018-0922-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00406-018-0922-2%26sid%3Dliteratum%253Aachs%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DC.%26atitle%3DIs%2520%2528S%2529-norketamine%2520an%2520alternative%2520antidepressant%2520for%2520esketamine%253F%26jtitle%3DEur.%2520Arch.%2520Psychiatry%2520Clin.%2520Neurosci.%26date%3D2019%26volume%3D269%26spage%3D867%26epage%3D868%26doi%3D10.1007%2Fs00406-018-0922-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defaix, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, S.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabresse, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardier, A. M.</span></span> <span> </span><span class="NLM_article-title">Common neurotransmission recruited in (R, S)-ketamine and (2R, 6R)-hydroxynorketamine–induced sustained antidepressant-like effects</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">e3</span>– <span class="NLM_lpage">e6</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2017.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2017.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29174592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFahtrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=e3-e6&author=T.+H.+Phamauthor=C.+Defaixauthor=X.+Xuauthor=S.-X.+Dengauthor=N.+Fabresseauthor=J.-C.+Alvarezauthor=D.+W.+Landryauthor=R.+A.+Brachmanauthor=C.+A.+Dennyauthor=A.+M.+Gardier&title=Common+neurotransmission+recruited+in+%28R%2C+S%29-ketamine+and+%282R%2C+6R%29-hydroxynorketamine%E2%80%93induced+sustained+antidepressant-like+effects&doi=10.1016%2Fj.biopsych.2017.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects</span></div><div class="casAuthors">Pham, Thu Ha; Defaix, Celine; Xu, Xiaoming; Deng, Shi-Xian; Fabresse, Nicolas; Alvarez, Jean-Claude; Landry, Donald W.; Brachman, Rebecca A.; Denny, Christine A.; Gardier, Alain M.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e3-e6</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this paper we discuss common neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant-like effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLsNONcnguX7Vg90H21EOLACvtfcHk0lhtu5Oux1Rg7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFahtrzO&md5=208712d9d888987b99379fe51c25b7d3</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2017.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2017.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DPham%26aufirst%3DT.%2BH.%26aulast%3DDefaix%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DDeng%26aufirst%3DS.-X.%26aulast%3DFabresse%26aufirst%3DN.%26aulast%3DAlvarez%26aufirst%3DJ.-C.%26aulast%3DLandry%26aufirst%3DD.%2BW.%26aulast%3DBrachman%26aufirst%3DR.%2BA.%26aulast%3DDenny%26aufirst%3DC.%2BA.%26aulast%3DGardier%26aufirst%3DA.%2BM.%26atitle%3DCommon%2520neurotransmission%2520recruited%2520in%2520%2528R%252C%2520S%2529-ketamine%2520and%2520%25282R%252C%25206R%2529-hydroxynorketamine%25E2%2580%2593induced%2520sustained%2520antidepressant-like%2520effects%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D84%26spage%3De3%26epage%3De6%26doi%3D10.1016%2Fj.biopsych.2017.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y.-C.</span></span> <span> </span><span class="NLM_article-title">(2R, 6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2018.06.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.neuropharm.2018.06.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29953886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1agt7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2018&pages=1-12&author=D.+Chouauthor=H.-Y.+Pengauthor=T.-B.+Linauthor=C.-Y.+Laiauthor=M.-C.+Hsiehauthor=Y.-C.+Wenauthor=A.-S.+Leeauthor=H.-H.+Wangauthor=P.-S.+Yangauthor=G.-D.+Chenauthor=Y.-C.+Ho&title=%282R%2C+6R%29-hydroxynorketamine+rescues+chronic+stress-induced+depression-like+behavior+through+its+actions+in+the+midbrain+periaqueductal+gray&doi=10.1016%2Fj.neuropharm.2018.06.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray</span></div><div class="casAuthors">Chou, Dylan; Peng, Hsien-Yu; Lin, Tzer-Bin; Lai, Cheng-Yuan; Hsieh, Ming-Chun; Wen, Yang-Cheng; Lee, An-Sheng; Wang, Hsueh-Hsiao; Yang, Po-Sheng; Chen, Gin-Den; Ho, Yu-Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">It has been widely reported that ketamine rescues chronic stress-induced depression-like behavior, but the underlying cellular mechanisms of the rapid antidepressant actions of ketamine remain largely unclear.  Both male and female Sprague-Dawley rats were used and received modified learned helplessness paradigm to induce depression-like behavior.  Depression-like behavior was assayed and manipulated using forced swim tests, sucrose preference tests and pharmacol. microinjection.  We conducted whole-cell patch-clamp electrophysiol. recordings in the midbrain ventrolateral periaqueductal gray (vlPAG) neurons.  Surface and cytosolic glutamate receptor 1 (GluR1) α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor expression were analyzed using Western blotting.  Phosphorylated GluR1 expression was quantified using Western blotting anal.  The results showed that a single systemic administration of a ketamine metabolite (2R,6R)-hydroxynorketamine (2R,6R-HNK) rapidly rescued chronic stress-induced depression-like behavior and persisted for up to 21 days.  Consistently, the chronic stress-induced diminished glutamatergic transmission and surface GluR1 expression in the vlPAG were also reversed by a single systemic injection of (2R,6R)-HNK.  Furthermore, bath application of (2R,6R)-HNK increased the frequency and amplitude of miniature excitatory postsynaptic currents (mEPSCs) in the vlPAG.  Further evidence for the antidepressant action of (2R,6R)-HNK is provided by the finding that microinjection of (2R,6R)-HNK into the vlPAG exhibited a rapid-acting and long-lasting antidepressant effect.  This antidepressant effect of (2R,6R)-HNK was prevented by the intra-vlPAG microinjection of AMPA receptor antagonist CNQX.  Together, the current results provide evidence that (2R,6R)-HNK rescues chronic stress-induced depression-like behavior with rapid-acting and long-lasting antidepressant effects through enhancement of AMPA receptor-mediated transmission in the vlPAG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVtK_JUYSLu7Vg90H21EOLACvtfcHk0lhtu5Oux1Rg7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1agt7vL&md5=a4fa7174f33d0620f3e2103193fa2d8e</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2018.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2018.06.033%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DD.%26aulast%3DPeng%26aufirst%3DH.-Y.%26aulast%3DLin%26aufirst%3DT.-B.%26aulast%3DLai%26aufirst%3DC.-Y.%26aulast%3DHsieh%26aufirst%3DM.-C.%26aulast%3DWen%26aufirst%3DY.-C.%26aulast%3DLee%26aufirst%3DA.-S.%26aulast%3DWang%26aufirst%3DH.-H.%26aulast%3DYang%26aufirst%3DP.-S.%26aulast%3DChen%26aufirst%3DG.-D.%26aulast%3DHo%26aufirst%3DY.-C.%26atitle%3D%25282R%252C%25206R%2529-hydroxynorketamine%2520rescues%2520chronic%2520stress-induced%2520depression-like%2520behavior%2520through%2520its%2520actions%2520in%2520the%2520midbrain%2520periaqueductal%2520gray%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D139%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.neuropharm.2018.06.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.-H.</span></span> <span> </span><span class="NLM_article-title">Neuronal correlates of depression</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">4825</span>– <span class="NLM_lpage">4848</span>, <span class="refDoi"> DOI: 10.1007/s00018-015-2044-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2Fs00018-015-2044-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26542802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyrsLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2015&pages=4825-4848&author=D.+Chaudhuryauthor=H.+Liuauthor=M.-H.+Han&title=Neuronal+correlates+of+depression&doi=10.1007%2Fs00018-015-2044-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal correlates of depression</span></div><div class="casAuthors">Chaudhury, Dipesh; Liu, He; Han, Ming-Hu</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4825-4848</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Major depressive disorder (MDD) is a common psychiatric disorder effecting approx. 121 million people worldwide and recent reports from the World Health Organization (WHO) suggest that it will be the leading contributor to the global burden of diseases.  At present, the most commonly used treatment strategies are still based on the monoamine hypothesis that has been the predominant theory in the last 60 years.  Clin. observations show that only a subset of depressed patients exhibits full remission when treated with classical monoamine-based antidepressants together with the fact that patients exhibit multiple symptoms suggest that the pathophysiol. leading to mood disorders may differ between patients.  Accumulating evidence indicates that depression is a neural circuit disorder and that onset of depression may be located at different regions of the brain involving different transmitter systems and mol. mechanisms.  This review synthesizes findings from rodent studies from which emerges a role for different, yet interconnected, mol. systems and assocd. neural circuits to the etiol. of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdQv5HpCdBALVg90H21EOLACvtfcHk0lhtu5Oux1Rg7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyrsLfJ&md5=72f3fa204417b9a68175147bdd696c17</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs00018-015-2044-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-015-2044-6%26sid%3Dliteratum%253Aachs%26aulast%3DChaudhury%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DM.-H.%26atitle%3DNeuronal%2520correlates%2520of%2520depression%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2015%26volume%3D72%26spage%3D4825%26epage%3D4848%26doi%3D10.1007%2Fs00018-015-2044-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ionescu, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felicione, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gosai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapero, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deckersbach, T.</span></span> <span> </span><span class="NLM_article-title">Ketamine-associated brain changes: a review of the neuroimaging literature</span>. <i>Harvard Rev. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">320</span>, <span class="refDoi"> DOI: 10.1097/HRP.0000000000000179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2FHRP.0000000000000179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29465479" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=320&author=D.+F.+Ionescuauthor=J.+M.+Felicioneauthor=A.+Gosaiauthor=C.+Cusinauthor=P.+Shinauthor=B.+G.+Shaperoauthor=T.+Deckersbach&title=Ketamine-associated+brain+changes%3A+a+review+of+the+neuroimaging+literature&doi=10.1097%2FHRP.0000000000000179"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1097%2FHRP.0000000000000179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FHRP.0000000000000179%26sid%3Dliteratum%253Aachs%26aulast%3DIonescu%26aufirst%3DD.%2BF.%26aulast%3DFelicione%26aufirst%3DJ.%2BM.%26aulast%3DGosai%26aufirst%3DA.%26aulast%3DCusin%26aufirst%3DC.%26aulast%3DShin%26aufirst%3DP.%26aulast%3DShapero%26aufirst%3DB.%2BG.%26aulast%3DDeckersbach%26aufirst%3DT.%26atitle%3DKetamine-associated%2520brain%2520changes%253A%2520a%2520review%2520of%2520the%2520neuroimaging%2520literature%26jtitle%3DHarvard%2520Rev.%2520Psychiatry%26date%3D2018%26volume%3D26%26spage%3D320%26doi%3D10.1097%2FHRP.0000000000000179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hare, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span> <span> </span><span class="NLM_article-title">Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1038/s41380-020-0685-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fs41380-020-0685-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32086434" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=B.+D.+Hareauthor=R.+S.+Duman&title=Prefrontal+cortex+circuits+in+depression+and+anxiety%3A+contribution+of+discrete+neuronal+populations+and+target+regions&doi=10.1038%2Fs41380-020-0685-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fs41380-020-0685-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41380-020-0685-9%26sid%3Dliteratum%253Aachs%26aulast%3DHare%26aufirst%3DB.%2BD.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DPrefrontal%2520cortex%2520circuits%2520in%2520depression%2520and%2520anxiety%253A%2520contribution%2520of%2520discrete%2520neuronal%2520populations%2520and%2520target%2520regions%26jtitle%3DMol.%2520Psychiatry%26date%3D2020%26doi%3D10.1038%2Fs41380-020-0685-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span> <span> </span><span class="NLM_article-title">Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">962</span>– <span class="NLM_lpage">977</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2011.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.neuron.2011.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=22405206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsFOhsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2012&pages=962-977&author=E.+Y.+Yuenauthor=J.+Weiauthor=W.+Liuauthor=P.+Zhongauthor=X.+Liauthor=Z.+Yan&title=Repeated+stress+causes+cognitive+impairment+by+suppressing+glutamate+receptor+expression+and+function+in+prefrontal+cortex&doi=10.1016%2Fj.neuron.2011.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex</span></div><div class="casAuthors">Yuen, Eunice Y.; Wei, Jing; Liu, Wenhua; Zhong, Ping; Li, Xiangning; Yan, Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">962-977</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Chronic stress could trigger maladaptive changes assocd. with stress-related mental disorders; however, the underlying mechanisms remain elusive.  In this study, we found that exposing juvenile male rats to repeated stress significantly impaired the temporal order recognition memory, a cognitive process controlled by the prefrontal cortex (PFC).  Concomitantly, significantly reduced AMPAR- and NMDAR-mediated synaptic transmission and glutamate receptor expression were found in PFC pyramidal neurons from repeatedly stressed animals.  All these effects relied on activation of glucocorticoid receptors and the subsequent enhancement of ubiquitin/proteasome-mediated degrdn. of GluR1 and NR1 subunits, which was controlled by the E3 ubiquitin ligase Nedd4-1 and Fbx2, resp.  Inhibition of proteasomes or knockdown of Nedd4-1 and Fbx2 in PFC prevented the loss of glutamatergic responses and recognition memory in stressed animals.  Our results suggest that repeated stress dampens PFC glutamatergic transmission by facilitating glutamate receptor turnover, which causes the detrimental effect on PFC-dependent cognitive processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4CR_jOqOg1rVg90H21EOLACvtfcHk0lhqFu7qUhkgJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsFOhsb0%253D&md5=0bf404138e8a4179a3eb20ad9b1bea98</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2011.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2011.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DYuen%26aufirst%3DE.%2BY.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DZ.%26atitle%3DRepeated%2520stress%2520causes%2520cognitive%2520impairment%2520by%2520suppressing%2520glutamate%2520receptor%2520expression%2520and%2520function%2520in%2520prefrontal%2520cortex%26jtitle%3DNeuron%26date%3D2012%26volume%3D73%26spage%3D962%26epage%3D977%26doi%3D10.1016%2Fj.neuron.2011.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanske, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heissler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schönfelder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessa, M.</span></span> <span> </span><span class="NLM_article-title">Neural correlates of emotion regulation deficits in remitted depression: the influence of regulation strategy, habitual regulation use, and emotional valence</span>. <i>NeuroImage</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">686</span>– <span class="NLM_lpage">693</span>, <span class="refDoi"> DOI: 10.1016/j.neuroimage.2012.03.089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.neuroimage.2012.03.089" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=22613776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC38nlt1WmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2012&pages=686-693&author=P.+Kanskeauthor=J.+Heisslerauthor=S.+Sch%C3%B6nfelderauthor=M.+Wessa&title=Neural+correlates+of+emotion+regulation+deficits+in+remitted+depression%3A+the+influence+of+regulation+strategy%2C+habitual+regulation+use%2C+and+emotional+valence&doi=10.1016%2Fj.neuroimage.2012.03.089"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Neural correlates of emotion regulation deficits in remitted depression: the influence of regulation strategy, habitual regulation use, and emotional valence</span></div><div class="casAuthors">Kanske Philipp; Heissler Janine; Schonfelder Sandra; Wessa Michele</div><div class="citationInfo"><span class="NLM_cas:title">NeuroImage</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">686-93</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Regulating emotions through reappraisal has been shown to elicit abnormal neural activation patterns in currently depressed patients.  It is, however, unclear if this deficit generalizes to other emotion regulation strategies, if it persists when patients recover, and if it is related to habitual use of reappraisal strategies.  Therefore, we measured the neural responses to emotional images with functional magnetic resonance imaging in remitted patients with previous episodes of major depression and healthy controls.  While viewing the images participants regulated the elicited emotions using either a reappraisal or a distraction strategy.  Habitual reappraisal use was measured with the Cognitive Emotion Regulation Questionnaire.  Depressed patients showed a selective deficit in down-regulating amygdala responses to negative emotional stimuli using reappraisal.  This down-regulation of amygdala activity was strongest in participants high in habitual reappraisal use.  Activity in the regulating control-network including anterior cingulate and lateral orbitofrontal cortex was increased during both emotion regulation strategies.  The findings in remitted patients with previous episodes of major depression suggest that altered emotion regulation is a trait-marker for depression.  This interpretation is supported by the relation of habitual reappraisal use to amygdala down-regulation success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGc8eyF2TnHEcLvDNbOD4DfW6udTcc2eZ69AEj72Q5WLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38nlt1WmsA%253D%253D&md5=34cc72d2862f5eff02a930fc9f1ab95d</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroimage.2012.03.089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroimage.2012.03.089%26sid%3Dliteratum%253Aachs%26aulast%3DKanske%26aufirst%3DP.%26aulast%3DHeissler%26aufirst%3DJ.%26aulast%3DSch%25C3%25B6nfelder%26aufirst%3DS.%26aulast%3DWessa%26aufirst%3DM.%26atitle%3DNeural%2520correlates%2520of%2520emotion%2520regulation%2520deficits%2520in%2520remitted%2520depression%253A%2520the%2520influence%2520of%2520regulation%2520strategy%252C%2520habitual%2520regulation%2520use%252C%2520and%2520emotional%2520valence%26jtitle%3DNeuroImage%26date%3D2012%26volume%3D61%26spage%3D686%26epage%3D693%26doi%3D10.1016%2Fj.neuroimage.2012.03.089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mickey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajilore, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peciña, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sikora, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Decoupling of the amygdala to other salience network regions in adolescent-onset recurrent major depressive disorder</span>. <i>Psychol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1055</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1017/S0033291715002615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1017%2FS0033291715002615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26784396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC28nhslWguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2016&pages=1055-1067&author=R.+Jacobsauthor=A.+Barbaauthor=J.+Gowinsauthor=H.+Klumppauthor=L.+Jenkinsauthor=B.+Mickeyauthor=O.+Ajiloreauthor=M.+Peci%C3%B1aauthor=M.+Sikoraauthor=K.+Ryan&title=Decoupling+of+the+amygdala+to+other+salience+network+regions+in+adolescent-onset+recurrent+major+depressive+disorder&doi=10.1017%2FS0033291715002615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Decoupling of the amygdala to other salience network regions in adolescent-onset recurrent major depressive disorder</span></div><div class="casAuthors">Jacobs R H; Barba A; Gowins J R; Klumpp H; Jenkins L M; Ajilore O; Phan K L; Langenecker S A; Mickey B J; Pecina M; Sikora M; Ryan K A; Hsu D T; Welsh R C; Zubieta J-K</div><div class="citationInfo"><span class="NLM_cas:title">Psychological medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1055-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recent meta-analyses of resting-state networks in major depressive disorder (MDD) implicate network disruptions underlying cognitive and affective features of illness.  Heterogeneity of findings to date may stem from the relative lack of data parsing clinical features of MDD such as phase of illness and the burden of multiple episodes.  METHOD:  Resting-state functional magnetic resonance imaging data were collected from 17 active MDD and 34 remitted MDD patients, and 26 healthy controls (HCs) across two sites.  Participants were medication-free and further subdivided into those with single v. multiple episodes to examine disease burden.  Seed-based connectivity using the posterior cingulate cortex (PCC) seed to probe the default mode network as well as the amygdala and subgenual anterior cingulate cortex (sgACC) seeds to probe the salience network (SN) were conducted.  RESULTS:  Young adults with remitted MDD demonstrated hyperconnectivity of the left PCC to the left inferior frontal gyrus and of the left sgACC to the right ventromedial prefrontal cortex (PFC) and left hippocampus compared with HCs.  Episode-independent effects were observed between the left PCC and the right dorsolateral PFC, as well as between the left amygdala and right insula and caudate, whereas the burden of multiple episodes was associated with hypoconnectivity of the left PCC to multiple cognitive control regions as well as hypoconnectivity of the amygdala to large portions of the SN.  CONCLUSIONS:  This is the first study of a homogeneous sample of unmedicated young adults with a history of adolescent-onset MDD illustrating brain-based episodic features of illness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFmF3n8no4EUbxh97K6Vt6fW6udTcc2eZ69AEj72Q5WLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nhslWguw%253D%253D&md5=fc241d735e24d9818978e356d2c750bf</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1017%2FS0033291715002615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0033291715002615%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DR.%26aulast%3DBarba%26aufirst%3DA.%26aulast%3DGowins%26aufirst%3DJ.%26aulast%3DKlumpp%26aufirst%3DH.%26aulast%3DJenkins%26aufirst%3DL.%26aulast%3DMickey%26aufirst%3DB.%26aulast%3DAjilore%26aufirst%3DO.%26aulast%3DPeci%25C3%25B1a%26aufirst%3DM.%26aulast%3DSikora%26aufirst%3DM.%26aulast%3DRyan%26aufirst%3DK.%26atitle%3DDecoupling%2520of%2520the%2520amygdala%2520to%2520other%2520salience%2520network%2520regions%2520in%2520adolescent-onset%2520recurrent%2520major%2520depressive%2520disorder%26jtitle%3DPsychol.%2520Med.%26date%3D2016%26volume%3D46%26spage%3D1055%26epage%3D1067%26doi%3D10.1017%2FS0033291715002615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisendrath, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathalon, D. H.</span></span> <span> </span><span class="NLM_article-title">Blunted amygdala activity is associated with depression severity in treatment-resistant depression</span>. <i>Cog. Affect. Behav. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1221</span>– <span class="NLM_lpage">1231</span>, <span class="refDoi"> DOI: 10.3758/s13415-017-0544-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.3758%2Fs13415-017-0544-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29063521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC1M7jvVCisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=1221-1231&author=J.+Ferriauthor=S.+J.+Eisendrathauthor=S.+L.+Fryerauthor=E.+Gillungauthor=B.+J.+Roachauthor=D.+H.+Mathalon&title=Blunted+amygdala+activity+is+associated+with+depression+severity+in+treatment-resistant+depression&doi=10.3758%2Fs13415-017-0544-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Blunted amygdala activity is associated with depression severity in treatment-resistant depression</span></div><div class="casAuthors">Ferri Jamie; Eisendrath Stuart J; Fryer Susanna L; Gillung Erin; Mathalon Daniel H; Fryer Susanna L; Roach Brian J; Mathalon Daniel H; Mathalon Daniel H</div><div class="citationInfo"><span class="NLM_cas:title">Cognitive, affective & behavioral neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1221-1231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Up to 50% of individuals with major depressive disorder (MDD) do not recover after two antidepressant medication trials, and therefore meet the criteria for treatment-resistant depression (TRD).  Mindfulness-based cognitive therapy (MBCT) is one promising treatment; however, the extent to which MBCT influences clinical outcomes relative to baseline neural activation remains unknown.  In the present study we investigated baseline differences in amygdala activation between TRD patients and healthy controls (HCs), related amygdala activation to depression symptoms, and examined the impacts of MBCT and amygdala activation on longitudinal depression outcomes.  At baseline, TRD patients (n = 80) and HCs (n = 37) participated in a functional magnetic resonance imaging task in which they identified either the emotion (affect labeling) or the gender (gender labeling) of faces, or passively viewed faces (observing).  The TRD participants then completed eight weeks of MBCT or a health enhancement program (HEP).  Relative to HCs, the TRD patients demonstrated less amygdala activation during affect labeling, and marginally less during gender labeling.  Blunted amygdala activation in TRD patients during affect labeling was associated with greater depression severity.  MBCT was associated with greater depression reductions than was HEP directly following treatment; however, at 52 weeks the treatment effect was not significant, and baseline amygdala activation across the task conditions predicted depression severity in both groups.  TRD patients have blunted amygdala responses during affect labeling that are associated with greater concurrent depression.  Furthermore, although MBCT produced greater short-term improvements in depression than did HEP, overall baseline amygdala reactivity was predictive of long-term clinical outcomes in both groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-jPRFFm4_MisZ1x6zOs0vfW6udTcc2ebO8u56bIuG0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7jvVCisQ%253D%253D&md5=b4f8ece6967a5f3192b410c94f037bc3</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.3758%2Fs13415-017-0544-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3758%252Fs13415-017-0544-6%26sid%3Dliteratum%253Aachs%26aulast%3DFerri%26aufirst%3DJ.%26aulast%3DEisendrath%26aufirst%3DS.%2BJ.%26aulast%3DFryer%26aufirst%3DS.%2BL.%26aulast%3DGillung%26aufirst%3DE.%26aulast%3DRoach%26aufirst%3DB.%2BJ.%26aulast%3DMathalon%26aufirst%3DD.%2BH.%26atitle%3DBlunted%2520amygdala%2520activity%2520is%2520associated%2520with%2520depression%2520severity%2520in%2520treatment-resistant%2520depression%26jtitle%3DCog.%2520Affect.%2520Behav.%2520Neurosci.%26date%3D2017%26volume%3D17%26spage%3D1221%26epage%3D1231%26doi%3D10.3758%2Fs13415-017-0544-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grueter, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothwell, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malenka, R. C.</span></span> <span> </span><span class="NLM_article-title">Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>487</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1038/nature11160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnature11160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=22785313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVWisrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=487&publication_year=2012&pages=183-189&author=B.+K.+Limauthor=K.+W.+Huangauthor=B.+A.+Grueterauthor=P.+E.+Rothwellauthor=R.+C.+Malenka&title=Anhedonia+requires+MC4R-mediated+synaptic+adaptations+in+nucleus+accumbens&doi=10.1038%2Fnature11160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens</span></div><div class="casAuthors">Lim, Byung Kook; Huang, Kee Wui; Grueter, Brad A.; Rothwell, Patrick E.; Malenka, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">487</span>
        (<span class="NLM_cas:issue">7406</span>),
    <span class="NLM_cas:pages">183-189</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chronic stress is a strong diathesis for depression in humans and is used to generate animal models of depression.  It commonly leads to several major symptoms of depression, including dysregulated feeding behavior, anhedonia and behavioral despair.  Although hypotheses defining the neural pathophysiol. of depression have been proposed, the crit. synaptic adaptations in key brain circuits that mediate stress-induced depressive symptoms remain poorly understood.  Here we show that chronic stress in mice decreases the strength of excitatory synapses on D1 dopamine receptor-expressing nucleus accumbens medium spiny neurons owing to activation of the melanocortin 4 receptor.  Stress-elicited increases in behavioral measurements of anhedonia, but not increases in measurements of behavioral despair, are prevented by blocking these melanocortin 4 receptor-mediated synaptic changes in vivo.  These results establish that stress-elicited anhedonia requires a neuropeptide-triggered, cell-type-specific synaptic adaptation in the nucleus accumbens and that distinct circuit adaptations mediate other major symptoms of stress-elicited depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKEc-kNRWIA7Vg90H21EOLACvtfcHk0liNuiLv-sfN9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVWisrbI&md5=4dcb328d8819479b72dad30948497755</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1038%2Fnature11160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11160%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DB.%2BK.%26aulast%3DHuang%26aufirst%3DK.%2BW.%26aulast%3DGrueter%26aufirst%3DB.%2BA.%26aulast%3DRothwell%26aufirst%3DP.%2BE.%26aulast%3DMalenka%26aufirst%3DR.%2BC.%26atitle%3DAnhedonia%2520requires%2520MC4R-mediated%2520synaptic%2520adaptations%2520in%2520nucleus%2520accumbens%26jtitle%3DNature%26date%3D2012%26volume%3D487%26spage%3D183%26epage%3D189%26doi%3D10.1038%2Fnature11160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kallarackal, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kvarta, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cammarata, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaberi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S. M.</span></span> <span> </span><span class="NLM_article-title">Chronic stress induces a selective decrease in AMPA receptor-mediated synaptic excitation at hippocampal temporoammonic-CA1 synapses</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">15669</span>– <span class="NLM_lpage">15674</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.2588-13.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1523%2FJNEUROSCI.2588-13.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=24089474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2lur3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=15669-15674&author=A.+J.+Kallarackalauthor=M.+D.+Kvartaauthor=E.+Cammarataauthor=L.+Jaberiauthor=X.+Caiauthor=A.+M.+Baileyauthor=S.+M.+Thompson&title=Chronic+stress+induces+a+selective+decrease+in+AMPA+receptor-mediated+synaptic+excitation+at+hippocampal+temporoammonic-CA1+synapses&doi=10.1523%2FJNEUROSCI.2588-13.2013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic stress induces a selective decrease in AMPA receptor-mediated synaptic excitation at hippocampal temporoammonic-CA1 synapses</span></div><div class="casAuthors">Kallarackal, Angy J.; Kvarta, Mark D.; Cammarata, Erin; Jaberi, Leelah; Cai, Xiang; Bailey, Aileen M.; Thompson, Scott M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">15669-15674</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Chronic stress promotes depression, but how it disrupts cognition and mood remains unknown.  Chronic stress causes atrophy of pyramidal cell dendrites in the hippocampus and cortex in human and animal models, and a depressive-like behavioral state.  We now test the hypothesis that excitatory temporoammonic (TA) synapses in the distal dendrites of CA1 pyramidal cells in rats are altered by chronic unpredictable stress (CUS) and restored by chronic antidepressant treatment, in conjunction with the behavioral consequences of CUS.  We obsd. a decrease in AMPAR-mediated excitation at TA-CA1 synapses, but not Schaffer collateral-CA1 synapses, after CUS, with a corresponding layer-specific decrease in GluA1 expression.  Both changes were reversed by chronic fluoxetine.  CUS also disrupted long-term memory consolidation in the Morris water maze, a function of TA-CA1 synapses.  The decreases in TA-CA1 AMPAR-mediated excitation and performance in the consolidation test were correlated pos. with decreases in sucrose preference, a measure of anhedonia.  We conclude that chronic stress selectively decreases AMPAR no. and function at specific synapses and suggest that this underlies various depressive endophenotypes.  Our findings provide evidence that glutamatergic dysfunction is an underlying cause of depression and that current first-line antidepressant drugs act by restoring excitatory synaptic strength.  Our findings suggest novel therapeutic targets for this debilitating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh57gzYtk14LVg90H21EOLACvtfcHk0liNuiLv-sfN9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2lur3J&md5=a0c5c4e70f4af188c00b63f4ddf9c397</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.2588-13.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.2588-13.2013%26sid%3Dliteratum%253Aachs%26aulast%3DKallarackal%26aufirst%3DA.%2BJ.%26aulast%3DKvarta%26aufirst%3DM.%2BD.%26aulast%3DCammarata%26aufirst%3DE.%26aulast%3DJaberi%26aufirst%3DL.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DBailey%26aufirst%3DA.%2BM.%26aulast%3DThompson%26aufirst%3DS.%2BM.%26atitle%3DChronic%2520stress%2520induces%2520a%2520selective%2520decrease%2520in%2520AMPA%2520receptor-mediated%2520synaptic%2520excitation%2520at%2520hippocampal%2520temporoammonic-CA1%2520synapses%26jtitle%3DJ.%2520Neurosci.%26date%3D2013%26volume%3D33%26spage%3D15669%26epage%3D15674%26doi%3D10.1523%2FJNEUROSCI.2588-13.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span> <span> </span><span class="NLM_article-title">Lateral habenula in the pathophysiology of depression</span>. <i>Curr. Opin. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.conb.2017.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.conb.2017.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29175713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVSitbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2018&pages=90-96&author=Y.+Yangauthor=H.+Wangauthor=J.+Huauthor=H.+Hu&title=Lateral+habenula+in+the+pathophysiology+of+depression&doi=10.1016%2Fj.conb.2017.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Lateral habenula in the pathophysiology of depression</span></div><div class="casAuthors">Yang, Yan; Wang, Hao; Hu, Ji; Hu, Hailan</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Neurobiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">90-96</span>CODEN:
                <span class="NLM_cas:coden">COPUEN</span>;
        ISSN:<span class="NLM_cas:issn">0959-4388</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Depression is a devastating disorder with a combination of diverse symptoms such as low self-esteem, lack of motivation, anhedonia, loss of appetite, low energy, and discomfort without a clear cause.  Depression has been suggested to be the result of maladaptive changes in specific brain circuits.  Recently, the lateral habenula (LHb) has emerged as a key brain region in the pathophysiol. of depression.  Increasing evidence from rodent, non-human primate and human studies indicates that the aberrant activity of the LHb is assocd. with depressive symptoms such as helplessness, anhedonia, and excessive neg. focus.  Revealing the mol., cellular and circuit properties of the LHb will help explain how abnormalities in LHb activity are linked to depressive disorders, and shed light on developing novel strategies for depression treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFwV1YLkSapLVg90H21EOLACvtfcHk0lgCFZgJCTyb_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVSitbfO&md5=4ddfadd5be1e86180eee06ca2623fc3c</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.conb.2017.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.conb.2017.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DH.%26atitle%3DLateral%2520habenula%2520in%2520the%2520pathophysiology%2520of%2520depression%26jtitle%3DCurr.%2520Opin.%2520Neurobiol.%26date%3D2018%26volume%3D48%26spage%3D90%26epage%3D96%26doi%3D10.1016%2Fj.conb.2017.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drevets, W.</span></span> <span> </span><span class="NLM_article-title">Neurocircuitry of mood disorders</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.1038/npp.2009.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnpp.2009.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=19693001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD1MfivVSkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=192-216&author=J.+Priceauthor=W.+Drevets&title=Neurocircuitry+of+mood+disorders&doi=10.1038%2Fnpp.2009.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Neurocircuitry of mood disorders</span></div><div class="casAuthors">Price Joseph L; Drevets Wayne C</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">192-216</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This review begins with a brief historical overview of attempts in the first half of the 20th century to discern brain systems that underlie emotion and emotional behavior.  These early studies identified the amygdala, hippocampus, and other parts of what was termed the 'limbic' system as central parts of the emotional brain.  Detailed connectional data on this system began to be obtained in the 1970s and 1980s, as more effective neuroanatomical techniques based on axonal transport became available.  In the last 15 years these methods have been applied extensively to the limbic system and prefrontal cortex of monkeys, and much more specific circuits have been defined.  In particular, a system has been described that links the medial prefrontal cortex and a few related cortical areas to the amygdala, the ventral striatum and pallidum, the medial thalamus, the hypothalamus, and the periaqueductal gray and other parts of the brainstem.  A large body of human data from functional and structural imaging, as well as analysis of lesions and histological material indicates that this system is centrally involved in mood disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcTdc2c-lnpb5XHngOXiV_fW6udTcc2eYTtmymbiDcGbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MfivVSkuw%253D%253D&md5=49a5c88147c5318509a3b994ce548e59</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2009.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2009.104%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DJ.%26aulast%3DDrevets%26aufirst%3DW.%26atitle%3DNeurocircuitry%2520of%2520mood%2520disorders%26jtitle%3DNeuropsychopharmacology%26date%3D2010%26volume%3D35%26spage%3D192%26epage%3D216%26doi%3D10.1038%2Fnpp.2009.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murrough, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacoviello, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumeister, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charney, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iosifescu, D. V.</span></span> <span> </span><span class="NLM_article-title">Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies</span>. <i>Neurobiol. Learn. Mem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">563</span>, <span class="refDoi"> DOI: 10.1016/j.nlm.2011.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.nlm.2011.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=21704176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2011&pages=553-563&author=J.+W.+Murroughauthor=B.+Iacovielloauthor=A.+Neumeisterauthor=D.+S.+Charneyauthor=D.+V.+Iosifescu&title=Cognitive+dysfunction+in+depression%3A+neurocircuitry+and+new+therapeutic+strategies&doi=10.1016%2Fj.nlm.2011.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies</span></div><div class="casAuthors">Murrough, James W.; Iacoviello, Brian; Neumeister, Alexander; Charney, Dennis S.; Iosifescu, Dan V.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Learning and Memory</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">553-563</span>CODEN:
                <span class="NLM_cas:coden">NLMEFR</span>;
        ISSN:<span class="NLM_cas:issn">1074-7427</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Major depressive disorder (MDD) is a disabling medical condition assocd. with significant morbidity, mortality and public health costs.  However, neurocircuitry abnormalities underlying depression remain incompletely understood and consequently current treatment options are unfortunately limited in efficacy.  Recent research has begun to focus specifically on cognitive aspects of depression and potential neurobiol. correlates.  Two fundamental types of cognitive dysfunction obsd. in MDD are cognitive biases, which include distorted information processing or attentional allocation toward neg. stimuli, and cognitive deficits, which include impairments in attention, short-term memory and executive functioning.  In this article, we present a selective review of current research findings in these domains and examine neuroimaging research that is beginning to characterize the neurocircuitry underlying these biases and deficits.  We propose that deficient cognitive functioning, attention biases and the sustained neg. affect characteristic of MDD can be understood as arising in part from dysfunctional prefrontal-subcortical circuitry and related disturbances in the cognitive control of emotion.  Finally, we highlight potential new pharmacol. and non-pharmacol. therapeutic strategies for MDD based on an evolving mechanistic understanding of the disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLIwSi3SXol7Vg90H21EOLACvtfcHk0lgCFZgJCTyb_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsL7E&md5=928d9c8f9f216690f1399616f759900c</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2Fj.nlm.2011.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nlm.2011.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DMurrough%26aufirst%3DJ.%2BW.%26aulast%3DIacoviello%26aufirst%3DB.%26aulast%3DNeumeister%26aufirst%3DA.%26aulast%3DCharney%26aufirst%3DD.%2BS.%26aulast%3DIosifescu%26aufirst%3DD.%2BV.%26atitle%3DCognitive%2520dysfunction%2520in%2520depression%253A%2520neurocircuitry%2520and%2520new%2520therapeutic%2520strategies%26jtitle%3DNeurobiol.%2520Learn.%2520Mem.%26date%3D2011%26volume%3D96%26spage%3D553%26epage%3D563%26doi%3D10.1016%2Fj.nlm.2011.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallak, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dursun, S. M.</span></span> <span> </span><span class="NLM_article-title">Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco–magnetic resonance imaging study</span>. <i>Arch. Gen. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1001/archgenpsychiatry.2007.37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1001%2Farchgenpsychiatry.2007.37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=18250253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FptFyksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=154-164&author=J.+W.+Deakinauthor=J.+Leesauthor=S.+McKieauthor=J.+E.+Hallakauthor=S.+R.+Williamsauthor=S.+M.+Dursun&title=Glutamate+and+the+neural+basis+of+the+subjective+effects+of+ketamine%3A+a+pharmaco%E2%80%93magnetic+resonance+imaging+study&doi=10.1001%2Farchgenpsychiatry.2007.37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study</span></div><div class="casAuthors">Deakin J F William; Lees Jane; McKie Shane; Hallak Jaime E C; Williams Steve R; Dursun Serdar M</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-64</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CONTEXT:  Ketamine evokes psychosislike symptoms, and its primary action is to impair N-methyl-D-aspartate glutamate receptor neurotransmission, but it also induces secondary increases in glutamate release.  OBJECTIVES:  To identify the sites of action of ketamine in inducing symptoms and to determine the role of increased glutamate release using the glutamate release inhibitor lamotrigine.  DESIGN:  Two experiments with different participants were performed using a double-blind, placebo-controlled, randomized, crossover, counterbalanced-order design.  In the first experiment, the effect of intravenous ketamine hydrochloride on regional blood oxygenation level-dependent (BOLD) signal and correlated symptoms was compared with intravenous saline placebo.  In the second experiment, pretreatment with lamotrigine was compared with placebo to identify which effects of ketamine are mediated by increased glutamate release.  SETTING:  Wellcome Trust Clinical Research Facility, Manchester, England.  PARTICIPANTS:  Thirty-three healthy, right-handed men were recruited by advertisements.  INTERVENTIONS:  In experiment 1, participants were given intravenous ketamine (1-minute bolus of 0.26 mg/kg, followed by a maintenance infusion of 0.25 mg/kg/h for the remainder of the session) or placebo (0.9% saline solution).  In experiment 2, participants were pretreated with 300 mg of lamotrigine or placebo and then were given the same doses of ketamine as in experiment 1.  MAIN OUTCOME MEASURES:  Regional BOLD signal changes during ketamine or placebo infusion and Brief Psychiatric Rating Scale and Clinician-Administered Dissociative States Scale scores.  RESULTS:  Ketamine induced a rapid, focal, and unexpected decrease in ventromedial frontal cortex, including orbitofrontal cortex and subgenual cingulate, which strongly predicted its dissociative effects and increased activity in mid-posterior cingulate, thalamus, and temporal cortical regions (r = 0.90).  Activations correlated with Brief Psychiatric Rating Scale psychosis scores.  Lamotrigine pretreatment prevented many of the BOLD signal changes and the symptoms.  CONCLUSIONS:  These 2 changes may underpin 2 fundamental processes of psychosis: abnormal perceptual experiences and impaired cognitive-emotional evaluation of their significance.  The results are compatible with the theory that the neural and subjective effects of ketamine involve increased glutamate release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRE58QpfpTcutyzdcP07UmufW6udTcc2ebKzGqizshGR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FptFyksg%253D%253D&md5=6e99c34faa15f1c1117740718c469622</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1001%2Farchgenpsychiatry.2007.37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchgenpsychiatry.2007.37%26sid%3Dliteratum%253Aachs%26aulast%3DDeakin%26aufirst%3DJ.%2BW.%26aulast%3DLees%26aufirst%3DJ.%26aulast%3DMcKie%26aufirst%3DS.%26aulast%3DHallak%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DS.%2BR.%26aulast%3DDursun%26aufirst%3DS.%2BM.%26atitle%3DGlutamate%2520and%2520the%2520neural%2520basis%2520of%2520the%2520subjective%2520effects%2520of%2520ketamine%253A%2520a%2520pharmaco%25E2%2580%2593magnetic%2520resonance%2520imaging%2520study%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D2008%26volume%3D65%26spage%3D154%26epage%3D164%26doi%3D10.1001%2Farchgenpsychiatry.2007.37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvadore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornwell, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colon-Rosario, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppola, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manji, H. K.</span></span> <span> </span><span class="NLM_article-title">Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2008.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2008.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=18822408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFeksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2009&pages=289-295&author=G.+Salvadoreauthor=B.+R.+Cornwellauthor=V.+Colon-Rosarioauthor=R.+Coppolaauthor=C.+Grillonauthor=C.+A.+Zarateauthor=H.+K.+Manji&title=Increased+anterior+cingulate+cortical+activity+in+response+to+fearful+faces%3A+a+neurophysiological+biomarker+that+predicts+rapid+antidepressant+response+to+ketamine&doi=10.1016%2Fj.biopsych.2008.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Increased Anterior Cingulate Cortical Activity in Response to Fearful Faces: A Neurophysiological Biomarker that Predicts Rapid Antidepressant Response to Ketamine</span></div><div class="casAuthors">Salvadore, Giacomo; Cornwell, Brian R.; Colon-Rosario, Veronica; Coppola, Richard; Grillon, Christian; Zarate, Carlos A.; Manji, Husseini K.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">289-295</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Background: Most patients with major depressive disorder (MDD) experience a period of lengthy trial and error when trying to find optimal antidepressant treatment; identifying biomarkers that could predict response to antidepressant treatment would be of enormous benefit.  We tested the hypothesis that pretreatment anterior cingulate cortex (ACC) activity could be a putative biomarker of rapid antidepressant response to ketamine, in line with previous findings that investigated the effects of conventional antidepressants.  We also investigated patterns of ACC activity to rapid presentation of fearful faces compared with the normal habituation obsd. in healthy subjects.  Methods: We elicited ACC activity in drug-free patients with MDD (n = 11) and healthy control subjects (n = 11) by rapidly presenting fearful faces, a paradigm known to activate rostral regions of the ACC.  Spatial-filtering analyses were performed on magnetoencephalog. (MEG) recordings, which offer the temporal precision necessary to est. ACC activity elicited by the rapid presentation of stimuli.  Magnetoencephalog. recordings were obtained only once for both patients and control subjects.  Patients were subsequently administered a single ketamine infusion followed by assessment of depressive symptoms 4 h later.  Results: Although healthy subjects had decreased neuromagnetic activity in the rostral ACC across repeated exposures, patients with MDD showed robust increases in pretreatment ACC activity.  Notably, this increase was pos. correlated with subsequent rapid antidepressant response to ketamine.  Exploratory analyses showed that pretreatment amygdala activity was neg. correlated with change in depressive symptoms.  Conclusions: Pretreatment rostral ACC activation may be a useful biomarker that identifies a subgroup of patients who will respond favorably to ketamine's antidepressant effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotbAnatv3btLVg90H21EOLACvtfcHk0lghGjstKZ8w7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFeksrk%253D&md5=900e392965797d3e5c41c96f2a9740b6</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2008.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2008.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DSalvadore%26aufirst%3DG.%26aulast%3DCornwell%26aufirst%3DB.%2BR.%26aulast%3DColon-Rosario%26aufirst%3DV.%26aulast%3DCoppola%26aufirst%3DR.%26aulast%3DGrillon%26aufirst%3DC.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DManji%26aufirst%3DH.%2BK.%26atitle%3DIncreased%2520anterior%2520cingulate%2520cortical%2520activity%2520in%2520response%2520to%2520fearful%2520faces%253A%2520a%2520neurophysiological%2520biomarker%2520that%2520predicts%2520rapid%2520antidepressant%2520response%2520to%2520ketamine%26jtitle%3DBiol.%2520Psychiatry%26date%3D2009%26volume%3D65%26spage%3D289%26epage%3D295%26doi%3D10.1016%2Fj.biopsych.2008.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvadore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornwell, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambataro, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colon-Rosario, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carver, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holroyd, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiazGranados, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado-Vieira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillon, C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1415</span>– <span class="NLM_lpage">1422</span>, <span class="refDoi"> DOI: 10.1038/npp.2010.24</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnpp.2010.24" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=20393460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtVSntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=1415-1422&author=G.+Salvadoreauthor=B.+R.+Cornwellauthor=F.+Sambataroauthor=D.+Latovauthor=V.+Colon-Rosarioauthor=F.+Carverauthor=T.+Holroydauthor=N.+DiazGranadosauthor=R.+Machado-Vieiraauthor=C.+Grillon&title=Anterior+cingulate+desynchronization+and+functional+connectivity+with+the+amygdala+during+a+working+memory+task+predict+rapid+antidepressant+response+to+ketamine&doi=10.1038%2Fnpp.2010.24"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Anterior Cingulate Desynchronization and Functional Connectivity with the Amygdala During a Working Memory Task Predict Rapid Antidepressant Response to Ketamine</span></div><div class="casAuthors">Salvadore, Giacomo; Cornwell, Brian R.; Sambataro, Fabio; Latov, David; Colon-Rosario, Veronica; Carver, Frederick; Holroyd, Tom; Diaz Granados, Nancy; Machado-Vieira, Rodrigo; Grillon, Christian; Drevets, Wayne C.; Zarate, Carlos A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1415-1422</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Pregenual anterior cingulate cortex (pgACC) hyperactivity differentiates treatment responders from non-responders to various pharmacol. antidepressant interventions, including ketamine, an N-methyl-D-aspartate receptor antagonist.  Evidence of pgACC hyperactivation during non-emotional working memory tasks in patients with major depressive disorder (MDD) highlights the importance of this region for processing both emotionally salient and cognitive stimuli.  However, it is unclear whether pgACC activity might serve as a potential biomarker of antidepressant response during working memory tasks as well, in line with previous research with emotionally arousing tasks.  This study tested the hypothesis that during the N-back task, a widely used working memory paradigm, low pretreatment pgACC activity, as well as coherence between the pgACC and the amygdala, would be correlated with the clin. improvement after ketamine.  Magnetoencephalog. (MEG) recordings were obtained from 15 drug-free patients with MDD during working memory performance 1 to 3 days before receiving a single ketamine infusion.  Functional activation patterns were analyzed using advanced MEG source anal.  Source coherence analyses were conducted to quantify the degree of long-range functional connectivity between the pgACC and the amygdala.  Patients who showed the least engagement of the pgACC in response to increased working memory load showed the greatest symptomatic improvement within 4 h of ketamine administration (r=0.82, p=0.0002, false discovery rate (FDR) <0.05).  Pretreatment functional connectivity between the pgACC and the left amygdala was neg. correlated with antidepressant symptom change (r=-0.73, p=0.0021, FDR <0.05).  These data implicate the pgACC and its putative interaction with the amygdala in predicting antidepressant response to ketamine in a working memory task context.  Neuropsychopharmacol. (2010) 35, 1415-1422; doi:10.1038/npp.2010.24; published online 10 March 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJVN7J6X5SOLVg90H21EOLACvtfcHk0lghGjstKZ8w7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtVSntrc%253D&md5=43264b2667165a6e7d150b18d5d0021d</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2010.24&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2010.24%26sid%3Dliteratum%253Aachs%26aulast%3DSalvadore%26aufirst%3DG.%26aulast%3DCornwell%26aufirst%3DB.%2BR.%26aulast%3DSambataro%26aufirst%3DF.%26aulast%3DLatov%26aufirst%3DD.%26aulast%3DColon-Rosario%26aufirst%3DV.%26aulast%3DCarver%26aufirst%3DF.%26aulast%3DHolroyd%26aufirst%3DT.%26aulast%3DDiazGranados%26aufirst%3DN.%26aulast%3DMachado-Vieira%26aufirst%3DR.%26aulast%3DGrillon%26aufirst%3DC.%26atitle%3DAnterior%2520cingulate%2520desynchronization%2520and%2520functional%2520connectivity%2520with%2520the%2520amygdala%2520during%2520a%2520working%2520memory%2520task%2520predict%2520rapid%2520antidepressant%2520response%2520to%2520ketamine%26jtitle%3DNeuropsychopharmacology%26date%3D2010%26volume%3D35%26spage%3D1415%26epage%3D1422%26doi%3D10.1038%2Fnpp.2010.24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Covington, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maze, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vialou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPlant, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouzon, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamminga, C. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">16082</span>– <span class="NLM_lpage">16090</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.1731-10.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1523%2FJNEUROSCI.1731-10.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=21123555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SlurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=16082-16090&author=H.+E.+Covingtonauthor=M.+K.+Loboauthor=I.+Mazeauthor=V.+Vialouauthor=J.+M.+Hymanauthor=S.+Zamanauthor=Q.+LaPlantauthor=E.+Mouzonauthor=S.+Ghoseauthor=C.+A.+Tamminga&title=Antidepressant+effect+of+optogenetic+stimulation+of+the+medial+prefrontal+cortex&doi=10.1523%2FJNEUROSCI.1731-10.2010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex</span></div><div class="casAuthors">Covington, Herbert E., III; Lobo, Mary Kay; Maze, Ian; Vialou, Vincent; Hyman, James M.; Zaman, Samir; La Plant, Quincey; Mouzon, Ezekiel; Ghose, Subroto; Tamminga, Carol A.; Neve, Rachael L.; Deisseroth, Karl; Nestler, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">16082-16090</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Brain stimulation and imaging studies in humans have highlighted a key role for the prefrontal cortex in clin. depression; however, it remains unknown whether excitation or inhibition of prefrontal cortical neuronal activity is assocd. with antidepressant responses.  Here, we examd. cellular indicators of functional activity, including the immediate early genes (IEGs) zif268 (egr1), c-fos, and arc, in the prefrontal cortex of clin. depressed humans obtained postmortem.  We also examd. these genes in the ventral portion of the medial prefrontal cortex (mPFC) of mice after chronic social defeat stress, a mouse model of depression.  In addn., we used viral vectors to overexpress channel rhodopsin 2 (a light-activated cation channel) in mouse mPFC to optogenetically drive "burst" patterns of cortical firing in vivo and examine the behavioral consequences.  Prefrontal cortical tissue derived from clin. depressed humans displayed significant redns. in IEG expression, consistent with a deficit in neuronal activity within this brain region.  Mice subjected to chronic social defeat stress exhibited similar redns. in levels of IEG expression in mPFC.  Interestingly, some of these changes were not obsd. in defeated mice that escape the deleterious consequences of the stress, i.e., resilient animals.  In those mice that expressed a strong depressive-like phenotype, i.e., susceptible animals, optogenetic stimulation of mPFC exerted potent antidepressant-like effects, without affecting general locomotor activity, anxiety-like behaviors, or social memory.  These results indicate that the activity of the mPFC is a key determinant of depression-like behavior, as well as antidepressant responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzHc8rw8jgcLVg90H21EOLACvtfcHk0lgCwcd6aVv8Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SlurrF&md5=f2d2161ea7771dfb2cb8ae650e58c638</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1731-10.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1731-10.2010%26sid%3Dliteratum%253Aachs%26aulast%3DCovington%26aufirst%3DH.%2BE.%26aulast%3DLobo%26aufirst%3DM.%2BK.%26aulast%3DMaze%26aufirst%3DI.%26aulast%3DVialou%26aufirst%3DV.%26aulast%3DHyman%26aufirst%3DJ.%2BM.%26aulast%3DZaman%26aufirst%3DS.%26aulast%3DLaPlant%26aufirst%3DQ.%26aulast%3DMouzon%26aufirst%3DE.%26aulast%3DGhose%26aufirst%3DS.%26aulast%3DTamminga%26aufirst%3DC.%2BA.%26atitle%3DAntidepressant%2520effect%2520of%2520optogenetic%2520stimulation%2520of%2520the%2520medial%2520prefrontal%2520cortex%26jtitle%3DJ.%2520Neurosci.%26date%3D2010%26volume%3D30%26spage%3D16082%26epage%3D16090%26doi%3D10.1523%2FJNEUROSCI.1731-10.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fuchikami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohleb, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Land, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiLeone, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aghajanian, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span> <span> </span><span class="NLM_article-title">Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">8106</span>– <span class="NLM_lpage">8111</span>, <span class="refDoi"> DOI: 10.1073/pnas.1414728112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1073%2Fpnas.1414728112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26056286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXps1Cks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=8106-8111&author=M.+Fuchikamiauthor=A.+Thomasauthor=R.+Liuauthor=E.+S.+Wohlebauthor=B.+B.+Landauthor=R.+J.+DiLeoneauthor=G.+K.+Aghajanianauthor=R.+S.+Duman&title=Optogenetic+stimulation+of+infralimbic+PFC+reproduces+ketamine%E2%80%99s+rapid+and+sustained+antidepressant+actions&doi=10.1073%2Fpnas.1414728112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions</span></div><div class="casAuthors">Fuchikami, Manabu; Thomas, Alexandra; Liu, Rongjian; Wohleb, Eric S.; Land, Benjamin B.; Di Leone, Ralph J.; Aghajanian, George K.; Duman, Ronald S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">8106-8111</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Ketamine produces rapid and sustained antidepressant actions in depressed patients, but the precise cellular mechanisms underlying these effects have not been identified.  Here we detd. if modulation of neuronal activity in the infralimbic prefrontal cortex (IL-PFC) underlies the antidepressant and anxiolytic actions of ketamine.  We found that neuronal inactivation of the IL-PFC completely blocked the antidepressant and anxiolytic effects of systemic ketamine in rodent models and that ketamine microinfusion into IL-PFC reproduced these behavioral actions of systemic ketamine.  We also found that optogenetic stimulation of the IL-PFC produced rapid and long-lasting antidepressant and anxiolytic effects and that these effects are assocd. with increased no. and function of spine synapses of layer V pyramidal neurons.  The results demonstrate that ketamine infusions or optogenetic stimulation of IL-PFC are sufficient to produce long-lasting antidepressant behavioral and synaptic responses similar to the effects of systemic ketamine administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaKumbToxsFrVg90H21EOLACvtfcHk0lgCwcd6aVv8Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXps1Cks7w%253D&md5=e1324a1064d8b4e275acffa28fe85c05</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1414728112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1414728112%26sid%3Dliteratum%253Aachs%26aulast%3DFuchikami%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DWohleb%26aufirst%3DE.%2BS.%26aulast%3DLand%26aufirst%3DB.%2BB.%26aulast%3DDiLeone%26aufirst%3DR.%2BJ.%26aulast%3DAghajanian%26aufirst%3DG.%2BK.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DOptogenetic%2520stimulation%2520of%2520infralimbic%2520PFC%2520reproduces%2520ketamine%25E2%2580%2599s%2520rapid%2520and%2520sustained%2520antidepressant%2520actions%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D8106%26epage%3D8111%26doi%3D10.1073%2Fpnas.1414728112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vollenweider, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leenders, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharfetter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maguire, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angst, J.</span></span> <span> </span><span class="NLM_article-title">Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F] fluorodeoxyglucose (FDG)</span>. <i>Eur. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1016/S0924-977X(96)00039-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2FS0924-977X%2896%2900039-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=9088881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK2sXhtlyisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=9-24&author=F.+Vollenweiderauthor=K.+Leendersauthor=C.+Scharfetterauthor=A.+Antoniniauthor=P.+Maguireauthor=J.+Missimerauthor=J.+Angst&title=Metabolic+hyperfrontality+and+psychopathology+in+the+ketamine+model+of+psychosis+using+positron+emission+tomography+%28PET%29+and+%5B18F%5D+fluorodeoxyglucose+%28FDG%29&doi=10.1016%2FS0924-977X%2896%2900039-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)</span></div><div class="casAuthors">Vollenweider, F. X.; Leenders, K. L.; Scharfetter, C.; Antonini, A.; Maguire, P.; Missimer, J.; Angst, J.</div><div class="citationInfo"><span class="NLM_cas:title">European Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-24</span>CODEN:
                <span class="NLM_cas:coden">EURNE8</span>;
        ISSN:<span class="NLM_cas:issn">0924-977X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">To date, the ketamine/PCP model of psychosis has been proposed to be one of the best pharmacol. models to mimic schizophrenic psychosis in healthy volunteers, since ketamine can induce both pos. and neg. symptoms of schizophrenia.  At subanesthetic doses, ketamine has been reported to primarily block N-methyl-D-aspartate (NMDA) receptor complex giving support to a glutamate deficiency hypothesis in schizophrenia.  Positron emission tomog. was used to study ketamine-induced psychotic symptom formation in relation to cerebral metabolic alterations in healthy volunteers.  This study shows that NMDA receptor blockade results in a hyperfrontal metabolic pattern.  Increased metabolic activity in the frontomedial and anterior cingulate cortex correlated pos. with psychotic symptom formation, in particular with ego pathol.  Anal. of correlations between syndrome scores and metabolic rate of glucose (CMRglu) or metabolic gradients (ratios) revealed that each psychopathol. syndrome was assocd. with a no. of metabolic alterations in cortical and subcortical brain regions, suggesting that not a single brain region, but distributed neuronal networks are involved in acute psychotic symptom formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqHFpuBLa-MbVg90H21EOLACvtfcHk0lgCwcd6aVv8Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhtlyisrw%253D&md5=37111d5ec36dbb3cb18483b661037292</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2FS0924-977X%2896%2900039-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0924-977X%252896%252900039-9%26sid%3Dliteratum%253Aachs%26aulast%3DVollenweider%26aufirst%3DF.%26aulast%3DLeenders%26aufirst%3DK.%26aulast%3DScharfetter%26aufirst%3DC.%26aulast%3DAntonini%26aufirst%3DA.%26aulast%3DMaguire%26aufirst%3DP.%26aulast%3DMissimer%26aufirst%3DJ.%26aulast%3DAngst%26aufirst%3DJ.%26atitle%3DMetabolic%2520hyperfrontality%2520and%2520psychopathology%2520in%2520the%2520ketamine%2520model%2520of%2520psychosis%2520using%2520positron%2520emission%2520tomography%2520%2528PET%2529%2520and%2520%255B18F%255D%2520fluorodeoxyglucose%2520%2528FDG%2529%26jtitle%3DEur.%2520Neuropsychopharmacol.%26date%3D1997%26volume%3D7%26spage%3D9%26epage%3D24%26doi%3D10.1016%2FS0924-977X%2896%2900039-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Långsjö, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaisti, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aalto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aantaa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikonen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sipilä, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvanto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinin, H.</span></span> <span> </span><span class="NLM_article-title">Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">614</span>– <span class="NLM_lpage">623</span>, <span class="refDoi"> DOI: 10.1097/00000542-200309000-00016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2F00000542-200309000-00016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=12960545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD3svitFGisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2003&pages=614-623&author=J.+W.+L%C3%A5ngsj%C3%B6author=K.+K.+Kaistiauthor=S.+Aaltoauthor=S.+Hinkkaauthor=R.+Aantaaauthor=V.+Oikonenauthor=H.+Sipil%C3%A4author=T.+Kurkiauthor=M.+Silvantoauthor=H.+Scheinin&title=Effects+of+subanesthetic+doses+of+ketamine+on+regional+cerebral+blood+flow%2C+oxygen+consumption%2C+and+blood+volume+in+humans&doi=10.1097%2F00000542-200309000-00016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans</span></div><div class="casAuthors">Langsjo Jaakko W; Kaisti Kaike K; Aalto Sargo; Hinkka Susanna; Aantaa Riku; Oikonen Vesa; Sipila Hannu; Kurki Timo; Silvanto Martti; Scheinin Harry</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">614-23</span>
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    </div><div class="casAbstract">BACKGROUND:  Animal experiments have demonstrated neuroprotection by ketamine.  However, because of its propensity to increase cerebral blood flow, metabolism, and intracranial pressure, its use in neurosurgery or trauma patients has been questioned.  METHODS:  15O-labeled water, oxygen, and carbon monoxide were used as positron emission tomography tracers to determine quantitative regional cerebral blood flow (rCBF), metabolic rate of oxygen (rCMRO2), and blood volume (rCBV), respectively, on selected regions of interest of nine healthy male volunteers at baseline and during three escalating concentrations of ketamine (targeted to 30, 100, and 300 ng/ml).  In addition, voxel-based analysis for relative changes in rCBF and rCMRO2 was performed using statistical parametric mapping.  RESULTS:  The mean +/- SD measured ketamine serum concentrations were 37 +/- 8, 132 +/- 19, and 411 +/- 71 ng/ml.  Mean arterial pressure was slightly elevated (maximally by 15.3%, P < 0.001) during ketamine infusion.  Ketamine increased rCBF in a concentration-dependent manner.  In the region-of-interest analysis, the greatest absolute changes were detected at the highest ketamine concentration level in the anterior cingulate (38.2% increase from baseline, P < 0.001), thalamus (28.5%, P < 0.001), putamen (26.8%, P < 0.001), and frontal cortex (25.4%, P < 0.001).  Voxel-based analysis revealed marked relative rCBF increases in the anterior cingulate, frontal cortex, and insula.  Although absolute rCMRO2 was not changed in the region-of-interest analysis, subtle relative increases in the frontal, parietal, and occipital cortices and decreases predominantly in the cerebellum were detected in the voxel-based analysis. rCBV increased only in the frontal cortex (4%, P = 0.022).  CONCLUSIONS:  Subanesthetic doses of ketamine induced a global increase in rCBF but no changes in rCMRO2.  Consequently, the regional oxygen extraction fraction was decreased.  Disturbed coupling of cerebral blood flow and metabolism is, however, considered unlikely because ketamine has been previously shown to increase cerebral glucose metabolism.  Only a minor increase in rCBV was detected.  Interestingly, the most profound changes in rCBF were observed in structures related to pain processing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTSfSswHFtZq-2mnZh2OgS0fW6udTcc2eZbTWjFC1vcyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svitFGisg%253D%253D&md5=5fb56ae54f786e3b0828e18dad28823f</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1097%2F00000542-200309000-00016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-200309000-00016%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25A5ngsj%25C3%25B6%26aufirst%3DJ.%2BW.%26aulast%3DKaisti%26aufirst%3DK.%2BK.%26aulast%3DAalto%26aufirst%3DS.%26aulast%3DHinkka%26aufirst%3DS.%26aulast%3DAantaa%26aufirst%3DR.%26aulast%3DOikonen%26aufirst%3DV.%26aulast%3DSipil%25C3%25A4%26aufirst%3DH.%26aulast%3DKurki%26aufirst%3DT.%26aulast%3DSilvanto%26aufirst%3DM.%26aulast%3DScheinin%26aufirst%3DH.%26atitle%3DEffects%2520of%2520subanesthetic%2520doses%2520of%2520ketamine%2520on%2520regional%2520cerebral%2520blood%2520flow%252C%2520oxygen%2520consumption%252C%2520and%2520blood%2520volume%2520in%2520humans%26jtitle%3DAnesthesiology%26date%3D2003%26volume%3D99%26spage%3D614%26epage%3D623%26doi%3D10.1097%2F00000542-200309000-00016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Långsjö, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaisti, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aalto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinkka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aantaa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oikonen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viljanen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvanto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinin, H.</span></span> <span> </span><span class="NLM_article-title">Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1065</span>– <span class="NLM_lpage">1071</span>, <span class="refDoi"> DOI: 10.1097/00000542-200405000-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1097%2F00000542-200405000-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=15114201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ivVKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2004&pages=1065-1071&author=J.+W.+L%C3%A5ngsj%C3%B6author=E.+Salmiauthor=K.+K.+Kaistiauthor=S.+Aaltoauthor=S.+Hinkkaauthor=R.+Aantaaauthor=V.+Oikonenauthor=T.+Viljanenauthor=T.+Kurkiauthor=M.+Silvantoauthor=H.+Scheinin&title=Effects+of+subanesthetic+ketamine+on+regional+cerebral+glucose+metabolism+in+humans&doi=10.1097%2F00000542-200405000-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans</span></div><div class="casAuthors">Langsjo Jaakko W; Salmi Elina; Kaisti Kaike K; Aalto Sargo; Hinkka Susanna; Aantaa Riku; Oikonen Vesa; Viljanen Tapio; Kurki Timo; Silvanto Martti; Scheinin Harry</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1065-71</span>
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    </div><div class="casAbstract">BACKGROUND:  The authors have recently shown with positron emission tomography that subanesthetic doses of racemic ketamine increase cerebral blood flow but do not affect oxygen consumption significantly.  In this study, the authors wanted to assess the effects of racemic ketamine on regional glucose metabolic rate (rGMR) in similar conditions to establish whether ketamine truly induces disturbed coupling between cerebral blood flow and metabolism.  METHODS:  18F-labeled fluorodeoxyglucose was used as a positron emission tomography tracer to quantify rGMR on 12 brain regions of interest of nine healthy male volunteers at baseline and during a 300-ng/ml ketamine target concentration level.  In addition, voxel-based analysis was performed for the relative changes in rGMR using statistical parametric mapping.  RESULTS:  The mean +/- SD measured ketamine serum concentration was 326.4+/-86.3 ng/ml.  The mean arterial pressure was slightly increased (maximally by 16.4%) during ketamine infusion (P < 0.001).  Ketamine increased absolute rGMR significantly in most regions of interest studied.  The greatest increases were detected in the thalamus (14.6+/-15.9%; P = 0.029) and in the frontal (13.6+/-13.1%; P = 0.011) and parietal cortices (13.1+/-11.2%; P = 0.007).  Absolute rGMR was not decreased anywhere in the brain.  The voxel-based analysis revealed relative rGMR increases in the frontal, temporal, and parietal cortices.  CONCLUSIONS:  Global increases in rGMR seem to parallel ketamine-induced increases in cerebral blood flow detected in the authors' earlier study.  Therefore, ketamine-induced disturbance of coupling between cerebral blood flow and metabolism is highly unlikely.  The previously observed decrease in oxygen extraction fraction may be due to nonoxidative glucose metabolism during ketamine-induced increase in glutamate release.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ87ax4Qk7-gpNiNltV31zlfW6udTcc2eZbTWjFC1vcyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ivVKjsA%253D%253D&md5=8ee9d5b6502d0f769b8b1319c8cab205</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1097%2F00000542-200405000-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-200405000-00006%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25A5ngsj%25C3%25B6%26aufirst%3DJ.%2BW.%26aulast%3DSalmi%26aufirst%3DE.%26aulast%3DKaisti%26aufirst%3DK.%2BK.%26aulast%3DAalto%26aufirst%3DS.%26aulast%3DHinkka%26aufirst%3DS.%26aulast%3DAantaa%26aufirst%3DR.%26aulast%3DOikonen%26aufirst%3DV.%26aulast%3DViljanen%26aufirst%3DT.%26aulast%3DKurki%26aufirst%3DT.%26aulast%3DSilvanto%26aufirst%3DM.%26aulast%3DScheinin%26aufirst%3DH.%26atitle%3DEffects%2520of%2520subanesthetic%2520ketamine%2520on%2520regional%2520cerebral%2520glucose%2520metabolism%2520in%2520humans%26jtitle%3DAnesthesiology%26date%3D2004%26volume%3D100%26spage%3D1065%26epage%3D1071%26doi%3D10.1097%2F00000542-200405000-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dranovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hen, R.</span></span> <span> </span><span class="NLM_article-title">Hippocampal neurogenesis: regulation by stress and antidepressants</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1136</span>– <span class="NLM_lpage">1143</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2006.03.082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2006.03.082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=16797263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVOitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=1136-1143&author=A.+Dranovskyauthor=R.+Hen&title=Hippocampal+neurogenesis%3A+regulation+by+stress+and+antidepressants&doi=10.1016%2Fj.biopsych.2006.03.082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Hippocampal Neurogenesis: Regulation by Stress and Antidepressants</span></div><div class="casAuthors">Dranovsky, Alex; Hen, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1136-1143</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Accumulating evidence implicates hippocampal neurogenesis in the pathophysiol. of depression.  Psychosocial stress reduces neurogenesis in rodents, whereas chronic treatment with antidepressants increases neurogenesis and blocks the effects of stress.  The effects of stress and antidepressant treatment on hippocampal neurogenesis parallel behavioral changes in animal models.  Moreover, ablating hippocampal neurogenesis renders antidepressants inactive in behavioral paradigms used to model antidepressant response and anxiety-like behavior in mice.  In humans, monoamine-modulating antidepressants demonstrate clin. efficacy in treating depression and anxiety, which are often pptd. by psychosocial stress.  This review examines the mounting evidence that stress and antidepressant treatment regulate neurogenesis in animals.  Special attention is paid to the cellular and mol. mechanisms by which this regulation takes place.  An anal. of current animal models used to study response to stress and antidepressants indicates the importance of modeling chronic treatment, which reflects both changes in neurogenesis and clin. response.  Exploring responses of hippocampal neurogenesis to exptl. challenges in appropriate animal models should delineate the role of adult-born neurons in hippocampal physiol.  Focusing on neurogenic response to exptl. paradigms of stress and antidepressant treatment is particularly interesting for understanding the pathophysiol. of major depressive disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdL0eOUELZLbVg90H21EOLACvtfcHk0lj_FTQ3Q62BEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVOitr0%253D&md5=2b7ca0bbd44242c38db77bc63b76ab77</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2006.03.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2006.03.082%26sid%3Dliteratum%253Aachs%26aulast%3DDranovsky%26aufirst%3DA.%26aulast%3DHen%26aufirst%3DR.%26atitle%3DHippocampal%2520neurogenesis%253A%2520regulation%2520by%2520stress%2520and%2520antidepressants%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D59%26spage%3D1136%26epage%3D1143%26doi%3D10.1016%2Fj.biopsych.2006.03.082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteggia, L. M.</span></span> <span> </span><span class="NLM_article-title">A neurotrophic model for stress-related mood disorders</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1116</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2006.02.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.biopsych.2006.02.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=16631126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtVOisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2006&pages=1116-1127&author=R.+S.+Dumanauthor=L.+M.+Monteggia&title=A+neurotrophic+model+for+stress-related+mood+disorders&doi=10.1016%2Fj.biopsych.2006.02.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">A Neurotrophic Model for Stress-Related Mood Disorders</span></div><div class="casAuthors">Duman, Ronald S.; Monteggia, Lisa M.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1116-1127</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  There is a growing body of evidence demonstrating that stress decreases the expression of brain-derived neurotrophic factor (BDNF) in limbic structures that control mood and that antidepressant treatment reverses or blocks the effects of stress.  Decreased levels of BDNF, as well as other neruotrophic factors, could contribute to the atrophy of certain limbic structures, including the hippocampus and prefrontal cortex that has been obsd. in depressed subjects.  Conversely, the neurotrophic actions of antidepressants could reverse neuronal atrophy and cell loss and thereby contribute to the therapeutic actions of these treatments.  This review provides a crit. examn. of the neurotrophic hypothesis of depression that has evolved from this work, including anal. of preclin. cellular (adult neurogenesis) and behavioral models of depression and antidepressant actions, as well as clin. neuroimaging and postmortem studies.  Although there are some limitations, the results of these studies are consistent with the hypothesis that decreased expression of BDNF and possibly other growth factors contributes to depression and that upregulation of BDNF plays a role in the actions of antidepressant treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozqx3V7lrUJLVg90H21EOLACvtfcHk0lgaJ44uhB-alw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtVOisbc%253D&md5=8fe1fca7e53b3002346c030243a595a5</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2006.02.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2006.02.013%26sid%3Dliteratum%253Aachs%26aulast%3DDuman%26aufirst%3DR.%2BS.%26aulast%3DMonteggia%26aufirst%3DL.%2BM.%26atitle%3DA%2520neurotrophic%2520model%2520for%2520stress-related%2520mood%2520disorders%26jtitle%3DBiol.%2520Psychiatry%26date%3D2006%26volume%3D59%26spage%3D1116%26epage%3D1127%26doi%3D10.1016%2Fj.biopsych.2006.02.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span> <span> </span><span class="NLM_article-title">Disrupted reward circuits is associated with cognitive deficits and depression severity in major depressive disorder</span>. <i>J. Psychiatr. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1016/j.jpsychires.2016.09.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.jpsychires.2016.09.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27673704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC2svktV2quw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2017&pages=9-17&author=L.+Gongauthor=Y.+Yinauthor=C.+Heauthor=Q.+Yeauthor=F.+Baiauthor=Y.+Yuanauthor=H.+Zhangauthor=L.+Lvauthor=H.+Zhangauthor=C.+Xieauthor=Z.+Zhang&title=Disrupted+reward+circuits+is+associated+with+cognitive+deficits+and+depression+severity+in+major+depressive+disorder&doi=10.1016%2Fj.jpsychires.2016.09.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Disrupted reward circuits is associated with cognitive deficits and depression severity in major depressive disorder</span></div><div class="casAuthors">Gong Liang; He Cancan; Ye Qing; Yin Yingying; Yuan Yonggui; Bai Feng; Zhang Zhijun; Zhang Haisan; Lv Luxian; Zhang Hongxing; Xie Chunming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of psychiatric research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Neuroimaging studies have demonstrated that major depressive disorder (MDD) patients show blunted activity responses to reward-related tasks.  However, whether abnormal reward circuits affect cognition and depression in MDD patients remains unclear.  Seventy-five drug-naive MDD patients and 42 cognitively normal (CN) subjects underwent a resting-state functional magnetic resonance imaging scan.  The bilateral nucleus accumbens (NAc) were selected as seeds to construct reward circuits across all subjects.  A multivariate linear regression analysis was employed to investigate the neural substrates of cognitive function and depression severity on the reward circuits in MDD patients.  The common pathway underlying cognitive deficits and depression was identified with conjunction analysis.  Compared with CN subjects, MDD patients showed decreased reward network connectivity that was primarily located in the prefrontal-striatal regions.  Importantly, distinct and common neural pathways underlying cognition and depression were identified, implying the independent and synergistic effects of cognitive deficits and depression severity on reward circuits.  This study demonstrated that disrupted topological organization within reward circuits was significantly associated with cognitive deficits and depression severity in MDD patients.  These findings suggest that in addition to antidepressant treatment, normalized reward circuits should be a focus and a target for improving depression and cognitive deficits in MDD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQSPV-njIIuiOxsqfvU0ziafW6udTcc2eaPeERlIFvtabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svktV2quw%253D%253D&md5=ef1f437945be250901d3c8678ab68dd5</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.jpsychires.2016.09.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpsychires.2016.09.016%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DL.%26aulast%3DYin%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DQ.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLv%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DZ.%26atitle%3DDisrupted%2520reward%2520circuits%2520is%2520associated%2520with%2520cognitive%2520deficits%2520and%2520depression%2520severity%2520in%2520major%2520depressive%2520disorder%26jtitle%3DJ.%2520Psychiatr.%2520Res.%26date%3D2017%26volume%3D84%26spage%3D9%26epage%3D17%26doi%3D10.1016%2Fj.jpsychires.2016.09.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-c.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">Comparison of ketamine, 7, 8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression</span>. <i>Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">4325</span>– <span class="NLM_lpage">4335</span>, <span class="refDoi"> DOI: 10.1007/s00213-015-4062-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1007%2Fs00213-015-4062-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVGnsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2015&pages=4325-4335&author=J.-c.+Zhangauthor=W.+Yaoauthor=C.+Dongauthor=C.+Yangauthor=Q.+Renauthor=M.+Maauthor=M.+Hanauthor=K.+Hashimoto&title=Comparison+of+ketamine%2C+7%2C+8-dihydroxyflavone%2C+and+ANA-12+antidepressant+effects+in+the+social+defeat+stress+model+of+depression&doi=10.1007%2Fs00213-015-4062-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression</span></div><div class="casAuthors">Zhang, Ji-chun; Yao, Wei; Dong, Chao; Yang, Chun; Ren, Qian; Ma, Min; Han, Mei; Hashimoto, Kenji</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Heidelberg, Germany)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4325-4335</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Rationale: Brain-derived neurotrophic factor (BDNF) and signaling at its receptor, tropomyosin-related kinase B (TrkB), are implicated in the rapid and long-lasting antidepressant effects of ketamine.  Moreover, a TrkB agonist, 7,8-dihydroxyflavone (7,8-DHF), and/or TrkB antagonist, ANA-12, shows antidepressant effects in animal models of depression.  Objective: The objective of this study is to compare the influence of ketamine, 7,8-DHF, and ANA-12 on antidepressant activity in the social defeat stress model.  Results: In the tail suspension and forced swimming tests, ketamine, 7,8-DHF, or ANA-12 markedly attenuated the increased immobility time in depressed mice compared with the vehicle-treated group.  In the sucrose preference test, all drugs significantly improved the reduced preference in depressed mice at both 1 and 3 days after a single dose.  Antidepressant effect of ketamine, but not 7,8-DHF or ANA-12, was still detectable 7 days after a single dose.  Western blot analyses showed that ketamine, but not 7,8-DHF or ANA-12, markedly attenuated reduced levels of BDNF and postsynaptic d. protein 95 (PSD-95) in the prefrontal cortex (PFC), dentate gyrus (DG), and CA3 of the hippocampus in depressed mice 8 days after a single dose.  Furthermore, ketamine markedly increased reduced levels of GluA1 in the PFC and DG of depressed mice.  In contrast, ketamine showed no effect against increased levels of BDNF, PSD-95, and GluA1 obsd. in the nucleus accumbens of depressed mice.  Conclusions: Compared with 7,8-DHF and ANA-12, ketamine is a longer-lasting antidepressant in the social defeat stress model, and synaptogenesis may be required for the mechanisms that promote sustained antidepressant effects of ketamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw85FFINDI-rVg90H21EOLACvtfcHk0lgaJ44uhB-alw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVGnsbbO&md5=1d933f735f89f53ed50741eea09f672c</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1007%2Fs00213-015-4062-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-015-4062-3%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.-c.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DM.%26aulast%3DHan%26aufirst%3DM.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DComparison%2520of%2520ketamine%252C%25207%252C%25208-dihydroxyflavone%252C%2520and%2520ANA-12%2520antidepressant%2520effects%2520in%2520the%2520social%2520defeat%2520stress%2520model%2520of%2520depression%26jtitle%3DPsychopharmacol.%26date%3D2015%26volume%3D232%26spage%3D4325%26epage%3D4335%26doi%3D10.1007%2Fs00213-015-4062-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-c.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span> <span> </span><span class="NLM_article-title">Rapid and sustained antidepressant action of the mGlu2/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine</span>. <i>Int. J. Neuropsychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1093/ijnp/pyw089</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1093%2Fijnp%2Fpyw089" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2016&pages=228-236&author=C.+Dongauthor=J.-c.+Zhangauthor=W.+Yaoauthor=Q.+Renauthor=M.+Maauthor=C.+Yangauthor=S.+Chakiauthor=K.+Hashimoto&title=Rapid+and+sustained+antidepressant+action+of+the+mGlu2%2F3+receptor+antagonist+MGS0039+in+the+social+defeat+stress+model%3A+comparison+with+ketamine&doi=10.1093%2Fijnp%2Fpyw089"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1093%2Fijnp%2Fpyw089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fijnp%252Fpyw089%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.-c.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DMa%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DChaki%26aufirst%3DS.%26aulast%3DHashimoto%26aufirst%3DK.%26atitle%3DRapid%2520and%2520sustained%2520antidepressant%2520action%2520of%2520the%2520mGlu2%252F3%2520receptor%2520antagonist%2520MGS0039%2520in%2520the%2520social%2520defeat%2520stress%2520model%253A%2520comparison%2520with%2520ketamine%26jtitle%3DInt.%2520J.%2520Neuropsychopharmacol.%26date%3D2016%26volume%3D20%26spage%3D228%26epage%3D236%26doi%3D10.1093%2Fijnp%2Fpyw089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotlib, I. H.</span></span> <span> </span><span class="NLM_article-title">Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">993</span>– <span class="NLM_lpage">1000</span>, <span class="refDoi"> DOI: 10.1038/mp.2008.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fmp.2008.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=18504424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1Knur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=993-1000&author=J.+P.+Hamiltonauthor=M.+Siemerauthor=I.+H.+Gotlib&title=Amygdala+volume+in+major+depressive+disorder%3A+a+meta-analysis+of+magnetic+resonance+imaging+studies&doi=10.1038%2Fmp.2008.57"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies</span></div><div class="casAuthors">Hamilton, J. P.; Siemer, M.; Gotlib, I. H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-1000</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Major depressive disorder has been assocd. with volumetric abnormality in the amygdala.  In this meta-anal. we examine results from magnetic resonance imaging volumetry studies of the amygdala in depression in order to assess both the nature of the relationship between depression and amygdala vol. as well as the influence of extraexperimental factors that may account for significant variability in reported findings.  We searched PubMed and ISI Web of Knowledge databases for articles published from 1985 to 2008 that used the wildcard terms Depress*' and Amygdal*' in the title, keywords or abstr.  From the 13 studies that met inclusion criteria for our meta-anal., we calcd. aggregate effect size and heterogeneity ests. from amygdala volumetric data; we then used meta-regression to det. whether variability in specific extraexperimental factors accounted for variability in findings.  The lack of a reliable difference in amygdala vol. between depressed and never-depressed individuals was accounted for by a pos. correlation between amygdala vol. differences and the proportion of medicated depressed persons in study samples: whereas the aggregate effect size calcd. from studies that included only medicated individuals indicated that amygdala vol. was significantly increased in depressed relative to healthy persons, studies with only unmedicated depressed individuals showed a reliable decrease in amygdala vol. in depression.  These findings are consistent with a formulation in which an antidepressant-mediated increase in levels of brain-derived neurotrophic factor promotes neurogenesis and protects against glucocorticoid toxicity in the amygdala in medicated but not in unmedicated depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNJXr9JjL0T7Vg90H21EOLACvtfcHk0liz7_R36x1P7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1Knur3O&md5=5e476f3dff204af5ed74fec701483b84</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fmp.2008.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmp.2008.57%26sid%3Dliteratum%253Aachs%26aulast%3DHamilton%26aufirst%3DJ.%2BP.%26aulast%3DSiemer%26aufirst%3DM.%26aulast%3DGotlib%26aufirst%3DI.%2BH.%26atitle%3DAmygdala%2520volume%2520in%2520major%2520depressive%2520disorder%253A%2520a%2520meta-analysis%2520of%2520magnetic%2520resonance%2520imaging%2520studies%26jtitle%3DMol.%2520Psychiatry%26date%3D2008%26volume%3D13%26spage%3D993%26epage%3D1000%26doi%3D10.1038%2Fmp.2008.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheidegger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henning, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraehenmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeker, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seifritz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, S.</span></span> <span> </span><span class="NLM_article-title">Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation</span>. <i>Hum. Brain Mapp.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1941</span>– <span class="NLM_lpage">1952</span>, <span class="refDoi"> DOI: 10.1002/hbm.23148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1002%2Fhbm.23148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26915535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC28jksVOqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=1941-1952&author=M.+Scheideggerauthor=A.+Henningauthor=M.+Walterauthor=M.+Lehmannauthor=R.+Kraehenmannauthor=H.+Boekerauthor=E.+Seifritzauthor=S.+Grimm&title=Ketamine+administration+reduces+amygdalo-hippocampal+reactivity+to+emotional+stimulation&doi=10.1002%2Fhbm.23148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine administration reduces amygdalo-hippocampal reactivity to emotional stimulation</span></div><div class="casAuthors">Scheidegger Milan; Lehmann Mick; Kraehenmann Rainer; Boeker Heinz; Seifritz Erich; Grimm Simone; Scheidegger Milan; Henning Anke; Henning Anke; Henning Anke; Seifritz Erich; Walter Martin; Kraehenmann Rainer; Grimm Simone</div><div class="citationInfo"><span class="NLM_cas:title">Human brain mapping</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1941-52</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Increased amygdala reactivity might lead to negative bias during emotional processing that can be reversed by antidepressant drug treatment.  However, little is known on how N-methyl-d-aspartate (NMDA) receptor antagonism with ketamine as a novel antidepressant drug target might modulate amygdala reactivity to emotional stimulation.  Using functional magnetic resonance imaging (fMRI) and resting-state fMRI (rsfMRI), we assessed amygdalo-hippocampal reactivity at baseline and during pharmacological stimulation with ketamine (intravenous bolus of 0.12 mg/kg, followed by a continuous infusion of 0.25 mg/kg/h) in 23 healthy subjects that were presented with stimuli from the International Affective Picture System (IAPS).  We found that ketamine reduced neural reactivity in the bilateral amygdalo-hippocampal complex during emotional stimulation.  Reduced amygdala reactivity to negative pictures was correlated to resting-state connectivity to the pregenual anterior cingulate cortex.  Interestingly, subjects experienced intensity of psychedelic alterations of consciousness during ketamine infusion predicted the reduction in neural responsivity to negative but not to positive or neutral stimuli.  Our findings suggest that the pharmacological modulation of glutamate-responsive cerebral circuits, which is associated with a shift in emotional bias and a reduction of amygdalo-hippocampal reactivity to emotional stimuli, represents an early biomechanism to restore parts of the disrupted neurobehavioral homeostasis in MDD patients.  Hum Brain Mapp 37:1941-1952, 2016. © 2016 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTNtjQKGMVmwv69nzq6467DfW6udTcc2eb4TcAf-bc1zLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jksVOqtg%253D%253D&md5=a3688908b69d0e85256429fbd4a545d9</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1002%2Fhbm.23148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhbm.23148%26sid%3Dliteratum%253Aachs%26aulast%3DScheidegger%26aufirst%3DM.%26aulast%3DHenning%26aufirst%3DA.%26aulast%3DWalter%26aufirst%3DM.%26aulast%3DLehmann%26aufirst%3DM.%26aulast%3DKraehenmann%26aufirst%3DR.%26aulast%3DBoeker%26aufirst%3DH.%26aulast%3DSeifritz%26aufirst%3DE.%26aulast%3DGrimm%26aufirst%3DS.%26atitle%3DKetamine%2520administration%2520reduces%2520amygdalo-hippocampal%2520reactivity%2520to%2520emotional%2520stimulation%26jtitle%3DHum.%2520Brain%2520Mapp.%26date%3D2016%26volume%3D37%26spage%3D1941%26epage%3D1952%26doi%3D10.1002%2Fhbm.23148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study</span>. <i>Hum. Brain Mapp.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1080</span>– <span class="NLM_lpage">1090</span>, <span class="refDoi"> DOI: 10.1002/hbm.23085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1002%2Fhbm.23085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26821769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC28nltlCguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=1080-1090&author=C.+T.+Liauthor=M.+H.+Chenauthor=W.+C.+Linauthor=C.+J.+Hongauthor=B.+H.+Yangauthor=R.+S.+Liuauthor=P.+C.+Tuauthor=T.+P.+Su&title=The+effects+of+low-dose+ketamine+on+the+prefrontal+cortex+and+amygdala+in+treatment-resistant+depression%3A+A+randomized+controlled+study&doi=10.1002%2Fhbm.23085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study</span></div><div class="casAuthors">Li Cheng-Ta; Chen Mu-Hong; Lin Wei-Chen; Hong Chen-Jee; Tu Pei-Chi; Su Tung-Ping; Li Cheng-Ta; Chen Mu-Hong; Lin Wei-Chen; Hong Chen-Jee; Tu Pei-Chi; Su Tung-Ping; Yang Bang-Hung; Liu Ren-Shyan; Su Tung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Human brain mapping</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1080-90</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Low-dose ketamine has been found to have robust and rapid antidepressant effects.  A hypoactive prefrontal cortex (PFC) and a hyperactive amygdala have been suggested to be associated with treatment-resistant depression (TRD).  However, it is unclear whether the rapid antidepressant mechanisms of ketamine on TRD involve changes in glutamatergic neurotransmission in the PFC and the amygdala.  METHODS:  A group of 48 TRD patients were recruited and equally randomized into three groups (A: 0.5 kg/mg-ketamine; B: 0.2 kg/mg-ketamine; and C: normal saline [NS]).  Standardized uptake values (SUV) of glucose metabolism measured by (18) F-FDG positron-emission-tomography before and immediately after a 40-min ketamine or NS infusion were used for subsequent region-of-interest (ROI) analyses (a priori regions: PFC and amygdala) and whole-brain voxel-wise analyses and were correlated with antidepressant responses, as defined by the Hamilton depression rating scale score.  The (18) F-FDG signals were used as a proxy measure of glutamate neurotransmission.  RESULTS:  The ROI analysis indicated that Group A and Group B, but not Group C, had increases in the SUV of the PFC (group-by-time interaction: F = 7.373, P = 0.002), whereas decreases in the SUV of the amygdala were observed in all three groups (main effect of time, P < 0.001).  The voxel-wise analysis further confirmed a significant group effect on the PFC (corrected for family-wise errors, P < 0.05; post hoc analysis: Group A<Group C, Group B<Group C).  The SUV differences in the PFC predicted the antidepressant responses at 40 and 240 min post-treatment.  The PFC changes did not differ between those with and without side effects.  CONCLUSION:  Ketamine's rapid antidepressant effects involved the facilitation of glutamatergic neurotransmission in the PFC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkiTiBcoX5VhLDWw4HIq2sfW6udTcc2eb4TcAf-bc1zLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28nltlCguw%253D%253D&md5=18ee8d99e65e80d75260aedaedd29049</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1002%2Fhbm.23085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhbm.23085%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%2BT.%26aulast%3DChen%26aufirst%3DM.%2BH.%26aulast%3DLin%26aufirst%3DW.%2BC.%26aulast%3DHong%26aufirst%3DC.%2BJ.%26aulast%3DYang%26aufirst%3DB.%2BH.%26aulast%3DLiu%26aufirst%3DR.%2BS.%26aulast%3DTu%26aufirst%3DP.%2BC.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DThe%2520effects%2520of%2520low-dose%2520ketamine%2520on%2520the%2520prefrontal%2520cortex%2520and%2520amygdala%2520in%2520treatment-resistant%2520depression%253A%2520A%2520randomized%2520controlled%2520study%26jtitle%3DHum.%2520Brain%2520Mapp.%26date%3D2016%26volume%3D37%26spage%3D1080%26epage%3D1090%26doi%3D10.1002%2Fhbm.23085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al Shweiki, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeckl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinacker, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barschke, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryce, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorner-Ciossek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schönfeldt-Lecuona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengerer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, M.</span></span> <span> </span><span class="NLM_article-title">S-ketamine induces acute changes in the proteome of the mouse amygdala</span>. <i>J. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>216</i></span>,  <span class="NLM_fpage">103679</span>, <span class="refDoi"> DOI: 10.1016/j.jprot.2020.103679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.jprot.2020.103679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32032757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFSqsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2020&pages=103679&author=M.+R.+Al+Shweikiauthor=P.+Oecklauthor=P.+Steinackerauthor=P.+Barschkeauthor=C.+Pryceauthor=C.+Dorner-Ciossekauthor=C.+Sch%C3%B6nfeldt-Lecuonaauthor=B.+Hengererauthor=M.+Otto&title=S-ketamine+induces+acute+changes+in+the+proteome+of+the+mouse+amygdala&doi=10.1016%2Fj.jprot.2020.103679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">S-ketamine induces acute changes in the proteome of the mouse amygdala</span></div><div class="casAuthors">Al Shweiki, Mhd rami; Oeckl, Patrick; Steinacker, Petra; Barschke, Peggy; Pryce, Christopher; Dorner-Ciossek, Cornelia; Schoenfeldt-Lecuona, Carlos; Hengerer, Bastian; Otto, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Proteomics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">216</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103679</span>CODEN:
                <span class="NLM_cas:coden">JPORFQ</span>;
        ISSN:<span class="NLM_cas:issn">1874-3919</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This study in mice aimed to investigate acute proteomic changes after ketamine administration in various brain regions including amygdala and hippocampus.  One hour after administration of s-ketamine, the brain-region tissues of interest were dissected out and analyzed using label-free shotgun proteomics.  The deep proteomic anal. of amygdala and hippocampus identified 89,526 peptides corresponding to 8000 proteins.  The anal. revealed a pronounced proteomic signature of the acute ketamine effect in the amygdala.  We anticipate that this proteomic dataset will improve understanding of the mechanism of action of ketamine and identification of new drug targets.  Major depressive disorder (MDD) is the leading cause of global disability and it presents a significant challenge to human health.  S-ketamine has been proposed as a rapid acting antidepressant and, indeed, the FDA recently approved it for treatment of resistant MDD.  However, the mechanism of action of s-ketamine as an antidepressant is still elusive.  In this context, we investigated the short-term proteomic changes after ketamine administration in mouse brain regions previously related to ketamine effects such as amygdala and hippocampus.  We anticipate that this proteomic dataset will provide highly useful information to improve our understanding of the mechanism of action of ketamine and identification of new drug targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLpc2uIQmOubVg90H21EOLACvtfcHk0lj7vn9bGFK1Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFSqsrc%253D&md5=3194e35b6df72c85d0b61cef98408362</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.jprot.2020.103679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jprot.2020.103679%26sid%3Dliteratum%253Aachs%26aulast%3DAl%2BShweiki%26aufirst%3DM.%2BR.%26aulast%3DOeckl%26aufirst%3DP.%26aulast%3DSteinacker%26aufirst%3DP.%26aulast%3DBarschke%26aufirst%3DP.%26aulast%3DPryce%26aufirst%3DC.%26aulast%3DDorner-Ciossek%26aufirst%3DC.%26aulast%3DSch%25C3%25B6nfeldt-Lecuona%26aufirst%3DC.%26aulast%3DHengerer%26aufirst%3DB.%26aulast%3DOtto%26aufirst%3DM.%26atitle%3DS-ketamine%2520induces%2520acute%2520changes%2520in%2520the%2520proteome%2520of%2520the%2520mouse%2520amygdala%26jtitle%3DJ.%2520Proteomics%26date%3D2020%26volume%3D216%26spage%3D103679%26doi%3D10.1016%2Fj.jprot.2020.103679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nestler, E. J.</span></span> <span> </span><span class="NLM_article-title">Role of the brain’s reward circuitry in depression: transcriptional mechanisms</span>. <i>Int. Rev. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/bs.irn.2015.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fbs.irn.2015.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26472529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlWrtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2015&pages=151-170&author=E.+J.+Nestler&title=Role+of+the+brain%E2%80%99s+reward+circuitry+in+depression%3A+transcriptional+mechanisms&doi=10.1016%2Fbs.irn.2015.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the brain's reward circuitry in depression: transcriptional mechanisms</span></div><div class="casAuthors">Nestler, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">International Review of Neurobiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">Nicotine Use in Mental Illness and Neurological Disorders</span>),
    <span class="NLM_cas:pages">151-170</span>CODEN:
                <span class="NLM_cas:coden">IRNEAE</span>;
        ISSN:<span class="NLM_cas:issn">0074-7742</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Increasing evidence supports an important role for the brain's reward circuitry in controlling mood under normal conditions and contributing importantly to the pathophysiol. and symptomatol. of a range of mood disorders, such as depression.  Here we focus on the nucleus accumbens (NAc), a crit. component of the brain's reward circuitry, in depression and other stress-related disorders.  The prominence of anhedonia, reduced motivation, and decreased energy level in most individuals with depression supports the involvement of the NAc in these conditions.  We conc. on several transcription factors (CREB, ΔFosB, SRF, NFκB, and β-catenin), which are altered in the NAc in rodent depression models - and in some cases in the NAc of depressed humans, and which produce robust depression- or antidepressant-like effects when manipulated in the NAc in animal models.  These studies of the NAc have established novel approaches toward modeling key symptoms of depression in animals and could enable the development of antidepressant medications with fundamentally new mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfsfNT6DKNB7Vg90H21EOLACvtfcHk0lj7vn9bGFK1Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlWrtLY%253D&md5=3f5c6c1e1e225f23dd3ff1fe6fc3be84</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fbs.irn.2015.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.irn.2015.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DNestler%26aufirst%3DE.%2BJ.%26atitle%3DRole%2520of%2520the%2520brain%25E2%2580%2599s%2520reward%2520circuitry%2520in%2520depression%253A%2520transcriptional%2520mechanisms%26jtitle%3DInt.%2520Rev.%2520Neurobiol.%26date%3D2015%26volume%3D124%26spage%3D151%26epage%3D170%26doi%3D10.1016%2Fbs.irn.2015.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bessa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morais, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palha, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, N.</span></span> <span> </span><span class="NLM_article-title">Stress-induced anhedonia is associated with hypertrophy of medium spiny neurons of the nucleus accumbens</span>. <i>Transl. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e266</span>– <span class="NLM_lpage">e266</span>, <span class="refDoi"> DOI: 10.1038/tp.2013.39</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Ftp.2013.39" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=23736119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSqsL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=e266-e266&author=J.+Bessaauthor=M.+Moraisauthor=F.+Marquesauthor=L.+Pintoauthor=J.+A.+Palhaauthor=O.+Almeidaauthor=N.+Sousa&title=Stress-induced+anhedonia+is+associated+with+hypertrophy+of+medium+spiny+neurons+of+the+nucleus+accumbens&doi=10.1038%2Ftp.2013.39"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Stress-induced anhedonia is associated with hypertrophy of medium spiny neurons of the nucleus accumbens</span></div><div class="casAuthors">Bessa, J. M.; Morais, M.; Marques, F.; Pinto, L.; Palha, J. A.; Almeida, O. F. X.; Sousa, N.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">June</span>),
    <span class="NLM_cas:pages">e266</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">There is accumulating evidence that the nucleus accumbens (NAc) has an important role in the pathophysiol. of depression.  As the NAc is a key component in the neural circuitry of reward, it has been hypothesized that anhedonia, a core symptom of depression, might be related to dysfunction of this brain region.  Neuronal morphol. and expression of plasticity-related mols. were examd. in the NAc of rats displaying anhedonic behavior (measured in the sucrose-consumption test) in response to chronic mild stress.  To demonstrate the relevance of our measurements to depression, we tested whether the obsd. changes were sensitive to reversal with antidepressants (imipramine and fluoxetine).  Data show that animals displaying anhedonic behavior display an hypertrophy of medium spiny neurons in the NAc and, in parallel, have increased expression of the genes encoding for brain-derived neurotrophic factor, neural cell adhesion mol. and synaptic protein synapsin 1.  Importantly, the reversal of stress-induced anhedonia by antidepressants is linked to a restoration of gene-expression patterns and dendritic morphol. in the NAc.  Using an animal model of depression, we show that stress induces anhedonic behavior that is assocd. with specific changes in the neuronal morphol. and in the gene-expression profile of the NAc that are effectively reversed after treatment with antidepressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUk0qbR2_HQbVg90H21EOLACvtfcHk0lj7vn9bGFK1Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSqsL%252FK&md5=8122d3671ddd70b7189ad24fa9f77696</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1038%2Ftp.2013.39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2013.39%26sid%3Dliteratum%253Aachs%26aulast%3DBessa%26aufirst%3DJ.%26aulast%3DMorais%26aufirst%3DM.%26aulast%3DMarques%26aufirst%3DF.%26aulast%3DPinto%26aufirst%3DL.%26aulast%3DPalha%26aufirst%3DJ.%2BA.%26aulast%3DAlmeida%26aufirst%3DO.%26aulast%3DSousa%26aufirst%3DN.%26atitle%3DStress-induced%2520anhedonia%2520is%2520associated%2520with%2520hypertrophy%2520of%2520medium%2520spiny%2520neurons%2520of%2520the%2520nucleus%2520accumbens%26jtitle%3DTransl.%2520Psychiatry%26date%3D2013%26volume%3D3%26spage%3De266%26epage%3De266%26doi%3D10.1038%2Ftp.2013.39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdallah, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coplan, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shungu, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, S. J.</span></span> <span> </span><span class="NLM_article-title">The nucleus accumbens and ketamine treatment in major depressive disorder</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1739</span>– <span class="NLM_lpage">1746</span>, <span class="refDoi"> DOI: 10.1038/npp.2017.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnpp.2017.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=28272497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlt1Srtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2017&pages=1739-1746&author=C.+G.+Abdallahauthor=A.+Jackowskiauthor=R.+Salasauthor=S.+Guptaauthor=J.+R.+Satoauthor=X.+Maoauthor=J.+D.+Coplanauthor=D.+C.+Shunguauthor=S.+J.+Mathew&title=The+nucleus+accumbens+and+ketamine+treatment+in+major+depressive+disorder&doi=10.1038%2Fnpp.2017.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder</span></div><div class="casAuthors">Abdallah, Chadi G.; Jackowski, Andrea; Salas, Ramiro; Gupta, Swapnil; Sato, Joao R.; Mao, Xiangling; Coplan, Jeremy D.; Shungu, Dikoma C.; Mathew, Sanjay J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1739-1746</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Animal models of depression repeatedly showed stress-induced nucleus accumbens (NAc) hypertrophy.  Recently, ketamine was found to normalize this stress-induced NAc structural growth.  Here, we investigated NAc structural abnormalities in major depressive disorder (MDD) in two cohorts.  Cohort A included a cross-sectional sample of 34 MDD and 26 healthy control (HC) subjects, with high-resoln. magnetic resonance imaging (MRI) to est. NAc vols.  Proton MR spectroscopy (1H MRS) was used to divide MDD subjects into two subgroups: glutamate-based depression (GBD) and non-GBD.  A sep. longitudinal sample (cohort B) included 16 MDD patients who underwent MRI at baseline then 24 h following i.v. infusion of ketamine (0.5 mg/kg).  In cohort A, we found larger left NAc vol. in MDD compared to controls (Cohen's d=1.05), but no significant enlargement in the right NAc (d=0.44).  Follow-up analyses revealed significant subgrouping effects on the left (d≥1.48) and right NAc (d≥0.95) with larger bilateral NAc in non-GBD compared to GBD and HC.  NAc vols. were not different between GBD and HC.  In cohort B, ketamine treatment reduced left NAc, but increased left hippocampal, vols. in patients achieving remission.  The cross-sectional data provided the first evidence of enlarged NAc in patients with MDD.  These NAc abnormalities were limited to patients with non-GBD.  The pilot longitudinal data revealed a pattern of normalization of left NAc and hippocampal vols. particularly in patients who achieved remission following ketamine treatment, an intriguing preliminary finding that awaits replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg-D1Z91MdLLVg90H21EOLACvtfcHk0lj7vn9bGFK1Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlt1Srtb4%253D&md5=679fe574d648d99060b3947886425776</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2017.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2017.49%26sid%3Dliteratum%253Aachs%26aulast%3DAbdallah%26aufirst%3DC.%2BG.%26aulast%3DJackowski%26aufirst%3DA.%26aulast%3DSalas%26aufirst%3DR.%26aulast%3DGupta%26aufirst%3DS.%26aulast%3DSato%26aufirst%3DJ.%2BR.%26aulast%3DMao%26aufirst%3DX.%26aulast%3DCoplan%26aufirst%3DJ.%2BD.%26aulast%3DShungu%26aufirst%3DD.%2BC.%26aulast%3DMathew%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520nucleus%2520accumbens%2520and%2520ketamine%2520treatment%2520in%2520major%2520depressive%2520disorder%26jtitle%3DNeuropsychopharmacology%26date%3D2017%26volume%3D42%26spage%3D1739%26epage%3D1746%26doi%3D10.1038%2Fnpp.2017.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokras, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalla, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ventura-Silva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sousa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pêgo, J.</span></span> <span> </span><span class="NLM_article-title">The positive effect on ketamine as a priming adjuvant in antidepressant treatment</span>. <i>Transl. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">e573</span>– <span class="NLM_lpage">e573</span>, <span class="refDoi"> DOI: 10.1038/tp.2015.66</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Ftp.2015.66" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26080090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOku73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=e573-e573&author=A.+Meloauthor=N.+Kokrasauthor=C.+Dallaauthor=C.+Ferreiraauthor=A.+Ventura-Silvaauthor=N.+Sousaauthor=J.+P%C3%AAgo&title=The+positive+effect+on+ketamine+as+a+priming+adjuvant+in+antidepressant+treatment&doi=10.1038%2Ftp.2015.66"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">The positive effect on ketamine as a priming adjuvant in antidepressant treatment</span></div><div class="casAuthors">Melo, A.; Kokras, N.; Dalla, C.; Ferreira, C.; Ventura-Silva, A. P.; Sousa, N.; Pego, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Translational Psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e573</span>CODEN:
                <span class="NLM_cas:coden">TPRSCF</span>;
        ISSN:<span class="NLM_cas:issn">2158-3188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ketamine is an anesthetic with antidepressant properties.  The rapid and lasting effect of ketamine obsd. in preclin. and clin. research makes it a promising therapeutic to improve current major depression (MD) treatment.  Our work intended to evaluate whether the combined use of classic antidepressants (imipramine or fluoxetine) and ketamine would improve the antidepressant response.  Using an animal model of depressive-like behavior, we show that the addn. of ketamine to antidepressants anticipates the behavioral response and accelerates the neuroplastic events when compared with the use of antidepressants alone.  In conclusion, our results suggest the need for a reappraisal of the current pharmacol. treatment of MD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIOYJR_IDgMrVg90H21EOLACvtfcHk0li1aoG2kKy6hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOku73E&md5=c10f4952e4250a8c39bf5db42334cd29</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1038%2Ftp.2015.66&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ftp.2015.66%26sid%3Dliteratum%253Aachs%26aulast%3DMelo%26aufirst%3DA.%26aulast%3DKokras%26aufirst%3DN.%26aulast%3DDalla%26aufirst%3DC.%26aulast%3DFerreira%26aufirst%3DC.%26aulast%3DVentura-Silva%26aufirst%3DA.%26aulast%3DSousa%26aufirst%3DN.%26aulast%3DP%25C3%25AAgo%26aufirst%3DJ.%26atitle%3DThe%2520positive%2520effect%2520on%2520ketamine%2520as%2520a%2520priming%2520adjuvant%2520in%2520antidepressant%2520treatment%26jtitle%3DTransl.%2520Psychiatry%26date%3D2015%26volume%3D5%26spage%3De573%26epage%3De573%26doi%3D10.1038%2Ftp.2015.66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Circuits and functions of the lateral habenula in health and in disease</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">277</span>, <span class="refDoi"> DOI: 10.1038/s41583-020-0292-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fs41583-020-0292-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32269316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmslejtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=277&author=H.+Huauthor=Y.+Cuiauthor=Y.+Yang&title=Circuits+and+functions+of+the+lateral+habenula+in+health+and+in+disease&doi=10.1038%2Fs41583-020-0292-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Circuits and functions of the lateral habenula in health and in disease</span></div><div class="casAuthors">Hu, Hailan; Cui, Yihui; Yang, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">277-295</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The past decade has witnessed exponentially growing interest in the lateral habenula (LHb) owing to new discoveries relating to its crit. role in regulating neg. motivated behavior and its implication in major depression.  The LHb, sometimes referred to as the brain's 'antireward center', receives inputs from diverse limbic forebrain and basal ganglia structures, and targets essentially all midbrain neuromodulatory systems, including the noradrenergic, serotonergic and dopaminergic systems.  Its unique anatomical position enables the LHb to act as a hub that integrates value-based, sensory and experience-dependent information to regulate various motivational, cognitive and motor processes.  Dysfunction of the LHb may contribute to the pathophysiol. of several psychiatric disorders, esp. major depression.  Recently, exciting progress has been made in identifying the mol. and cellular mechanisms in the LHb that underlie neg. emotional state in animal models of drug withdrawal and major depression.  A future challenge is to translate these advances into effective clin. treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBr-Nvh01I6rVg90H21EOLACvtfcHk0li1aoG2kKy6hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmslejtbY%253D&md5=15553af7487f9556aa380288ecab5567</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fs41583-020-0292-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41583-020-0292-4%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DH.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DCircuits%2520and%2520functions%2520of%2520the%2520lateral%2520habenula%2520in%2520health%2520and%2520in%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2020%26volume%3D21%26spage%3D277%26doi%3D10.1038%2Fs41583-020-0292-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piriz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirrione, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proulx, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henn, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malinow, R.</span></span> <span> </span><span class="NLM_article-title">Synaptic potentiation onto habenula neurons in the learned helplessness model of depression</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>470</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">539</span>, <span class="refDoi"> DOI: 10.1038/nature09742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnature09742" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=21350486" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVagtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=470&publication_year=2011&pages=535-539&author=B.+Liauthor=J.+Pirizauthor=M.+Mirrioneauthor=C.+Chungauthor=C.+D.+Proulxauthor=D.+Schulzauthor=F.+Hennauthor=R.+Malinow&title=Synaptic+potentiation+onto+habenula+neurons+in+the+learned+helplessness+model+of+depression&doi=10.1038%2Fnature09742"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Synaptic potentiation onto habenula neurons in the learned helplessness model of depression</span></div><div class="casAuthors">Li, Bo; Piriz, Joaquin; Mirrione, Martine; Chung, Chi Hye; Proulx, Christophe D.; Schulz, Daniela; Henn, Fritz; Malinow, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">470</span>
        (<span class="NLM_cas:issue">7335</span>),
    <span class="NLM_cas:pages">535-539</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The cellular basis of depressive disorders is poorly understood.  Recent studies in monkeys indicate that neurons in the lateral habenula (LHb), a nucleus that mediates communication between forebrain and midbrain structures, can increase their activity when an animal fails to receive an expected pos. reward or receives a stimulus that predicts aversive conditions (i.e., disappointment or anticipation of a neg. outcome).  LHb neurons project to, and modulate, dopamine-rich regions, such as the ventral tegmental area (VTA), that control reward-seeking behavior and participate in depressive disorders.  Here we show that in two learned helplessness models of depression, excitatory synapses onto LHb neurons projecting to the VTA are potentiated.  Synaptic potentiation correlates with an animal's helplessness behavior and is due to an enhanced presynaptic release probability.  Depleting transmitter release by repeated elec. stimulation of LHb afferents, using a protocol that can be effective for patients who are depressed, markedly suppresses synaptic drive onto VTA-projecting LHb neurons in brain slices and can significantly reduce learned helplessness behavior in rats.  Our results indicate that increased presynaptic action onto LHb neurons contributes to the rodent learned helplessness model of depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYrvQS3-PHAbVg90H21EOLACvtfcHk0li1aoG2kKy6hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVagtbo%253D&md5=7eb3ff7d5da8ee4d70921875fd1c65dc</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fnature09742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09742%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DPiriz%26aufirst%3DJ.%26aulast%3DMirrione%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DC.%26aulast%3DProulx%26aufirst%3DC.%2BD.%26aulast%3DSchulz%26aufirst%3DD.%26aulast%3DHenn%26aufirst%3DF.%26aulast%3DMalinow%26aufirst%3DR.%26atitle%3DSynaptic%2520potentiation%2520onto%2520habenula%2520neurons%2520in%2520the%2520learned%2520helplessness%2520model%2520of%2520depression%26jtitle%3DNature%26date%3D2011%26volume%3D470%26spage%3D535%26epage%3D539%26doi%3D10.1038%2Fnature09742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span> <span> </span><span class="NLM_article-title">Ketamine blocks bursting in the lateral habenula to rapidly relieve depression</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>554</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1038/nature25509</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fnature25509" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=29446381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisl2kuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=554&publication_year=2018&pages=317-322&author=Y.+Yangauthor=Y.+Cuiauthor=K.+Sangauthor=Y.+Dongauthor=Z.+Niauthor=S.+Maauthor=H.+Hu&title=Ketamine+blocks+bursting+in+the+lateral+habenula+to+rapidly+relieve+depression&doi=10.1038%2Fnature25509"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine blocks bursting in the lateral habenula to rapidly relieve depression</span></div><div class="casAuthors">Yang, Yan; Cui, Yihui; Sang, Kangning; Dong, Yiyan; Ni, Zheyi; Ma, Shuangshuang; Hu, Hailan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">554</span>
        (<span class="NLM_cas:issue">7692</span>),
    <span class="NLM_cas:pages">317-322</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine has attracted enormous interest in mental health research owing to its rapid antidepressant actions, but its mechanism of action has remained elusive.  Here the authors show that blockade of NMDAR-dependent bursting activity in the 'antireward center', the lateral habenula (LHb), mediates the rapid antidepressant actions of ketamine in rat and mouse models of depression.  LHb neurons show a significant increase in burst activity and theta-band synchronization in depressive-like animals, which is reversed by ketamine.  Burst-evoking photostimulation of LHb drives behavioral despair and anhedonia.  Pharmacol. and modeling expts. reveal that LHb bursting requires both NMDARs and low-voltage-sensitive T-type calcium channels (T-VSCCs).  Furthermore, local blockade of NMDAR or T-VSCCs in the LHb is sufficient to induce rapid antidepressant effects.  The results suggest a simple model whereby ketamine quickly elevates mood by blocking NMDAR-dependent bursting activity of LHb neurons to disinhibit downstream monoaminergic reward centers, and provide a framework for developing new rapid-acting antidepressants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXd9LBRBR0nbVg90H21EOLACvtfcHk0ljn4mtmz6ZVUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisl2kuro%253D&md5=0f81f4413d5eec5a5fe5e0f81c860a78</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1038%2Fnature25509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature25509%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DCui%26aufirst%3DY.%26aulast%3DSang%26aufirst%3DK.%26aulast%3DDong%26aufirst%3DY.%26aulast%3DNi%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DH.%26atitle%3DKetamine%2520blocks%2520bursting%2520in%2520the%2520lateral%2520habenula%2520to%2520rapidly%2520relieve%2520depression%26jtitle%3DNature%26date%3D2018%26volume%3D554%26spage%3D317%26epage%3D322%26doi%3D10.1038%2Fnature25509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pittenger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duman, R. S.</span></span> <span> </span><span class="NLM_article-title">Stress, depression, and neuroplasticity: a convergence of mechanisms</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">109</span>, <span class="refDoi"> DOI: 10.1038/sj.npp.1301574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fsj.npp.1301574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=17851537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlKltb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2008&pages=88-109&author=C.+Pittengerauthor=R.+S.+Duman&title=Stress%2C+depression%2C+and+neuroplasticity%3A+a+convergence+of+mechanisms&doi=10.1038%2Fsj.npp.1301574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms</span></div><div class="casAuthors">Pittenger, Christopher; Duman, Ronald S.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-109</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Increasing evidence demonstrates that neuroplasticity, a fundamental mechanism of neuronal adaptation, is disrupted in mood disorders and in animal models of stress.  Here we provide an overview of the evidence that chronic stress, which can ppt. or exacerbate depression, disrupts neuroplasticity, while antidepressant treatment produces opposing effects and can enhance neuroplasticity.  We discuss neuroplasticity at different levels: structural plasticity (such as plastic changes in spine and dendrite morphol. as well as adult neurogenesis), functional synaptic plasticity, and the mol. and cellular mechanisms accompanying such changes.  Together, these studies elucidate mechanisms that may contribute to the pathophysiol. of depression.  Greater appreciation of the convergence of mechanisms between stress, depression, and neuroplasticity is likely to lead to the identification of novel targets for more efficacious treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-fTJjJ9kw07Vg90H21EOLACvtfcHk0ljn4mtmz6ZVUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlKltb%252FL&md5=55728b3984de6deef40e4df161f619b3</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1301574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1301574%26sid%3Dliteratum%253Aachs%26aulast%3DPittenger%26aufirst%3DC.%26aulast%3DDuman%26aufirst%3DR.%2BS.%26atitle%3DStress%252C%2520depression%252C%2520and%2520neuroplasticity%253A%2520a%2520convergence%2520of%2520mechanisms%26jtitle%3DNeuropsychopharmacology%26date%3D2008%26volume%3D33%26spage%3D88%26epage%3D109%26doi%3D10.1038%2Fsj.npp.1301574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardier, A. M.</span></span> <span> </span><span class="NLM_article-title">Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2019.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.pharmthera.2019.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30851296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXltVSgu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2019&pages=58-90&author=T.+H.+Phamauthor=A.+M.+Gardier&title=Fast-acting+antidepressant+activity+of+ketamine%3A+highlights+on+brain+serotonin%2C+glutamate%2C+and+GABA+neurotransmission+in+preclinical+studies&doi=10.1016%2Fj.pharmthera.2019.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies</span></div><div class="casAuthors">Pham, Thu Ha; Gardier, Alain M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-90</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays a fast antidepressant activity in treatment-resistant depression and in rodent models of anxiety/depression.  A large body of evidence concerning the cellular and mol. mechanisms underlying its fast antidepressant-like activity comes from animal studies.  Although structural remodeling of frontocortical/hippocampal neurons has been proposed as crit., the role of excitatory/inhibitory neurotransmitters in this behavioral effect is unclear.  Neurochem. and behavioral changes are maintained 24h after ketamine administration, well beyond its plasma elimination half-life.  Thus, ketamine is believed to initiate a cascade of cellular mechanisms supporting its fast antidepressant-like activity.  To date, the underlying mechanism involves glutamate release, then downstream activation of AMPA receptors, which trigger mammalian target of rapamycin (mTOR)-dependent structural plasticity via brain-derived neurotrophic factor (BDNF) and protein neo-synthesis in the medial prefrontal cortex (mPFC), a brain region strongly involved in ketamine therapeutic effects.  However, these mPFC effects are not restricted to glutamatergic pyramidal cells, but extend to other neurotransmitters (GABA, serotonin), glial cells, and brain circuits (mPFC/dorsal raphe nucleus-DRN).  It could be also mediated by one or several ketamine metabolites (e.g., (2R,6R)-HNK).  The present review focuses on evidence for mPFC neurotransmission abnormalities in major depressive disorder (MDD) and their potential impact on neural circuits (mPFC/DRN).  We will integrate these considerations with results from recent preclin. studies showing that ketamine, at antidepressant-relevant doses, induces neuronal adaptations that involve the glutamate-excitatory/GABA-inhibitory balance.  Our analyses will help direct future studies to further elucidate the mechanism of action of fast-acting antidepressant drugs, and to inform development of novel, more efficacious therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSlrIAPlq7PbVg90H21EOLACvtfcHk0ljn4mtmz6ZVUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXltVSgu7s%253D&md5=7e501b0e6491aa594c06322cfa121f9e</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2019.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2019.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DPham%26aufirst%3DT.%2BH.%26aulast%3DGardier%26aufirst%3DA.%2BM.%26atitle%3DFast-acting%2520antidepressant%2520activity%2520of%2520ketamine%253A%2520highlights%2520on%2520brain%2520serotonin%252C%2520glutamate%252C%2520and%2520GABA%2520neurotransmission%2520in%2520preclinical%2520studies%26jtitle%3DPharmacol.%2520Ther.%26date%3D2019%26volume%3D199%26spage%3D58%26epage%3D90%26doi%3D10.1016%2Fj.pharmthera.2019.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lodge, D. a.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercier, M.</span></span> <span> </span><span class="NLM_article-title">Ketamine and phencyclidine: the good, the bad and the unexpected</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">4254</span>– <span class="NLM_lpage">4276</span>, <span class="refDoi"> DOI: 10.1111/bph.13222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1111%2Fbph.13222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=26075331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ent73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=4254-4276&author=D.+a.+Lodgeauthor=M.+Mercier&title=Ketamine+and+phencyclidine%3A+the+good%2C+the+bad+and+the+unexpected&doi=10.1111%2Fbph.13222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine and phencyclidine: the good, the bad and the unexpected</span></div><div class="casAuthors">Lodge, D.; Mercier, M. S.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4254-4276</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The history of ketamine and phencyclidine from their development as potential clin. anesthetics through drugs of abuse and animal models of schizophrenia to potential rapidly acting antidepressants is reviewed.  The discovery in 1983 of the NMDA receptor antagonist property of ketamine and phencyclidine was a key step to understanding their pharmacol., including their psychotomimetic effects in man.  This review describes the historical context and the course of that discovery and its expansion into other hallucinatory drugs.  The relevance of these findings to modern hypotheses of schizophrenia and the implications for drug discovery are reviewed.  The findings of the rapidly acting antidepressant effects of ketamine in man are discussed in relation to other glutamatergic mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcDQQWyFfaSrVg90H21EOLACvtfcHk0ljn4mtmz6ZVUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ent73F&md5=fc1b6f9b5ba8b1760681ac5bce12d7d7</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1111%2Fbph.13222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13222%26sid%3Dliteratum%253Aachs%26aulast%3DLodge%26aufirst%3DD.%2Ba.%26aulast%3DMercier%26aufirst%3DM.%26atitle%3DKetamine%2520and%2520phencyclidine%253A%2520the%2520good%252C%2520the%2520bad%2520and%2520the%2520unexpected%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D4254%26epage%3D4276%26doi%3D10.1111%2Fbph.13222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span> <span> </span><span class="NLM_article-title">Ketamine abuse potential and use disorder</span>. <i>Brain Res. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.brainresbull.2016.05.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.brainresbull.2016.05.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27261367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvFehtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2016&pages=68-73&author=Y.+Liuauthor=D.+Linauthor=B.+Wuauthor=W.+Zhou&title=Ketamine+abuse+potential+and+use+disorder&doi=10.1016%2Fj.brainresbull.2016.05.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine abuse potential and use disorder</span></div><div class="casAuthors">Liu, Yu; Lin, Deyong; Wu, Boliang; Zhou, Wenhua</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">Part_1</span>),
    <span class="NLM_cas:pages">68-73</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Ketamine is a noncompetitive antagonist of N-methyl-D-asparate (NMDA) receptor and has been long used as an anesthetic agent in humans and veterinary medicine.  The present article reviews the epidemiol., pharmacol., neurochem., and treatment of ketamine abuse.  Ketamine has a unique mood controlling property and a no. of studies have demonstrated a significant and rapid antidepressant effect of ketamine.  However, the therapeutic value of ketamine to treat psychiatric disorders faces a major challenge that ketamine also owns significant reinforcing and toxic effects.  Its abuse has posted severe harms on individuals and society.  Disrupted learning and memory processing has long been related with ketamine use.  It is hypothesized that ketamine blocks NMDA receptors on gamma-aminobutyric acid (GABA) neurons inside the thalamic reticular nucleus, which leads to disinhibition of dopaminergic neurons and increased release of dopamine.  Currently, there is no specific treatment for treating every ketamine patient presenting peripheral toxicity.  Interestingly, ketamine psychotherapy has been suggested to be a promising approach to treat addiction of other drugs.  Future research can continue to develop creative ways to investigate potential mechanism and treatments related to ketamine abuse that have posted severe individual and social harms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLfMHEo19ttLVg90H21EOLACvtfcHk0lgi-ogX14RtPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvFehtbw%253D&md5=7820f78cc85a789ab72433fce29a48dd</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresbull.2016.05.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresbull.2016.05.016%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DW.%26atitle%3DKetamine%2520abuse%2520potential%2520and%2520use%2520disorder%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2016%26volume%3D126%26spage%3D68%26epage%3D73%26doi%3D10.1016%2Fj.brainresbull.2016.05.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipsky, R. H.</span></span> <span> </span><span class="NLM_article-title">Repeated ketamine administration alters N-methyl-D-aspartic acid receptor subunit gene expression: implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans</span>. <i>Exp. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>240</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">155</span>, <span class="refDoi"> DOI: 10.1177/1535370214549531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1177%2F1535370214549531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktl2qtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=240&publication_year=2015&pages=145-155&author=K.+Xuauthor=R.+H.+Lipsky&title=Repeated+ketamine+administration+alters+N-methyl-D-aspartic+acid+receptor+subunit+gene+expression%3A+implication+of+genetic+vulnerability+for+ketamine+abuse+and+ketamine+psychosis+in+humans&doi=10.1177%2F1535370214549531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Repeated ketamine administration alters N-methyl-D-aspartic acid receptor subunit gene expression: implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans</span></div><div class="casAuthors">Xu, Ke; Lipsky, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Biology and Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">240</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-155</span>CODEN:
                <span class="NLM_cas:coden">EBMMBE</span>;
        ISSN:<span class="NLM_cas:issn">1535-3699</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  For more than 40 years following its approval by the Food and Drug Administration (FDA) as an anesthetic, ketamine, a noncompetitive N-methyl-D-aspartic acid (NMDA) receptor antagonist, has been used as a tool of psychiatric research.  As a psychedelic drug, ketamine induces psychotic symptoms, cognitive impairment, and mood elevation, which resemble some symptoms of schizophrenia.  Recreational use of ketamine has been increasing in recent years.  However, little is known of the underlying mol. mechanisms responsible for ketamine-assocd. psychosis.  Recent animal studies have shown that repeated ketamine administration significantly increases NMDA receptor subunit gene expression, in particular subunit 1 (NR1 or GluN1) levels.  This results in neurodegeneration, supporting a potential mechanism where up-regulation of NMDA receptors could produce cognitive deficits in chronic ketamine abuse patients.  In other studies, NMDA receptor gene variants are assocd. with addictive behavior.  Here, we focus on the roles of NMDA receptor gene subunits in ketamine abuse and ketamine psychosis and propose that full sequencing of NMDA receptor genes may help explain individual vulnerability to ketamine abuse and ketamine-assocd. psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0TPUOBfX_xLVg90H21EOLACvtfcHk0lgi-ogX14RtPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktl2qtLw%253D&md5=3371142f300e7c443b1e0b66f3816967</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1177%2F1535370214549531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1535370214549531%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLipsky%26aufirst%3DR.%2BH.%26atitle%3DRepeated%2520ketamine%2520administration%2520alters%2520N-methyl-D-aspartic%2520acid%2520receptor%2520subunit%2520gene%2520expression%253A%2520implication%2520of%2520genetic%2520vulnerability%2520for%2520ketamine%2520abuse%2520and%2520ketamine%2520psychosis%2520in%2520humans%26jtitle%3DExp.%2520Biol.%2520Med.%26date%3D2015%26volume%3D240%26spage%3D145%26epage%3D155%26doi%3D10.1177%2F1535370214549531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahajan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span> <span> </span><span class="NLM_article-title">Repurposing potential of ketamine: Opportunities and challenges</span>. <i>Ind. J. Psychol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.4103/IJPSYM.IJPSYM_228_19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.4103%2FIJPSYM.IJPSYM_228_19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=31997862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BB38%252FmtFSmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2020&pages=22&author=C.+Gautamauthor=S.+S.+Mahajanauthor=J.+Sharmaauthor=H.+Singhauthor=J.+Singh&title=Repurposing+potential+of+ketamine%3A+Opportunities+and+challenges&doi=10.4103%2FIJPSYM.IJPSYM_228_19"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing Potential of Ketamine: Opportunities and Challenges</span></div><div class="casAuthors">Gautam C S; Mahajan Sonia S; Sharma Jatin; Singh Harmanjit; Singh Jagjit</div><div class="citationInfo"><span class="NLM_cas:title">Indian journal of psychological medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-29</span>
        ISSN:<span class="NLM_cas:issn">0253-7176</span>.
    </div><div class="casAbstract">Ketamine is a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor which also interacts with various other receptors that account for its myriad actions.  Originally approved as a general anesthetic, it is being explored to be repurposed for numerous other indications such as depressive disorders, suicidal ideation, substance-use disorders, anxiety disorders, chronic pain, refractory status epilepticus, and bronchial asthma exacerbations.  Numerous trials are ongoing for the same.  The nasal spray of esketamine, a more potent S (+) enantiomer of ketamine, has been approved by the United States Food and Drug Administration (USFDA) for treatment-resistant depression along with the oral antidepressants.  However, there are concerns about its safety on long term use, given its psychedelic effects and potential abuse.  In this review, we discuss repurposing ketamine for potential therapeutic use and about the safety concerns related to ketamine and esketamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbNOcjfUVimZNiNltV31zlfW6udTcc2eb1u8PjztgRarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38%252FmtFSmsg%253D%253D&md5=56495360ebea692ca8626e5aa056ecb5</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.4103%2FIJPSYM.IJPSYM_228_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252FIJPSYM.IJPSYM_228_19%26sid%3Dliteratum%253Aachs%26aulast%3DGautam%26aufirst%3DC.%26aulast%3DMahajan%26aufirst%3DS.%2BS.%26aulast%3DSharma%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DH.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DRepurposing%2520potential%2520of%2520ketamine%253A%2520Opportunities%2520and%2520challenges%26jtitle%3DInd.%2520J.%2520Psychol.%2520Med.%26date%3D2020%26volume%3D42%26spage%3D22%26doi%3D10.4103%2FIJPSYM.IJPSYM_228_19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokane, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armant, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolaños-Guzmán, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrotti, L. I.</span></span> <span> </span><span class="NLM_article-title">Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>384</i></span>,  <span class="NLM_fpage">112548</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2020.112548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.bbr.2020.112548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=32061748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1amsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=384&publication_year=2020&pages=112548&author=S.+S.+Kokaneauthor=R.+J.+Armantauthor=C.+A.+Bola%C3%B1os-Guzm%C3%A1nauthor=L.+I.+Perrotti&title=Overlap+in+the+neural+circuitry+and+molecular+mechanisms+underlying+ketamine+abuse+and+its+use+as+an+antidepressant&doi=10.1016%2Fj.bbr.2020.112548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant</span></div><div class="casAuthors">Kokane, Saurabh S.; Armant, Ross J.; Bolanos-Guzman, Carlos A.; Perrotti, Linda I.</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">384</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112548</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Ketamine, a dissociative anesthetic and psychedelic compd., has revolutionized the field of psychopharmacol. by showing robust, and rapid-acting antidepressant activity in patients suffering from major depressive disorder (MDD), suicidal tendencies, and treatment-resistant depression (TRD).  Ketamine's efficacy, however, is transient, and patients must return to the clinic for repeated treatment as they experience relapse.  This is cause for concern because ketamine is known for its abuse liability, and repeated exposure to drugs of abuse often leads to drug abuse/dependence.  Though the mechanism(s) underlying its antidepressant activity is an area of current intense research, both clin. and preclin. evidence shows that ketamine's effects are mediated, at least in part, by mol. adaptations resulting in long-lasting synaptic changes in mesolimbic brain regions known to regulate natural and drug reward.  This review outlines our limited knowledge of ketamine's neurobiol. and biochem. underpinnings mediating its antidepressant effects and correlates them to its abuse potential.  Depression and addiction share overlapping neural circuitry and mol. mechanisms, and though speculative, repeated use of ketamine for the treatment of depression could lead to the development of substance use disorder/addiction, and thus should be tempered with caution.  There is much that remains to be known about the long-term effects of ketamine, and our lack of understanding of neurobiol. mechanisms underlying its antidepressant effects is a clear limiting factor that needs to be addressed systematically before using repeated ketamine in the treatment of depressed patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6ZwmRuUnbTLVg90H21EOLACvtfcHk0lhqt6wnjOBVMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1amsbc%253D&md5=919879a81ef28509d119f283db4048f1</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2020.112548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2020.112548%26sid%3Dliteratum%253Aachs%26aulast%3DKokane%26aufirst%3DS.%2BS.%26aulast%3DArmant%26aufirst%3DR.%2BJ.%26aulast%3DBola%25C3%25B1os-Guzm%25C3%25A1n%26aufirst%3DC.%2BA.%26aulast%3DPerrotti%26aufirst%3DL.%2BI.%26atitle%3DOverlap%2520in%2520the%2520neural%2520circuitry%2520and%2520molecular%2520mechanisms%2520underlying%2520ketamine%2520abuse%2520and%2520its%2520use%2520as%2520an%2520antidepressant%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2020%26volume%3D384%26spage%3D112548%26doi%3D10.1016%2Fj.bbr.2020.112548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fox, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobo, M. K.</span></span> <span> </span><span class="NLM_article-title">The molecular and cellular mechanisms of depression: a focus on reward circuitry</span>. <i>Mol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1798</span>, <span class="refDoi"> DOI: 10.1038/s41380-019-0415-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1038%2Fs41380-019-0415-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=30967681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FjsleitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1798&author=M.+E.+Foxauthor=M.+K.+Lobo&title=The+molecular+and+cellular+mechanisms+of+depression%3A+a+focus+on+reward+circuitry&doi=10.1038%2Fs41380-019-0415-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular and cellular mechanisms of depression: a focus on reward circuitry</span></div><div class="casAuthors">Fox Megan E; Lobo Mary Kay</div><div class="citationInfo"><span class="NLM_cas:title">Molecular psychiatry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1798-1815</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Depression is a complex disorder that takes an enormous toll on individual health.  As affected individuals display a wide variation in their clinical symptoms, the precise neural mechanisms underlying the development of depression remain elusive.  Although it is impossible to phenocopy every symptom of human depression in rodents, the preclinical field has had great success in modeling some of the core affective and neurovegetative depressive symptoms, including social withdrawal, anhedonia, and weight loss.  Adaptations in select cell populations may underlie these individual depressive symptoms and new tools have expanded our ability to monitor and manipulate specific cell types.  This review outlines some of the most recent preclinical discoveries on the molecular and neurophysiological mechanisms in reward circuitry that underlie the expression of behavioral constructs relevant to depressive symptoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCCVnFOX46mEGy1nwu7K2mfW6udTcc2ebKXWmcwgPb5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FjsleitQ%253D%253D&md5=ae1b49ef4844340646eb9f70cbc0647a</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1038%2Fs41380-019-0415-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41380-019-0415-3%26sid%3Dliteratum%253Aachs%26aulast%3DFox%26aufirst%3DM.%2BE.%26aulast%3DLobo%26aufirst%3DM.%2BK.%26atitle%3DThe%2520molecular%2520and%2520cellular%2520mechanisms%2520of%2520depression%253A%2520a%2520focus%2520on%2520reward%2520circuitry%26jtitle%3DMol.%2520Psychiatry%26date%3D2019%26volume%3D24%26spage%3D1798%26doi%3D10.1038%2Fs41380-019-0415-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikonomidou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miksa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittigau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vöckler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dikranian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tenkova, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefovska, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olney, J. W.</span></span> <span> </span><span class="NLM_article-title">Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1126/science.283.5398.70</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1126%2Fscience.283.5398.70" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=9872743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADyaK1MXktFSitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1999&pages=70-74&author=C.+Ikonomidouauthor=F.+Boschauthor=M.+Miksaauthor=P.+Bittigauauthor=J.+V%C3%B6cklerauthor=K.+Dikranianauthor=T.+I.+Tenkovaauthor=V.+Stefovskaauthor=L.+Turskiauthor=J.+W.+Olney&title=Blockade+of+NMDA+receptors+and+apoptotic+neurodegeneration+in+the+developing+brain&doi=10.1126%2Fscience.283.5398.70"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain</span></div><div class="casAuthors">Ikonomidou, Chrysanthy; Bosch, Friederike; Miksa, Michael; Bittigau, Petra; Vockler, Jessica; Dikranian, Krikor; Tenkova, Tanya I.; Stefovska, Vanya; Turski, Lechoslaw; Olney, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">5398</span>),
    <span class="NLM_cas:pages">70-74</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Programmed cell death (apoptosis) occurs during normal development of the central nervous system.  However, the mechanisms that det. which neurons will succumb to apoptosis are poorly understood.  Blockade of N-methyl-D-aspartate (NMDA) glutamate receptors for only a few hours during late fetal or early neonatal life triggered widespread apoptotic neurodegeneration in the developing rat brain, suggesting that the excitatory neurotransmitter glutamate, acting at NMDA receptors, controls neuronal survival.  These findings may have relevance to human neurodevelopmental disorders involving prenatal (drug-abusing mothers) or postnatal (pediatric anesthesia) exposure to drugs that block NMDA receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9KhLG5igGBbVg90H21EOLACvtfcHk0lhqt6wnjOBVMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXktFSitA%253D%253D&md5=ba2750c3a0894b313353327ffa958398</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1126%2Fscience.283.5398.70&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.283.5398.70%26sid%3Dliteratum%253Aachs%26aulast%3DIkonomidou%26aufirst%3DC.%26aulast%3DBosch%26aufirst%3DF.%26aulast%3DMiksa%26aufirst%3DM.%26aulast%3DBittigau%26aufirst%3DP.%26aulast%3DV%25C3%25B6ckler%26aufirst%3DJ.%26aulast%3DDikranian%26aufirst%3DK.%26aulast%3DTenkova%26aufirst%3DT.%2BI.%26aulast%3DStefovska%26aufirst%3DV.%26aulast%3DTurski%26aufirst%3DL.%26aulast%3DOlney%26aufirst%3DJ.%2BW.%26atitle%3DBlockade%2520of%2520NMDA%2520receptors%2520and%2520apoptotic%2520neurodegeneration%2520in%2520the%2520developing%2520brain%26jtitle%3DScience%26date%3D1999%26volume%3D283%26spage%3D70%26epage%3D74%26doi%3D10.1126%2Fscience.283.5398.70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Effects of ketamine on levels of inflammatory cytokines IL-6, IL-1β, and TNF-α in the hippocampus of mice following acute or chronic administration</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">139</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.3389%2Ffphar.2017.00139" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=28373844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVKmsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=139&author=Y.+Liauthor=R.+Shenauthor=G.+Wenauthor=R.+Dingauthor=A.+Duauthor=J.+Zhouauthor=Z.+Dongauthor=X.+Renauthor=H.+Yaoauthor=R.+Zhao&title=Effects+of+ketamine+on+levels+of+inflammatory+cytokines+IL-6%2C+IL-1%CE%B2%2C+and+TNF-%CE%B1+in+the+hippocampus+of+mice+following+acute+or+chronic+administration&doi=10.3389%2Ffphar.2017.00139"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of ketamine on levels of inflammatory cytokines IL-6, IL-1β, and TNF-α in the hippocampus of mice following acute or chronic administration</span></div><div class="casAuthors">Li, Yanning; Shen, Ruipeng; Wen, Gehua; Ding, Runtao; Du, Ao; Zhou, Jichuan; Dong, Zhibin; Ren, Xinghua; Yao, Hui; Zhao, Rui; Zhang, Guohua; Lu, Yan; Wu, Xu</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">139/1-139/14</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Ketamine is an injectable anesthetic and recreational drug of abuse commonly used worldwide.  Many exptl. studies have shown that ketamine can impair cognitive function and induce psychotic states.  Neuroinflammation has been suggested to play an important role in neurodegeneration.  Meanwhile, ketamine has been shown to modulate the levels of inflammatory cytokines.  We hypothesized that the effects of ketamine on the central nervous system are assocd. with inflammatory cytokines.  Therefore, we set out to establish acute and chronic ketamine administration models in C57BL/6 mice, to evaluate spatial recognition memory and emotional response, to analyze the changes in the levels of the inflammatory cytokines interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) in the mouse hippocampus, employing behavioral tests, Western blot, quant. reverse transcriptase-polymerase chain reaction (qRT-PCR) and immunohistochem.  Our results showed that ketamine at the dose of 60 mg/kg induced spatial recognition memory deficit and reduced anxietylike behaviors in mice after chronic administration.  Moreover, we found that ketamine increased the hippocampal levels of IL-6 and IL-1β after single, multiple and long-term administration in a dose-dependent manner.  However, the expression level of TNF-α differed in the mouse hippocampus under different conditions.  Single administration of ketamine increased the level of TNF-α, whereas multiple and long-term administration decreased it significantly.  We considered that TNF-α expression could be controlled by a bi-directional regulatory pathway, which was assocd. with the dose and duration of ketamine administration.  Our results suggest that the alterations in the levels of inflammatory cytokines IL-6, IL-1β, and TNF-α may be involved in the neurotoxicity of ketamine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquYGobwrzgWLVg90H21EOLACvtfcHk0lheGI7S1uf-Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVKmsb4%253D&md5=a1501fccc6e446a4e33b316f8df3d14b</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00139%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWen%26aufirst%3DG.%26aulast%3DDing%26aufirst%3DR.%26aulast%3DDu%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DR.%26atitle%3DEffects%2520of%2520ketamine%2520on%2520levels%2520of%2520inflammatory%2520cytokines%2520IL-6%252C%2520IL-1%25CE%25B2%252C%2520and%2520TNF-%25CE%25B1%2520in%2520the%2520hippocampus%2520of%2520mice%2520following%2520acute%2520or%2520chronic%2520administration%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D139%26doi%3D10.3389%2Ffphar.2017.00139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pomarol-Clotet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honey, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corlett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Absalom, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullmore, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, P.</span></span> <span> </span><span class="NLM_article-title">Psychological effects of ketamine in healthy volunteers: phenomenological study</span>. <i>Br. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>189</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1192/bjp.bp.105.015263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1192%2Fbjp.bp.105.015263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=16880489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BD28vls1aisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2006&pages=173-179&author=E.+Pomarol-Clotetauthor=G.+Honeyauthor=G.+Murrayauthor=P.+Corlettauthor=A.+Absalomauthor=M.+Leeauthor=P.+McKennaauthor=E.+Bullmoreauthor=P.+Fletcher&title=Psychological+effects+of+ketamine+in+healthy+volunteers%3A+phenomenological+study&doi=10.1192%2Fbjp.bp.105.015263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Psychological effects of ketamine in healthy volunteers. Phenomenological study</span></div><div class="casAuthors">Pomarol-Clotet E; Honey G D; Murray G K; Corlett P R; Absalom A R; Lee M; McKenna P J; Bullmore E T; Fletcher P C</div><div class="citationInfo"><span class="NLM_cas:title">The British journal of psychiatry : the journal of mental science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">173-9</span>
        ISSN:<span class="NLM_cas:issn">0007-1250</span>.
    </div><div class="casAbstract">BACKGROUND:  The psychosis-inducing effect of ketamine is important evidence supporting the glutamate hypothesis of schizophrenia.  However, the symptoms the drug produces have not been described systematically.  AIM:  To examine the effects of ketamine in healthy people using a structured psychiatric interview.  METHOD:  Ketamine (200 ng/ml) or placebo was administered by continuous infusion to 15 healthy volunteers.  Symptoms were rated using the Present State Examination, the Thought, Language and Communication Scale and the Scale for Assessment of Negative Symptoms.  RESULTS:  Ketamine induced a range of perceptual distortions, but not hallucinations.  Referential ideas were seen in nearly half the sample.  There were only mild and infrequent ratings on the thought disorder scale.  Affective flattening and alogia were seen in some volunteers.  CONCLUSIONS:  Ketamine does not reproduce the full picture of schizophrenia.  The main point of similarity concerns referential thinking.  Phenomena resembling negative symptoms are also seen, but the distinction of these from the drug's sedative effects requires further elucidation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpNGPgVkzx2hFwe7cAcrfPfW6udTcc2eZbbXXIULr5w7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vls1aisQ%253D%253D&md5=06dcc502462b6c7faed99af971964312</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1192%2Fbjp.bp.105.015263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1192%252Fbjp.bp.105.015263%26sid%3Dliteratum%253Aachs%26aulast%3DPomarol-Clotet%26aufirst%3DE.%26aulast%3DHoney%26aufirst%3DG.%26aulast%3DMurray%26aufirst%3DG.%26aulast%3DCorlett%26aufirst%3DP.%26aulast%3DAbsalom%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DMcKenna%26aufirst%3DP.%26aulast%3DBullmore%26aufirst%3DE.%26aulast%3DFletcher%26aufirst%3DP.%26atitle%3DPsychological%2520effects%2520of%2520ketamine%2520in%2520healthy%2520volunteers%253A%2520phenomenological%2520study%26jtitle%3DBr.%2520J.%2520Psychiatry%26date%3D2006%26volume%3D189%26spage%3D173%26epage%3D179%26doi%3D10.1192%2Fbjp.bp.105.015263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbrock, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorner-Ciossek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rast, G.</span></span> <span> </span><span class="NLM_article-title">Effects of specific nicotinic acetylcholine receptor agonists on hippocampal long-term potentiation</span>. <i>Alzheimer's Dementia</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">S116</span>, <span class="refDoi"> DOI: 10.1016/j.jalz.2011.05.295</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.jalz.2011.05.295" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=S116&author=H.+Rosenbrockauthor=C.+Dorner-Ciossekauthor=K.+Krokerauthor=G.+Rast&title=Effects+of+specific+nicotinic+acetylcholine+receptor+agonists+on+hippocampal+long-term+potentiation&doi=10.1016%2Fj.jalz.2011.05.295"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2011.05.295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2011.05.295%26sid%3Dliteratum%253Aachs%26aulast%3DRosenbrock%26aufirst%3DH.%26aulast%3DDorner-Ciossek%26aufirst%3DC.%26aulast%3DKroker%26aufirst%3DK.%26aulast%3DRast%26aufirst%3DG.%26atitle%3DEffects%2520of%2520specific%2520nicotinic%2520acetylcholine%2520receptor%2520agonists%2520on%2520hippocampal%2520long-term%2520potentiation%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2011%26volume%3D7%26spage%3DS116%26doi%3D10.1016%2Fj.jalz.2011.05.295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Myers, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluth, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, W. W.</span></span> <span> </span><span class="NLM_article-title">Ketamine: a cause of urinary tract dysfunction</span>. <i>Clin. Lab. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1016/j.cll.2016.07.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.cll.2016.07.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=27842789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BC2snlvFKiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=721-744&author=F.+A.+Myersauthor=M.+H.+Bluthauthor=W.+W.+Cheung&title=Ketamine%3A+a+cause+of+urinary+tract+dysfunction&doi=10.1016%2Fj.cll.2016.07.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: A Cause of Urinary Tract Dysfunction</span></div><div class="casAuthors">Myers Frank Anthony Jr; Bluth Martin H; Cheung Wellman W</div><div class="citationInfo"><span class="NLM_cas:title">Clinics in laboratory medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">721-744</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Drug addiction as a result of improper use of prescribed and illicit use has been on the increase globally.  The effects of such use have implications in the urologic disease space.  To this end, Ketamine has been reported to affect urologic function, causing a number of voiding symptoms.  It may also confound the differential diagnosis of urologic diseases, such as interstitial cystitis, among others.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRuNhWGuJIGbCnGiHuhFGv8fW6udTcc2eZbbXXIULr5w7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2snlvFKiug%253D%253D&md5=d094eb8e30f35f319e70d8086ea2e56b</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2Fj.cll.2016.07.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cll.2016.07.008%26sid%3Dliteratum%253Aachs%26aulast%3DMyers%26aufirst%3DF.%2BA.%26aulast%3DBluth%26aufirst%3DM.%2BH.%26aulast%3DCheung%26aufirst%3DW.%2BW.%26atitle%3DKetamine%253A%2520a%2520cause%2520of%2520urinary%2520tract%2520dysfunction%26jtitle%3DClin.%2520Lab.%2520Med.%26date%3D2016%26volume%3D36%26spage%3D721%26epage%3D744%26doi%3D10.1016%2Fj.cll.2016.07.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Acevedo-Diaz, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanaugh, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadriu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarate, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, L. T.</span></span> <span> </span><span class="NLM_article-title">Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression</span>. <i>J. Affective Disord.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>263</i></span>,  <span class="NLM_fpage">568</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1016/j.jad.2019.11.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.jad.2019.11.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=31791675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlWktLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=2020&pages=568-575&author=E.+E.+Acevedo-Diazauthor=G.+W.+Cavanaughauthor=D.+Greensteinauthor=C.+Krausauthor=B.+Kadriuauthor=C.+A.+Zarateauthor=L.+T.+Park&title=Comprehensive+assessment+of+side+effects+associated+with+a+single+dose+of+ketamine+in+treatment-resistant+depression&doi=10.1016%2Fj.jad.2019.11.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression</span></div><div class="casAuthors">Acevedo-Diaz, Elia E.; Cavanaugh, Grace W.; Greenstein, Dede; Kraus, Christoph; Kadriu, Bashkim; Zarate, Carlos A.; Park, Lawrence T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Affective Disorders</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">263</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">568-575</span>CODEN:
                <span class="NLM_cas:coden">JADID7</span>;
        ISSN:<span class="NLM_cas:issn">0165-0327</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Concerns about ketamine for treating depression include abuse potential and the occurrence of psychotomimetic effects.  This study sought to comprehensively assess side effects (SEs) assocd. with a single subanesthetic-dose i.v. ketamine infusion.  A secondary aim was to examine the relationship between Clinician-Administered Dissociative States Scale (CADSS) scores and dissociative symptoms reported on a comprehensive, clinician-administered SE questionnaire.  Data from 188 participants were pooled from four placebo-controlled, crossover ketamine trials and one open-label study (n = 163 with either treatment-resistant major depressive disorder or bipolar disorder and 25 healthy controls).  SEs were actively solicited in a standardized fashion and monitored over the time-course of each study.  Statistical analyses assessed the effect of drug (ketamine, placebo) on SEs and measured the relationship between CADSS total score and SEs contemporaneously endorsed during structured interviews.  Forty-four of 120 SEs occurred in at least 5% of participants over all trials.  Thirty-three of these 44 SEs were significantly assocd. with active drug administration (vs. placebo).  The most common SE was feeling strange/weird/loopy.  Most SEs peaked within an hour of ketamine administration and resolved completely by two hours post-infusion.  No serious drug-related adverse events or increased ketamine craving/abuse post-administration were obsd.  A pos. correlation was found between dissociative SEs and total CADSS score.  The post-hoc nature of the anal.; the limited generalizability of a single subanesthetic-dose ketamine infusion; and the lack of formal measures to assess ketamine's cognitive, urol., or addictive potential.  No long-lasting significant SEs occurred over the approx. three-month follow-up period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocM-t8h_mvrbVg90H21EOLACvtfcHk0limGch83hJUtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlWktLfP&md5=0cbdb90cc86e441c2aa114211532191e</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.jad.2019.11.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jad.2019.11.028%26sid%3Dliteratum%253Aachs%26aulast%3DAcevedo-Diaz%26aufirst%3DE.%2BE.%26aulast%3DCavanaugh%26aufirst%3DG.%2BW.%26aulast%3DGreenstein%26aufirst%3DD.%26aulast%3DKraus%26aufirst%3DC.%26aulast%3DKadriu%26aufirst%3DB.%26aulast%3DZarate%26aufirst%3DC.%2BA.%26aulast%3DPark%26aufirst%3DL.%2BT.%26atitle%3DComprehensive%2520assessment%2520of%2520side%2520effects%2520associated%2520with%2520a%2520single%2520dose%2520of%2520ketamine%2520in%2520treatment-resistant%2520depression%26jtitle%3DJ.%2520Affective%2520Disord.%26date%3D2020%26volume%3D263%26spage%3D568%26epage%3D575%26doi%3D10.1016%2Fj.jad.2019.11.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trivedi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzucco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hough, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thase, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shelton, R. C.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">438</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2019.19020172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1176%2Fappi.ajp.2019.19020172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=31109201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A280%3ADC%252BB3M7nvVSjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=428-438&author=V.+Popovaauthor=E.+J.+Dalyauthor=M.+Trivediauthor=K.+Cooperauthor=R.+Laneauthor=P.+Limauthor=C.+Mazzuccoauthor=D.+Houghauthor=M.+E.+Thaseauthor=R.+C.+Shelton&title=Efficacy+and+safety+of+flexibly+dosed+esketamine+nasal+spray+combined+with+a+newly+initiated+oral+antidepressant+in+treatment-resistant+depression%3A+a+randomized+double-blind+active-controlled+study&doi=10.1176%2Fappi.ajp.2019.19020172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study</span></div><div class="casAuthors">Popova Vanina; Daly Ella J; Trivedi Madhukar; Cooper Kimberly; Lane Rosanne; Lim Pilar; Mazzucco Christine; Hough David; Thase Michael E; Shelton Richard C; Molero Patricio; Vieta Eduard; Bajbouj Malek; Manji Husseini; Drevets Wayne C; Singh Jaskaran B</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">428-438</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants.  This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active comparator) plus placebo nasal spray.  METHODS:  This was a phase 3, double-blind, active-controlled, multicenter study conducted at 39 outpatient referral centers.  The study enrolled adults with moderate to severe nonpsychotic depression and a history of nonresponse to at least two antidepressants in the current episode, with one antidepressant assessed prospectively.  Confirmed nonresponders were randomly assigned to treatment with esketamine nasal spray (56 or 84 mg twice weekly) and an antidepressant or antidepressant and placebo nasal spray.  The primary efficacy endpoint, change from baseline to day 28 in Montgomery-ÅAsberg Depression Rating Scale (MADRS) score, was assessed by a mixed-effects model using repeated measures.  RESULTS:  Of 435 patients screened, 227 underwent randomization and 197 completed the 28-day double-blind treatment phase.  Change in MADRS score with esketamine plus antidepressant was significantly greater than with antidepressant plus placebo at day 28 (difference of least square means=-4.0, SE=1.69, 95% CI=-7.31, -0.64); likewise, clinically meaningful improvement was observed in the esketamine plus antidepressant arm at earlier time points.  The five most common adverse events (dissociation, nausea, vertigo, dysgeusia, and dizziness) all were observed more frequently in the esketamine plus antidepressant arm than in the antidepressant plus placebo arm; 7% and 0.9% of patients in the respective treatment groups discontinued study drug because of an adverse event.  Adverse events in the esketamine plus antidepressant arm generally appeared shortly after dosing and resolved by 1.5 hours after dosing.  CONCLUSIONS:  Current treatment options for treatment-resistant depression have considerable limitations in terms of efficacy and patient acceptability.  Esketamine is expected to address an unmet medical need in this population through its novel mechanism of action and rapid onset of antidepressant efficacy.  The study supports the efficacy and safety of esketamine nasal spray as a rapidly acting antidepressant for patients with treatment-resistant depression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjG6m4HxP7vLrIbt-tGZmxfW6udTcc2ebEVRiM-IWG_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7nvVSjsA%253D%253D&md5=29fccbe859b33f8ced55216a5ca06aa9</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2019.19020172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2019.19020172%26sid%3Dliteratum%253Aachs%26aulast%3DPopova%26aufirst%3DV.%26aulast%3DDaly%26aufirst%3DE.%2BJ.%26aulast%3DTrivedi%26aufirst%3DM.%26aulast%3DCooper%26aufirst%3DK.%26aulast%3DLane%26aufirst%3DR.%26aulast%3DLim%26aufirst%3DP.%26aulast%3DMazzucco%26aufirst%3DC.%26aulast%3DHough%26aufirst%3DD.%26aulast%3DThase%26aufirst%3DM.%2BE.%26aulast%3DShelton%26aufirst%3DR.%2BC.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520flexibly%2520dosed%2520esketamine%2520nasal%2520spray%2520combined%2520with%2520a%2520newly%2520initiated%2520oral%2520antidepressant%2520in%2520treatment-resistant%2520depression%253A%2520a%2520randomized%2520double-blind%2520active-controlled%2520study%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2019%26volume%3D176%26spage%3D428%26epage%3D438%26doi%3D10.1176%2Fappi.ajp.2019.19020172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Potter, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choudhury, M.</span></span> <span> </span><span class="NLM_article-title">Ketamine: repurposing and redefining a multifaceted drug</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1854</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2014.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.drudis.2014.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=25224017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1SqtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1848-1854&author=D.+E.+Potterauthor=M.+Choudhury&title=Ketamine%3A+repurposing+and+redefining+a+multifaceted+drug&doi=10.1016%2Fj.drudis.2014.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Ketamine: repurposing and redefining a multifaceted drug</span></div><div class="casAuthors">Potter, David E.; Choudhury, Mahua</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1848-1854</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">This short review will highlight recent clin. and basic research that supports the therapeutic utility of ketamine as a rapid-acting, life-saving antidepressant and a versatile analgesic.  After 50 years of use as a dissociative anesthetic and misuse as a street drug, ketamine has re-emerged as a useful off-label agent for ameliorating various types of pain and resistant depression.  In addn. to its ability to inhibit N-methyl-D-aspartate (NMDA) receptors, the diverse actions of ketamine might involve epigenetic mechanisms such as microRNA regulation.  Thus, ketamine is transitioning from being the pharmacologist's nightmare to one of the most interesting developments in the pharmacol. of depression and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLqKHY-SNpN7Vg90H21EOLACvtfcHk0limGch83hJUtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1SqtbfK&md5=4c337cd5187299b2bf5e7116f7248fb2</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2014.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2014.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DPotter%26aufirst%3DD.%2BE.%26aulast%3DChoudhury%26aufirst%3DM.%26atitle%3DKetamine%253A%2520repurposing%2520and%2520redefining%2520a%2520multifaceted%2520drug%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D1848%26epage%3D1854%26doi%3D10.1016%2Fj.drudis.2014.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rüschoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietmaier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bocker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brockhoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofstädter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fishel, R.</span></span> <span> </span><span class="NLM_article-title">Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">11301</span>– <span class="NLM_lpage">11306</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.19.11301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1073%2Fpnas.95.19.11301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=9736731" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=11301-11306&author=J.+R%C3%BCschoffauthor=S.+Wallingerauthor=W.+Dietmaierauthor=T.+Bockerauthor=G.+Brockhoffauthor=F.+Hofst%C3%A4dterauthor=R.+Fishel&title=Aspirin+suppresses+the+mutator+phenotype+associated+with+hereditary+nonpolyposis+colorectal+cancer+by+genetic+selection&doi=10.1073%2Fpnas.95.19.11301"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.19.11301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.19.11301%26sid%3Dliteratum%253Aachs%26aulast%3DR%25C3%25BCschoff%26aufirst%3DJ.%26aulast%3DWallinger%26aufirst%3DS.%26aulast%3DDietmaier%26aufirst%3DW.%26aulast%3DBocker%26aufirst%3DT.%26aulast%3DBrockhoff%26aufirst%3DG.%26aulast%3DHofst%25C3%25A4dter%26aufirst%3DF.%26aulast%3DFishel%26aufirst%3DR.%26atitle%3DAspirin%2520suppresses%2520the%2520mutator%2520phenotype%2520associated%2520with%2520hereditary%2520nonpolyposis%2520colorectal%2520cancer%2520by%2520genetic%2520selection%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D11301%26epage%3D11306%26doi%3D10.1073%2Fpnas.95.19.11301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeBusk, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepine, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glasser, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shpilsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeRiesthal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease</span>. <i>Am. J. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1016/j.amjcard.2003.09.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=10.1016%2Fj.amjcard.2003.09.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=14715338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjsFSquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=147-153&author=R.+F.+DeBuskauthor=C.+J.+Pepineauthor=D.+B.+Glasserauthor=A.+Shpilskyauthor=H.+DeRiesthalauthor=M.+Sweeney&title=Efficacy+and+safety+of+sildenafil+citrate+in+men+with+erectile+dysfunction+and+stable+coronary+artery+disease&doi=10.1016%2Fj.amjcard.2003.09.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease</span></div><div class="casAuthors">DeBusk, Robert F.; Pepine, Carl J.; Glasser, Dale B.; Shpilsky, Arkady; DeRiesthal, Herb; Sweeney, Michael</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cardiology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">147-153</span>CODEN:
                <span class="NLM_cas:coden">AJCDAG</span>;
        ISSN:<span class="NLM_cas:issn">0002-9149</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">This was a double-blind, placebo-controlled, flexible-dose study of the efficacy and safety of sildenafil in men with erectile dysfunction (ED) and clin. stable coronary artery disease (CAD).  Patients were randomized to receive sildenafil or placebo for 12 wk.  Primary outcomes were questions 3 and 4 of the International Index of Erectile Function (IIEF).  Secondary outcomes included the other IIEF questions and functional domains, the Life Satisfaction Checklist, the Erectile Dysfunction Inventory of Treatment Satisfaction, 2 global efficacy assessment questions, and intercourse success rate.  By week 12, sildenafil-treated patients (n = 70) showed significant improvements on questions 3 and 4 compared with placebo-treated patients (n = 72; p <0.01).  Larger percentages of sildenafil-treated patients reported improved erections (64%) and improved intercourse (65%) compared with placebo-treated patients (21% and 19%, resp.).  Sildenafil-treated patients were highly satisfied with treatment and their sexual life compared with placebo-treated patients.  Forty-seven percent of sildenafil- and 32% of placebo-treated patients experienced adverse events, including transient headache, hypertension, flushing, and dyspepsia.  There were no serious drug-related cardiovascular effects.  Thus, sildenafil is an effective and well-tolerated treatment for ED in men with CAD.  Sildenafil was not assocd. with addnl. safety risks in this patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBnCWMLPT17LVg90H21EOLACvtfcHk0lij7sp-ZmCkwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjsFSquw%253D%253D&md5=3042796c98ddc503fe006c505d62f7df</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.amjcard.2003.09.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjcard.2003.09.030%26sid%3Dliteratum%253Aachs%26aulast%3DDeBusk%26aufirst%3DR.%2BF.%26aulast%3DPepine%26aufirst%3DC.%2BJ.%26aulast%3DGlasser%26aufirst%3DD.%2BB.%26aulast%3DShpilsky%26aufirst%3DA.%26aulast%3DDeRiesthal%26aufirst%3DH.%26aulast%3DSweeney%26aufirst%3DM.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520sildenafil%2520citrate%2520in%2520men%2520with%2520erectile%2520dysfunction%2520and%2520stable%2520coronary%2520artery%2520disease%26jtitle%3DAm.%2520J.%2520Cardiol.%26date%3D2004%26volume%3D93%26spage%3D147%26epage%3D153%26doi%3D10.1016%2Fj.amjcard.2003.09.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01193&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01193%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-22" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01193" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a69d7bfb13d24","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
